smiles,lipo,description
Cn1c(CN2CCN(CC2)c3ccc(Cl)cc3)nc4ccccc14,3.54,
COc1cc(OC)c(cc1NC(=O)CSCC(=O)O)S(=O)(=O)N2C(C)CCc3ccccc23,-1.18,
COC(=O)[C@@H](N1CCc2sccc2C1)c3ccccc3Cl,3.69,
OC[C@H](O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.37,
Cc1cccc(C[C@H](NC(=O)c2cc(nn2C)C(C)(C)C)C(=O)NCC#N)c1,3.1,
OC1(CN2CCC1CC2)C#Cc3ccc(cc3)c4ccccc4,3.14,
COc1cc(OC)c(cc1NC(=O)CCC(=O)O)S(=O)(=O)NCc2ccccc2N3CCCCC3,-0.72,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)cc2C)n1,0.34,
COc1ccc(cc1)C2=COc3cc(OC)cc(OC)c3C2=O,3.05,
Oc1ncnc2scc(c3ccsc3)c12,2.25,
CS(=O)(=O)c1ccc(Oc2ccc(cc2)C#C[C@]3(O)CN4CCC3CC4)cc1,1.51,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(C)nc1C#N)c3ccc(F)cn3,2.61,
O=C1CCCCCN1,-0.08,"This molecule is a clear to milky white-colored solution with a mild, disagreeable odor. Contact may cause slight irritation to skin, eyes, and mucous membranes. May be mildly toxic by ingestion. The primary hazard is the threat to the environment. Immediate steps should be taken to limit its spread to the environment. As a liquid it can easily penetrate the soil and contaminate groundwater and nearby streams. Used to make other chemicals. This molecule is a member of the class of caprolactams that is azepane substituted by an oxo group at position 2. It has a role as a human blood serum metabolite. This molecule is used in the manufacture of synthetic fibers. Acute (short-term) exposure to caprolactam may result in irritation and burning of the eyes, nose, throat, and skin in humans. Headaches, malaise, confusion, and nervous irritation have been observed in workers exposed to caprolactam by inhalation. Chronic (long-term) exposure of workers to caprolactam has been observed to cause peeling of the hands and some eye, nose, and throat irritation, but no other effects on general health. EPA has not classified caprolactam for carcinogenicity. This molecule is a natural product found in Fagopyrum esculentum, Nicotiana tabacum, and Vitis vinifera with data available."
CCCSc1ncccc1C(=O)N2CCCC2c3ccncc3,1.95,
CC1CCCCC1NC(=O)c2cnn(c2NS(=O)(=O)c3ccc(C)cc3)c4ccccc4,1.34,
Nc1ccc(cc1)c2nc3ccc(O)cc3s2,3.2,
COc1ccc(cc1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N,1.6,
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c2ccccc2,3.77,
COc1cc(ccc1N2CC[C@@H](O)C2)N3N=Nc4cc(sc4C3=O)c5ccc(Cl)cc5,3.15,
CO[C@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@H]1NCc4ccc5OCC(=O)Nc5n4,0.32,
CC(C)(CCCCCOCCc1ccccc1)NCCc2ccc(O)c3nc(O)sc23,2.92,
Clc1ccc(cc1)C(=O)Nc2oc(nn2)C(=O)Nc3ccc(cc3)N4CCOCC4,1.92,
COc1ccc(Oc2cccc(CN3CCCC(C3)N4C=C(C)C(=O)NC4=O)c2)cc1,3.17,
OC(=O)c1cccc(c1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.17,
CNCC[C@@H](Oc1ccccc1C)c2ccccc2,1.2,
Clc1ccc(N2CCN(CC2)C(=O)CCCc3ccncc3)c(Cl)c1,3.93,
COc1cnc(nc1N(C)C)c2ccccn2,1.9,
C(CCCCNc1cc(nc2ccccc12)c3ccccc3)CCCNc4cc(nc5ccccc45)c6ccccc6,2.27,
CSc1c(cnn1c2ccc(cc2)C(=O)O)C(=O)NC3C4CC5CC(CC3C5)C4,1.2,
CNC1=Nc2ncccc2C(=NC1c3cccs3)c4occn4,1.14,
CS(=O)(=O)C1(CC1)c2cc(nc(n2)c3cccc4[nH]ccc34)N5CC6CCC(C5)O6,2.6,
CN([C@@H]1CCN(Cc2ccc(cc2)C(F)(F)F)C[C@@H]1F)C(=O)Cc3ccc(cc3)n4cnnn4,3.3,
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,3.94,"This molecule is a white powder. Melting point 121 Â°C. Stable in air. Insoluble in water. A female sex hormone. Low toxicity. This molecule is a C21-steroid hormone in which a pregnane skeleton carries oxo substituents at positions 3 and 20 and is unsaturated at C(4)-C(5). As a hormone, it is involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species. It has a role as a contraceptive drug, a progestin, a progesterone receptor agonist, a human metabolite and a mouse metabolite. It is a 20-oxo steroid, a 3-oxo-Delta(4) steroid and a C21-steroid hormone. It derives from a hydride of a pregnane. This molecule is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. This molecule is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy.  Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone.  Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin. This molecule is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes. This molecule is a This molecule. This molecule is the therapeutic form of the naturally occurring hormone progesterone.  Progesterone binds to the progesterone receptor, resulting in dissociation of heat shock proteins, receptor phosphorylation, and transcription activation through direct or indirect interaction with transcription factors.  This agent exerts inhibitory effects on estrogens by decreasing the number of estrogen receptors and increasing its metabolism to inactive metabolites.  Progesterone induces secretory changes in the endometrium, decreases uterine contractility during pregnancy, and maintains pregnancy. This molecule is produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development. This molecule is any synthetic steroid hormone that resembles the naturally occurring hormone and has progesterone-like properties. This molecule is a natural product found in Abedus herberti, Cota palaestina, and other organisms with data available. This molecule is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. Progesterone is a C-21 steroid hormone involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species. Progesterone belongs to a class of hormones called progestagens, and is the major naturally occurring human progestagen. During implantation and gestation, progesterone appears to decrease the maternal immune response to allow for the acceptance of the pregnancy. Progesterone decreases contractility of the uterine smooth muscle. The fetus metabolizes placental progesterone in the production of adrenal mineralo- and glucosteroids. A drop in progesterone levels is possibly one step that facilitates the onset of labor. In addition progesterone inhibits lactation during pregnancy. The fall in progesterone levels following delivery is one of the triggers for milk production."
CS(=O)(=O)c1ccccc1C(=O)NC[C@@H](O)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,2.34,
O=C(NCc1ccncc1)c2ccc(Oc3ccccc3C#N)cc2,2.57,
CN(C)c1ccnc2sc(C(=O)NCc3ccccc3)c(N)c12,3.62,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5cscn5)ccc4C,2.06,
Cn1cncc1c2c3C(=O)N(CC4CC4)C(=O)N(CC5CC5)c3nn2Cc6ccnc7ccc(Cl)cc67,4.33,
COc1ccc2ncc(C#N)c(CCN3CCC(CC3)NCc4cc5SCOc5cn4)c2c1,2.55,
CNC(=O)C1(CCN(CC[C@H](CN(C)C(=O)c2c(OC)c(cc3ccccc23)C#N)c4ccc(Cl)c(Cl)c4)CC1)N5CCCCC5=O,2.78,
OB1N(C(=O)Nc2ccccc12)c3ccccc3,1.4,
CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C,-0.54,
NC(=NC#N)c1sc(Nc2ccccc2)nc1N,2.91,
CCS(=O)(=O)c1ccc(c(C)c1)c2cc(ccc2O[C@H](C)C(=O)O)C(F)(F)F,-0.4,
OC(=O)COc1ccc(cc1c2cc(ccc2F)C#N)C(F)(F)F,-0.16,
COc1ccc(cn1)C2=Cc3c(C)nc(N)nc3N([C@@H]4CC[C@H](CC4)OCCO)C2=O,2.2,
CC(Nc1ncnc2ccccc12)c3ccccc3,3.4,
CC(C)c1ccc2Oc3nc(N)c(cc3C(=O)c2c1)C(=O)O,1.1,
O[C@@H](CNCCCOCCOCCc1cccc2ccccc12)c3ccc(O)c4NC(=O)Sc34,2.28,
COc1ccccc1Cn2c(C)nc3ccccc23,3.47,
OC(=O)c1ccc(NC(=O)c2cc(OCc3ccccc3F)cc(OCc4ccccc4F)c2)nc1,3.0,
NC(Cc1c[nH]c2ccccc12)C(=O)O,-1.17,"This molecule is an amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of tryptophan; major species at pH 7.3. It is a tautomer of a tryptophan. This molecule is a white solid. (NTP, 1992) This molecule is an alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3. It has a role as a Daphnia magna metabolite. It is an alpha-amino acid, an aminoalkylindole, a polar amino acid and an aromatic amino acid. It contains a 1H-indol-3-ylmethyl group. It is a conjugate base of a tryptophanium. It is a conjugate acid of a tryptophanate. It is a tautomer of a tryptophan zwitterion. This molecule is a natural product found in Smallanthus sonchifolius, Drosophila melanogaster, and other organisms with data available."
OC(=O)CCC[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4cc(F)ccc4[nH]3,1.95,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C(=O)O)n4ccc(n4)C(F)(F)F,-0.99,
C[C@H](NC(=O)c1c(C)nn(C2CCCC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,2.0,
N(c1ccccc1)c2cc(Nc3ccccc3)[nH]n2,3.8,
COCCNC(=O)c1cccc(Nc2ncc3cc(ccc3n2)c4ccncc4)c1,3.21,
CCC(CC)NC(=O)c1cnn(C)c1NS(=O)(=O)c2ccc(C)cc2,0.36,
NC(=O)c1cc(F)cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,2.14,
O=C1NC(=NC(=C1C#N)c2ccccc2)SCCc3ccccc3,1.71,
OC(C(=O)OC1CN2CCC1CC2)(c3ccccc3)c4ccccc4,1.19,
Cc1ccccc1NC(=O)CCS(=O)(=O)c2ccc(Br)s2,2.7,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)N(C)C)ncc2F,2.77,
COc1cccc(c1)c2c[nH]c(n2)c3ccccc3,3.8,
O=C(COc1ccccc1)c2ccccc2,2.87,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1NCCN(C)C,1.91,
CO[C@@H]1CC[C@@]2(CC1)Cc3ccc(OCC(C)C)cc3C24N=C(C)C(=N4)N,3.4,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCCC4,3.13,
O=C1CCOc2cc(COc3ccccc3)ccc12,3.0,
Clc1cccc2cn[nH]c12,2.33,
CNC(=O)c1ccc(CC(=O)N(C)C2CCN(Cc3ccc(cc3)C(F)(F)F)CC2)cc1,2.8,
COCCNCc1ccc(CCNC[C@H](O)c2ccc(O)c3NC(=O)Sc23)cc1,-0.54,
Cn1cncc1c2c3C(=O)N(CC#C)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56,3.16,
C[C@H](NC(=O)c1cccnc1Oc2ccccc2)c3ccccc3,2.91,
Clc1ccc(CN2CC3CNCC(C2)O3)cc1C(=O)NCC45CC6CC(CC(C6)C4)C5,1.55,
COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1,0.2,"This molecule is a sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. It has a role as an antiinfective agent, an antimicrobial agent, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of pyrimidines, a sulfonamide, a substituted aniline, an aromatic ether and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. This molecule is a sulfonamide antibiotic. This molecule is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. This molecule inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. This molecule is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.  In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective. This molecule is a long-acting sulfonamide antibiotic used in veterinary medicine. This molecule inhibits bacterial synthesis of folic acid by competing with para-aminobenzoic acid (PABA) for the binding site on dihydropteroate synthase. This molecule is a natural product found in Brassica napus with data available."
Cc1cc(CCC2CCN(CC2)S(=O)(=O)CC3(CCOCC3)N(O)C=O)c(C)cn1,1.43,
C[C@H](Nc1ncc(F)c(Nc2cc([nH]n2)C3CC3)n1)c4ncc(F)cn4,2.47,
CC(=O)Nc1ccc2c(c1)c(cn2CCCO)c3cc(NC4CC4)n5ncc(C#N)c5n3,2.48,
CC1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(=O)O,-0.45,
CC1(CC1)c2nc(ncc2C(=O)N[C@@H]3C4CC5CC3C[C@@](O)(C5)C4)N6CCOCC6,2.0,
COC(=O)c1ccc(C)c(NS(=O)(=O)c2ccc3N(C)SC(=O)c3c2)c1,2.6,
COc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,3.5,
CNCCCC12CCC(c3ccccc13)c4ccccc24,0.89,
Oc1cc(nc2ccnn12)c3ccccc3,1.3,
Fc1cc(cc(F)c1C2=CCN(CC2)C=O)N3C[C@H](COc4ccon4)OC3=O,2.01,
CC(C#C)N1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c3C1=O)c6cncn6C,3.59,
C[C@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1C(=O)Cc3ccccc3,0.18,
COc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Br)n[nH]1,2.6,
Cc1nc(C)c(nc1C(=O)N)c2ccc([C@@H]3CC[C@@H](CC(=O)O)CC3)c(F)c2,1.3,
COc1ccnc(CCc2nc3c(C)ccnc3[nH]2)c1,2.1,
Cc1cc(CCCOc2c(Cl)cc(cc2Cl)C3=NCCO3)on1,3.72,
CN(C)C(=O)c1ccc(CN2CCc3cc4nc(N)sc4cc3CC2)cc1,1.72,
COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,1.65,
CCN1CCN(CC1)c2ccc(Nc3cc(ncn3)N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)cc2,3.7,
CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]2O[C@H]([C@H](O)[C@@H]2O)n3cnc4c(N)ncnc34,2.2,
CCN(CC)CCCCNc1ncc2CN(C(=O)N(Cc3cccc(NC(=O)C=C)c3)c2n1)c4c(Cl)c(OC)cc(OC)c4Cl,2.04,
CCSc1c(Cc2ccccc2C(F)(F)F)sc3N(CC(C)C)C(=O)N(C)C(=O)c13,4.49,
COc1ccc(Cc2c(N)n[nH]c2N)cc1,0.2,
CCN(CCN(C)C)S(=O)(=O)c1ccc(cc1)c2cnc(N)c(n2)C(=O)Nc3cccnc3,2.0,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4ccccc4)c3)C(=O)NC1=O,1.49,
C1Oc2ccccc2C3=NN(CC13)c4ccccc4,4.28,
CNC(=C[N+](=O)[O-])NCCSCc1oc(CN(C)C)cc1,-0.95,
CC(C)CC(N1NC(=O)c2nc3cc(Cl)ccc3c(O)c2C1=O)c4ccncc4,1.64,
FC(F)c1nc2ccccc2[nH]1,2.02,
O[C@@H](CNC1CCN(Cc2ccc(Cl)c(Cl)c2)CC1)COc3cccc(c3)C#N,3.09,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1N4CCN(C)CC4,2.18,
Oc1ccccc1OC(=O)c2cccc3ccccc23,4.4,
COc1ccccc1CNc2cc(C)ccn2,3.28,
Nc1nc(Nc2cccc(Br)c2)c3nc[nH]c3n1,3.04,
Nc1c2CCN(c3ccccc3)c2nc4ccc(Br)cc14,3.12,
COc1cc(OC)c(cc1NC(=O)CCC(=O)O)S(=O)(=O)N(c2ccc(C)cc2)c3ccc(C)cc3,0.06,
OC(C(=O)c1ccc(F)cc1)c2ccc(F)cc2,2.49,
CC(C)C[C@H](N)c1oc(nn1)S(=O)(=O)Cc2ccc(F)cc2,1.11,
CC(C)COc1cccc(c1)C(=O)Nc2ccc(C)c(c2)C(=O)Nc3cccnc3,2.81,
COc1ccc(OC)c(CNC(=O)c2cccnc2Oc3ccccc3)c1,3.52,
NC1(CCC1)c2ccc(cc2)c3nc4C=CN5C(=O)NN=C5c4cc3c6ccccc6,2.5,
CC(C(Cc1nc2ccccc2[nH]1)c3nc4ccccc4[nH]3)c5ccccc5,4.48,
Clc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,1.33,
OC(=O)Cc1ccc(cc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,1.83,
COc1cc2ncc(C(=O)N)c(Nc3cccc(Cl)c3F)c2cc1OC,3.6,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)C4CCC4,3.2,
NC(=N)NC(=O)c1nc(Cl)c(NCc2ccccn2)nc1N,-0.56,
Nc1c(NC2CC3CCC2C3)nc(nc1N4CCOCC4)C#N,3.53,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)NCc4c(F)cccc4F,4.3,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NCc4ccc(Cl)cc4,2.88,
CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24,3.08,
Cc1ncc(nc1C(=O)N)c2ccc(cc2)[C@@H]3CC[C@@H](CC(=O)O)CC3,1.0,
Cn1ncnc1COc2nn3c(nnc3cc2C(C)(C)C)c4cc(F)ccc4F,2.4,
CNCC[C@H](Oc1ccc(cc1)C(F)(F)F)c2ccccc2,1.89,
Cc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)cc4Cl,1.52,
O=C1C=COc2cc(OCc3ccccc3)ccc12,3.33,
[O-][S+](c1ccccc1)c2ccc3nnnn3n2,0.79,
[O-][N+](=O)c1ccc2OC(CN(c2c1)c3cccc[n+]3[O-])(C(F)F)C(F)F,3.2,
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,0.1,"This molecule is a cardioselective beta-blocker used in the treatment of hypertension. This molecule has not been linked to instances of clinically apparent drug induced liver injury. This molecule is a secondary alcohol and a secondary amine. It has a role as an antihypertensive agent, a beta-adrenergic antagonist, an anti-arrhythmia drug and a sympatholytic agent. This molecule is a cardioselective Î²1-adrenergic blocking agent used to treat high blood pressure. It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. This molecule is generally well tolerated, likely due to its Î²1-adrenergic receptor selectivity and is a useful alternative to non-selective Î²-blocker drugs in the treatment of hypertension such as [Carvedilol] and [Labetalol]. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity. This molecule is a beta-Adrenergic Blocker. The mechanism of action of bisoprolol is as an Adrenergic beta-Antagonist. This molecule is a selective beta-1 adrenergic receptor antagonist with antihypertensive activity and devoid of intrinsic sympathomimetic activity. This molecule selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. In addition, bisoprolol prevent the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels."
Cc1ncc(nc1c2ccc(cc2)[C@@H]3CC[C@H](CC3)C(=O)O)C(=O)N,0.22,
Nc1nnc(CCSCCc2nnc(NC(=O)Cc3ccccc3)s2)s1,2.0,
COc1cc(OC2CCN(CC2)C(=O)C)ccc1Nc3ncc(Cl)c(n3)c4cnc5ccccn45,4.0,
COc1ccc(cc1)C2=CC(=O)c3ccccc3N2,2.71,
COC1\C=C\OC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)\C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)\C,0.7,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cc(cn6C)C#N)c3C1=O,3.67,
CN1SC(=NC1=O)NC(=O)c2cccc(Cl)c2,0.87,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4nccn4C,2.83,
CC(=O)Nc1ccc(cc1)C(=O)Nc2ccccc2N,0.82,
Oc1ccc2C(=O)C=C(Oc2c1)N3CCOCC3,1.0,
Oc1nc(nc2CCSCc12)c3ccc(cc3)C(F)(F)F,3.07,
Clc1ccc(N2CCN(CC2)C(=O)COCc3cscn3)c(Cl)c1,3.07,
Oc1ccc(cc1)N2C=Nc3cc(O)ccc3C2=O,1.6,
O[C@@H](CNCCc1ccccc1CNCCc2ccccc2F)c3ccc(O)c4NC(=O)Sc34,1.58,
OCC(CO)N1C=Cc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2C1=O,2.62,
COc1ccc(c(OC)n1)c2c(F)ccc3c(N)c(nnc23)C(=O)NC4CC4,3.37,
Clc1ccccc1c2cnn[nH]2,2.68,
NC(=O)c1ccc(Oc2cccc3cccnc23)c(c1)[N+](=O)[O-],1.7,
NC(=O)Nc1cc(sc1C(=O)N)c2cccc(O)c2,2.21,
Nc1ccc(cc1)S(=O)(=O)Nc2nccs2,-0.37,
COC(=O)C1=Nc2c(N[C@H](C)CO)nc(SCc3cccc(F)c3F)nc2NC1=O,2.49,
COc1cccc(NC(=O)Cn2cc(Oc3ncnc4cc(OC)c(OC)cc34)cn2)c1,3.11,
CC1CCc2cc(F)cc3C(=O)C(=CN1c23)C(=O)O,0.74,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cn3c(C)nc(Cl)c3Cl)c2C(=O)N4CC[C@@H](O)C4,1.61,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4ncc(C#N)s4,1.2,
Cc1ccc(NC(=N)N)cc1C,-1.34,
Clc1ccc(cc1C(=O)NCC2CCCCC2)N3N=CC(=O)NC3=O,1.26,
O=C(Oc1ccccc1)N2CCOCC2,1.3,
CC(C)(C#N)c1cnc(s1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,1.9,
FC(F)(F)c1nnc2ccc(nn12)N3CCCCC3,3.0,
Cc1c(Sc2ccc(Cl)cc2)c3c(NS(=O)(=O)C)cccc3n1CC(=O)O,0.21,
CCCNC(=O)CSc1ccc(cn1)S(=O)(=O)N2CCCC2,1.55,
C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc5ccccn5)c3)c12)C(=O)N6CCOCC6,2.82,
COc1ccc(Cn2cc3N(CC(C)C)C(=O)N(C)C(=O)c3c2)cc1,3.52,
COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCn4cncn4,3.2,
CCN1CCC[C@H]1CNC(=O)c2c(O)c(Cl)cc(Cl)c2OC,1.09,
CC(=O)Nc1nc(C)c(s1)c2cnc(F)c(NS(=O)(=O)c3sc(C)nc3C)c2,0.55,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4ccc(cc34)C(F)(F)F,1.78,
CSc1ncccc1C(=O)Nc2nccs2,1.43,
CCOc1ncc(C)c2NC(=C([C@@H](c3ccc(cc3OC)C#N)c12)C(=O)N)C,2.51,
Cc1nc2ccc(Cl)cn2c1c3ccnc(N)n3,2.49,
CC1CC(CC(C)(C)C1)OC(=O)C(O)c2ccccc2,2.31,
C[C@@H](NC(=O)C1CCCCN1C)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,3.34,
CN(C)C(=O)CN1CCN(CCc2c([nH]c3sc(cc23)C(C)(C)C(=O)N4C5CCC4CC5)c6cc(C)cc(C)c6)CC1,4.13,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(F)cc2)C1)C(C)(C)C,3.12,
NC1(CCC1)c2ccc(cc2)c3ncc4ccncc4c3c5ccccc5,2.2,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NS(=O)(=O)C)C(=O)C(F)(F)F,1.77,
C[C@@H]1CN([C@@H](C)CN1C(=O)c2ccc(cc2)C#N)C(=O)[C@@](C)(O)C(F)(F)F,1.5,
CCOc1ccccc1c2ccc(cc2)c3nc4ccc(F)cc4c(N[C@H](C)C(=O)O)c3C#N,2.5,
Clc1ccc(CC2CCNCC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,1.49,
CC[C@H](NC(=O)c1c(c(nc2ccccc12)c3ccccc3)S(=O)(=O)C)c4ccccc4,3.17,
Fc1ccc(NC(=O)c2cccnc2Oc3ccccc3)cc1,3.19,
CC(CN1CCCCC1)C(=O)c2ccc(C)cc2,1.65,
CC(C)OC(=O)N1CCC(CC1)Oc2ncnc(Nc3ccc(nc3C)S(=O)(=O)C)c2C,2.8,
Cc1ccccc1c2c(C(=O)O)n(CCCOc3cccc4ccccc34)c5ccccc25,3.89,
C[C@@H](NCc1ccccc1c2ccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)cc2)c5ccccc5,2.28,
Nc1nc(Nc2ccc(F)c(Cl)c2)c3nc[nH]c3n1,2.75,
CCCSc1nc(N[C@@H]2C[C@H]2c3ccccc3)c4nnn([C@@H]5C[C@H](O)[C@@H](O)[C@H]5O)c4n1,3.97,
CSc1ccc(cc1)N2C(=NC(=NC2(C)C)N)N,-0.84,
C[C@@H]1N[S@@](=O)(=NC1=O)c2cccc(c2)c3ccc(C)cc3,1.6,
Nc1nc(N)nc(n1)c2cccc(c2)C(F)(F)F,2.4,
Cc1cccc(CN2CCN(CC2)C(c3ccccc3)c4ccc(Cl)cc4)c1,3.39,
Fc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.79,
OC(=O)COc1ccc(Cl)cc1CN2CCCN(CC2)S(=O)(=O)Cc3ccccc3,1.01,
Clc1cccc(c1Cl)n2nnnc2NCc3ccccc3Oc4ccccn4,3.62,
CN1CCCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,2.36,
Clc1ccccc1CCNC(=O)c2cc(ccc2Cl)N3N=CC(=O)NC3=O,1.29,
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(Cc4ccccn4)C3=O,1.1,
C[C@@H](NC(=O)[C@H]1CCCCN1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,2.15,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3cccc4ncccc34)c2C(=O)N5CC[C@@H](O)C5,1.98,
C[C@H](NC(=O)[C@@H]1CCCC[C@H]1C(=O)N2CCc3[nH]c4ccc(F)cc4c3C2)C#N,3.5,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NS(=O)(=O)N)C(=O)C(F)(F)F,1.17,
OC(=O)C1CCN(CC1)c2ncccc2c3ccc(Cl)c(c3)C(=O)NCC4CCCCCC4,2.53,
Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1,1.13,
Cc1ccc(cc1)c2cccc(c2)c3nn[nH]n3,1.3,
Cc1ccc2c(n1)c(Sc3ccc(Cl)cc3)c(C)n2CC(=O)O,0.35,
CN(C1CCN(C)CC1)c2nccc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)n2,1.8,
CCCCCC[C@H]1OC(=O)CNC(=O)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H]1C)[C@H](C)CC)[C@H](C)O,3.2,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCN(C2)C(=O)c3ccccc3,0.82,
Cc1cnc([nH]1)c2ccc(C)c(NC(=O)c3ccc(OCc4ccccn4)cc3)c2,3.19,
O=C(NCCSCc1ccccc1)c2ccccc2,3.3,
OC(=O)[C@@H](Cc1ccccc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.5,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3c[nH]c4ccccc34)c2C(=O)N5CC[C@@H](O)C5,2.35,
C[C@H](Nc1cnc(C)c(Nc2cc(C)[nH]n2)n1)c3ccc(F)cn3,1.73,
C(CN1CCCCC1)C2CCc3cc(OCc4ccc(cc4)c5ccccc5)ccc3C2,3.3,
Nc1ccccc1NC(=O)c2ccc(cc2)C3CCN(Cc4ccc(cc4)C(=O)NC5CC5)CC3,2.31,
CC(Cc1cccc(CNCCc2c(Cl)cccc2Cl)c1)NC[C@H](O)c3ccc(O)c4NC(=O)Sc34,2.41,
OCC[C@@]1(CCCNC1)c2ccc(Cl)c(Cl)c2,0.61,
COc1ccccc1C(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N3CCN(Cc4ccc(F)cc4)CC3)C#N,3.57,
CN(C)c1nc(N[C@@H]2CC[C@@H](CC2)NC(=O)c3ccc(F)c(F)c3)nc4ccccc14,3.13,
CCCNC[C@@H](O)COc1ccccc1C(=O)CCc2ccccc2,1.56,
Oc1c2C(=O)N(NC(=O)c2nc3cc(Cl)ccc13)C(C4CC4)c5ccncc5,0.7,
Cc1cc(OC2CCN(CC3CCN(CC3)[C@@](C)(Cc4ccc(F)cc4)C(=O)O)CC2)ccc1Cl,2.08,
O=C(CCc1ccccc1)c2ccccc2,3.77,
CCCCc1ncc(\C=C(/Cc2cccs2)\C(=O)O)n1Cc3ccc(cc3)C(=O)O,-0.9,
OC(=O)[C@H](Cc1ccccc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.5,
C(C(C1CCCCC1)C2CCCCC2)C3CCCCN3,3.02,
COc1cc(Nc2nccc(n2)N(C)c3cc(CO)ccc3C)cc(c1)N4CCOCC4,3.9,
O=C(Nc1nc2C(=O)NC=Nc2s1)c3ccccc3,1.94,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2ccccc12)c3ccc(F)cc3)c4ccccc4,3.72,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4cccc(c4)C(F)(F)F)c3)C(=O)NC1=O,2.27,
COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC,1.7,This molecule is under investigation in clinical trial NCT00464243 (Efficacy and Safety of This molecule on Sleep Maintenance Insomnia - Polysomnographic Study).
COc1ccc2nc(N[C@H]3CCC[C@@H](C3)NCc4ccsc4)ccc2c1,2.43,
CN1CCN(CC1)c2ncnc3c2sc4nc(C)cc(C)c34,3.2,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3ccc(cc3)S(=O)(=O)C)cn2,3.27,
O=C(COc1ccccc1)N2CCOCC2,0.75,
Cc1nnsc1C(=O)Nc2ccccc2,0.97,
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,1.07,
CC1=CN([C@H]2CCCN(Cc3ccc(C(=O)O)c(Oc4cccc(c4)C(F)(F)F)c3)C2)C(=O)NC1=O,-0.38,
COc1cc(O)cc2OC=C(C(=O)c12)c3ccc(O)cc3,2.0,
O=C(C1CCCCC1)N2CC3N(CCc4ccccc34)C(=O)C2,2.43,
Cc1ccccc1N2C(=Nc3cccc(C)c3C2=O)Cn4nc(c5ccc(O)c(F)c5)c6c(N)ncnc46,3.55,
Nc1cc(nc2ccc(Nc3cc(nc(N)n3)c4cccc(Cl)c4)cc12)c5ccc(F)cc5,2.5,
O=C1NC=Nc2[nH]ncc12,-0.42,
C[C@H](NC(=O)c1c(C)nn(C2CCOC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,0.78,
Fc1ccc(SC2=NN3C=NC(=O)C(=C3C=C2)c4c(Cl)cccc4Cl)c(F)c1,2.74,
CC(C(=O)O)n1c(C)c(Sc2ccc(Cl)cc2)c3cc(Cl)ccc13,3.56,
NC(=O)c1sc(cc1N)c2ccccc2,2.33,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4cc(Cl)ccc34,1.59,
COc1ccc2ncc(F)c(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2n1,1.46,
CS(=O)(=O)c1ccc(cc1)c2cnc(N)c(c2)c3ccc(nc3)C(F)(F)F,2.4,
O=C1CCOc2nc(CCc3ccccc3)ccc12,2.5,
Clc1ccc2OC(=O)Nc2c1,2.16,
CC(C)C(=O)NCCNCC(O)COc1ccc(O)cc1,-0.15,
NC1(CCC1)c2ccc(cc2)c3nn4cccc4cc3c5ccccc5,3.3,
OC(=O)COc1ccc(cc1CN2CCN(CC2)S(=O)(=O)c3ccccc3)C(F)(F)F,0.4,
CSCCC(NC(=O)c1sccc1Cl)c2nc3ccccc3[nH]2,3.69,
COc1ccnc(CCc2nc3cccnc3[nH]2)c1,1.69,
[O-][N+](=O)c1cccc(c1)C(=O)Nc2nc3ccccc3n2CCN4CCOCC4,3.3,
CC(C)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1,2.3,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2cccnc2)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,3.05,
COc1ccc2nccc([C@H](O)C3CC4CCN3CC4C=C)c2c1,2.16,
N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,2.55,
Clc1ccc(Cl)c(c1)S(=O)(=O)Nc2nccs2,1.14,
O=C1COC2(CCN(CC2)S(=O)(=O)c3ccc(cc3)c4ccc5cnccc5c4)CN1C6CC6,3.32,
COc1ccc(cc1)c2cc(Nc3ccn(C)n3)n4ncc(C#N)c4n2,2.97,
Cc1cc(C(=O)CN2C=C(C=CC2=O)C(F)(F)F)c(C)n1Cc3ccccc3,3.46,
Oc1ccc2nc(sc2c1)c3ccccc3,3.99,
NS(=O)(=O)c1nc2ccccc2s1,1.35,This molecule is a member of benzothiazoles and a sulfonamide.
CS(=O)(=O)c1ccc(c(Cl)c1)c2cc(Cl)ccc2OCC(=O)O,-0.75,
OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)n2nnc3c(N[C@@H]4C[C@H]4c5ccc(F)c(F)c5)nc(SCCC(F)(F)F)nc23,3.99,
NC(=O)c1ccccc1OCc2ccccc2,2.5,
CC1CC(=O)Nc2ccccc2N1,0.56,This molecule is a benzodiazepine.
NC(=O)N1c2ccccc2CC(=O)c3ccccc13,1.28,
Cc1ccc(F)cc1S(=O)(=O)N[C@@H]2CCN(Cc3ccc(cc3)c4ccccc4)C2,4.0,
COc1ccc(cc1OC)C2=COc3cc(O)cc(O)c3C2=O,2.8,
CC(=O)Nc1ccc2c(c1)c(Sc3ccc(Cl)cc3)c(C)n2CC(=O)O,0.2,
O=C1CCOc2nc(ccc12)C#CC3CCCC3,3.0,
CN1CCN2C(C1)c3ccccc3Cc4cccnc24,2.82,
COc1ccccc1c2nnc(N)[nH]2,0.91,
COc1ccc(cc1OC)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,1.4,
CCN(C1CCN(CCC(c2ccccc2)c3ccc(NS(=O)(=O)C)cc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.84,
O[C@@H](CNCCSCCCNCCc1ccccc1)c2ccc(O)c3NC(=O)Sc23,0.12,
CC(C)(C)NS(=O)(=O)c1cncc(c1)c2ccc3nc(NC(=O)NCC(=O)N4CCOCC4)nn3c2,0.96,
CC[C@H](NC(=O)c1c([S+]([O-])C(C)C)c(nc2ccccc12)c3ccccc3)c4ccccc4,3.81,
COc1cc(OC)c(cc1NC(=O)COC(=O)C)S(=O)(=O)N2C(C)CCc3ccccc23,2.07,
C[C@]1(CCCN1c2nc(Nc3cc([nH]n3)C4CC4)c5cccn5n2)C(=O)Nc6ccc(F)nc6,3.16,
CC1CN(C(=O)c2ccccc2)c3ccccc3NC1=O,1.73,
COc1cc2ncn(c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(=O)O)c2cc1OC,0.84,
O[C@@H](CNCCCSCCNCCc1cccc(Cl)c1Cl)c2ccc(O)c3NC(=O)Sc23,1.74,
NC(=O)Nc1cc(sc1C(=O)N[C@H]2CCCNC2)c3cccc(F)c3F,1.32,
CC(C)C(=O)Nc1nc(cc2ccccc12)c3ccccn3,2.7,
Nc1nc(N)c2nc(c(N)nc2n1)c3ccccc3,1.16,
C[C@@](O)(C(=O)Nc1ccc(cc1Cl)S(=O)(=O)NCC=C)C(F)(F)F,3.07,
COc1ccc(cc1)C(=O)NCc2cn(nn2)c3cc(C)nc4ccc(OC)cc34,3.5,
Oc1ccc(CCNCCCS(=O)(=O)NCCOCCc2cccc(Cl)c2)c3sc(O)nc13,1.92,
NC12CC3CC(CC(C3)C1)C2,-0.98,"This molecule is a primary amine that has both antiviral and dopaminergic activity and is used in the therapy of influenza A and management of Parkinson disease. This molecule has not been associated with clinically apparent liver injury. This molecule is a member of the class of adamantanes that is used as an antiviral and antiparkinson drug. It has a role as an antiviral drug, an antiparkinson drug, a dopaminergic agent, an analgesic, a NMDA receptor antagonist and a non-narcotic analgesic. It is a primary aliphatic amine and a member of adamantanes. It is a conjugate base of an adamantan-1-aminium. It derives from a hydride of an adamantane. This molecule is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. This molecule is an Influenza A M2 Protein Inhibitor. The mechanism of action of amantadine is as a M2 Protein Inhibitor. This molecule is a synthetic tricyclic amine with antiviral, antiparkinsonian, and antihyperalgesic activities. This molecule appears to exert its antiviral effect against the influenza A virus by interfering with the function of the transmembrane domain of the viral M2 protein, thereby preventing the release of infectious viral nucleic acids into host cells. Furthermore, this agent prevents virus assembly during virus replication. This molecule exerts its antiparkinsonian effects by stimulating the release of dopamine from striatal dopaminergic nerve terminals and inhibiting its pre-synaptic reuptake. This agent may also exert some anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine, resulting in antihyperalgesia. This molecule is a natural product found in Microcystis ichthyoblabe with data available. This molecule is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake. [PubChem]"
CNC(=O)c1cc(c2nc(cc(n2)C3(CC3)S(=O)(=O)C)N4CCOCC4)c5cc[nH]c5c1,1.7,
O=C1Nc2ccccc2C(=O)C=C1,1.02,
CC[C@@H](NC1=C(Nc2cccc(C(=O)N(C)C)c2O)C(=O)C1=O)c3oc(C)cc3,2.32,
Fc1ccc(CN2CCN(CC2)C3=Nn4c(CC3)nnc4C(F)(F)F)cc1,2.8,
Clc1ccc(cc1)C2(CCCC2)C(=O)Nc3oc(nn3)C(=O)Nc4ccc(cc4)N5CCOCC5,3.72,
CC[C@H](NC(=O)c1c(CN(C)C)c(nc2ccccc12)c3ccccc3)c4ccccc4,4.18,
CCOC(=O)Nc1cccc(c1)[C@H](N2CCN(Cc3nc[nH]c3C)CC2)c4ccc(cc4)C(=O)N(C)CC,2.32,
Nc1nc(cs1)c2ccccc2,2.43,
COc1ccnc(CCc2nc3cc(Br)cnc3[nH]2)c1,2.92,
Nc1nnc(c(N)n1)c2cccc(Cl)c2Cl,1.38,
CCOc1ccc2oc(C(=O)NC(CCSC)c3nc4ncccc4[nH]3)c(C)c2c1,4.23,
CCOC(=O)C(CCc1ccccc1)NC2CCc3ccccc3N(CC(=O)O)C2=O,-0.2,
COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1,2.0,"This molecule is an inhibitor of Src tyrosine kinase, with potential antineoplastic activity. Upon administration, Src kinase inhibitor M-475271 targets and binds to Src kinase. This inhibits Src-mediated signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival."
CS(=O)(=O)C1(CC1)c2cc(nc(n2)c3cccc(N)c3)N4CCOCC4,1.35,
Nc1ncc(nc1C(=O)Nc2cccnc2)c3ccc(cc3)S(=O)(=O)N4CCOCC4,2.83,
CS(=O)(=O)NCC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.1,
CN1CCN(CC1)c2ccc(NC(=O)c3oc(Nc4ccccc4F)nn3)cn2,2.36,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2cc(Br)ccc12)c3ccccc3)c4ccccc4,3.18,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4c(F)cc(F)cn34)N5CCN(CC5)C(=O)C,3.2,
CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc3N(CC(C)C)C(=O)N(C)C(=O)c13,2.23,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(C4CC4)c5ccc(Cl)cc5,3.4,
O[C@H](CNC(=O)c1n[nH]c2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.95,
COc1cc(N2CCN(C)CC2)c3nc(cc(N(C)C)c3c1)C(=O)Nc4ccc(cc4)N5CCOCC5,3.3,
CN1CCC(CC1)n2cc(c(C)n2)c3cnc(N)c(c3)c4oc5ccccc5n4,3.4,
CC1N(C(=O)c2ccccc2)c3ccccc3NC1=O,2.11,
CC(C)N1CCN(Cc2oc(nc2)c3cc(cc4[nH]ncc34)c5cccc6[nH]ccc56)CC1,3.49,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2ccccc2)NC(=O)OCC(F)(F)F)C(=O)C(F)(F)F,2.37,
Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,2.33,"This molecule is an aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. It has a role as a non-steroidal anti-inflammatory drug, an antirheumatic drug, an antineoplastic agent, an anticonvulsant, an analgesic, an antipyretic, an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is an aminobenzoic acid, a secondary amino compound and an organochlorine compound. It is a conjugate acid of a meclofenamic acid(1-). A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis."
COc1ccc2N=CC(=O)N(CCN3CC[C@@H](NCc4cc5OCCOc5cn4)[C@@H](O)C3)c2c1,0.78,
CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC,3.29,
CCNc1nc(Nc2ccccc2)nc(n1)C#N,3.11,
O=C1CCOc2nc(\C=C\c3ccccc3)ccc12,3.2,
COc1cc2ncnc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)c2cc1OCCN6CCCC6,2.7,
NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F,1.78,
C(CNCc1ccccc1)NCc2ccccc2,0.73,
CNCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c2ccccc2,1.96,
Cc1cc(Oc2ccc3OCOc3c2)nc(Oc4ccc(cc4)n5ccnc5)n1,3.47,
CS(=O)(=O)Cc1cc(nc(n1)c2cnc3[nH]ccc3c2)N4CCOCC4,1.92,
COC(=O)CCCC(=O)Nc1ccc2C(=O)C(=O)c3ccccc3c2c1,2.96,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)c4noc(n4)C5CC5,3.1,
CCN(CC)S(=O)(=O)c1ccc(cc1)c2oc(SCC(=O)N3CCc4ccccc34)nn2,3.9,
OC(=O)C[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4sc(Cl)c(Cl)c4[nH]3,2.53,
Cc1ccc(cc1NC(=O)c2cnn(c2N)c3ccccc3F)C(=O)Nc4ccon4,2.6,
CN1CCN(CC1)c2cc(F)cc3C(=O)C=C(Nc23)C(=O)Nc4ccc(cc4)N5CCOCC5,2.7,
CC(C)Oc1cc(OCCc2cccnc2)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,0.81,
Cn1c(nc2ccccc12)c3ccc(O)nc3,1.2,
CCOC(=O)C1(CCCN(CC2CC2)C1)c3cccc(O)c3,1.89,
OCCCn1c(NC(=O)c2cccc(c2)[N+](=O)[O-])nc3ccccc13,3.0,
CCC(CC)NC(=O)c1cnn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3Cl,0.65,
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(Cc4ccsc4)C3=O,1.11,
Cc1cc2cc(C)c3nnc(SCC(=O)N4CCN(CC4)C(=O)c5occc5)n3c2cc1C,2.8,
Cc1cc(NC(=O)Nc2ccc(Cl)cc2)n(C)n1,2.96,
CC1(C)N(Cc2ccnc(c2)N3CCOCC3)C(=O)N(C1=O)c4ccc(SC(F)(F)F)cc4,3.73,
CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(C)ccc3Cl)ncn2)cc1,2.16,
CN(C)S(=O)(=O)c1ccc2C(=CNC(=O)c2c1)C(=O)NC[C@@H](O)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.13,
C[C@@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)C,3.67,
CC(CN(C)C)CN1c2ccccc2CCc3ccccc13,2.95,
CC(C)n1ncc2c(cc(nc12)C3CC3)C(=O)NCc4c(C)cc(C)nc4O,3.8,
Cc1cc(Cl)ccc1OC2CCN(C[C@H](O)CNC(=O)c3c[nH]nc3C(F)(F)F)CC2,3.02,
Clc1ccc(NS(=O)(=O)c2ccc(Cl)s2)c(c1)C(=O)Nc3ccc(cc3)S(=O)(=O)N4CCOCC4,3.02,
CN(C)CC(O)COc1ccc(Nc2cc(ncn2)N(CC#N)c3cc(Cl)ccc3Cl)cc1,2.1,
CCN1CCC[C@H]1CNC(=O)c2c(OC)ccc(Br)c2OC,0.05,
C[C@@H](CNC(=O)c1c(O)c(O)cc2c(O)c(c(C)cc12)c3c(C)cc4c(C(=O)NC[C@H](C)c5ccccc5)c(O)c(O)cc4c3O)c6ccccc6,3.48,
COc1ccc(cc1C(=O)N)c2ccc3c(nc(nc3n2)N4CCOC[C@@H]4C)N5CCOC[C@@H]5C,2.82,
Oc1cc(ccc1NC(=O)Nc2ccccc2Br)[N+](=O)[O-],3.9,
COc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.39,
C[C@H](CN(C)C(=O)CO)Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12,3.22,
Clc1ccc(O[C@H]2CCCNC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,2.18,
COCCS(=O)(=O)N1CCN(CC1)c2ccc(Nc3nccc(n3)c4cnc(C)n4C(C)C)cc2,2.75,
Oc1ccc(cc1)C2=CC(=O)c3ccc(O)cc3O2,3.2,
Cc1cccc(Nc2ccccc2C(=O)O)c1C,1.89,"This molecule is an aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis. It has a role as an analgesic, an antirheumatic drug, a non-steroidal anti-inflammatory drug, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, an environmental contaminant and a xenobiotic. It is an aminobenzoic acid and a secondary amino compound. A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. This molecule is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of mefenamic acid is as a Cyclooxygenase Inhibitor. This molecule is an anthranilic acid and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Mefenamic acid inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of mefenamic acid. Mefenamic acid also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation."
CCCc1c(O)c(ccc1OCc2ccc(C(=O)O)c(Br)c2)C(=O)C,2.3,
CC1CCC(CC(=O)Nc2cccc3ncccc23)CC1,3.56,
CCCN[C@H]1CCc2nc(N)sc2C1,3.15,"This molecule is a selective dopamine receptor agonist used in the therapy of Parkinson disease. This molecule therapy is associated with a low rate of transient serum enzyme elevations during treatment, but has not been implicated in cases of clinically apparent acute liver injury. These molecules is a member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively. It has a role as an antiparkinson drug, a dopamine agonist, an antidyskinesia agent and a radical scavenger. It is a member of benzothiazoles and a diamine. It is a conjugate base of a pramipexole(2+). This molecule is a drug used to treat the symptoms of Parkinson's Disease (PD).  It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016.  This increase may be attributed to an aging population along with other contributing factors.  In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (RLS). RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs. This molecule is a Nonergot Dopamine Agonist. The mechanism of action of pramipexole is as a Dopamine Agonist. This molecule is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. This molecule has shown robust effects on pilot studies in bipolar disorder. This molecule is classified as a non-ergoline dopamine agonist."
Nc1nc(OCc2nccs2)nc3c1ncn3[C@@H]4O[C@H](CF)[C@@H](O)[C@H]4O,0.47,
CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c3cc(OC)ccc3n4c(C)nnc14,2.46,
Nc1ccccc1NC(=O)c2ccc(cc2)c3ncc(CN4CCC4)cc3F,1.69,
O=C(N1CCN(CC1)c2ncccn2)c3cccc(CC4=NNC(=O)c5ccccc45)c3,2.13,
O[C@@H](CNCCCSCCNCCc1ccccc1Cl)c2ccc(O)c3NC(=O)Sc23,0.99,
Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c3ccc4ncccc4c3,3.87,
c1ccc(cc1)c2nnc(s2)c3ccccc3,4.2,
CC(C)(C)NCC(O)COc1nsnc1N2CCOCC2,-0.35,
Cc1ccc(cc1)S(=O)(=O)Nc2c(cnn2c3ccccc3)C(=O)NCc4ccccc4,1.9,
CN1CCCC(CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,1.98,
CCCCN(CCNC[C@H](O)c1ccc(O)c2NC(=O)Sc12)C(=O)CCOCCc3ccccc3,2.51,
Cc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)cc4,1.6,
C[C@]1(CCSC(=N1)N)c2cc(c(F)cc2F)c3cncnc3,0.8,
CC(C)Oc1cc(n[nH]1)n2cnc3cnc(N[C@@H](C)c4ncc(F)cn4)nc23,2.41,
Nc1[nH]ncc1c2cc(Cl)ccc2Oc3cc(F)c(cc3Cl)S(=O)(=O)Nc4cscn4,2.3,
Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,0.31,
OC(=O)c1ccccc1Cn2nnc(n2)c3cccc(OCc4ccc5ccccc5n4)c3,2.1,
Clc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)C3CC3,2.72,
COCCNCc1cccc(CCNC[C@H](O)c2ccc(O)c3NC(=O)Sc23)c1,0.01,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3)c2cc1OC,2.82,
O=C(Nc1cccc(NC(=O)c2ccccc2)n1)c3ccccc3,4.02,
NCC[C@@H](Oc1cc(Cl)ccc1C#N)c2ccccc2,0.76,
CCc1[nH]nc(NC(=O)Cc2ncc(Oc3ccnc4cc(OC)c(OC)cc34)cc2OC)c1C,2.79,
CN(C)CC(O)COc1ccc(Nc2cc(ncn2)N(CC#C)c3cc(Cl)ccc3Cl)cc1,2.8,
Nc1ccc2ncccc2c1,1.33,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCN(CCc3ccccc3)C2,1.65,
Cc1c(Sc2ccc(Cl)cc2)c3c(Cl)nccc3n1CC(=O)O,0.92,
Brc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,1.42,
CC(C)N1CCN(Cc2cnc(c(Cl)c2)c3ccc(cc3)C(=O)Nc4ccccc4N)CC1,1.68,
CC(C)CNc1nc(nc(N2CCNCC2)c1N)C#N,0.7,
C[C@@H](O)[C@H](NC(=O)c1ccc(cc1)C#Cc2ccc(CN3CCOCC3)cc2)C(=O)NO,2.03,
O[C@H](CNC(=O)N1C(=O)Nc2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,4.46,
Cc1c(Oc2ccc(Cl)cc2)c3cc(ccc3n1CC(=O)O)C(F)(F)F,2.28,
CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)c2ccc(cc2)S(=O)(=O)C)C(F)(F)F)C(=O)NC3(CC3)C#N,2.9,
CN(C)CCCN1c2ccccc2CCc3ccccc13,2.49,
CN1CCOc2cc(COC3CCCCC3)cnc12,3.1,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)CN3CCOCC3)C(=O)C(F)(F)F,2.0,
COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC,2.61,
COc1ccccc1Nc2cc(Oc3cc(C)c(C)nc3c4ccccn4)ccn2,3.37,
Fc1cc(C(=O)Nc2cccc(c2)c3nnn[nH]3)c4nc[nH]c4c1,0.29,
Clc1cccc(c1)N2CCN(CCCN3N=C4C=CC=CN4C3=O)CC2,2.67,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CC[C@@H](O)C4,2.74,
CC(=O)c1ncccc1NC(=O)[C@@H]2CC[C@H](CC2)N3C(=O)[C@@H]4[C@@H]5CC[C@@H](C5)[C@@H]4C3=O,3.01,
CC(=O)Nc1ccc2nc(cc(O)c2c1)c3cccc(F)c3,2.41,
COc1ccc2nc(N[C@H]3CCC[C@@H](C3)NCc4ccsc4)cc(C)c2c1,2.41,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4c(F)cccn34)N5CCN(CC5)C(=O)C,3.5,
CC(C)NCC(O)COc1ccccc1OCC=C,0.2,
COc1ccc2N=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2n1,0.83,
O=C(N1CCCCC1)c2scc3CCCCc23,3.16,
NC(=O)Nc1sc(cc1C(=O)N)c2ccc(OCCN3CCCCC3)cc2,1.2,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2cccs2)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,2.02,
CS(=O)(=O)c1ccc2nc(sc2c1)N3CCN(CC3)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,1.49,
Oc1ccc(cc1)C2CNCCc3c(Cl)c(O)c(O)cc23,0.87,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4OCOc34)n2)c1,3.13,
CCS(=O)(=O)c1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,-0.11,
COc1ccc(OC)c(c1)c2cccc3c(N)c(nnc23)C(=O)NC(C)C,3.65,
O=C1C=C(Oc2c1cccc2c3cccc(c3)c4ccsc4)N5CCOCC5,4.2,
CC(C)(C)c1cc2nc3C(=O)N(Cc4ccccc4)Cc3c(O)n2n1,1.9,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccccc3)n2,3.58,
[O-]c1c2c(nn1c3ccc(Cl)cc3)c4ccccc4c[n+]2Cc5ccccc5,4.5,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCc4oc5ccccc5c4C3,3.01,
COc1ccc(CNC(=O)Nc2ncc(s2)[N+](=O)[O-])cc1,2.9,
Oc1cc(O)c2C(=O)C(=COc2c1)c3ccc(O)c(O)c3,2.45,
CO[C@@H]1CC[C@@]2(CC1)Cc3ccc(cc3C24N=C(C)C(=N4)N)c5cncc(Br)c5,3.4,
O[C@@H](CNCCc1cccc(CN2CCCC2)c1)c3ccc(O)c4NC(=O)Sc34,-0.28,
COc1ccc(cc1)C2=C(C)c3ccc(OC)cc3OC2=O,3.31,
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)\[C@H](C)[C@@H](O)[C@]1(C)O,1.8,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1OC,2.95,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3ccncc3)cn2,3.4,
CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2F)nc3nc(N)sc13,4.5,
CNC(=O)[C@H]1CCCN1Cc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC,3.65,
CCn1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c2ccc(C)cc2,0.95,
Cc1ccc(O)c(O)c1,1.37,"This molecule is a methylcatechol having a single methyl substituent at the 4-position. It has been isolated from Picea abies. It has a role as a hapten, a carcinogenic agent, an antioxidant, a human metabolite and a plant metabolite. This molecule is a natural product found in Camellia sinensis, Geosmithia langdonii, and Bistorta manshuriensis with data available."
CCc1c2CN3C(=O)C4=C(C=C3c2nc5ccc(O)cc15)[C@@](O)(CC)C(=O)OC4,1.6,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN4CCCCC4,4.1,
Nc1n[nH]cc1c2cc(ccc2Oc3cc(F)c(cc3Cl)S(=O)(=O)Nc4cscn4)C(F)(F)F,2.65,
Fc1ccc(cc1C#N)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,2.71,
CC(=O)Nc1ccc2ccn(c3cc(NC4COC4)n5ncc(C#N)c5n3)c2c1,2.24,
CCNC(=O)C[C@H]1N=C(c2ccc(Cl)cc2)c3cc(OC)ccc3n4c(C)nnc14,2.42,
COc1ccc(cc1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.13,
Cc1ncc(CO)c(CO)c1O,-0.58,"This molecule is a hydroxymethylpyridine with hydroxymethyl groups at positions 4 and 5, a hydroxy group at position 3 and a methyl group at position 2. The 4-methanol form of vitamin B6, it is converted intoto pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters, sphingolipids and aminolevulinic acid. It has a role as a cofactor, a human metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a monohydroxypyridine, a vitamin B6, a member of methylpyridines and a hydroxymethylpyridine. This molecule is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for normal functioning of many biological systems within the body. While many plants and microorganisms are able to synthesize pyridoxine through endogenous biological processes, animals must obtain it through their diet.   More specifically, pyridoxine is converted to pyridoxal 5-phosphate in the body, which is an important coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, and aminolevulinic acid. It's important to note that Vitamin B6 is the collective term for a group of three related compounds, pyridoxine, pyridoxal, and pyridoxamine, and their phosphorylated derivatives, pyridoxine 5'-phosphate, pyridoxal 5'-phosphate and pyridoxamine 5'-phosphate. Although all six of these compounds should technically be referred to as vitamin B6, the term vitamin B6 is commonly used interchangeably with just one of them, pyridoxine.   Vitamin B6, principally in its biologically active coenzyme form pyridoxal 5'-phosphate, is involved in a wide range of biochemical reactions, including the metabolism of amino acids and glycogen, the synthesis of nucleic acids, hemogloblin, sphingomyelin and other sphingolipids, and the synthesis of the neurotransmitters serotonin, dopamine, norepinephrine and gamma-aminobutyric acid (GABA).   This molecule is used medically for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy (due to [DB00951]'s mechanism of action which competitively inhibits the action of pyridoxine in the above-mentioned metabolic functions). It is also used in combination with [DB00366] (as the commercially available product Diclectin) for the treatment of nausea and vomiting in pregnancy. This molecule is a Vitamin B6 Analog. The chemical classification of pyridoxine is Vitamin B 6, and Analogs/Derivatives. This molecule is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). This molecule is a metabolite found in or produced by Saccharomyces cerevisiae. This molecule is a natural product found in Cyberlindnera jadinii, Glycine max, and other organisms with data available. This molecule is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Pyridoxal 5-phosphate is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid.  Although pyridoxine and vitamin B6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading. This molecule is one of the compounds that can be called vitamin B6. This molecule assists in the balancing of sodium and potassium as well as promoting red blood cell production. It is linked to cancer immunity and helps fight the formation of homocysteine. It has been suggested that This molecule might help children with learning difficulties, and may also prevent dandruff, eczema, and psoriasis. In addition, pyridoxine can help balance hormonal changes in women and aid in immune system. Lack of pyridoxine may cause anemia, nerve damage, seizures, skin problems, and sores in the mouth. Deficiency, though rare because of widespread distribution in foods, leads to the development of peripheral neuritis in adults and affects the central nervous system in children."
NC(=O)Nc1sc(cc1C(=O)N)c2ccc(CNC3CCCC3)cc2,1.22,
CCCSc1nc2ccc(NC(=O)CCC(=O)O)cc2s1,0.5,
CS(=O)(=O)Nc1ccc(CCOCCCS(=O)(=O)CCNCCc2ccc(O)c3nc(O)sc23)cc1,1.34,
Cc1cccc(c1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.84,
C[C@@H]1CN(CCN1C(=O)[C@@H]2CCCC[C@H]2C(=O)NC3(CC3)C#N)c4ccc5c(C)nnc(C)c5c4,1.93,
CC(=O)Nc1ccc2CCN(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,3.3,
Fc1cc(F)cc(c1)c2cc(on2)N(CCCN3CCCCCC3)Cc4ccc5OCOc5c4,3.84,
COc1ccc2nc(C)cc(N3CC(CNC(=O)C4CC4)OC3=O)c2c1,1.55,
CC(C)c1ccccc1Nc2nc(SCc3cccs3)n[nH]2,4.21,
Nc1nc2ccc(F)cc2s1,2.2,This molecule is a member of benzothiazoles.
COc1cc(N2CC[C@H](C2)N(C)C)c3NC(=CC(=O)c3c1)C(=O)Nc4ccc(cc4)N5CCOCC5,2.7,
Oc1ccc(cc1)S(=O)(=O)Nc2nccs2,0.36,
Clc1cccc(Nc2ncnc3ccccc23)c1,3.9,
O=C(N1CCCC1)c2ccc(cc2)C(=C3CCN(Cc4cscn4)CC3)c5cccc6cccnc56,2.75,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccc(F)c(Cl)c4,2.94,
O=C(NC1CCCC1)C(N(Cc2occc2)C(=O)c3ccc([nH]3)c4ccccc4)c5ccncc5,4.36,
CN1C(=N)N(CC(=O)c2ccc(Cl)cc2)c3ccccc13,1.63,
CN1CCN(CC1)C(=O)c2cc3cc(Br)ccc3[nH]2,2.79,
COc1cccc(c1)C(=O)N2CCC(CC2)N3C(=O)Nc4ccccc34,2.65,
CCCS(=O)(=O)N1CCCC(C1)C(=O)N2CCC(Cc3ccccc3)CC2,3.44,
COC1(CCOCC1)c2ccc(NC(=O)C3=CC(=O)c4cc(F)cc(c4O3)c5c(C)nn(C)c5C)cn2,2.98,
CNC(=O)c1ccc(CCC(COc2ccc(cc2)c3cccc(c3)[N+](=O)[O-])N4C(=O)CSC4=O)cc1,3.5,
CN1CCCC1c2cccnc2,0.5,
Oc1nc2cc(Cl)cc(Cl)c2c(O)c1c3ccccc3,1.6,
CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc3cnccn3,0.9,
Oc1ccc(cc1)C2CC(=O)c3ccc(O)cc3O2,2.4,
NCc1nc2ccccc2[nH]1,0.4,
OC(=O)c1cc(nc2ccc(F)cc12)c3ccncc3,-0.8,
Nc1nccc(n1)c2ccccc2,2.0,
OCCN1CC=CC[C@@H](C1)c2ccc(Cl)c(Cl)c2,2.37,
CN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCCCC4)n1)c5cc(CO)ccc5C,4.2,
Oc1ccc(cc1)c2cnc3ccccc3n2,3.3,
COc1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,2.4,
CC(CCc1cccc(OCc2ccc3ccccc3n2)c1)CC(=O)O,2.4,
FC(F)(F)Oc1ccc(CNC(=O)C2N(CC3CC(F)(F)C3)C(=O)c4ccccc24)cc1,3.9,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N(C)C,2.9,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2C[C@@H]3CC[C@H]2N(CCc4ccccc4)C3,1.64,
FC(F)(F)c1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,4.2,
CCCc1c(OCCCSc2ccc(CC(=O)O)cc2Cl)ccc3c(CC)noc13,3.92,
OC(=O)c1cc(ccc1O)c2ccc(F)cc2F,0.59,
CCOc1ccc(Oc2ccc(cc2)S(=O)(=O)NC(=O)c3cccc(c3)c4ccc(Cl)c(Cl)c4)cc1,2.94,
OC1=CC=Cc2cc(O)c(O)c(O)c2C1=O,2.03,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4cc(F)cc(Cl)c4)c3)C(=O)NC1=O,2.35,
O[C@@H](CNCCSCCCNCCc1cccc(c1)C(F)(F)F)c2ccc(O)c3NC(=O)Sc23,1.21,
Cc1c(Sc2ccc(Cl)cc2)c3cc(Cl)ccc3n1CC(=O)O,2.87,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4cn(C)c(C)n4,2.71,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)NCc4ccccc4,4.0,
CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c3ccccc3)c4ccccc4,1.49,
O[C@@H](CNCCc1cccc(CN2CCC(CC2)c3ccccc3)c1)c4ccc(O)c5NC(=O)Sc45,1.99,
Oc1cccc(c1)N2C(=O)c3ccc(O)cc3C2=O,2.0,
NS(=O)(=O)c1ccc(NCc2ccccc2)cc1,1.7,This molecule is an aromatic amine.
CCCN(c1cccnc1)P(=O)(c2ccccc2)c3ccccc3,2.6,
CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)NC3CCN(CC3)c4ccc(cn4)C(F)(F)F)C(=O)C2,3.84,
FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2,1.13,
CN1CC=CCC(C1)c2oc3ccccc3c2,2.47,
CCN(C1CCN(CCC(c2ccc(NC(=O)C)cc2)c3cccc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.41,
CC(=O)Nc1ccc2ccn(c3cc(Nc4ccn(C)n4)n5ncc(C#N)c5n3)c2c1,3.57,
COc1ccc(cc1F)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)F,2.8,
O=C(Nc1nnn[nH]1)C2=CC(=C3C=CC=CN3C2=O)Oc4ccccc4,0.67,
COc1cccc2c(O)cc(nc12)c3ccccc3,2.3,
Cc1onc(n1)c2ccc(OCC3CN(C3)c4ccc(C)nn4)cc2,2.62,
C(N(Cc1ccccc1)c2nn[nH]n2)c3ccccc3,1.37,
CN1CCN(CC1)c2nc(CCOc3ccc(C[C@H](Nc4ccccc4C(=O)c5ccccc5)C(=O)O)cc3)c(C)s2,2.58,
CC(=O)c1ccc(nc1)N2CCN(CC2)S(=O)(=O)C[C@]34CC[C@H](CC3=O)C4(C)C,2.21,
Clc1cccc(CN2C=CN3C(=O)C=C(N=C23)N4CCOCC4)c1Cl,3.3,
C[C@@H](NC1=CC(=O)NCC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,3.02,
C[C@H]1CN(Cc2cc(Cl)ccc2CCC(=O)O)CCN1C(=O)Cc3ccccc3,1.52,
Clc1cccc(\C=C\2/SC(=O)NC2=O)c1N3CCNCC3,0.68,
CSc1nc(nn1Cc2ccccc2)c3ccccc3,3.83,
Nc1ccc2c3ccccc3C(=O)C(=O)c2c1,2.23,
Nc1ccccc1NC(=O)c2ccc(cc2)C3CCN(CCC(=O)Nc4ccccc4F)CC3,2.76,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N4CCOCC4)n2,2.88,
CN(c1ccnc(Nc2cc(CN3CCOCC3)cc(c2)N4CCOCC4)n1)c5cc(CO)ccc5C,3.0,
NC(=O)c1cc(O)cc2nc(oc12)c3ccc(O)cc3,2.3,
COc1ccc(N(C(C(=O)NC2CCCC2)c3ccccc3F)C(=O)c4occc4)c(OC)c1,3.09,
C[C@H](C1=CNC(=S)N1)c2cccc(C)c2C,2.9,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2cc(F)ccc12)c3ccccc3)c4ccccc4,3.62,
CCc1ccccc1c2ccc(cc2)c3nc4ccncc4c(O)c3C#N,3.5,
CN(C)CCOc1cc(NS(=O)(=O)c2c(Cl)cc(cc2Cl)C(F)(F)F)ccc1Cl,2.99,
Oc1ccc(cc1)C2=Cc3ccc(O)cc3OC2=O,2.9,
COc1cc(C)c(c(C)c1)S(=O)(=O)N(C)CCOCC(=O)N2CCN(CC2)C3CCN(C)CC3,-0.4,
CC(C)(C)c1cc(O)n2nc(N)nc2n1,-0.2,
COc1ccc(cc1)c2cc(O)c3cc(Cl)ccc3n2,2.7,
Oc1ccc(cc1)c2csc(n2)c3ccc(O)cc3,3.7,
C[C@]12Cc3cnn(c3C=C1CC[C@@]2(O)CCc4ccc(F)cc4C(=O)N)c5ccc(F)cc5,3.8,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4cc(ccn34)N5CCCC5)N6CCN(CC6)C(=O)C,3.5,
Cc1ccc2[nH]ccc2c1c3nc(cc(n3)C4(CC4)S(=O)(=O)C)N5CCOCC5,1.7,
Nc1ccc(Cl)c(c1)C(=O)NCC23CC4CC(CC(C4)C2)C3,3.45,
O=C(Nc1cccc2cccnc12)c3ccc(cc3)N4C(=O)[C@@H]5[C@H]6C[C@H](C=C6)[C@@H]5C4=O,3.28,
CCCCSc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,1.51,
Oc1ccc(cc1)c2ccc3cc(O)ccc3c2,4.0,
Nc1cc(nc2c(cnn12)C#N)c3cccs3,2.3,
CCC(N(CCCN)C(=O)c1ccc(OC)cc1)C2=Nc3ccsc3C(=O)N2Cc4ccccc4,1.39,
Cc1cc(N)c2cc(NC(=O)CCCCC(=O)Nc3ccc4nc(C)cc(N)c4c3)ccc2n1,0.53,
CN(C)CC(O)COc1ccc(Nc2cc(ncn2)N(CC#N)c3ccc(C)cc3Br)cc1,2.24,
NC(=O)C1=CN(Cc2ccc(F)c(F)c2)C(=O)C=C1,1.37,
COc1ccc(c(C)n1)c2cccc3c(N)c4C(=O)N(Cc4nc23)C5CCC5,3.92,
OC(=O)c1ccc(cc1)c2ccc(Cl)c(c2)C(=O)NCC34CC5CC(CC(C5)C3)C4,2.48,
COc1cc2c(Nc3ncc(CC(=O)Nc4cccc(F)c4)s3)ncnc2cc1OCCCN5CCC(CO)CC5,2.89,
C[C@H]1CN(Cc2cc(Cl)ccc2OC(C)(C)C(=O)O)CCN1S(=O)(=O)c3ccccc3,0.54,
CCCSc1nc(NC[C@@H]2CC[C@H](CC2)C(=O)O)ccc1C(=O)NC3CCCCC3,2.61,
Cc1ccccc1CN2C=CN3C(=O)C=C(N=C23)N4CCOCC4,2.3,
CNC(=O)c1c(F)cccc1Nc2nc(Nc3cc4N(CCc4cc3OC)C(=O)CN(C)C)nc5[nH]ccc25,2.61,
O[C@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NC5CCCS(=O)(=O)C5)cc3,1.4,
CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1,1.93,This molecule is a benzoate ester.
OC(=O)C(N1CCC(CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)CC1)c4ccccc4,2.17,
OCC[C@]1(CCCNC1)c2oc3ccccc3c2,0.06,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CC(C)(O)C4,3.18,
Oc1ccc2OC(=O)C(=Cc2c1)c3ccccc3,3.12,
CN(C1CCN(Cc2ccc(cn2)C(F)(F)F)CC1)C(=O)Cc3ccc(cc3)n4cnnn4,1.9,
Nc1n[nH]c(Nc2ccccc2)n1,1.06,
CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN4CCN(C)CC4)\c2c1,3.16,
CN(c1ccnc(Nc2cc(cc(c2)N3CCN(C)CC3)N4CCOCC4)n1)c5cc(CO)ccc5C,2.61,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3C#N)n2)cc1,1.2,
Oc1c(I)cc(I)c2cccnc12,2.19,"These molecules is a monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine. It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis. It has a role as an antiamoebic agent, an antibacterial agent, an antiseptic drug and an antiprotozoal drug. It is a monohydroxyquinoline and an organoiodine compound. This molecule is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products."
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(CC#Cc4ccccc4)C3=O,1.78,
O[C@@H](CNCCc1ccc(CNCCc2ccccc2F)cc1)c3ccc(O)c4NC(=O)Sc34,1.3,
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c3ccccc13,3.15,
Cc1cc(COc2cnc(nc2)N3CCN(CC3)C(=O)OC(C)(C)C)ccn1,3.7,
CCCN(C)c1nc(ccc1C(=O)NC2CCCCC2)N3CCC[C@@H](CC(=O)O)C3,2.28,
NC12CCC(CC1)(CC2)c3ccccc3,0.29,
COc1cc(ccc1Cn2ccc3ccc(NC(=O)OC4CCCC4)cc23)c5nn[nH]n5,2.7,
CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(=O)(=O)C,1.24,
CNc1nc2ccccc2n1Cc3sc4N(CC(C)C)C(=O)N(C)C(=O)c4c3C(=O)N5CC[C@@H](O)C5,1.61,
CC(C)Oc1ccc(cc1)C(=O)Nc2cc(NC(=O)c3cccc(c3)N(C)C)ccc2C,3.1,
CC(=O)Nc1nnc(s1)S(=O)(=O)N,-0.78,
CCC[C@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1S(=O)(=O)c3ccccc3,1.02,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(NC(=O)C)cc4,2.9,
Nc1ncnc2sc(nc12)c3c(ncn3C[C@H]4CCCO4)c5ccccc5,2.65,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1C2CCCCC2)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,2.87,
NC1(CCC1)c2ccc(cc2)c3ncc4ncccc4c3c5ccccc5,2.0,
CC(=O)Nc1ccc2ccn(c3cc(NCCCCO)n4ncc(C#N)c4n3)c2c1,2.58,
COC1=CC(=N/C/1=C\c2[nH]c(C)cc2C)c3cc4ccccc4[nH]3,2.55,
Nc1ccccc1NC(=O)c2ccc(cc2)N3CCOCC3,1.2,
CCC(CCNC)Oc1cc(Cl)ccc1C#N,0.38,
O=C(Nc1ccccc1)c2oc3ccccc3c2,3.44,
COc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(C)c3)c2cc1OC,3.6,
COCCC(=O)N[C@H](C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.08,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2ccc(F)cc2)NC(=O)OCc3ccncc3)C(=O)C(F)(F)F,2.22,
COc1cc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2cc1OCCCN5CCC(CO)CC5,2.11,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4c(F)cccc34,0.53,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCN(C2)C(=O)Cc3ccccc3,0.81,
CCC(C)NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,0.66,
CN(C)c1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(C)c4Cl,2.0,
COc1ccc2c(c1)c(CC(=O)O)c(C)n2c3ccnc4cc(Cl)ccc34,1.68,
NC(=N)Nc1cc(Cl)nc(n1)c2ccccc2,2.16,
COc1cccc(Nc2oc(nn2)C(=O)Nc3ccc(nc3)N4CCOCC4)c1,2.8,
CC(C)Oc1cc(OCCCN2CCCC2)cc3ncnc(Nc4c(Cl)ccc5OCOc45)c13,3.1,
CCN(CC)CCOc1ccc(cc1OC)N(C)C(=O)c2ccc(cc2)c3ccc(cc3)C(F)(F)F,3.13,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)C(C)(C)C)C(C)(C)C,1.84,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4c(Cl)cccc34,1.27,
COc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)c3occc3,2.42,
COc1cc(Nc2ncnc3cccc(O[C@H](C)C(=O)N4CCOCC4)c23)ccc1Oc5ccc(C)nc5,3.6,
COc1ccc(C=NN=Cc2ccc(OC)c(OC)c2)cc1OC,3.38,
CS(=O)(=O)c1ccccc1C(=O)NCC(O)CNC2CCN(Cc3ccc(Cl)c(Cl)c3)CC2,1.21,
CN(C1CCN(Cc2nc3CCCCc3s2)CC1)C(=O)Cc4ccc(cc4)n5cnnn5,2.5,
C[C@H](Oc1ccc(Cl)cc1CN2CCN([C@@H](C)C2)C(=O)Cc3ccc(Cl)cc3)C(=O)O,1.66,
CN1SC(=NC1=O)NCc2ccccc2,1.2,
CC(C)N1CCC[C@H](CN2C(=Nc3ccc(cc3C2=O)c4ccc(Cl)cc4)C)C1,3.3,
Clc1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.65,
COc1cccc(CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)c2)c1,0.91,
Nc1ncc2cc(c(N)nc2n1)c3c(Br)cccc3Br,2.06,
OC(=O)c1cccc(CN2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2)c1,1.26,
Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc3ccccc3,3.41,
C[C@H]1CN(CCN1c2ncc(OCc3ccc(cc3)S(=O)(=O)C)cn2)C(=O)OC(C)(C)C,3.5,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c3C1=O)c6ncnn6C,3.8,
CCN(CC)c1ccc(cc1)c2nn3c(nnc3s2)c4[nH]nc5CCCc45,3.37,
Nc1ncnc2sccc12,1.19,
CC(O)(C(=O)Nc1ccc2c(c1)c3ccccc3S2(=O)=O)C(F)(F)F,3.0,
CC(C)(C(=O)O)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,0.42,
Nc1c(nnc2c(c(F)ccc12)c3ncccn3)C(=O)NC4CC4,1.59,
NC(=N)NCCC[C@H](NC(=O)COCC(c1ccccc1)c2ccccc2)C(=O)O,0.18,
OC[C@H](O)C(=O)N1CCC(=CC1)c2ccc(cc2F)N3C[C@H](COc4ccon4)OC3=O,1.09,
Cc1nc(C)c(nc1C(=O)N)c2ccc3c(CC[C@@]34CC[C@@H](CC4)C(=O)O)c2,1.2,
COc1c2OC(=O)C=Cc2cc3ccoc13,1.97,
CC(C)CNCc1ccc(cc1)c2ccccc2S(=O)(=O)N3CCCC3,1.9,
Fc1cc(Cl)ccc1N2CCN(CC2)C(=O)COCc3ccncc3,2.55,
OCCNCc1cc(Br)ccc1OCc2ccc(Cl)cc2,2.98,
FC(F)Oc1ccc(cc1OCC2CC2)C(=O)Nc3c(Cl)cncc3Cl,3.95,
Cc1cccc(C(=O)N)c1NC(=O)c2ccccc2,1.09,
Cc1nnc(N)s1,-0.4,This molecule is a member of thiadiazoles.
Cc1cc(Cl)ccc1OC2CCN(C[C@H](O)CNC(=O)C3=CNC(=O)c4c(F)cccc34)CC2,3.0,
NC(=N)c1ccc(cc1)C(=O)N2CCN(CC2)S(=O)(=O)c3ccc4cc(Br)ccc4c3,0.36,
CC(N1NC(=O)c2nc3cc(Cl)ccc3c(O)c2C1=O)c4ccccn4,0.51,
C1Oc2ccc(Oc3ccnc(Oc4ccc(cc4)n5ccnc5)n3)cc2O1,3.27,
CC(C)Oc1cc(Oc2ccc(cc2)S(=O)(=O)C)cc(c1)C(=O)Nc3nccs3,3.61,
NS(=O)(=O)c1ccc(CCNc2ccc3nnc(c4ccccc4)n3n2)cc1,2.19,
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc4C(=O)C(=CN1c24)C(=O)O,-0.35,
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,2.8,"This molecule is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. This molecule has been linked to rare instances of acute liver injury. This molecule is a member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. It has a role as an insulin-sensitizing drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor, a xenobiotic, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor, a ferroptosis inhibitor, a cardioprotective agent, a PPARgamma agonist, an antidepressant, a geroprotector and a hypoglycemic agent. It is a member of thiazolidinediones, an aromatic ether and a member of pyridines. This molecule is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medications, which also includes [rosiglitazone] and [troglitazone], exerts its pharmacological effect primarily by promoting insulin sensitivity and the improved uptake of blood glucose via agonism at the peroxisome proliferator-activated receptor-gamma (PPARÎ³). PPARs are ligand-activated transcription factors that are involved in the expression of more than 100 genes and affect numerous metabolic processes, most notably lipid and glucose homeostasis.  Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus. This molecule is a Peroxisome Proliferator Receptor alpha Agonist, and Peroxisome Proliferator Receptor gamma Agonist, and Thiazolidinedione. The mechanism of action of pioglitazone is as a Peroxisome Proliferator-activated Receptor alpha Agonist, and Peroxisome Proliferator-activated Receptor gamma Agonist. This molecule is an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity. This molecule activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis. This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. This molecule is used for the treatment of diabetes mellitus type 2. This molecule selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver."
CC[C@H](NC(=O)c1c(N)c(nc2ccccc12)c3cccc(F)c3)c4ccccc4,4.05,
COc1cc2c(Nc3ccc(F)cc3F)c(cnc2cc1N4CCN(C)CC4)C(=O)N,1.75,
CNC(=O)c1ccc(Oc2ccc(cc2)C#C[C@]3(O)CN4CCC3CC4)cc1,1.99,
Nc1c(NC2CCOC2)nc(nc1N3CCOCC3)C#N,1.6,
CN1C(=O)C=C(CCc2ccccc2)N=C1N,2.0,
CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)c5cccc6[nH]ncc56)CC1,3.3,
CC1(C)Oc2ncnc(N)c2N=C1c3ccc(cc3)[C@@H]4CC[C@@H](CC(=O)O)CC4,1.32,
CN(C)c1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.7,
COCCC(=O)Nc1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,2.78,
Cc1cc(OC2CCN(CC3CCN(CC3)[C@@H](Cc4ccc(F)cc4)C(=O)O)CC2)ccc1Cl,2.54,
COc1cc2ncnc(Nc3ccc(Cl)c(O)c3)c2cc1OC,3.3,
CS(=O)(=O)NCCC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.2,
CS(=O)(=O)N1CCc2c1nc(nc2c3cnc(N)nc3)N4CCOCC4,1.2,
Nc1nc(N)c2cc(NCc3ccc(Cl)c(Cl)c3)ccc2n1,2.22,
Cc1c(Sc2ccc(Cl)cc2)c3ccc(cc3n1CC(=O)O)S(=O)(=O)C,0.79,
COc1cc(c(OC)nn1)c2c(F)ccc3c(N)c(nnc23)C(=O)NC4CC4,2.75,
CN1CCN(CC1)c2ccc3ncc(C(=O)N)c(Nc4ccc(F)cc4F)c3c2,2.3,
CCn1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)NC)n2,2.53,
OC1(CCN(Cc2c[nH]c3ccccc23)CC1)c4ccc(Cl)cc4,2.25,
CCCc1cc(Nc2nc(NCc3onc(C)c3)ncc2Br)n[nH]1,3.63,
CCNCc1cnc(s1)c2ccc(cc2)C(=O)Nc3ccccc3N,0.95,
Fc1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NCC#N,2.77,
Clc1cc(Cl)cc(CS(=O)(=O)NCC(N2CCCCCC2)c3ccccc3)c1,3.23,
CS(=O)(=O)c1ccc(cc1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N,0.67,
FC(F)(F)c1nnc2ccc(nn12)N3CCN(Cc4ccc(cc4)C#N)CC3,2.9,
COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,2.0,"This molecule is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity which is widely used in the therapy of gastroesophageal reflux and peptic ulcer disease. This molecule therapy is associated with a low rate of transient and asymptomatic serum aminotransferase elevations and is a rare cause of clinically apparent liver injury. This molecule is a member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2. It has a role as an anti-ulcer drug, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, a xenobiotic and an environmental contaminant. It is a member of benzimidazoles, a member of pyridines, an aromatic ether, an organofluorine compound and a sulfoxide. It is a conjugate acid of a pantoprazole(1-). This molecule is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of H. pylori infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole].  This molecule exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists longer than 24 hours.  Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal C. difficile), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.  PPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.  This molecule doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase in hypersecretion. This molecule is a Proton Pump Inhibitor. The mechanism of action of pantoprazole is as a Proton Pump Inhibitor. This molecule is a substituted benzimidazole and proton pump inhibitor with antacid activity. This molecule is a lipophilic weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulphenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production."
FC(F)c1nc2ccccc2n1c3nc(nc(n3)N4CCOCC4)N5CCOCC5,3.04,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccccc2)C1)C(C)(C)C,1.46,
CC1CCN(CC1)C(=O)c2scc3OCCOc23,2.26,
C[C@H](NC1=NC(=O)C(C)(S1)C(F)(F)F)c2ccccc2F,3.1,
COc1ccc(Cl)cc1NC(=O)CCS(=O)(=O)c2ccc(Br)cc2,3.4,
COCCNCc1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,1.86,
Nc1ccc(cc1)S(=O)(=O)N2CCCC2,0.98,
CC[C@H](NC(=O)c1c(N)c(nc2ccccc12)c3ccccc3)c4ccccc4,3.89,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4ccccc4,1.99,
COc1cc2ncnc(N3CC[C@H](C3)Oc4cnc5ccccc5n4)c2cc1OC,4.04,
CCc1csc(n1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,2.1,
Cc1ccc(cc1)n2c(C)cc(C(=O)NS(=O)(=O)c3ccc(C)cc3)c2C,2.5,
O[C@@H](CNCCCCCCCCCN1CCC(CC1)OC(=O)Nc2ccccc2c3ccccc3)c4ccc(O)c5NC(=O)C=Cc45,2.16,
CNc1c(Cl)cnc2[nH]c(nc12)c3ccc(OCCN4CCOCC4)cc3,2.63,
COc1c(N2CCO[C@@H](CN(C)C)C2)c(F)cc3C(=O)C(=CN(C4CC4)c13)C(=O)O,-0.62,
O=C(NC1CCCCC1)c2cccnc2Sc3ccccc3,3.01,
C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O,3.72,
C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O,3.4,
CCS(=O)(=O)c1ccc(c(C)c1)c2cc(ccc2OCC(=O)N)C(F)(F)F,2.77,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(NC4CC4)sc13,4.37,
O=C(CSc1ccncc1)Nc2ccc(cc2)C(=O)c3ccccc3,3.6,
Oc1cc(O)c2C(=O)C(=COc2c1)c3ccc(cc3)[N+](=O)[O-],3.24,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CCC4,3.46,
C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)SC3CN(C3)C4=NCCS4,2.1,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cc(oc6C)C#N)c3C1=O,4.26,
COc1cc2c(NC(=O)Nc3c(Cl)cccc3Cl)ncnc2cc1OCC4CCN(C)CC4,2.7,
Cc1c(c2c(NS(=O)(=O)C)cccc2n1CC(=O)O)S(=O)(=O)c3ccc(Cl)cc3,-0.83,
C[C@H](Nc1ccc2ncn(c3cc([nH]n3)C4CC4)c2n1)c5ncc(F)cn5,2.74,
CN(c1ccc(c(C)c1)c2cc(ccc2OCC(=O)O)C(F)(F)F)S(=O)(=O)C,-0.59,
CC\C(=C(/c1ccccc1)\c2ccc(\C=C\C(=O)O)cc2)\c3ccccc3,3.89,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(cc2)C(F)(F)F)C1)C(C)(C)C,2.85,
CCCCC1C(=O)N(N(C1=O)c2ccccc2)c3ccccc3,0.45,
CC(=O)NC1CC2CCCC(C1)N2C(=O)Nc3ccc(Cl)c(c3)C(F)(F)F,2.79,
COc1c(Nc2ccc(nc2C)S(=O)(=O)C)ncnc1OC3CCN(CC3)C(=O)OC(C)C,2.4,
CC(=O)Nc1ccc(cc1)c2ccnc(Nc3ccc(cc3)N4CCOCC4)n2,2.91,
OC(=O)c1[nH]c2ccccc2c1CCCOc3cccc4ccccc34,2.75,
C[C@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1C(=O)Cc3ccc(Cl)cc3,1.21,
Cc1nc2nc(nn2c(O)c1Cc3ccccc3)c4cccnc4,1.52,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)cc(n1)N3CCOCC3)c4ncc(F)cn4,1.91,
COc1ccc(NC(=O)CSc2nnc(C)n2c3ccc(C)cc3)cc1,2.94,
CC1CC(CN)CC(CO)C1,-1.4,
FC(F)(F)c1nnc2ccc(NCc3cccnc3)nn12,2.06,
COc1cc2nnc(C(=O)N)c(Nc3ccc(C)cc3F)c2cc1N4CCN(C)CC4,2.36,
CC(C)c1nc2ccccc2n1c3nc(N4CCOCC4)c5nc(OC6CN(C6)C7CCS(=O)(=O)CC7)n(C)c5n3,2.9,
CCN(CC)CCOC(=O)C1(CCCC1)c2ccccc2,2.3,
OC1(CNCCc2ccccc12)c3ccccc3,1.38,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCOCC3)c(F)c2,0.67,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)c4ncc(F)cn4,3.4,
Cc1cnc(NC(=O)Cc2ccccc2)s1,2.9,
c1ccc2ncncc2c1,1.0,"This molecule is a mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms. It is a mancude organic heterobicyclic parent, a member of quinazolines, an azaarene and an ortho-fused heteroarene. This molecule is a natural product found in Nicotiana tabacum with data available."
CS(=O)(=O)Cc1cc(nc(n1)c2cccc3cc[nH]c23)N4CCOCC4,2.8,
CC(C)(C)NS(=O)(=O)c1cncc(c1)c2ccc3nc(N)nn3c2,1.41,
O[C@@H](CNCCSCCCOCCc1ccccc1)c2ccc(O)c3NC(=O)Sc23,2.54,
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,3.7,
C[C@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1C(=O)Cc3ccccc3Cl,1.1,
CC[C@@H](NC1=C(Nc2cccc(C(=O)N(C)C)c2O)C(=O)C1=O)c3ccccc3,2.14,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccccc4CO,3.18,
Cc1ccc(NC(=O)c2cccc(c2)N3CCOCC3)cc1NC(=O)c4ccc(OCc5ccccn5)cc4,3.2,
NC1=NC(Nc2c(F)ccc(F)c12)c3occc3,1.2,
CC(C)NC(=O)c1cnc(N2CCC(CC2)N3C(=O)OCc4ccccc34)c(Cl)c1,3.57,
CC(=O)CC(C1=C(O)c2ccccc2OC1=O)c3ccccc3,0.86,
CC(C)C(CCCN(C)CCc1ccccc1)(C#N)c2ccccc2,3.6,
Oc1ccc(CCNCCS(=O)(=O)CCCOCCSc2ccccc2)c3sc(O)nc13,2.68,
C[C@@H](O)[C@@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(N)sc13,2.83,
Fc1ccc(cc1)C(=O)C2CCN(CCN3C(=O)Nc4ccccc4C3=O)CC2,2.9,
OC1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NCc5ccncc5)cc3,2.48,
CS(=O)(=O)c1ccc2c3CN(CCc3[nH]c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,1.5,
C[C@@H](NC(=O)C)c1ccc(Nc2ncc3cc(c(C)cc3n2)c4ccncc4)cc1,3.45,
CC[C@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,0.22,
O=C1Nc2ccccc2C=C1,1.32,
CN(CCO)Cc1ccc(cc1)c2cc(C(=O)N)c(NC(=O)N)s2,0.97,
COc1ccc(C=C2SC(=O)NC2=O)cc1OC,1.17,
OC(=O)COc1ccccc1N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.0,
COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1,3.85,
CCCc1c(O)c(ccc1OCc2cccc(NC(=O)c3ccccc3C(=O)O)c2)C(=O)C,1.9,
Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)C3=CNC(=O)c4cc(ccc34)S(=O)(=O)C)CC2)c1Cl,2.83,
COc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)c3ccc(F)cc3,2.92,
CC(C)NC[C@@H](C(=O)N1CCN(CC1)c2ncnc3[C@H](O)C[C@@H](C)c23)c4ccc(Cl)cc4,1.3,
CC1=CN([C@H]2CCCN(Cc3ccc(C(=O)O)c(Oc4cccc(Br)c4)c3)C2)C(=O)NC1=O,-0.51,
COc1cc(ccc1Cn2ncc3ccc(NC(=O)OC4CCCC4)cc23)C(=O)NS(=O)(=O)c5ccccc5,1.8,
O[C@H](CNC(=O)C1=CNC(=O)c2cc(ccc12)S(=O)(=O)NC3CC3)CN4CCC(CC4)Oc5ccc(Cl)c(Cl)c5,3.67,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5ccc(cc5)C#N)ccc4C,2.73,
Fc1cccc2[nH]c3CCN(Cc3c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.2,
NC1C2CN(CC12)c3nc4N(C=C(C(=O)O)C(=O)c4cc3F)c5ccc(F)cc5F,0.3,
[O-][N+](=O)c1ccc2c(c1)nc3CCCCCn23,2.58,
Oc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.52,
CC1(CC1)c2c(cnn2c3ccc(cc3)C(=O)O)C(=O)NC4C5CC6CC(CC4C6)C5,1.11,
COc1ccc2c(C)cc(N[C@H]3CCC[C@@H](C3)NCc4ccsc4)nc2c1,2.46,
OCC[C@@]1(CCCNC1)c2oc3ccccc3c2,0.12,
Oc1ccc(cc1)c2nc3ccc(O)cc3s2,3.65,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2cc(CN(C)C)ccc12)c3ccccc3)c4ccccc4,2.75,
CC(=O)c1ccc2NC(=CC(=O)c2c1)c3cccnc3,1.41,
OC(=O)c1cccc(c1)C(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.23,
Cc1c(Sc2ccc(Cl)cc2)c3cc(F)ccc3n1CC(=O)O,1.84,
COc1ccc2c(C)cc(N[C@H]3CCC[C@@H](C3)NCc4cccc(OC(F)(F)F)c4)nc2c1,3.61,
COc1cccc(Nc2nc(NCC3CCCO3)c4ccccc4n2)c1,3.9,
CCOc1cc2nnc(C(=O)N)c(Nc3cccc(Cl)c3F)c2cc1N4CCN(C)CC4,1.99,
COc1ccc(cc1OC)C(C)NC(=O)C2(N)CCN(CC2)c3ncnc4[nH]ccc34,1.8,
CN(c1cccc(c1)C(=O)Nc2ccc(C)c(NC(=O)c3ccc4ncccc4c3)c2)S(=O)(=O)C,2.8,
CC(C)[C@H](N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3cc(Cl)ccc3C(=O)N2Cc4ccccc4,2.88,
Cc1ccsc1CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3,1.15,
CC(=O)N1CCN(CCOc2ccc(cc2)C3CCN(CC3)c4ccc5nnc(n5n4)C(F)(F)F)CC1,3.2,
Cc1cc(C)c2c(N)c(sc2n1)C(=O)NC3CC3,2.53,
CN1C(=O)c2c(onc2c3ccccc3)C=C1c4ccncc4,2.61,
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1,1.02,"This molecule is an amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. It has a role as a cyclooxygenase 2 inhibitor and a non-steroidal anti-inflammatory drug. It is an organofluorine compound, an organochlorine compound, an amino acid, a secondary amino compound and a monocarboxylic acid. This molecule is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug."
COC(=O)CCC(=O)Nc1ccc2C(=O)C(=O)c3ccccc3c2c1,2.72,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccncc4,0.77,
Cc1cccc(c1)N(Cc2cc(F)c(F)cc2F)C(=O)O[C@H]3CN4CCC3CC4,2.24,
CCCC(=O)N1CCN(CC1)c2nnc(c3ccccc3)c4ccccc24,3.2,
C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c3cc4c(cn(C)c4cc3Cl)C(=O)C(=O)N(C)C,3.6,
O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(cc45)C#N)CC3)nc2N1,0.23,
CN1SC(=NC1=O)NC(=O)c2ccccc2,1.13,
C[C@H]1[C@@H]2CN(CCN3CCOCC3)CC[C@H]2Cc4[nH]c5ccc(cc5c14)C(F)(F)F,2.87,
CC(C)NCC(O)COc1cccc2[nH]ccc12,-0.12,"This molecule is a nonselective beta adrenergic receptor blocker that is widely used for the therapy of hypertension and angina pectoris. This molecule has yet to be convincingly associated with clinically apparent liver injury. This molecule is a member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol. It has a role as a serotonergic antagonist, a beta-adrenergic antagonist, an antihypertensive agent, a vasodilator agent and an antiglaucoma drug. It is a member of indoles and a secondary amine. This molecule is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s.  This molecule was granted FDA approval on 3 September 1982. This molecule is a beta-Adrenergic Blocker. The mechanism of action of pindolol is as an Adrenergic beta-Antagonist. This molecule is an aryloxypropanolamine derivative with antihypertensive property. This molecule competitively binds to beta-adrenergic receptors, resulting in a decrease in beta-adrenergic activities, i.e., vasodilation, and negative chronotropic and inotropic effects. In addition, this agent blocks serotonin (5-HT) 1A receptors, thereby increasing the available serotonin in the brain. Increased serotonin levels augment the antidepressant action of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors."
C[C@H](Nc1ncc(C)c(Nc2cc(C)[nH]n2)n1)c3ncc(F)cn3,1.75,
CN(C)CCNCc1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,1.4,
Cc1ccccc1Nc2ncnc3ccccc23,2.85,
Cn1c(CN2CCN(CC2)c3ccccc3)nc4ccccc14,3.11,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CCCCC4,4.07,
Nc1c(NC2CCCC2)nc(nc1N3CCOCC3)C#N,2.59,
C1CN2C[C@@H](N=C2S1)c3ccccc3,0.81,
CCCCOc1nc(N)c2NC(=O)N(Cc3cccc(CC(=O)OC)c3)c2n1,3.76,
CC(C)(C)OC(=O)N1CCN(CC1)c2ccc(OCc3ccc(cc3)S(=O)(=O)C)cc2,3.9,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccc(cn34)N(C)C)N5CCN(CC5)C(=O)C,4.1,
Fc1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.0,
COc1ccc(NC(=O)c2ccnc(N)n2)cc1,1.72,
O[C@H](CNC(=O)C1=CNC(=O)c2cc(ccc12)S(=O)(=O)N3CCC3)CN4CCC(CC4)Oc5ccc(Cl)c(Cl)c5,3.02,
CC(C)c1ccccc1Cc2cc(C(=O)Nc3ccc(cc3)S(=O)(=O)c4ccccc4C(C)(C)C)c(O)c(O)c2O,3.44,
COc1cccc(c1)c2cc(O)c3cc(NC(=O)C)ccc3n2,2.41,
CCC(CC)C[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,1.68,
CN(c1ccnc(Nc2cccc(c2)S(=O)(=O)C)n1)c3cccc4[nH]ncc34,3.21,
O=C(N[C@H]1CN2CCC1CC2)c3ccc(s3)c4ccccn4,0.7,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(C)nc1C#N)c3ncc(F)cn3,1.92,
OCCc1cccc(NC(=O)c2cc3cc(Cl)ccc3[nH]2)c1,3.83,
COc1cc(F)ccc1c2cncc(CNC(=O)c3ccccc3)c2,3.76,
COc1cc(OC)c(cc1NC(=O)CSc2ccncc2)S(=O)(=O)N3C(C)CCc4ccccc34,2.82,
Cc1cc(Nc2ccccc2)n(CCC#N)n1,2.3,
CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,3.8,
COc1cc(OC)nc(n1)N2N=CC(=C(Cl)C2=O)Cl,1.4,
Oc1ccc(CCNCCS(=O)(=O)CCCOCCc2oc3ccccc3c2)c4sc(O)nc14,2.86,
C[C@H](NC(=O)c1c(C)nn(C2CCN(C)CC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,0.8,
NC1(CCC1)c2ccc(cc2)c3c(ccn4ncnc34)c5ccccc5,1.7,
CN1CCN(CC1)C(=O)c2cc3ccccc3n2C,1.71,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccc(Cl)cc3)n2)cc1,2.6,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccnc4ccccc34)c2C(=O)N5C[C@H](O)CO5,2.14,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4c(OC)cccn34)N5CCN(CC5)C(=O)C,3.5,
CCCSc1c(cnn1c2ccc(cc2)C(=O)O)C(=O)N(C)C3CCCCC3,0.59,
O=S(=O)(Cc1cc(nc(n1)c2ccccn2)N3CCOCC3)c4ccccc4,1.34,
CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1,2.73,
CCOC(=O)C1(CCN(C)CC1)c2ccccc2,1.4,
O=C(NC1=CC(=CNC1=O)c2ccncc2)[C@H](Cc3ccccc3)NC4(CC4)c5ccccn5,3.44,
CNC(=O)C[C@H](Nc1ncc(Cl)c(Nc2cc([nH]n2)C3CC3)n1)c4ccc(F)cc4,2.23,
Cc1cc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)cc(c1)C(=O)N,2.08,
Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1,2.11,
CCCSc1ncccc1C(=O)N(C)[C@@H]2[C@@H]3CC4C[C@H]2C[C@@](O)(C4)C3,2.49,
CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl,0.44,
COCCNC(=O)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1C,2.78,
Cc1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,2.99,
Cc1cc(N)c2cc(NC(=O)CCC(=O)Nc3ccc4nc(C)cc(N)c4c3)ccc2n1,1.39,
COc1cccc2c(ccnc12)c3c(C)n(CC(=O)O)c4ccc(C)cc34,0.49,
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,0.77,"This molecule is a derivative of chloroquine that has both antimalarial and antiinflammatory activities and is now most often used as an antirheumatologic agent in systemic lupus erythematosis and rheumatoid arthritis. This molecule therapy has not been associated with liver function abnormalities and is an extremely rare cause of clinically apparent acute liver injury. This molecule is an aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions. It has a role as an antimalarial, an antirheumatic drug, a dermatologic drug and an anticoronaviral agent. It is an aminoquinoline, an organochlorine compound, a primary alcohol, a secondary amino compound and a tertiary amino compound. It is functionally related to a chloroquine. It is a conjugate base of a hydroxychloroquine(2+). This molecule is a racemic mixture consisting of an R and S enantiomer. This molecule is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. This molecule is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.  **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.**  This molecule was granted FDA approval on 18 April 1955.  A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19. This molecule is an Antirheumatic Agent and Antimalarial. This molecule is a 4-aminoquinoline with immunosuppressive, antiautophagy, and antimalarial activities. Although the precise mechanism of action is unknown, hydroxychloroquine may suppress immune function by interfering with the processing and presentation of antigens and the production of cytokines. As a lysosomotropic agent, hydroxychloroquine raises intralysosomal pH, impairing autophagic protein degradation; hydroxychloroquine-mediated accumulation of ineffective autophagosomes may result in cell death in tumor cells reliant on autophagy for survival.  In addition, this agent is highly active against the erythrocytic forms of P. vivax and malariae and most strains of P. falciparum but not the gametocytes of P. falciparum. This molecule is only found in individuals that have used or taken this drug. It is a chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Although the exact mechanism of action is unknown, it may be based on ability of hydroxychloroquine to bind to and alter DNA. This molecule has also has been found to be taken up into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid metabolism. In suppressive treatment, hydroxychloroquine inhibits the erythrocytic stage of development of plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity against the erythrocytic stages of plasmodial infection. As an antirheumatic, hydroxychloroquine is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown."
C1CC1Nc2ccc3nnc(c4ccccc4)n3n2,3.15,
CC(=O)NCC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.4,
CC(=O)N1CCN(CC1)c2ccc(Nc3nccc(n3)c4cnc5ccccn45)cc2,2.82,
Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]nc3C(F)(F)F)CC2)c1Cl,3.66,
NC1(CCC1)c2ccc(cc2)c3c(ncc4nccn34)c5ccccc5,1.7,
CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,1.54,
NC1(CCC1)c2ccc(cc2)c3ncc4cccnc4c3c5ccccc5,1.7,
ON=Cc1oc(cc1)[N+](=O)[O-],1.31,
CC(C)OC(=O)C1=CN(Cc2c(F)cccc2F)c3sc(c(CN(C)Cc4ccccc4)c3C1=O)c5ccc(NC(=O)C(C)C)cc5,3.5,
Clc1cccc(C(=O)N2CCN(CC2)c3ccccn3)c1Cl,2.98,
CC(=O)Nc1ccc2[nH]cc(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,2.65,
C1Cc2ncc(c3ccc4OCCOc4c3)n2C1,2.33,
CNC1=Nc2ncccc2C(=NC1c3cccs3)c4occc4,1.85,
Oc1c(C#N)c(nc2ccncc12)c3ccc(cc3)c4ccccc4C(F)(F)F,3.3,
C[Si](C)(C)C#Cc1cn(C[C@H]2CN(C(=O)O2)c3ccc(C4=CCS(=O)(=O)CC4)c(F)c3)nn1,1.26,
C[C@@H](NC(=O)C)c1ccc(Nc2ncc3cc(cc(C)c3n2)c4ccncc4)cc1,3.46,
CN1CCN(CC1)S(=O)(=O)c2ccc(c3cnc(N)c(n3)C(=O)Nc4cccnc4)c(c2)C(F)(F)F,3.25,
CCC(CC)NC(=O)c1cnn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,0.79,
CC(=O)C1=CN(Cc2ccccc2)C(=O)N(Cc3ccc(F)cc3)C1=O,3.2,
Cc1nc(C)c(nc1C(=O)N)c2ccc(cc2)C34CCC(CC3)(CC4)C(=O)O,1.3,
Cc1sc2ncnc(SCC(=O)N3CCN(CC3)C(=O)c4occc4)c2c1C,2.7,
OC(=O)CCCS(=O)(=O)c1cccc(c1)C(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,0.66,
CN(C)CC(O)COc1ccc(Nc2ncc(Cl)c(Nc3ccccc3)n2)cc1,2.25,
CCOC(=O)[C@H](Cc1ccc(cc1)[N+](=O)[O-])NC(=O)c2ccccc2,2.79,
CCc1cccc(c1)N(C)C(=N)Nc2cccc3ccccc23,1.57,
CC[S+]([O-])c1ncccc1C2(O)CCN(CC34CC(c5ccccc35)c6ccccc46)CC2,2.0,
C[C@]12CCC(=O)C=C1CC[C@H]3[C@@H]4CC[C@](O)(C(=O)CO)[C@@]4(C)CC(=O)[C@H]23,1.4,
CN1C(=O)C=C(CCc2cccc(c2)c3ccccc3)N=C1N,3.8,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4occc4,2.07,
C[C@@H](NC1=CC(=O)CC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,3.2,
CCCSc1ncccc1C(=O)NC2CCCCC2,3.24,
C[C@@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3)C(C)(C)C,1.2,
COc1cc2ncnc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)c2cc1OCCN6CCOCC6,3.19,
COc1ccc2N=CC(=O)N(CCN3CC[C@H](NCc4cc5OCCOc5cn4)[C@H](O)C3)c2c1,0.77,
O[C@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NCc5ccnc6ccccc56)cc3,3.88,
CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2,1.72,
CCN(CC)c1ccc2C=C(C(=O)O)C(=O)Oc2c1,-0.2,
CC(C)N1CCN[C@H](C1)C(=O)N2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3,2.21,
CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c2cc(C)on2)C(C)C)Cc3ccc(F)cc3,2.8,
C[C@@H]1CN(C[C@H](C)O1)c2nc(N3CCOC[C@@H]3C)c4ccc(nc4n2)c5ccccc5,3.75,
CN1N(C(=O)C=C1C)c2ccccc2,0.11,
CC1=CN([C@H]2CCCN(Cc3ccc(C(=O)O)c(Oc4cccc(F)c4)c3)C2)C(=O)NC1=O,-1.03,
CC(C)[C@H](N)C(=O)OCCOCn1cnc2C(=O)N=C(N)Nc12,-1.3,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(CCc3ccccc3)C2,1.65,
CNc1c(Br)cnc2[nH]c(nc12)c3ccc(cc3)S(=O)(=O)C,2.88,
Clc1ccc(CN2C[C@@H]3C[C@H]2CN3)cc1C(=O)NCC45CC6CC(CC(C6)C4)C5,1.45,
Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl,1.86,
OC(=O)c1cccnc1N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,1.71,
CC(=O)Nc1nc(N)n(n1)c2ccccc2,-0.2,
CC(C)NC[C@H](O)COc1cccc2ccccc12,0.99,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)Cc3ccccc3C(=O)O)C(=O)C(F)(F)F,1.14,
CCN(CC)c1ccc2C=C(C(=O)C)C(=O)Oc2c1,2.0,
CCOC(=O)c1c(nc2cc(C)ccn12)c3ccccc3,3.8,
CN(c1ccc(cc1)c2cc(ccc2OCC(=O)O)C(F)(F)F)S(=O)(=O)C,-0.81,
CN(c1ccccc1)c2ccnc(Nc3cc(cc(c3)N4CCOCC4)N5CCOCC5)n2,3.47,
Nc1ncnc2c1ncn2[C@@H]3O[C@H](CSCCCNC(=O)NCc4ccccc4)[C@@H](O)[C@H]3O,0.9,
COc1cc2ncnc(Nc3cc4ccccc4cn3)c2cc1OC,3.9,
Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](Oc1c25)c7[nH]c8ccccc8c7C[C@@]36O,2.7,
CNC(=O)c1cnn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,-0.54,
COCCNC(=O)c1ccc(Nc2ncc3cc(ccc3n2)c4ccnc(C)c4)cc1,3.56,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3c[nH]c4ncccc34)c2C(=O)N5C[C@H](O)CO5,2.04,
O=S(=O)(Nc1nc(nn1Cc2ccccc2)c3ccccc3)c4ccccc4,1.25,
CNC(=O)Nc1nc2ccc(cn2n1)c3cncc(c3)S(=O)(=O)NC(C)(C)C,1.58,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CCN(CCO)CC5,3.2,
NC1(CCC1)c2ccc(cc2)N3C(=O)c4ccccc4N=C3c5ccccc5,1.6,
CC(=O)c1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.37,
CCN(CC)CCOC(=O)c1ccc(N)cc1,0.0,"This molecule is a benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol. It has a role as a local anaesthetic, a central nervous system depressant, a peripheral nervous system drug and a drug allergen. It is a benzoate ester, a substituted aniline and a tertiary amino compound. It is functionally related to a 2-diethylaminoethanol and a 4-aminobenzoic acid. It is a conjugate base of a procaine(1+). A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). Procaine has also been investigated as an oral entry inhibitor in treatment-experienced HIV patients. This molecule is a benzoic acid derivative with local anesthetic and antiarrhythmic properties. This molecule binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. In addition, this agent increases electrical excitation threshold, reduces rate of rise of action potential and slows nerve impulse propagation thereby causing loss of sensation. This molecule is only found in individuals that have used or taken this drug. It is a local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). [PubChem]This molecule acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. This molecule has also been shown to bind or antagonize the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex."
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)S(=O)(=O)CC4CCCO4)n2,2.82,
CC1(O)CN(C1)S(=O)(=O)c2ccc3C(=CNC(=O)c3c2)C(=O)NC[C@@H](O)CN4CCC(CC4)Oc5ccc(Cl)c(Cl)c5,2.54,
NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O,0.97,"This molecule is a phenylalanine derivative. This molecule is a racemic mixture of liothyronine, a synthetic version of triiodothyronine (T3), the primary active thyroid hormone. Like endogenous T3, DL-liothyronine exerts its many metabolic effects through control of gene expression, thereby resulting in the production of proteins that are involved in normal metabolism, growth, and development. Other physiologic effects of liothyronine include promoting gluconeogenesis, increasing utilization and mobilization of glycogen stores, and elevating basal metabolic rate."
O=C1C(=O)c2ccccc2c3ccccc13,2.6,
Clc1ccc(CN2CCNCC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,1.84,
CC1(C)CCC(=C(CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc6ccccc6)c(c4)S(=O)(=O)C(F)(F)F)C1)c7ccc(Cl)cc7,0.64,
Fc1ccc(cc1)n2cc(C3CCNCC3)c4cc(Cl)ccc24,2.4,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4ccoc34)n2)c1,3.52,
CCN1C=C(C=C(C)C1=O)[C@@]2(N=C(N)c3c(F)cccc23)c4cccc(c4)c5cc(ccn5)C#CC,4.4,
COC(=O)NC1=CN=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C1=O)c2ccc(F)cc2,1.82,
CCCCNc1nc(N)c2NC(=O)N(Cc3ccc(OCCN(C)C)nc3)c2n1,1.9,
CC(N)C(=O)Nc1c(C)cccc1C,-0.15,
NC1CCN(CC1)c2nccc(C(=O)NCC34CC5CC(CC(C5)C3)C4)c2Cl,1.19,
COc1ccc(cc1)C(=O)N2CCC(CC2)C(=O)c3ccc(F)cc3,2.92,
Cc1ccc(OC(=O)N2CCN3CCC2CC3)cc1,1.02,
CC(=O)Nc1ccc2cnn(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,3.44,
CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc4ccccc24)c(O)c1,0.77,
CN1CCOc2nc(ccc12)C#Cc3ccccc3,3.8,
CCOC(=O)CN(c1ccccc1C)S(=O)(=O)c2ccc(Cl)cc2,4.03,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(C2)C(=O)Cc3ccccc3,1.32,
[O-][n+]1cc(ccc1Cl)C(=O)Nc2ccc(F)cc2,1.38,
N#Cc1ccc(Nc2nccc(NC3CC3)n2)cc1,3.01,
Nc1ccccc1NC(=O)c2ccc(cc2)c3ncc(CN4CCC4)cc3C#N,1.22,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)C(=O)OCC(F)F,2.3,
CN(C)CC(O)COc1ccc(Nc2nccc(n2)N(CC#N)c3cc(Cl)ccc3Cl)cc1,2.4,
CN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCCC4)n1)c5cc(CO)ccc5C,3.8,
Cn1nc(cc1NC(=O)Nc2ccc(Cl)cc2)C(C)(C)C,3.97,
CC1Nc2cc(Cl)c(cc2C(=O)N1c3ccccc3C)S(=O)(=O)N,1.64,
Cn1cnc(c2ccccc2)c1C#Cc3ccnc(N)n3,2.94,
CNC(=O)c1cc(C(=O)c2ccc(Cl)cc2)c(Br)[nH]1,3.1,
CN1CC(C1)n2nccc2c3cc(Cl)ccc3Oc4cc(F)c(cc4F)S(=O)(=O)Nc5ncns5,1.0,
Oc1ccc(Nc2nc(cs2)c3ccc(cc3)C#N)cc1,4.1,
CCN(C1CCN(CCC(c2ccccc2)c3ccc(NC(=O)C)cc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.09,
Cc1ccc(cc1)S(=O)(=O)c2ccccc2,2.74,
CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(F)cc4,2.4,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1NCCN4CCCCC4,2.52,
COc1ccc(Sc2c(C)n(CC(=O)O)c3ccc(C)cc23)cc1,1.01,
CC(NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3)C(C)(C)C,1.21,
Cc1ccc2c(c1)c(Sc3ccc(Cl)cc3)c(C)n2CC(=O)O,2.18,
Clc1cccc(NC(=O)c2ccccn2)c1,3.4,
CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@@H]3CC[C@@H](C)CC3)C1=O,1.73,
Clc1ccc(cc1)c2oc(cc2)C(=O)N(Cc3ccccn3)c4ccc(cc4)N5CCNCC5,3.0,
O=C1NC=Nc2scc(c3cccs3)c12,2.18,
CC(C)N1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cncn6C)c3C1=O,4.02,
OCCN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,3.6,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4nc5ncccc5s4,1.4,
Nc1ccccc1NC(=O)c2ccc(cc2)c3nccs3,2.3,
CCN1CCOc2cc(COc3ccccc3)cnc12,3.7,
Nc1ncc([nH]1)c2ccc(F)cc2,1.39,
Clc1cc(Nc2ncnc3[nH]nc(OCCN4CCCC4)c23)ccc1OCc5ccccn5,2.87,
COc1ccc(cn1)c2ccc3nc(N)sc3c2,3.2,
COc1ccc(cc1)c2ccnc(N)n2,2.08,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCc4[nH]c5ccccc5c4C3,2.66,
NC(=O)NC(=O)C(Nc1ccc2CCCc2c1)c3ccccc3,3.3,
COc1cc2nnc(C(=O)N)c(Nc3cccc(Cl)c3F)c2cc1N4CCN(C)CC4,2.35,
CS(=O)(=O)Cc1cc(nc(n1)c2cccc(CO)c2)N3CCOCC3,1.0,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4c(cccc34)C#N,0.52,
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,3.24,"This molecule is an anthelmintic agent used predominantly in treatment of echinococcosis, a parasitic worm that causes cysts in liver and lung. This molecule therapy is commonly associated with mild and transient serum enzyme elevations and rarely can lead to clinically apparent acute liver injury. This molecule is a carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a propylsulfanyl group at position 5. It is commonly used in the treatment of parasitic worm infestations. It has a role as a tubulin modulator, a microtubule-destabilising agent and an anthelminthic drug. It is a carbamate ester, a benzimidazolylcarbamate fungicide, an aryl sulfide and a member of benzimidazoles. This molecule is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) This molecule is an Anthelmintic. The mechanism of action of albendazole is as a Cytochrome P450 1A Inducer. This molecule is a broad-spectrum, synthetic benzimidazole-derivative anthelmintic. This molecule interferes with the reproduction and survival of helminths by inhibiting the formation of microtubules from tubulin. This leads to an impaired uptake of glucose, a depletion of glycogen stores, and results in the worm's death. This molecule is used in the treatment of dog and pork tapeworm-causing diseases, including hydatid disease and neurocysticercosis. This molecule may also be used to treat a variety of other roundworm infections. (NCI05) This molecule is an anti-parasitic prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of two types of parasitic infections: neurocysticercosis and hydatid disease. This molecule is only found in individuals that have used or taken this drug. It is a benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38). This molecule causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies."
CCOc1ccc2nc(N)sc2c1,2.4,"This molecule is an off-white powder. (NTP, 1992)"
N(c1ccccc1)c2ccnc3ccccc23,2.78,
C[C@]12N[C@H](Cc3ccccc13)c4ccccc24,1.6,
COc1cc(ccc1Cn2ccc3ccc(cc23)C(=O)NCC4CCCC4)C(=O)NS(=O)(=O)c5ccccc5,1.93,
NC1=NN(CC1)c2cccc(c2)C(F)(F)F,2.55,
O[C@@H](CNCCCOCCNCCc1cccc(Cl)c1)c2ccc(O)c3NC(=O)Sc23,-0.03,
CC(C)(C(=O)Nc1oc(nn1)C(=O)Nc2ccc(cc2)N3CCOCC3)c4ccc(Cl)cc4,2.96,
Cc1ccc(cc1)C(=O)N2CCC(CC2)C(=O)c3ccc(Cl)cc3,3.79,
c1ccc(nc1)c2nc3ccccc3[nH]2,2.5,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCN(Cc3ccc(F)cc3)CC2)c4cccnc4,3.65,
OC(=O)CO[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4sc(Cl)c(Cl)c4[nH]3,1.38,
COc1cc(CCc2cc(Nc3ccnc(NCc4ccccn4)n3)n[nH]2)cc(OC)c1,3.5,
[O-][N+](=O)c1cc(ccc1NCCSc2ccccc2)S(=O)(=O)NC(=O)c3ccc(cc3)N4CCNCC4,-0.04,
Nc1cc(nc2ccc(Nc3cc(nc(N)n3)c4ccc(cc4)C(F)(F)F)cc12)c5ccc(F)cc5,1.54,
Fc1cnc(NC(=O)[C@H](CC2CCOCC2)c3ccc(cc3)S(=O)(=O)C4CC4)s1,3.19,
NC(=N)SCc1ccc(Cl)c(Cl)c1,1.28,
N#Cc1ccc(cc1)C(c2ccc(cc2)C#N)n3cncn3,1.7,
Cc1ccc(COC(=O)N2CCC(CNc3ncccn3)CC2)cc1,3.6,
COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,1.5,
Oc1ncc(NCc2ccccc2)c(O)n1,0.82,
COc1cc(ccc1Nc2ccccc2C(=O)O)c3ccc(Nc4ccccc4C(=O)O)c(OC)c3,1.8,
COc1cc(cc(OC)c1OC)C(=O)c2cc(Cl)ccc2N,3.38,
Nc1ccccc1NC(=O)c2ccc(cc2)c3ncccc3C#N,1.58,
CN(C)CC1CCn2c(C1)c(C3=C(C(=O)NC3=O)c4cn(C)c5ccccc45)c6ccccc26,2.88,
COc1ccc2cc(CCC(=O)C)ccc2c1,3.06,
C[C@@H]1CN(CCN1C(=O)[C@@H]2CCCC[C@H]2C(=O)NC3(CC3)C#N)c4ccc5c(C)noc5c4,2.67,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCN(Cc3ccccc3)C2,1.49,
Oc1ccc(NC(=O)c2ccc(O)cc2)cc1,1.5,
COC(=O)[C@H](Cc1ccc(cc1)[N+](=O)[O-])NC(=O)c2cccc3ccccc23,3.58,
COc1cc(ccc1Nc2ncc3N(C)C(=O)CCN(C4CCCCC4)c3n2)C(=O)NC5CCN(C)CC5,2.87,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)N)n2,2.39,
Cc1ccc(OCC(=O)O)c(c1)n2nc3ccccc3n2,-0.84,
C[C@@H]1CNc2c(sc3ccc4nc(ccc4c23)c5ccc(C)nc5)C(=O)N1,3.6,
CC1=C(Cc2ccccc2)C(=O)n3nc(NCc4ccc(Cl)cc4)nc3N1,3.7,
Fc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.9,
N(c1ccccc1)c2ccccc2,3.2,
CSCCC(NC(=O)c1ccccc1)c2nc3ccccc3n2Cc4ccc(cc4)C#N,4.24,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)C(=O)OC(C)(C)C,3.33,
Oc1cccc2ccccc12,2.5,"This molecule is a naphthol carrying a hydroxy group at position 1. It has a role as a genotoxin and a human xenobiotic metabolite. This molecule is a natural product found in Selaginella sinensis, Juglans nigra, and Magnolia liliiflora with data available. This molecule is a metabolite of carbaryl and naphthalene that is an intermediate in Metabolism of xenobiotics by cytochrome P450. It is generated by spontaneous reaction from (1R,2S)-Naphthalene epoxide then is it converted to 1,4-Dihydroxynaphthalene. Although 1-Naphthol is not persistent in the body, a single urine sample may adequately predict exposure over several months to chlorpyrifos, which is a broad-spectrum organophosphate insecticide. In adult men, TCPY and 1N were associated with reduced testosterone levels  (A3198, A3199)."
CCN1CCN(CC1)C(=O)c2cc3cc(Cl)ccc3[nH]2,3.14,
COc1cccc2c1c(NS(=O)(=O)c3ccc(Cl)s3)nn2Cc4cccc(CNC(=O)[C@@H]5COCCN5)c4,1.61,
COc1ccc2c(c1)cc(C(=O)O)n2Cc3ccc(Cl)c(Cl)c3,1.66,
NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,1.61,
C[C@H](N)C(=O)N[C@@H](CCc1ccccc1)\C=C\S(=O)(=O)c2ccccc2,1.66,
CN1CCNc2nc(CCOc3ccc(C[C@H](NC(=O)c4c(Cl)cccc4Cl)C(=O)O)cc3)ccc12,0.07,
C(Sc1nc2cccnc2[nH]1)c3ccccc3,3.22,
OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c2ccccc2)(C(F)(F)F)C(F)(F)F,4.5,
C[C@H](Nc1nc(Nc2ncc(C#N)s2)cc(n1)N3CCOCC3)c4ncc(F)cn4,2.26,
CCN(CC)CCNC(=O)c1ccc(N)cc1,-0.92,"This molecule is a benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. It has a role as a sodium channel blocker, an anti-arrhythmia drug and a platelet aggregation inhibitor. A derivative of procaine with less CNS action. This molecule is an Antiarrhythmic. This molecule is an oral antiarrhythmic agent that has been in use for more than 60 years. Long term procainamide therapy is known to induce hypersensitivity reactions, autoantibody formation and a lupus-like syndrome but is a rare cause of clinically apparent acute liver injury."
CC(C)Oc1cc(OCCc2ccsc2)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,1.74,
O=C(Nc1ccc(Nc2ccc(NC(=O)c3ccccc3)c4C(=O)c5ccccc5C(=O)c24)c6C(=O)c7ccccc7C(=O)c16)c8ccccc8,2.63,
COc1ccc(cc1OC)C(=O)Nc2cc(NC(=O)c3cccc(c3)N(C)C)ccc2Br,3.49,
COc1ccccc1CN[C@H]2CCCN[C@H]2c3ccccc3,1.5,
NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CC4CC4)c1,0.07,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)OCc3cc(C)nc(C)c3)C(=O)C(F)(F)F,2.38,
COCCCNS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4ccccn34)cc1,3.41,
CN[C@@H](C)[C@H](O)c1ccccc1,-1.15,"This molecule is a phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively. It has a role as a nasal decongestant, a sympathomimetic agent, a vasoconstrictor agent, a xenobiotic, an environmental contaminant, a plant metabolite and a bacterial metabolite. It is a member of phenylethanolamines and a phenethylamine alkaloid. It is a conjugate base of a (-)-ephedrinium. This molecule was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. This molecule acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine from storage vesicles. This molecule is used for its vasoconstrictive, positive chronotropic, and positive inotropic effects. This molecule and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists. This molecule was granted a type 7 FDA Approval on 29 April 2016. This molecule is an alpha-Adrenergic Agonist, and beta-Adrenergic Agonist, and Norepinephrine Releasing Agent. The mechanism of action of ephedrine is as an Adrenergic alpha-Agonist, and Adrenergic beta-Agonist. The physiologic effect of ephedrine is by means of Increased Norepinephrine Activity. This molecule is an alkaloid that is an hydroxylated form of phenethylamineand sympathomimetic amine, with potential bronchodilatory and anti-hypotensive activities. Following administration, ephedrine activates post-synaptic noradrenergic receptors. Activation of alpha-adrenergic receptors in the vasculature induces vasoconstriction, and activation of beta-adrenergic receptors in the lungs leads to bronchodilation. This molecule is a natural product found in Ephedra likiangensis, Ephedra pachyclada, and other organisms with data available. This molecule is only found in individuals who have consumed this drug. This molecule is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists. [PubChem] This molecule is similar in molecular structure to the well-known drugs phenylpropanolamine and methamphetamine, as well as to the important neurotransmitter epinephrine (adrenalin). Chemically, it is an alkaloid with a phenethylamine skeleton found in various plants in the genus Ephedra (family Ephedraceae). It works mainly by increasing the activity of norepinephrine (noradrenalin) on adrenergic receptors. It is most usually marketed as the hydrochloride or sulfate salt."
FC(F)(F)c1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.75,
OC(=O)[C@H](Cc1ccc(OCCNc2nc3ccccc3[nH]2)cc1)NC(=O)c4c(Cl)cccc4Cl,0.6,
COc1nc(N)nc2c1ncn2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O,-0.58,
C[C@@H]1NC(C)(C)CO[C@@]1(O)c2cccc(Cl)c2,1.69,
CCN(C1CCN(CCC(N2CCN(CC2)c3ccccc3)c4ccccc4)CC1)C(=O)Cc5ccc(cc5)S(=O)(=O)C,2.67,
CN1CCN(CC1)C(=O)[C@@H]2CCCC[C@H]2C(=O)NCC#N,-0.1,
Fc1ccc(cc1Cl)C2CNCC=CC2,1.33,
Clc1cc(Cl)cc(c1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.36,
CN1CCC(CC1)(c2cc(nc(n2)c3cccc4[nH]ccc34)N5CCOCC5)S(=O)(=O)C,1.9,
C[C@@H](NC(=O)c1cccnc1Oc2ccccc2)c3ccccc3,3.14,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4ccc(Cl)cc4)c3)C(=O)NC1=O,2.12,
CCN(C1CCN(CC[C@H](C2CCN(CC2)S(=O)(=O)C)c3cc(C)cc(C)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.93,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(OC)cc2)C1)C(C)(C)C,1.45,
COC(=O)COc1ccc(O)cc1,0.92,
C(=C\c1nn[nH]n1)/c2ccccc2,-0.4,
CN(C)CCC=C1c2ccccc2C=Cc3ccccc13,2.83,
Oc1ccc(CCNCCCCCCNC(=O)Nc2ccccc2)c3sc(O)nc13,1.26,
CC1SC2=C(C(=O)O)C(=O)c3cc(F)c(cc3N12)N4CCNCC4,-1.1,
COc1ccccc1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,0.89,
O[C@H]([C@H](Cc1ccccc1)NC(=O)c2cc3cc(Cl)ccc3[nH]2)C(=O)N4C[C@@H](O)[C@@H](O)C4,2.8,
CCOc1ccc(cc1)N2C(=O)c3cccnc3N=C2[C@@H](C)N(CC4CCN(C)CC4)C(=O)Cc5ccc(F)c(c5)C(F)(F)F,1.4,
CC1(C)Cc2c(c3ccccc3)c(c(CC(=O)O)n2C1)c4ccc(Cl)cc4,3.07,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Oc3cccc4ccccc34)c2C(=O)N5CC[C@@H](O)C5,2.87,
Fc1ccccc1COc2cc(OCCCN3CCCC3)ccc2C(=O)Nc4ccccc4,3.85,
CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,2.57,
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,2.5,
Oc1ccc(CC(=O)c2ccc(O)cc2O)cc1,2.54,
Clc1cccc(Cl)c1c2nnc3cccc(Cl)n23,2.66,
CNCCCN1c2ccccc2CCc3ccccc13,1.24,
C[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,-0.3,
O[C@@H](CNCCc1cccc(CNCCc2ccccn2)c1)c3ccc(O)c4NC(=O)Sc34,-0.07,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(F)c2)n3ccc(c3)C#N,1.6,
CS(=O)(=O)C1(CC1)c2cc(nc(n2)c3ccccc3)N4CCOCC4,2.6,
COc1ccc2N=CC(=O)N(CCN3CC[C@H](NCc4ccc5OCC(=O)Nc5n4)[C@H](O)C3)c2c1,0.39,
Clc1ccc(cc1)S(=O)(=O)Nc2nnc(s2)c3ccccc3,1.14,
CN1SC(=O)c2cc(ccc12)S(=O)(=O)NC3CC3,1.3,
COc1ccc(cc1OC)c2cc(NC(=O)Cc3ccc4ccccc4c3)[nH]n2,3.1,
CN([C@@H]1CCN(Cc2ccc(nc2)C(F)(F)F)C[C@@H]1F)C(=O)Cc3ccc(cc3)n4cnnn4,1.8,
COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4,0.9,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)c4noc(C)n4,2.6,
COc1cc(ccc1Cn2ccc3ccc(NC(=O)OC4CCCC4)cc23)C(=O)NS(=O)(=O)c5ccccc5,2.2,
CCCc1c(O)c(ccc1OCc2ccc(cc2)C(=O)O)C(=O)C,2.1,
Clc1ccc(c(Cl)c1)c2nnc3cccc(Cl)n23,2.88,
CCn1c(C)ncc1c2ccnc(Nc3ccc(cc3)S(=O)(=O)NCCOC)n2,2.44,
ONC(=O)c1ccc(NS(=O)(=O)c2ccccc2)cc1,0.75,
CN1CCCCC1CCN2c3ccccc3Sc4ccc(cc24)[S+](C)[O-],1.6,
Nc1ccnc(n1)c2cccnc2,0.44,
Cc1nc(C)c(nc1C(=O)N)c2ccc(cc2)[C@@H]3CC[C@@H](CC(=O)N)CC3,2.7,
Oc1c2C(=O)N(NC(=O)c2nc3cc(Cl)ccc13)C(C4CCCC4)c5ccccn5,1.9,
Cc1cccc(NS(=O)(=O)c2ccc(cc2)c3ccc(cc3)C#N)n1,2.42,
C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,2.33,
Cc1onc(C)c1CCC2CCN(CC2)S(=O)(=O)CC3(CCOCC3)N(O)C=O,0.9,
Cc1ccccc1C(=O)NCC23CC4CC(CC(C4)C2)C3,4.28,
CN1CCN(CC1)C(=O)c2ccc(cc2)C(=C3CCN(Cc4cscn4)CC3)c5cccc6cccnc56,1.98,
CC1(C)N=C(N)N=C(N)N1c2ccc(Oc3ccc(Cl)cc3)c(Cl)c2,0.79,
COc1ccc(cc1)n2cnc3cc(NS(=O)(=O)c4ccccc4)ccc23,3.7,
OC(=O)c1ccccc1CN2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.48,
CNc1nc(C)c(s1)c2nc(Nc3cccc(c3)N4CCCN(CC4)C(=O)C)ncc2C#N,3.2,
Fc1cc(cc(F)c1CN2CCOCC2)c3cccc4ncc(nc34)c5cnn(c5)C6CCNCC6,1.86,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4cccnc4,0.01,
OC(=O)c1cc2cc(OCc3ccccc3)ccc2[nH]1,0.4,
OC(=O)c1ccccc1C(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.73,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4c[nH]c(C)n4,2.97,
CCc1c(C)nc(SCC(=O)Nc2nc(cs2)c3ccc(OC)cc3)nc1O,3.78,
CO[C@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@H]1NCc4cc5OCCOc5cn4,0.63,
Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,2.7,
OC(=O)CCc1ccc(OCc2cc(Cl)ccc2c3ccccc3)cc1,3.22,
COc1ccc2CC3C4C=CC(O)C5Oc1c2C45CCN3C,0.8,
CNC(=O)c1cc(sc1NC(=O)N)c2ccccc2,3.19,
C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)NC2C(=O)N(C)c3ccccc3c4ccccc24,3.6,
C[C@H](NC(=O)c1cccc2CCN(Cc3ccc(Cl)cc3)c12)c4ccc(cc4)C(=O)O,1.47,
CC(=O)Nc1cccc(Nc2ncnc(n2)N3CCC(CC3)OCc4ccc(OC(F)(F)F)cc4)c1C,4.4,
CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c2ccc(F)cc2)C(F)(F)F,3.12,
C[C@@H]1CN(C[C@H](C)N1)c2c(F)c(N)c3C(=O)C(=CN(C4CC4)c3c2F)C(=O)O,-0.15,
Cc1sc2c(C(=N[C@@H](CC(=O)OC(C)(C)C)c3nnc(C)n23)c4ccc(Cl)cc4)c1C,3.82,
CSc1ccc(OCc2ccccc2)c(c1)C(=O)Nc3ccc(cn3)C(=O)O,1.6,
Oc1ccc(cc1)c2nc3ccccc3s2,4.1,
COc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)nc(N4CCOCC4)c2Cl)n[nH]1,2.85,
Clc1cccc(NNC(=O)c2cccnc2Cl)c1,1.87,
Cc1ccc(NC(=O)CCC2CCCCC2)cc1NC(=O)c3ccc(O)cc3,4.13,
CCc1c(C(=O)C(=O)N)c2c(OCC(=O)N)cccc2n1Cc3ccccc3,2.1,
Nc1cccc2C(=O)C(=O)c3ccccc3c12,2.31,
COc1ccc2cc(ccc2c1)C(C)C(=O)O,0.23,
CCOC(=O)Nc1cccc(c1)[C@H](N2CCN(Cc3cccnc3)CC2)c4ccc(cc4)C(=O)N5CCC5,3.02,
C1NC(Cc2ccccc12)c3ccccc3,1.9,
CCN(CC)S(=O)(=O)c1ccc(cc1)c2cc(ccc2OCC(=O)O)C(F)(F)F,0.67,
CN(C)CCOC(C)(c1ccccc1)c2ccccn2,-0.2,
NCCc1ccc(O)c2nc(O)sc12,0.33,
COc1ccc(C(=O)Nc2c(Cl)cncc2Cl)c3cccnc13,2.09,
CN(C)CC(O)COc1ccc(Nc2nccc(n2)N(CC#C)c3cc(Cl)ccc3Cl)cc1,3.2,
COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,2.23,
OCC(=O)N1CCC[C@@H]1COc2cccc3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23,3.71,
CCN(CC)C(C)C(=O)c1ccccc1,1.18,"This molecule is a sympathomimetic amine and anorectic agent used for the short-term therapy of obesity. This molecule has not been linked to either serum enzyme elevations or to clinically apparent acute liver injury. This molecule is an aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity. It has a role as an appetite depressant. It is a tertiary amine and an aromatic ketone. It is functionally related to a propiophenone. A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290) This molecule is a Sympathomimetic Amine Anorectic. The physiologic effect of diethylpropion is by means of Appetite Suppression, and Increased Sympathetic Activity. This molecule is an amphetamine derivative and a sympathomimetic stimulant with anti-obesity and appetite-suppressant properties. This molecule stimulates neurons to release and maintain high levels of catecholamines including dopamine and norepinephrine resulting in a suppression of hunger signals and appetite. This agent may also indirectly affect leptin-neuropeptide Y (NPY) neurotransmission, which exerts control on metabolic processes such as food intake and body weight homeostasis. Via elevated catecholamine, diethylpropion indirectly elevates leptin levels in the brain, which in turn inhibits production of NPY, a potent stimulator of feeding behavior, thereby preventing the initiation of eating, increasing energy expenditure, and decreasing fat storage. This molecule is only found in individuals that have used or taken this drug. It is a appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)This molecule is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. This molecule (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. This molecule is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Stimulants substance."
CCCN(CCC)C(=O)c1cccc(c1)C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc3cccc(OC)c3,2.7,
Oc1cc(nc2ccccc12)c3ccccc3,2.54,
Cc1cc(O)ccc1N2C(=O)c3ccc(O)cc3C2=O,2.0,
FC(F)(F)c1cc(COCC(N2CCNCC2)c3cccc(Cl)c3)cc(c1)C(F)(F)F,4.2,
COc1cc2ncnc(Nc3cc(NC(=O)c4cccc(c4)N(C)C)ccc3Cl)c2cc1OC,4.26,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OCC45CC6CC(CC(C6)C4)C5)nc23,3.58,
CC(C)NC(=O)c1ccc(C)c(c1)N2C=Nc3ccc(cc3C2=O)N4CCN(C)CC4,1.56,
C[C@H](Nc1nc(Nc2ncc(C)s2)c(F)c(n1)N3CCOCC3)c4ncc(F)cn4,3.27,
OC(=O)c1ccc(cc1)c2nnn(Cc3ccccc3F)n2,0.3,
CC(C)NCC(O)COc1nccs1,-0.97,
CNC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,1.93,
CC(C)NCC(O)COc1ccccc1CC=C,0.99,
CC(=O)Nc1ccc2c(c1)c(cn2CCO)c3cc(NC4CC4)n5ncc(C#N)c5n3,2.71,
OC(=O)c1ccccc1O,-1.36,
Cn1cnc(c2ccccc2)c1c3cc4c(N)ncnc4s3,2.94,
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,0.44,"This molecule appears as white crystals. (NTP, 1992) This molecule is an N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position. It has a role as a hypoglycemic agent, a potassium channel blocker, a human metabolite and an insulin secretagogue. This molecule is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating Î² cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic Î² cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. This molecule appears to be metabolized in the liver. This molecule and its metabolites are excreted in urine (75-85%) and feces. This molecule is a Sulfonylurea. This molecule is a short-acting, first-generation sulfonylurea with hypoglycemic activity. Compared to second-generation sulfonylureas, tolbutamide is more likely to cause adverse effects, such as jaundice. This agent is rapidly metabolized by CYPC29. This molecule is a natural product found in Homo sapiens with data available."
CC(C)C[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,0.91,
COc1ccc(Cl)c(Nc2ncnc3cc(OC)cc(OC4CCN(C)CC4)c23)c1,3.6,
CCOC(=O)c1ccc(OCCC2CCN(CC2)c3ccc(C)nn3)nc1,3.76,
Cc1ccc2nc(CCNCCCO)ccc2c1NC(=O)CC34CC5CC(CC(C5)C3)C4,1.18,
OCC(CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(NC4CC4)sc13,3.11,
CCN(C1CCN(CCC(c2ccccc2)c3ccc(cc3)C#N)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.76,
C[C@@H](COCCCS(=O)(=O)CCNCCc1ccc(O)c2nc(O)sc12)c3ccccc3,2.32,
CN(C)CC(O)COc1ccc(Nc2ncc(C)c(Nc3ccccc3)n2)cc1,2.0,
CCCSc1nc(ccc1C(=O)NC2CCCCC2)N3CCCC(C3)C(=O)O,1.72,
C[C@@H]1CCCN1CCc2oc3ccc(cc3c2)c4ccc(cc4)C#N,3.51,
COc1cc2ncc(C(=O)N)c(Nc3cccc(Cl)c3)c2cc1OC,3.5,
Brc1ccc(cc1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.21,
Oc1ccccc1CCC(=O)Nc2ccccc2,2.71,
C[C@@H]1CN[C@@H]2[C@@H](C1)O[C@]3(CC[C@H]4[C@@H]5CC=C6C[C@@H](O)CC[C@]6(C)[C@H]5CC4=C3C)[C@@H]2C,2.63,
NC(=O)N1c2ccccc2C[C@H](O)c3ccccc13,0.79,
Nc1nnc(s1)c2ccccc2,1.8,
Fc1ccc(C2CCN(CC2)C(=S)COCc3ccncc3)c(Cl)c1,4.23,
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,-0.73,"This molecule is a sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial. It has a role as an antibacterial drug and an antimalarial. It is a sulfonamide and a member of pyrimidines. This molecule is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. This molecule is a Sulfonamide. This molecule is a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with bacteriostatic and antimalarial properties. This molecule competes with PABA for the bacterial enzyme dihydropteroate synthase, thereby preventing the incorporation of PABA into dihydrofolic acid, the immediate precursor of folic acid. This leads to an inhibition of parasitic folic acid synthesis and de novo synthesis of purines and pyrimidines, ultimately resulting in cell growth arrest and cell death."
C[C@H]1CCCN1CCc2oc3ccc(cc3c2)c4ccc(cc4)C#N,3.25,
COc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)n[nH]1,2.53,
CC(N1NC(=O)C2=C(C1=O)C(=O)c3ccc(Cl)cc3N2)c4ccsc4,0.9,
CCN1CCN(CC1)C(=O)c2cc3cc(F)ccc3[nH]2,2.28,
CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2)nc3nc(N)sc13,4.2,
CN1CCC[C@@H]1CCO[C@](C)(c2ccccc2)c3ccc(Cl)cc3,3.48,
O=C(N[C@H]1CN2CCC1CC2)c3ccc(s3)c4ccccc4,1.9,
CC(NCC(O)c1ccc(cc1)[N+](=O)[O-])C23CC4CC(CC(C4)C2)C3,3.53,
CC1=CN(C2CCCN(Cc3cccc(Oc4ccc(C)cc4)c3)C2)C(=O)NC1=O,3.38,
CCCN(CCNCCc1ccc(O)c2NC(=O)Sc12)C(=O)CCOCCc3ccccc3,2.23,
O=C1N=C(NCc2ccccc2)SN1Cc3ccccc3,3.01,
COc1cc(OC)c(cc1NC(=O)Cc2ccnc(F)c2)S(=O)(=O)N3c4ccccc4Oc5ccccc35,3.37,
OC(=O)c1ccc2c(c1)nc(Nc3cccc(Cl)c3)c4ccncc24,1.29,
NC(=N)Nc1nc(CSCCC(=N)NS(=O)(=O)N)cs1,-0.6,
CN(CCO)C(=O)c1ccc(cc1)[C@@H](N2CCN(Cc3ccc(F)cc3)CC2)c4cccc(NC(=O)C5CC5)c4,3.38,
CCN(C1CCN(CC[C@H](C2CCN(CC2)S(=O)(=O)C)c3cccc(c3)C(F)(F)F)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.9,
CN1CCCC(COc2nccc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)n2)C1,1.9,
O[C@H](CNC(=O)C1=CNC(=O)c2c(F)cccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.15,
CN(C)CCCN(C)S(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4ccccn34)cc1,2.16,
OC1=CC(=O)C2=C(O1)c3ccccc3N(Cc4ccccc4)C2=O,1.97,
CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c2ccc(O)cc2)C(F)(F)F,2.78,
CCCSc1ncccc1C(=O)N(C)[C@H]2[C@@H]3CC4C[C@H]2C[C@@](O)(C4)C3,2.48,
Cn1cncc1c2c3C(=O)N(CC#CCO)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56,2.55,
Fc1cccc(F)c1CS(=O)(=O)N2CCN(CC2)c3ncccc3C(F)(F)F,3.9,
CS(=O)(=O)c1ccc(cc1)c2cc(C(=O)N[C@H]3CCCNC3)c(NC(=O)N)s2,0.68,
Cc1onc(C(=O)N)c1C(=O)Nc2nccs2,1.63,
CNCCC(Oc1ccc(cc1)C(F)(F)F)c2ccccc2,1.92,
CCn1cnc(c2ccccc2)c1c3nc4c(N)ncnc4s3,2.97,
CCCc1c(O)c(ccc1OCCCCSCC(=O)O)C(=O)C,1.3,
CN(c1ncccc1CNc2nc(Nc3ccc4NC(=O)Cc4c3)ncc2C(F)(F)F)S(=O)(=O)C,2.63,
CCc1nc2cc(O)ccc2c(Oc3ccc(\C=C\C(=O)O)cc3)c1c4ccccc4,3.0,
Cc1ccc(s1)C(NC(=O)c2ccccc2O)C(=O)Nc3c(C)cccc3C,4.05,
COCCOc1nc(N)c2NC(=O)N(Cc3cccc(CC(=O)OC)c3)c2n1,1.86,
C[S+]([O-])c1ccc(cc1)c2nc(c3ccc(F)cc3)c([nH]2)c4ccncc4,3.34,
CCC(CC)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c2ccc(C)cc2,1.88,
CN1CCN(CC(=O)Nc2ccc(C3=CC=CN4C(=O)C=C(N=C34)N5CCOCC5)c6sc7ccccc7c26)CC1,2.6,
NC1=NC2(CCN(CC2)C(=O)c3ccc(nc3)C#N)Nc4c(F)ccc(F)c14,0.79,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3Cc4cccnc4C3)c(F)c2,2.88,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2ccccc12)c3ccccc3)c4cccnc4,2.2,
OCC(=O)N1CCC(CC1)c2[nH]nc(c3ccc(Cl)cc3F)c2c4ccncn4,1.79,
CC(C)Oc1cc(n[nH]1)n2cnc3ccc(N[C@@H](CO)c4ccc(F)cn4)nc23,2.79,
NC(=O)c1cnc2[nH]c(nc2c1NCCCNC(=O)C3CCC3)c4ccc(OCCN5CCCCC5)cc4,2.48,
CNC(=O)OC[C@@H](C)N(c1cc(Cl)ccc1CO)S(=O)(=O)c2ccc(Cl)cc2,3.0,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)n2,1.96,
CC1(CCC(=O)N1Cc2cccs2)C(=O)NC3CCCCC3,2.15,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)N,3.3,
NC(=O)c1cccc(c1)[S+]([O-])[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4,1.1,
CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(cc3)C(F)(F)F)cc2)nc(N(C)C)c1CC(=O)O,1.46,
CCC(CC)NC(=O)c1nnn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,0.46,
Nc1nc(SCc2ccccc2)nc3c1ncn3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O,1.24,
CN1C(=O)N(C)c2[nH]c(nc2C1=O)c3cccnc3,0.7,
CO[C@@H]1CN(Cc2ccc(cc2)C(F)(F)F)CC[C@@H]1N(C)C(=O)Cc3ccc(cc3)n4cnnn4,3.1,
COc1ccc2cc(ccc2c1)[C@H](C)C(=O)O,0.13,
CN(C)C1=C(C)N(C)N(C1=O)c2ccccc2,0.78,
CCC(CC)CNC(=O)c1ccc2c(c1)c(Cc3ccc(cc3OC)C(=O)NS(=O)(=O)c4ccccc4C)cn2C,2.7,
NC(=O)c1cncc(c1)c2ccc(cc2)[C@@H]3CC[C@@H](CC(=O)O)CC3,0.22,
CC(C(=O)O)c1ccc(c(F)c1)c2ccccc2,0.85,
COc1cc(ccc1Nc2ncc(c(n2)c3cnc4ccccn34)C(F)(F)F)N5CCN(CC5)C(=O)C,3.7,
NC1(CCC1)c2ccc(cc2)c3ncc4nccn4c3c5ccccc5,1.3,
COC[C@H](C)Oc1cc(Oc2cc(F)cc(F)c2)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,1.36,
CCC(C)(C)C[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,1.37,
Fc1cccc(c1)C(COCc2cc(cc(c2)C(F)(F)F)C(F)(F)F)N3CCNCC3,3.2,
COc1cc(F)ccc1c2cncc(CNC(=O)c3ccccn3)c2,3.2,
CSCc1cc(nc(n1)c2ccccc2)N3CCOCC3,3.26,
CN(C)CCCNc1cc(nc2c(cnn12)C#N)n3ccc4ccc(NC(=O)C)cc34,1.62,
CC(=O)Nc1ccc2ccn(c3cc(NCCN4CCCC4)n5ncc(C#N)c5n3)c2c1,2.24,
Clc1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.59,
Oc1ccc(cc1)C2=COc3cc(O)ccc3C2=O,2.46,
Nc1ccc2[nH]c(Cc3ccc(Oc4ccccc4)cc3)nc2c1,3.8,
CN1C(=O)C(=Cc2cnc(NC(CCO)CCO)nc12)Oc3ccc(F)cc3F,1.5,
CCc1ccc(NC(=O)c2ccc3cc(ccc3c2)C(=N)N)cc1,1.1,
CC#Cc1ccnc(c1)c2cc(ccc2O)C3(N=C(C)C(=N3)N)C4CC4,3.6,
Fc1ccc(cc1)C(NC(=O)CC2CCN(Cc3ccn(c3)c4ccc(cc4)C(F)(F)F)CC2)C5=CNC(=O)C(=C5)Cl,3.12,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC=O)C(=O)C(F)(F)F,1.84,
COc1cc(ccc1Nc2ncc(C)c(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)C,2.9,
Nc1cccc2C(=O)N(Cc3cccc(Cl)c3)C(=O)c12,3.18,
NC(=O)Nc1cc(sc1C(=O)N[C@H]2CCCNC2)c3ccccc3,1.04,
Nc1nc(Cl)nc(NCc2ccccc2)n1,2.26,
COc1cccc(COCC(O)CN2CCC(CC2)C(=O)N)c1,-0.5,
Oc1ccc(CCNCCCCCCOCCc2ccccc2)c3sc(O)nc13,2.21,
COC[C@H](C)Oc1cc(Oc2ccccc2)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,0.95,
Clc1ccc2ncc(c3cccc(NC4CNC4)n3)n2c1,1.19,
NC(=N)Nc1ccc(cc1)C(=O)Oc2ccccc2,-0.21,
NC1(CCC1)c2ccc(cc2)C3=NN4C=CC(=O)N=C4C=C3c5ccccc5,0.2,
CCOc1ccc(NC(=O)C)cc1,1.5,
O=C(CC12CC3CC(CC(C3)C1)C2)Nc4ccc5[nH]ncc5c4,4.03,
OC(=O)Cc1csc(n1)c2ccc(Cl)cc2,-0.22,
Cc1oc(cc1)c2ccc(cc2F)S(=O)(=O)N3CCC[C@H]3C(=O)N4CC[C@@H](N)C4,1.2,
Cc1onc(c1)[C@H](O)[C@](C)(OCc2ccc(cc2)c3ccccc3)C(=O)NO,2.88,
COc1cccc(Oc2cncnc2O)c1,0.59,
CC(C)Oc1cc(Nc2nc3c(cc2F)ncn3[C@@H](CO)c4ccc(F)cn4)n[nH]1,2.97,
OC(=O)c1cccc(c1)c2ccc3c(C(=O)NCC45CC6CC(CC(C6)C4)C5)c(Cl)ccc3n2,2.84,
Nc1nc(N)c(nc1Cl)C(=O)Nc2ccccn2,2.67,
CN1CCN(CC1)C(=O)c2cc3cc(Cl)ccc3[nH]2,2.4,
CCn1c(C)c(C(=O)O)c(c2cccc(c2)N3CCN(CC3)c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc7ccccc7)c(c5)S(=O)(=O)C(F)(F)F)cc4)c1c8ccc(Cl)cc8,4.2,
CC1CN(C1)C(=O)c2nnc3c(cccc3c2N)c4ncccn4,1.21,
OC[C@H](Nc1ncc(Cl)c(Nc2cc([nH]n2)C3CC3)n1)c4ccc(F)cc4,3.75,
C[C@H]1COCCN1c2cc(CS(=O)(=O)C)nc(n2)c3ccc4[nH]ccc4c3,2.38,
COCCCc1cc(Nc2nc(NCc3onc(C)c3)ncc2Br)n[nH]1,3.07,
OCc1ccc(OC2CCN(CC3CCN(CC3)[C@@H](Cc4ccccc4)C(=O)O)CC2)cc1Cl,0.8,
OC(=O)CNCCNc1ccc(Cl)c(c1)C(=O)NCC23CC4CC(CC(C4)C2)C3,1.94,
COc1cc(ccc1C2CC2)N3CCN([C@H](C)C3)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.49,
CCNC(=O)c1ccc(C)c(c1)N2C=Nc3ccc(cc3C2=O)N4CCN(C)CC4,1.47,
O=C(Nc1nc(cs1)c2ccccc2)c3cccnc3,3.62,
CS(=O)(=O)n1c2ccccc2c3cc(NC(=O)CCc4ccncc4)ccc13,3.4,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)C(=O)OCC(F)(F)F,3.0,
Nc1nnc(Cc2ccc(Cl)cc2)s1,2.34,
OC(=O)c1c(C#N)c2ccccc2n1Cc3ccc(Cl)c(Cl)c3,1.26,
O[C@@H](CNCCc1cccc(c1)c2cccc(CNCc3ccccc3)c2)c4ccc(O)c5NC(=O)Sc45,2.32,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)S(=O)(=O)CCCN4CCOCC4)n2,2.43,
C[C@H](CO)Nc1nc(SCc2ccccc2F)nc3nc(N)sc13,3.12,
OCC[C@]1(CCCNC1)c2ccc(Cl)c(Cl)c2,0.62,
C=CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Nc4ccccc4,3.6,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(cc2)C#N)c3ccc(F)cc3)C(C)(C)C,0.45,
OC(=O)[C@H](Cc1ccc(F)cc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.98,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4ncoc34)n2)c1,2.5,
COCCC(=O)N(C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.23,
C[C@@H]1CN(CCN1c2ncc(OCc3ccc(cc3)C#N)cn2)C(=O)OC(C)(C)C,2.89,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N4CCN(CC4)S(=O)(=O)CCN(C)C)n2,2.52,
Nc1ccc2ccccc2n1,1.7,This molecule is an aminoquinoline. This molecule is a natural product found in Leucopaxillus albissimus with data available.
CCCCN1Cc2c(O)n3nc(cc3nc2C1=O)c4occc4,0.8,
CN1C=C(C(=O)NC[C@@H](O)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)C(=CC1=O)C(F)(F)F,2.76,
Nc1nc2ccc(cc2s1)c3cccc(O)c3,3.1,
CC#CCN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c3C1=O)c6cncn6C,3.61,
C[C@@H]1CN(CCN1C(=O)[C@@H]2CCCC[C@H]2C(=O)NC3(CC3)C#N)c4ccc5c(C)nn(C)c5c4,2.7,
Cc1nccc(c1Cl)c2ccc(cc2)c3nc4ccncc4c(O)c3C#N,2.0,
O=C1C=C(Oc2c1cccc2c3ccccc3)N4CCOCC4,2.9,
COc1ncc2C=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2n1,0.2,
COc1cc(ccc1Cc2cn(C)c3ccc(NC(=O)CC4CCCC4)cc23)C(=O)O,2.0,
Cc1c(c2cc(F)ccc2n1CC(=O)O)S(=O)(=O)c3ccc(Cl)cc3,-0.16,
NS(=O)(=O)c1ccc(Nc2nccc(Nc3c(Cl)ccc4OCOc34)n2)cc1,2.7,
CCC(C)(CC)C[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Br)c4)c3,1.97,
CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)N3CCN(CC3)c4ccc(cn4)C#N)C(=O)C2,2.46,
NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl,0.37,
Cc1nc2ncnn2c(O)c1CCOC(=O)c3ccccc3F,0.99,
O[C@H](CNS(=O)(=O)c1cccc(c1)C#N)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,3.42,
O=C(NCCCCc1ccccc1)c2ccccc2,3.8,
CC(C)C[C@H](NC(=O)N1CCOCC1)C(=O)NCC#N,0.08,
NC(=O)C1CCCCC1,0.9,
CN(C)c1ncnc2nc[nH]c12,0.95,This molecule is a tertiary amine that is adenine substituted at N-6 by geminal methyl groups. It is functionally related to an adenine. This molecule is a natural product found in Spiraea formosana with data available.
Nc1nonc1\C(=N\O)\Nc2ccc(F)c(Cl)c2,2.7,
COc1ccc(cc1)S(=O)(=O)Nc2ccccn2,0.87,
Cc1ccc(cc1)c2csc3ncnc(O)c23,2.59,
CCOc1ccccc1c2ccc(cc2)c3nc4ccncc4c(O)c3C#N,3.0,
COc1ccc(NC(=O)C=C)cc1,1.68,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4cccc(Br)c4)c3)C(=O)NC1=O,2.3,
CS(=O)(=O)c1ccc2C(=CNC(=O)c2c1)C(=O)NC[C@@H](O)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.63,
CN1CCC[C@H]1c2ccccn2,0.44,
Oc1ccc(cc1)c2oc3ccc(O)cc3n2,3.4,
CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,2.72,
Cn1c(Nc2ccc(cc2)C(F)(F)F)nc3cc(Oc4ccnc(c4)c5ncc([nH]5)C(F)(F)F)ccc13,3.45,
Nc1nc(ns1)c2ccccc2,2.2,
N\C(=C(/C#N)\c1ccccc1C(F)(F)F)\Sc2ccc(N)cc2,3.4,
CC(N(O)C(=O)N)c1cc2ccccc2s1,2.05,
Cc1onc(NC(=O)CSc2nc(C)cc(C)n2)c1,1.52,
COc1c(cc2ccccc2c1C(=O)N(C)C[C@@H](CCN3CCC(CC3)N4CCCNC4=O)c5ccc(Cl)c(Cl)c5)C#N,3.0,
CNC1=Nc2ncccc2C(=NC1c3ccns3)c4occc4,1.44,
CN1C(=O)N(C)c2ncn(CC(O)CO)c2C1=O,-1.25,
CN1C(=O)CC(C)(CCc2cccc(c2)c3ccccc3)N=C1N,2.03,
COc1cc(ccc1Cc2cn(C)c3ccc(cc23)C(=O)NCCc4ccccc4)C(=O)NS(=O)(=O)c5ccccc5C,2.51,
Cc1ccc(cc1)c2nn(c3ncnc(N)c23)C(C)(C)C,4.1,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC4CCN(CC(=O)N)CC4,3.1,
NC(=O)c1ccc(Br)cc1,1.75,
C1CCN(CC1)c2ncnc3[nH]cnc23,1.84,
CCOc1cccc(Nc2oc(nn2)C(=O)Nc3ccc(nc3)N4CCOCC4)c1,3.6,
C[C@H](Oc1ccc(SCCCCCc2ccccc2)cc1)C(=O)c3nc(C)c(CCCC(=O)O)s3,2.03,
Fc1ccc(CN2CCN(CC2)[C@H](c3ccc(cc3)C(=O)N4CCC4)c5cccc(NC(=O)C6CC6)c5)cc1,3.58,
N[C@H](Cc1c[nH]c2ccccc12)C(=O)O,-0.92,"This molecule is zwitterionic form of D-tryptophan having an anionic carboxy group and a protonated alpha-amino group; major species at pH 7.3. It is a tautomer of a D-tryptophan. This molecule is a metabolite found in or produced by Saccharomyces cerevisiae. This molecule is the D-enantiomer of tryptophan. It has a role as a bacterial metabolite. It is a tryptophan and a D-alpha-amino acid. It is a conjugate base of a This moleculeium. It is a conjugate acid of a This moleculeate. It is an enantiomer of a L-tryptophan. It is a tautomer of a This molecule zwitterion. This molecule is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. The D-stereoisomer is occasionally found in naturally produced peptides (for example, the marine venom peptide contryphan). The distinguishing structural characteristic of tryptophan is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats. This molecule is a natural product found in Solanum lycopersicum and Vitis vinifera with data available."
CC(C)CN1C(=O)N(C)C(=O)c2c(SCCCO)c(Cc3ccccc3C(F)(F)F)sc12,4.05,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6oc(cc6Cl)S(=O)(=O)C)c3C1=O,3.97,
C[C@H](NC(=O)c1c(C)nn(C2CCC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,1.57,
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(Cc4cccs4)C3=O,1.52,
COc1ccc2N=CC(=O)N(CCN3CC[C@@H](NCc4ccc5OCC(=O)Nc5n4)[C@@H](F)C3)c2c1,0.83,
O=C(Nc1ccc(nc1)n2ccnc2)c3ccc(cc3)C#N,2.2,
Nc1[nH]ncc1S(=O)(=O)c2ccccc2,1.1,
Cc1ccc(cc1)S(=O)(=O)Nc2c(C(=O)NCC(C)(C)C)c(C)nn2c3ccccc3,1.46,
CS(=O)(=O)Cc1cc(nc(n1)c2cccc3[nH]ccc23)N4CCOCC4,1.7,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OCC4CCC(F)(F)CC4)nc23,1.72,
CCn1c2ccccc2c3cc(NC(=O)CCc4ccncc4)ccc13,3.75,
CCS(=O)(=O)c1ccc(c2cc(Cl)ccc2OCC(=O)O)c(c1)C(F)(F)F,0.62,
COc1ccccc1C[C@H](N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2)C(=O)O,2.77,
COc1cc2nnc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1N4CCN(C)CC4,2.36,
Fc1ccc2cn[nH]c2c1,2.3,
CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]2O[C@H]([C@H](O)[C@@H]2O)n3ccc4c(N)ncnc34,2.4,
CCC1(CCC(=O)NC1=O)c2ccc(N)cc2,0.6,
OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,1.47,
NC1=NC2(CCN(CC2)C(=O)c3ccc(cc3)C#N)Nc4cccc(F)c14,0.66,
Cc1ccc(cc1c2ccc(nc2)C(=O)NCC3CC3)C(=O)NC4CC4,3.36,
CC(C)N=C1C=C2N(c3ccc(Cl)cc3)c4ccccc4N=C2C=C1Nc5ccc(Cl)cc5,3.17,
CO[C@@H]1CN(CCN2C(=O)C=Nc3ccc(OC)cc23)CC[C@H]1NCc4ccc5OCC(=O)Nc5n4,0.97,
Oc1cc(OCc2ccccc2)ccn1,1.69,
CN(C)CC(O)COc1ccc(Nc2cc(Nc3cc(Cl)ccc3Cl)ncn2)cc1,2.6,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4C[C@H](O)CO4,3.15,
CN1CCN(CC1)c2ccc(Nc3ncc(C)c(Nc4cccc(c4)S(=O)(=O)NC(C)(C)C)n3)cc2,2.84,
COc1cc2ncnc(Nc3ccncc3)c2cc1OC,2.22,
N(c1ccccc1)c2[nH]nnc2c3ccccc3,3.37,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4nc5cnccc5s4,1.66,
O[C@@H](CNCCc1ccc(CNCCc2ccccc2)cc1)c3ccc(O)c4NC(=O)Sc34,1.11,
NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(=O)(=O)N,0.92,
Fc1ccc(cc1)c2cn3ccccc3n2,3.1,
Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1N4C(=O)CCC4=O,1.0,
O=C(Nc1cc(nn1c2ccccc2)c3ccccc3)c4cccc(c4)C#N,3.82,
CN(C)c1cccc2c(cccc12)S(=O)(=O)N(C)CC(=O)O,-1.45,
Cc1cc(on1)c2ccc(cc2F)N3C[C@H](Cn4ccnn4)OC3=O,1.99,
COc1ccnc(NC2CCN(CC2)C(=O)c3ccccc3)c1,2.06,
CCC(=O)N[C@H]1CC[C@H](C1)C(=O)N(C)c2ccc(cc2)c3oc4ccccc4n3,3.4,
Nc1c(cnn1c2ccc(F)cc2)C(=O)c3cccc(OC[C@H](O)CO)c3,1.94,
O=C1C=C(N=C2N(Cc3cccc4ccccc34)C=CN12)N5CCOCC5,3.3,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN4CCN(C)CC4,3.3,
O=C1NCCc2[nH]c(cc12)c3ccncc3,1.49,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,3.0,
COc1cc(ccc1OCCN2CCCC2)N3C=Nc4cc(sc4C3=O)c5ccc(Cl)cc5,2.74,
CN(C)c1ccnc2sc3C(=O)N(C=Nc3c12)c4ccccc4,2.34,
CN1CCc2c(NC(=O)Cc3ccccc3)c4ccccc4nc12,2.8,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OC(C4CC4)C(F)(F)F)nc23,1.83,
Cc1c[nH]c(\C=C\2/C(=O)Nc3ccccc23)c1CCC(=O)O,1.2,
COc1ccc(Nc2nccc(n2)c3cnc(C)n3C(C)C)cc1,3.43,
C[C@H](Oc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c3ncc(F)cn3,1.82,
Clc1cnc(cc1C(=O)NCC23CC4CC(CC(C4)C2)C3)N5CCNCC5,2.09,
Cc1c(Sc2ccc(Cl)cc2)c3cc(Cl)ccc3n1Cc4nnn[nH]4,3.25,
CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C2=O)C(=O)O,-0.86,
CN(C)CCOC(c1ccccc1)c2ccccc2C,1.47,
CC(C)c1noc(n1)N2CCN([C@H](C)C2)c3ncc(OCc4ccncc4C#N)cn3,3.1,
C[C@@H](N(CC1CCS(=O)(=O)CC1)C(=O)Cc2ccc(c(F)c2)C(F)(F)F)C3=Nc4ncccc4C(=O)N3c5ccc(Cl)cc5,2.9,
CCOc1ccc2nc(NC(=O)CC)sc2c1,3.4,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3)C(=O)NC1=O,-1.28,
[O-][N+](=O)c1ccc(cc1)C2=Nc3ccccc3C(=O)N2,2.5,
O=C(NCc1ccccn1)c2ccc(Oc3ccccc3)cc2,2.7,
CN1CCN(CC1)S(=O)(=O)c2ccc(cc2F)c3cnc(N)c(n3)C(=O)Nc4cccnc4,2.66,
COc1ccccc1C2=COc3cc(O)ccc3C2=O,2.55,
Cn1cc(CN2CCc3cc4nc(N)sc4cc3CC2)cn1,1.06,
Fc1ccc(cc1F)N2C=CN=C(SCC(=O)NC3CCCC3)C2=O,2.0,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)OCc3ccccn3)C(=O)C(F)(F)F,1.91,
Cn1c(SCc2c(Cl)cccc2Cl)nnc1c3ccc4nonc4c3,3.35,
COc1ccc(cc1)C(=O)CS(=O)(=O)c2ccccc2,1.96,
CN(C)CC\C=C\1/c2ccccc2Sc3ccc(Cl)cc13,3.42,
Clc1ccc(cc1)C2(CCC2)C(=O)Nc3oc(nn3)C(=O)Nc4ccc(cc4)N5CCOCC5,3.2,
C[C@H](CO)Nc1nc(SCc2ccccc2)nc3NC(=O)Nc13,2.75,
COCCN(C)Cc1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,2.65,
CC(COc1ccccc1)NC(C)C(O)c2ccc(O)cc2,0.56,
CN(C1CCN(Cc2ccc(cc2)C(F)(F)F)CC1)C(=O)Cc3ccc(NC(=O)C)cc3,2.9,
C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCN(CCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c3ncc(F)cn3,3.27,
CN1CCN(CC1)c2ccc(Nc3ncc(F)c(N[C@@H]4[C@@H]5C[C@@H](C=C5)[C@@H]4C(=O)N)n3)cc2C,2.9,
Cc1ccc2c(c1)c(Sc3ccccc3)c(CC(=O)O)n2C,1.74,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)N4CC(C4)NC(=O)C)ncc2F,2.76,
NC(=O)c1cc2ccccc2nc1N,1.07,
O=C(N1CCNCC1)c2cc3ccccc3[nH]2,0.6,
N#CCc1c[nH]c2ccc(OCc3ccccc3)cc12,3.71,
CN([C@@H]1CCN(Cc2nc3ccccc3s2)C[C@@H]1F)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.1,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CC[C@H]3CCN(CCc4ccccc4)C[C@@H]23,2.47,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2ccc(F)cc2)N)C(=O)C(F)(F)F,1.05,
Cc1cc(Nc2ccnc(NCc3onc(c3)C4CC4)n2)n[nH]1,2.5,
COc1ccc2CCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.66,
COc1cccc(c1)C(=O)NCCCOc2cccc3ccc(N)nc23,2.46,
Cc1ccc(cc1)c2ccc(F)cc2COc3ccc(CCC(=O)O)cc3,3.24,
CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC,-0.46,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@@H](C)C(=O)N,3.42,
OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc3ccccc3,1.52,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)NCc3cccnc3)C(=O)C(F)(F)F,2.84,
CC[C@H](NC(=O)c1c([S+]([O-])CC)c(nc2ccccc12)c3ccccc3)c4ccccc4,3.45,
Nc1n[nH]c2c(Cl)cccc12,1.7,
NC(=O)c1cccc(OC2CCN(CC3CC3)CC2)c1,0.49,
Cc1cc(CN2Cc3ccccc3C2C(=O)Nc4ccc(Cl)cc4)ccc1OCC(=O)O,1.38,
CC(C)CN1C(=O)N(C)C(=O)c2c(SC3CCCC3)c(Cc4ccccc4C(F)(F)F)sc12,4.21,
OC(=O)[C@H](Cc1cccc(F)c1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.68,
CC1SC2=C(C(=O)O)C(=O)c3cc(F)c(cc3N12)N4CCN(CC5=C(C)OC(=O)O5)CC4,0.47,
CN([C@H]1CCN(Cc2ccc(cc2)C(F)(F)F)C[C@H]1F)C(=O)Cc3ccc(cc3)n4cnnn4,3.3,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(F)c2)n3cc(nn3)C#N,0.8,
COC(=O)c1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.83,
Clc1ccc2OCOc2c1Nc3ccnc(Nc4ccccc4)n3,3.9,
COc1cc(OC2CCN(C)CC2)c3c(Nc4c(Cl)ccc5OCOc45)ncnc3c1,2.98,
Cc1cc(CN2Cc3ccccc3C[C@H]2C(=O)Nc4ccc(Cl)cc4Cl)ccc1OCC(=O)O,2.41,
Oc1ccc(cc1)C2=Cc3ccc(O)cc3OC2,3.8,
OB(O)c1ccccc1C=O,0.83,
O=C(N1CC(=O)Nc2ccccc12)c3occc3,1.21,
Oc1ccc(CCNCCCS(=O)(=O)NCCOCCc2ccc(F)cc2)c3sc(O)nc13,1.57,
CCN(C1CCN(CC[C@H](c2ccc(cc2)S(=O)(=O)C)c3cc(F)c(F)c(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.55,
C[C@@H]1CN(CCN1c2ncc(OCC3CCN(CC3)S(=O)(=O)C)cn2)C(=O)OC(C)(C)C,3.5,
O=C1C=CN=C2C=CC=CN12,0.2,
O[C@@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@@H]1NCc4ccc5OCC(=O)Nc5n4,0.11,
CNC(=O)c1ccc2C(=O)C=C(Nc2c1)c3cccnc3,1.01,
Clc1n[nH]c2cccc(Nc3ccnc(Nc4cc(cc(c4)N5CCOCC5)N6CCOCC6)n3)c12,2.78,
Nc1ccccc1NC(=O)c2ccc(cc2)c3ncc(CN4CCCCC4)s3,2.82,
COc1cc(ccc1OC[C@H](OP(=O)(O)O)C2CC2)N3C=Nc4cc(sc4C3=O)c5ccc(Cl)cc5,-0.04,
CCCC(=O)Nc1ccc(Cl)c(c1)c2oc3cccnc3n2,3.37,
O=C(Nc1cccc(c1)c2nnn[nH]2)c3cccc4[nH]cnc34,-0.05,
Cc1c(Sc2ccc(Cl)cc2)c3cc(ccc3n1CC(=O)O)S(=O)(=O)C,0.54,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)S(=O)(=O)c3ccc(Cl)cc3,0.06,
CCC1(CCCCN(C)C1)c2cccc(O)c2,0.8,
COc1ccc(cc1)S(=O)(=O)NC2=CC=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C2=O)c3ccccc3,2.5,
COc1cc(OC)c(cc1NC(=O)CCC(=O)O)S(=O)(=O)N2c3ccccc3Oc4ccccc24,-0.53,
Oc1ccc(CCNCCCS(=O)(=O)NCCOCCc2cccc(c2)C(F)(F)F)c3sc(O)nc13,2.62,
CCCSc1nc2ccc(NC(=O)CCNC(=O)N)cc2s1,2.9,
CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc3NC(=O)Sc13,4.3,
CCC(N1NC(=O)c2nc3cc(Cl)ccc3c(O)c2C1=O)c4cccnc4,0.7,
COc1cc(Nc2cc(nc(N[C@@H](C)c3ncc(F)cn3)n2)N4CCOCC4)n[nH]1,2.18,
NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c(F)c1,2.1,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(Cl)cc4,3.5,
Nc1ncccc1NCc2cccc(c2)c3cccnc3,3.0,
Clc1ccc(NC(=O)N2CCN(C[C@@H]3CCCN(C3)C4CC4)CC2)cc1Cl,3.57,
Nc1nnc(CCSCCc2nnc(N)s2)s1,-0.1,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)cc2F)n1,-0.05,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N4CCN(CC4)C(=O)C)n2,2.39,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6oc(cc6)S(=O)(=O)C)c3C1=O,2.71,
COCCC(=O)NC(C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,2.98,
CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(=O)(=O)C,0.51,
COC(=O)CCCCCCC(=O)Nc1ccc2C(=O)C(=O)c3ccccc3c2c1,2.6,
Oc1cc(O)c2C(=O)C(=COc2c1)c3ccc(F)cc3,3.6,
CC(=O)Nc1cnc2ccn(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,2.69,
CC[C@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1S(=O)(=O)c3ccccc3,0.44,
C(Cc1nc2ccccc2[nH]1)c3nc4ccccc4[nH]3,3.3,
CC[C@H](CO)Nc1nc(SCc2ccccc2)nc3NC(=O)Sc13,3.22,
O[C@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NC5CCS(=O)(=O)C5)cc3,1.64,
COc1cc(cc(OC)c1OC)C(=O)Nc2cc(NC(=O)c3cccc(c3)N(C)C)ccc2C,2.54,
Fc1cccc(COc2cc(OCCCN3CCCC3)ccc2C(=O)Nc4ccccc4)c1,3.67,
C[C@H](NC(=O)c1c(NS(=O)(=O)c2ccc(C)cc2)n(nc1C(F)(F)F)c3ccccc3)C(C)(C)C,2.35,
NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c3ncnc(N)c13,-0.87,
COc1ccc(Oc2ncccc2C(=O)NCc3ccccc3Cl)cc1,3.59,
COc1cc2ncc(C(=O)N)c(Nc3ccccc3F)c2cc1OC,2.81,
CC(C)NCCCOc1ccc(NC(=O)C)cc1CC=C,-0.01,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)N4CCOCC4)ncc2F,3.01,
CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc4cnc(C)cn4)cn1,2.1,
C(=C\c1c(nc2sccn12)c3ccccc3)/c4ccncn4,3.4,
CCOc1ccc(cc1)N2C(=Nc3ccccc3C2=O)CC,3.27,
CCCc1c(O)c(ccc1OCCCSc2ccc(CC(=O)O)cc2Cl)C(=O)CC,3.57,
CC1=NC(=C(NC1=O)c2ccc(CN3CCC(CC3)N4C(=O)Nc5ccccc45)cc2)c6ccccc6,3.9,
ON(C=O)C1(CS(=O)(=O)N2CCN(CC2)c3ccc(F)cc3)CCC1,1.34,
O=C(Nc1ccccn1)c2ccc3[nH]c(nc3c2)c4ccc(NC(=O)C56CC7CC(CC(C7)C5)C6)cc4,4.24,
Nc1ccccc1NC(=O)c2ccc(CNc3nccc(n3)c4cccnc4)cc2,2.28,
CCCSc1nc(N[C@@H]2C[C@H]2c3ccccc3)c4nnn([C@@H]5C[C@@H]([C@@H](O)[C@H]5O)C(=O)N)c4n1,2.05,
COc1ccc2nc(C)cc(c2c1)n3cc(CN4CCN(CC4)C(=O)C)nn3,1.3,
C1NCC(CC=C1)c2ccc3ccccc3c2,1.64,
C(Cc1ccccc1)NCc2ccccc2,1.65,
CCC1(C(=O)NC(=O)NC1=O)c2ccccc2,0.05,
O[C@@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NCc5ccncn5)cc3,1.77,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5ccccc5F)ccc4C,2.75,
Oc1ccc(cc1)C2=COc3cc(O)cc(O)c3C2=O,3.06,
CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(OC)c(OC)cc34)cc2OC)cn1,3.42,
COCCNS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4cccnn34)cc1,2.8,
Cc1c(Sc2ccc(Cl)cc2)c3c(cccc3n1CC(=O)O)c4ccccc4,2.61,
CN(c1ccnc(Nc2cc(cc(c2)S(=O)(=O)C)N3CCOCC3)n1)c4cc(CO)ccc4C,2.9,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2ccc(F)cc2)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,2.47,
Cc1nocc1C(=O)Nc2ccc(c(N)n2)c3ccccc3OC(F)(F)F,3.7,
CC1(COc2cc(ccc2NC(=O)CN3CCOCC3)c4cccc5C(=O)C=C(Oc45)N6CCOCC6)COC1,2.2,
Oc1ccc(cc1)c2nc3ccccc3nc2c4ccc(O)cc4,2.7,
Clc1cnc(OC2CCNCC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,1.56,
Cc1nc(C)c(nc1C(=O)N)c2ccc(cc2)C34CCC(CC(=O)O)(CC3)CC4,1.6,
Oc1ccc(C(=O)Cc2ccccc2)c(O)c1,3.09,
C(N1CCN(CC1)c2nc3ccccc3s2)c4nnnn4Cc5cccs5,3.65,
N[C@@H]1CCCN(C1)c2c(\C=C\3/SC(=O)NC3=O)cccc2c4ccncc4,1.56,
Cc1ccc(NC(=O)c2cccc(c2)C(F)(F)F)cc1NC(=O)c3cccnc3,3.11,
CCCN(CCC)C(=O)c1cccc(c1)C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNC3Cc4ccccc4C3,3.3,
OC(=O)c1ccc2cccc(O)c2n1,3.3,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccc(cc4)C(=O)N5CCOCC5,2.77,
Nc1[nH]nc2ccccc12,1.0,This molecule is a member of indazoles.
CS(=O)(=O)NC(=O)CCCc1c([nH]c2ccc(cc12)C#N)c3ccc(F)cc3,1.5,
CCCCCSc1nc(O)c2sc(N)nc2n1,2.86,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(F)c2)n3cnc(c3)C#N,1.51,
COc1ncccc1c2cccc3c(N)c4C(=O)N(Cc4nc23)C5CCC5,3.26,
COCCC(C)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c2ccc(C)cc2,0.78,
Nc1ccccc1NC(=O)c2ccc(cc2)C3CCN(Cc4ccccc4)CC3,2.51,
CC(C)C[C@H](CO)Nc1nc(SCc2ccncc2)nc3nc(N)sc13,2.9,
CCCC1=CC(=O)NC(=S)N1,0.7,
O=C1N2CCOC2=Nc3ccccc13,0.6,
NC(=O)c1cc(cc(c1)[N+](=O)[O-])[N+](=O)[O-],0.81,
NC(=O)COc1ccc(OCCNCC(O)COc2ccccc2)cc1,0.63,
COc1ccc(OC)c(c1)c2cccc3c(N)c(nnc23)C(=O)NC4(C)CCC4,4.48,
CCC1(C)CC(=O)NC1=O,0.23,"This molecule is an succinimide based anticonvulsant commonly used for absence (petit mal) seizures in both adults and children. This molecule has been associated with rare instances of serum enzyme elevations during treatment, but has not been linked to cases of clinically apparent liver injury with jaundice. These molecules is a dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures. It has a role as an anticonvulsant, a geroprotector and a T-type calcium channel blocker. It is a pyrrolidinone and a dicarboximide. An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. This molecule is an Anti-epileptic Agent. The physiologic effect of ethosuximide is by means of Decreased Central Nervous System Disorganized Electrical Activity. This molecule is a succinimide with anticonvulsant activity. The exact mechanism of action is not entirely understood, but most likely ethosuximide exerts its effects by partial antagonism of T-type calcium channels of the thalamic neurons.  This leads to a decrease in burst firing of thalamocortical neurons, which stabilizes the nerve activity in the brain and prevents seizures. This molecule is only found in individuals that have used or taken this drug. It is an anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. [PubChem]Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the low-voltage activated (LVA) group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes."
NC(=O)c1ccn2c(c3ccccc3)c(nc2c1)c4ccc(cc4)C5(N)CCC5,2.0,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccc[nH]4,3.29,
CC(C)N1CCN(Cc2cnc(c(F)c2)c3ccc(cc3)C(=O)Nc4ccccc4N)CC1,1.6,
CN([C@@H]1CCN(Cc2ccc(cn2)C(F)(F)F)C[C@@H]1F)C(=O)Cc3ccc(cc3)n4cnnn4,2.1,
CCCCCC\N=C\1/C=CN(Cc2ccccc2)c3cc(Cl)ccc13,0.98,
CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)C(=O)O,-1.1,
OC(=O)CC(=O)N[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4sc(Cl)c(Cl)c4[nH]3,1.18,
Nc1nc2ccccc2s1,2.0,"This molecule is an odorless gray to white powder. (NTP, 1992) This molecule is a member of benzothiazoles."
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)NCCO)n2,2.09,
Cc1ccc(F)c(Nc2ccnc(Nc3ccc(cc3)S(=O)(=O)N)n2)c1,3.1,
CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,1.69,"This molecule is an imidazoquinoline. A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells. It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. This molecule is an imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. This molecule exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of other transcription factors. This may lead to an increase in mRNA levels and subsequent production of cytokines, especially interferon-alpha (INF-a) and other cytokines, thereby enhancing T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate Langerhans' cells, leading to an enhanced activation of T-lymphocytes. Due to its immunostimulatory activity, this agent may potentially be useful as a vaccine adjuvant."
FC(F)(F)c1nnc2ccc(nn12)n3ccnc3,0.91,
CCOC(=O)c1ccc(CCN2CCN(CC2)c3ccc(C)nn3)cc1,2.58,
Cc1cc(ccn1)c2ccc(cc2)c3nc4ccncc4c(O)c3C#N,1.6,
Cn1cnc(c2ccccc2)c1\C=C\c3ccnc(N)n3,2.61,
Cc1cc(C)c(C(=O)N[C@@H](Cc2ccc(OCCCNc3ccccn3)cc2)C(=O)O)c(C)c1,0.49,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)c(Cl)c3)c2cc1OC,3.22,
OC(=O)c1cc(nc2ccccc12)c3ccccc3,-0.7,
N[C@H]1CCN(C1)c2c(Cl)cccc2\C=C\3/SC(=O)NC3=O,1.89,
OC(=O)c1ccccc1c2ccc(Cl)c(c2)C(=O)NCC3(O)CCCCCC3,-0.34,
CC(C)N1CCN(CC1)C(=O)NCc2ccc(Cl)c(Cl)c2,2.75,
C[C@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,-0.26,
COc1ccc(N(C(C(=O)NC[C@@H](C)O)c2ccccc2F)C(=O)c3occc3CO)c(OC)c1,1.37,
NC1(CCC1)c2ccc(cc2)c3ncc4cccn4c3c5ccccc5,2.5,
NC(Cc1ccc(cc1)N(CCCl)CCCl)C(=O)O,0.39,
CC(C)Nc1nc(NCc2ccccc2)c3sccc3n1,3.9,
CNS(=O)(=O)c1ccc(Oc2ccc(cc2)C#C[C@]3(O)CN4CCC3CC4)cc1,2.03,
Cc1ccc(Oc2ccnc(Nc3ccc(cc3)S(=O)(=O)N)c2)c(C)n1,2.47,
CCOC(=O)c1ccc(COCC2CCN(CC2)c3ccc(C)nn3)cc1,2.68,
Clc1ccc(COC(Cn2ccnc2)c3ccc(Cl)cc3Cl)cc1,2.54,
Cc1cc(Oc2ccnc(Nc3ccc(cc3)N4CCOCC4)c2)c(nc1C)c5ccccn5,2.59,
CS(=O)(=O)c1ccc2C(=CNC(=O)c2c1)C(=O)NC[C@@H](O)CN3CCC(CC3)Oc4ccc(C#N)c(Cl)c4,1.41,
C[C@H]1O[C@H]([C@H](O)[C@H]1Cl)n2cnc3c(N)nc(OC4CCCC4)nc23,3.18,
Nc1ncnc2[nH]ccc12,1.78,
Fc1cc(Oc2ccc(cc2c3ccnnc3)C(F)(F)F)c(Cl)cc1S(=O)(=O)Nc4nncs4,1.15,
NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3CCc4ccccc4)c1,2.0,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)N)ncc2F,2.7,
Clc1ccc2[nH]ncc2c1,2.44,
CN1CCN(CC1)C(=O)c2cc3ccccc3[nH]2,1.7,
NC(=O)c1cccc(S[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,2.22,
NC(=O)C[S+]([O-])C(c1ccccc1)c2ccccc2,1.12,
CC(=O)Nc1ccc(CNc2[nH]nc3ccnc(Oc4ccccc4)c23)cc1,3.03,
NC(=N)N1CCc2ccccc2C1,-1.01,
NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc3c(F)cc(Br)cc3F,2.5,
O=S(=O)(C1CCNCC1)C2(CC2)c3cc(nc(n3)c4cccc5[nH]ccc45)N6CCOCC6,1.1,
Cc1ccc2c(c(C)n(CC(=O)O)c2c1)c3ccnc4cc(Cl)ccc34,2.41,
CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,3.3,
Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1,0.88,This molecule is a quinoxaline derivative.
CNC(=O)c1ccc(C)c(c1)N2C(=CC(=C(Br)C2=O)OCc3ccc(F)cc3F)C,2.8,
Oc1ccc(Cl)cc1C(=O)Nc2ccccc2,2.9,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccnc4ccccc34)c2C(=O)N5C[C@@H](O)[C@@H](O)C5,1.18,
O=C1N([Se]c2ccccc12)c3ccccc3,3.31,
COc1ccc2C=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2c1,1.31,
CC(C)COc1cc(OC(C)C)cc(c1)C(=O)Nc2ccc(cn2)C(=O)O,1.6,
Clc1ccc2NC(=O)CN(C(c3ccccc3)c2c1)C(=O)c4ccccc4,3.31,
CNC(=O)c1ccc(Nc2nccc(n2)c3cnc(C4CC4)n3C(C)C)cc1,2.77,
CC(C)CC(N1NC(=O)c2nc3cc(Cl)ccc3c(O)c2C1=O)c4ccccn4,1.83,
CC(C)C[C@H](NC(=O)N1CCOCC1)C(=O)N[C@@H](CCc2ccccc2)\C=C\S(=O)(=O)c3ccccc3,3.4,
O=C(CN1CCOCC1)Nc2c(cnn2c3ccccc3)C#N,0.5,
CC1=C(C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O)C4=C(C)C(=O)c5c(CCc6ccc(C)cc6)c(O)c(O)cc5C4=O,3.36,
CCN(CC)CC(=O)Nc1c(cnn1c2ccccc2)C#N,0.4,
CCN1CCN(CC(=O)Nc2ccc(c3cccc4C(=O)C=C(Nc34)N5CCOCC5)c6sc7ccccc7c26)CC1,2.6,
CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,3.3,"This molecule appears as odorless white or yellowish-white crystals or a white or creamy-white crystalline powder. (NTP, 1992) This molecule is a steroid ester. This molecule is a slower-releasing anabolic steroid with a short half-life. It is a synthetic androstane steroid derivative of testosterone in the form of 17Î² propionate ester of testosterone. This molecule was developed initially by Watson labs, and FDA approved on February 5, 1974. Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC. This molecule is a short acting oil-based injectable formulation of testosterone.  Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels.  In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males. (NCI04) An ester of testosterone with a propionate substitution at the 17-beta position."
CCCC(C)(COC(=O)N)COC(=O)NC(C)C,2.01,
CC(=O)Nc1ccc(O)cc1OC[C@@H](O)CN2CCC3(CC2)Cc4cc(Cl)ccc4O3,2.76,
[O-][N+](=O)c1ccc2[nH]ncc2c1,2.2,
Cc1cc(C)cc(c1)c2[nH]c3ccccc3c2CCNCCCCc4ccncc4,3.3,
COC(CN1C(=O)NC2=C(C=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C2=O)c3ccccc3)C1=O)OC,1.56,
O=S(=O)(Cc1ccccc1)NCC(N2CCCCCC2)c3ccccc3,2.83,
CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN4CCOCC4)c2c1,3.1,
OC(=O)[C@H](Cc1ccccc1C#N)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.12,
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,0.72,"This molecule is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia. This molecule therapy is associated with mild and transient serum aminotransferase elevations and with rare instances of acute liver injury. This molecule is an aromatic ether. It has a role as an antilipemic drug. It is functionally related to a valeric acid. This molecule is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias. This molecule is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.  This molecule was granted FDA approval on 21 December 1981. This molecule is a Peroxisome Proliferator Receptor alpha Agonist. The mechanism of action of gemfibrozil is as a Peroxisome Proliferator-activated Receptor alpha Agonist. This molecule is a fibric acid derivative with hypolipidemic effects. This molecule interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C). A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established."
O=S(=O)(NCC(N1CCCCCC1)c2ccccc2)c3cccnc3,2.1,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)N,2.4,
O=S(=O)(Nc1cccnc1)c2ccccc2,0.84,
COC(=O)[C@@H]1C2CCC(C[C@@H]1c3ccc(I)cc3)N2CCCF,2.3,
COCCOc1cc2nccc(Nc3cc(O)c(Cl)cc3F)c2cc1OC,2.64,
CC(C)N1CCN(Cc2cnc(c3ccc(cc3)C(=O)Nc4ccccc4N)c(c2)C#N)CC1,1.28,
O=C(Nc1oc(nn1)C(=O)Nc2ccc(cc2)N3CCOCC3)c4ccccc4,1.02,
Cc1ccc(cc1)n2nc(cc2NC(=O)Nc3ccc(OCCN4CCOCC4)c5ccccc35)C(C)(C)C,4.49,
COc1cc2c(Nc3ccc(F)c(Cl)c3)c(cnc2cc1OCCCN4CCN(C)CC4)C(=O)N,1.2,
Cn1cnc2cc(cnc12)C#Cc3ccccc3,3.5,
C[C@H](Nc1ncc(F)c(Nc2cc([nH]n2)N(C)C)n1)c3ncc(F)cn3,1.98,
O=C1C2=Nc3ccccc3CN2c4ccccc14,2.71,
CCNC1=CC=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C1=O)c2ccccc2,2.37,
Cc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(F)c(F)c4,0.75,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3NC(=O)C(=O)Nc13,2.48,
COc1ccc(Cl)cc1NC(=O)Nc2cnccn2,3.63,
CCOC(=O)Nc1cccc(c1)[C@H](N2CCN(Cc3c[nH]c(C)n3)CC2)c4ccc(cc4)C(=O)N(C)CC,2.11,
Cc1ccc(NC(=O)c2ccc(Cl)c(c2)C(F)(F)F)cc1C(=O)Nc3cccnc3,2.83,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3c(F)cccc3Cl)C(=O)O)cc2)n1,-0.42,
NCc1ccc(NC(=O)c2cc(Nc3ncccn3)c4cc(ccc4c2)\C(=N\O)\N)cc1,-0.85,
CCS(=O)(=O)c1cccc(c1)c2cc(ccc2OCC(=O)O)C(F)(F)F,-0.66,
CCOc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1N4CCC(O)CC4,2.74,
CN1CCN(CC1)c2cc3c(Nc4ccc(F)cc4F)c(cnc3cc2F)C(=O)N,2.63,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CC6CN(CCO)CC(C5)O6,2.5,
NC1(CCC1)c2ccc(cc2)c3nn4ccccc4c3c5ccccc5,3.2,
CN(C)C(=O)N[C@@H]1CC[C@H](CCN2[C@@H]3CC[C@H]2C[C@H](C3)Oc4cccc(c4)C(=O)N)CC1,0.22,
COCCNC(=O)c1ccc(Nc2ncc3cc(ccc3n2)c4cccnc4)cc1,3.11,
CCOC(=O)c1ccc(OCCC2CN(C2)c3ccc(C)nn3)cc1,3.22,
OC1CCN(CC1)C(=O)[C@H](Cc2ccccc2)NC(=O)c3cc4cc(Cl)ccc4[nH]3,3.6,
C=CCOc1cc(ccc1NC(=O)CN2CCOCC2)c3cccc4C(=O)C=C(Oc34)N5CCOCC5,3.0,
Cc1cccc(n1)C#Cc2ccccc2,3.6,
CCN(C1CCN(CCC(C2CCN(CC2)S(=O)(=O)CC)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.63,
CCc1cccc2c(cn(CC(=O)NCCOC)c12)C#N,1.95,
COc1cccc2sc(NC(=O)c3ccccc3)nc12,3.96,
Nc1nc(nn1Cc2ccccc2)c3ccccc3,1.91,
COc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2c1,1.24,
CC(NC(=O)c1cc(O)nc2ccccc12)c3ccccc3,2.2,
COc1ccnc(c1)N(C)c2ccnc(Nc3cc(cc(c3)N4CCOCC4)N5CCOCC5)n2,2.23,
Nc1nc(OC2CCCC2)nc3c1ncn3[C@@H]4O[C@H](CF)[C@@H](O)[C@H]4O,1.5,
Oc1oc(c2ccccc2)c(n1)c3ccccc3,3.42,
COc1ccc(\C=C/2\CCc3ccccc3C2=O)cc1CN4CCOCC4,3.8,
CC(C)(C)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,3.99,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccc(F)c(F)c4,2.17,
O[C@@H](CNCCCOCCOCCc1ccccc1)c2ccc(O)c3NC(=O)Sc23,1.09,
FC(F)(F)c1cccc(C(=O)N[C@H]([C@@H]2CCCCN2)c3ccccc3)c1Cl,2.61,
COc1cc(cc(OC)c1OC)C(=O)Nc2ccc(Cl)c(c2)c3nc4ccccc4[nH]3,3.83,
FC(F)(F)c1csc(n1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,2.4,
CC(C)Nc1nc(nc(N2CCOCC2)c1N)C#N,2.04,
O=C1NC=Cc2nc(c3ccc(CN4CCC(CC4)c5n[nH]c(n5)c6ccccn6)cc3)c(cc12)c7ccccc7,3.9,
Cc1cc(N)nc(CCNC(=O)c2ccc(cc2)C#N)c1,1.62,
CCNC1=Nc2ccccc2C(=NC1c3cccs3)c4ccccc4,3.98,
Cc1ccc(c(C)c1)c2nnc(O)c3ccccc23,3.41,
Fc1ccc(cc1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,2.12,
Cc1nc(nc(N2CCCC2)c1Cl)c3ccccn3,3.2,
C[C@@H](NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,3.3,
COc1ccc(Cl)c(c1)C(=O)NCC23CC4CC(CC(C4)C2)C3,4.39,
C[C@@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)C[C@H](C)N1C(=O)Cc3ccccc3,0.7,
Cc1ccc(cc1)C(=O)N(CCCN)CC2=Nc3cc(Cl)ccc3C(=O)N2Cc4ccccc4,1.47,
O=C(NCC#N)[C@@H]1CCCC[C@H]1C(=O)N2CCc3ccccc3C2,1.91,
COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,3.35,
CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,3.7,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(O)cc2)C1)C(C)(C)C,0.77,
CCOC(=O)c1ccc(OCC2CCN(C2)c3ccc(C)nn3)cc1,3.44,
OC(=O)[C@H](Cc1ccc(OCCc2ccc3OCCNc3n2)cc1)NC(=O)c4c(Cl)cccc4Cl,-0.18,
O.O.O.CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]3(C)[C@@H]2[C@H](OC(=O)c4ccccc4)[C@]5(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c6ccccc6)C(=C([C@@H](O)C3=O)C5(C)C)C,3.4,
[O-][S+](CCC1C(=O)N(N(C1=O)c2ccccc2)c3ccccc3)c4ccccc4,-0.51,
COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,2.81,"This molecule is a benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum. It has a role as a vasodilator agent and an antispasmodic drug. It is a benzylisoquinoline alkaloid, a member of isoquinolines and a dimethoxybenzene. An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. This molecule is an opiate alkaloid isolated from the plant Papaver somniferum and produced synthetically.  As a direct-acting smooth muscle relaxant, papaverine is not closely related to the other opium alkaloids in structure or pharmacological actions; its mechanism of action may involve the non-selective inhibition of phosphodiesterases and direct inhibition of calcium channels. This agent also exhibits antiviral activity against respiratory syncytial virus, cytomegalovirus, and HIV. (NCI04) This molecule is a natural product found in Papaver rhoeas, Papaver armeniacum, and other organisms with data available."
COc1ccc(C)c(c1)N(C)c2ccnc(Nc3cc(cc(c3)N4CCOCC4)N5CCOCC5)n2,3.18,
Clc1ccc(CN(Cc2ccc(Cl)cc2)c3nn[nH]n3)cc1,2.74,
Cc1c(F)ccc2c1c(Sc3ccc(Cl)cc3)c(C)n2CC(=O)O,2.23,
CN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,2.94,
Nc1n[nH]c(N)c1Cc2ccc3OCOc3c2,0.47,
CCCCSc1nc(N)c2ncn(Cc3c(F)ccc(C)c3F)c2n1,3.0,
COc1ccc(cc1CNCCO)c2ccc3c(nc(nc3n2)N4C[C@@H](C)O[C@@H](C)C4)N5CCOCC5,1.31,
OC(=O)c1cc2ccccc2n1Cc3ccccc3,0.78,
COc1cccc(c1)C(COCc2cc(cc(c2)C(F)(F)F)C(F)(F)F)N3CCNCC3,3.1,
Nc1ccc2C(=O)C(=O)c3ccccc3c2c1,2.39,
Cc1cc(CNc2ncc(Br)c(Nc3cc(C)[nH]n3)n2)on1,2.92,
COc1ccc(CCN2CNC(=NC2)SCc3ccc(Cl)cc3)cc1OC,2.41,
Clc1ccc(NC(=O)N2CCN(C[C@@H]3CCCN(Cc4ccccc4)C3)CC2)cc1Cl,4.26,
CC(=O)Nc1nc(ns1)c2ccccc2,2.8,
OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+](=O)[O-],1.15,
NS(=O)(=O)NC(=O)CCCc1c([nH]c2ccc(cc12)C#N)c3ccc(F)cc3,1.95,
O[C@@H](CNCCSCCCNCCc1cccc(Cl)c1Cl)c2ccc(O)c3NC(=O)Sc23,2.2,
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,-0.7,"These molecules is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug and a dopaminergic agent. It is a member of hydrazines, a monocarboxylic acid and a member of catechols. This molecule presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.   The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014. On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992. This molecule is the anhydrous, levorotatory isomer of a synthetic hydrazine derivative of the neurotransmitter dopamine. Carbidopa, a peripheral dopa decarboxylase inhibitor, is used as an adjunct with levodopa to prevent levodopa degradation to dopamine in extracerebral tissue, thereby decreasing the peripheral side effects of levodopa. Carbidopa does not penetrate the blood brain barrier; therefore, it does not interfere with the central nervous system (CNS) metabolism of levodopa to the active neurotransmitter dopamine which, in high concentrations in the brain, has anti-parkinsonian effects. This molecule is a natural product found in Pisum sativum with data available."
CC(=O)Nc1cccc2c1c(Oc3ccc(Cl)cc3)c(C)n2CC(=O)O,-1.41,
COC[C@H](C)Oc1cc(Oc2ccc(cc2)S(=O)(=O)C)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,-0.41,
CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1,2.05,
Cc1nc(CS(=O)(=O)c2ccc(Cl)cc2)cc(n1)N3CCOCC3,1.8,
COc1c(N2CCNC(C)C2)c(F)cc3C(=O)C(=CN(C4CC4)c13)C(=O)O,-0.82,
OC(=O)[C@H](Cc1ccc(F)cc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)cc4)CC2,1.9,
COc1ccc2nc(C)cc(OCC(=O)Nc3ccccc3OC)c2c1,3.9,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCN(Cc3ccc(F)cc3)CC2)c4ccccn4,3.28,
CCCCCCCN(CC)CCCC(O)c1ccc(NS(=O)(=O)C)cc1,1.2,
CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.7,
C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@@]4(C)[C@H]3CC[C@@]45CCC(=O)O5,3.2,
Cc1ccc2c(c1)c(Sc3cccc(Cl)c3)c(C)n2CC(=O)O,1.85,
COc1ccc2c(C)nc(NC(=N)N)nc2c1,-0.51,
CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)c3ccccc3)c4ccccc4,3.91,
Fc1ccc(CNc2ncc(Br)c(Nc3cc([nH]n3)C4CC4)n2)cc1,4.28,
OC(=O)COc1ccc(cc1c2ccc(Cl)cc2)C(F)(F)F,0.9,
COCCCc1cc(Nc2ccnc(NCc3onc(C)c3)n2)n[nH]1,2.04,
CC(O)(C(=O)c1ccccc1)c2ccccc2,2.92,
C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F,1.7,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)c4ccc(cc4)C5=NOC(=O)N5)cc1Cl,2.24,
COc1cc(CO)cc(c1)N(C)c2ccnc(Nc3cc(cc(c3)N4CCOCC4)N5CCOCC5)n2,3.0,
CC(C)NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,0.46,
CN1CCC[C@H]1CCN2CCCc3cc(NC(=N)c4cccs4)ccc23,0.37,
COC1=CC=C2C(=CC1=O)C(CCc3cc(OC)c(OC)c(OC)c23)NC(=O)C,1.12,
Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@H](C3)Oc4cccc(c4)C(=O)N)s1,2.39,
OB1N(C(=Nc2ccccc12)S)c3cccnc3,-0.62,
COc1ccccc1CCNCc2cccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)c2,0.82,
Cn1c(C(=O)O)c(CCCOc2cccc3ccccc23)c4ccccc14,2.99,
O=S(=O)(c1ccccc1)C2(CC2)c3cc(nc(n3)c4cccc5[nH]ccc45)N6CCOCC6,3.4,
FC(F)(F)c1ccc(cc1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,4.29,
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)c3ccccn3)c(Cl)c1,2.84,
Cc1nc(N)c2nc(O)n(Cc3ccccc3)c2n1,2.04,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)C#N,3.9,
O=C(Nc1ccccc1)c2ccccc2,2.8,
CCC(CO)NCCNC(CC)CO,-1.42,This molecule is an amino alcohol.
CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,-0.33,"This molecule is a white crystalline powder with a slight odor. (NTP, 1992) This molecule is an N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. This molecule is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification. It has a role as a hypoglycemic agent and an insulin secretagogue. It is a N-sulfonylurea and a member of monochlorobenzenes. This molecule is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating Î² cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic Î² cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. This molecule is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia. This molecule is a Sulfonylurea. This molecule is a long-acting, first-generation sulfonylurea with hypoglycemic activity. Compared to other sulfonylureas, chlorpropamide has an increased risk of prolonged hypoglycemia because of its long half-life."
CCN1CCO[C@@H](CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,2.68,
COC[C@H](N1CCN(C[C@@H]1C)C2(C)CCN(CC2)C(=O)c3c(C)ncnc3C)c4ccc(cc4)C(F)(F)F,2.7,
COc1ccc(cc1OC)S(=O)(=O)Nc2ccc(\C=C\C(=O)Nc3ccccc3N)cc2,2.56,
OC(=O)C(N1CCC(CC1)N2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)c4ccccc4,2.23,
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)C)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]4(C)C=CC(=O)C=C14,2.65,
Clc1ccccc1CNC(=O)c2ccccc2Oc3ccccc3,3.58,
CC1(COc2ccc3c(c2)ncn3c4ccc5cccc(N6CCC(N)CC6)c5n4)COC1,1.99,
OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3,2.67,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3)C(C)(C)C,1.44,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)Cc3cccc(c3)C(=O)O)C(=O)C(F)(F)F,0.68,
OC(=O)CCC(=O)c1ccc(cc1)c2ccccc2,0.58,
CCCSc1c(cnn1[C@@H]2CC[C@@H](CC2)C(=O)O)C(=O)NC3CCCCC3,1.39,
COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,3.5,
Nc1c(nnc2c(cccc12)c3ncccn3)C(=O)NC4CC4,1.5,
C[C@H](NC(=O)c1c(C)nn(CC(F)(F)F)c1NS(=O)(=O)c2ccc(C)cc2)C(C)(C)C,0.93,
CC(C)(C)OC(=O)N1C[C@@H]2CC[C@H]1CN2c3ncc(OCc4ccc(cc4)S(=O)(=O)C)cn3,3.4,
CC[C@@]1(O)C(=O)OCC2=C1C=C3N(Cc4cc5c(CN(C)C)c(O)ccc5nc34)C2=O,0.31,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(CCCc3ccccc3)C2,2.6,
COc1cc2c(Nc3c(Cl)ccc4OCOc34)ncnc2cc1OCC5CCN(C)CC5,1.83,
Clc1ccccc1CNC(=O)c2cccnc2Oc3ccccc3,3.68,
NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23,0.97,
Cc1cc(OCCCS(=O)(=O)C)cc(C)c1c2cccc(COc3ccc4[C@H](CC(=O)O)COc4c3)c2,2.3,
COc1ccc2nc(NC(=O)CCc3ccc(OC)c(OC)c3)sc2c1,3.57,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(C(=O)NCCN(C)C)c(F)c3)ncc2F,2.26,
CN1CCN(CC1)C(=O)c2cc3cc(C)ccc3[nH]2,2.22,
CNc1cccc(CCCc2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)s2)n1,0.78,
COc1cc(OC)c(cc1NC(=O)CCc2nn[nH]n2)S(=O)(=O)N3C(C)CCc4ccccc34,-0.34,
CCOC(=O)c1ccc(OCCC2CCN(CC2)c3ccc(C)nn3)cn1,2.63,
CC(C)(C(=O)c1cccnc1)c2cccnc2,1.45,
CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C4CCC4)nc1,1.45,
CC(C)(C)OC(=O)N1CCN(CC1)c2ccc(OCc3ccc(cc3)S(=O)(=O)C)cn2,3.2,
Fc1cccc(c1F)c2cncc(CNCC3CC3)n2,1.82,
OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O,2.38,
CCCNC(=O)c1nnc2c(cccc2c1N)c3cncc(c3)C(=O)N4CCC4,2.79,
CS(=O)(=O)c1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,1.7,
CN(C)CCCNS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4cccnn34)cc1,1.4,
Nc1c2CCCCc2nc3ccccc13,0.38,
O=C(C1CCN(CC1)c2nnc(s2)n3cccc3)N4CCc5ccccc5C4,3.7,
COc1ccc(CN2CCc3c(C2)[nH]c4ccccc34)cc1OC,3.1,
CNC1=Nc2ncccc2C(=NC1c3cccs3)c4cccs4,2.63,
Clc1ccc2NC(=O)CN(C(c3ccccc3)c2c1)C(=O)c4occc4,3.0,
CC(C)CNc1nc(nc(NC2CCS(=O)(=O)C2)c1N)C#N,2.3,
Cn1cc(nc1c2c3C(=O)N(CC#C)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56)C#N,3.4,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4cc(F)ccn34)N5CCN(CC5)C(=O)C,3.7,
O[C@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NCc5ccncn5)cc3,1.78,
CN(C)CCNC(=O)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,2.29,
CC1=CC2=NNC(=O)N2c3ccccc13,2.35,
Cc1cc(c(S)cc1Cl)S(=O)(=O)Nc2nc(Nc3ccc(Cl)cc3)n[nH]2,2.09,
CCCCC[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Br)c4)c3,1.69,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4ccc(Cl)cc4,2.32,
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c5ccc6OCOc6c5)C1=O,2.6,
CCC(CC)NC(=O)c1cnn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccn3,0.27,
CC1=C(OCc2ccccc2)C(=O)C=CO1,1.87,
O=C(CC12CC3CC(CC(C3)C1)C2)Nc4cccc5ncccc45,3.83,
O=C1C(=O)c2cccnc2c3ccccc13,1.88,
COc1ccccc1OCC(O)CO,0.24,"This molecule is a member of methoxybenzenes. This molecule is readily available and used as an expectorant. Since that time the agent has been a combination component of various prescription and non-prescription over-the-counter cough and cold products and is currently a widely available over-the-counter generic medication. Although it is principally believed that guaifenesin elicits an action to facilitate productive cough to manage chest congestion, it is not known whether the agent can reliably mitigate coughing.  Regardless, on March 1, 2007, the FDA received a petition asking the FDA to notify the public that some antitussives, expectorants, decongestants, antihistamines, and cough/cold combinations are not known to be safe and effective in children under the age of 6 years. After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008.  Furthermore, there has also been contemporary research to suggest that guaifenesin possesses and is capable of demonstrating anticonvulsant and muscle relaxant effects to some degree possibly by acting as an NMDA receptor antagonist. This molecule is a glyceryl guaiacolate with expectorant effects. This molecule increases respiratory tract mucus secretions, acts as an irritant to gastric vagal receptors and recruits efferent parasympathetic reflexes that cause glandular exocytosis. This agent reduces the viscosity of mucus secretion by reducing adhesiveness and surface tension as well as increasing hydration of mucus. This molecule promotes the efficiency of the mucociliary mechanism important in removing accumulated secretions from the upper and lower airway. This molecule is an Expectorant. The physiologic effect of guaifenesin is by means of Decreased Respiratory Secretion Viscosity, and Increased Respiratory Secretions. This molecule is a natural product found in Plectranthus with data available. An expectorant that also has some muscle relaxing action. It is used in many cough preparations. [PubChem]"
CNc1c(Br)cnc2[nH]c(nc12)c3cnn(c3)C4CCN(C)CC4,2.5,
CN(CC[C@@H](Oc1ccc(cc1)c2ccccc2)c3ccc(F)cc3)CC(=O)O,2.86,
CCc1cccc2c3CCOC(CC)(CC(=O)O)c3[nH]c12,0.49,
CS(=O)(=O)c1ccc(cc1)[C@H](CC2CCCC2)C(=O)Nc3nccs3,3.88,
CN1CC(c2ccccc2)c3cccc(N)c3C1,2.08,
Nc1cccc(NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2)c1,1.6,
CCc1c(cnn1c2ccc(cc2)C(=O)O)C(=O)NC3C4CC5CC(CC3C5)C4,0.9,
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,2.12,"This molecule is an aminoketone antidepressant that is widely used in therapy of depression and smoking cessation. This molecule therapy can be associated with transient, usually asymptomatic elevations in serum aminotransferase levels and has been linked to rare instances of clinically apparent acute liver injury. This molecule is an aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring. It has a role as an antidepressant, an environmental contaminant and a xenobiotic. It is a secondary amino compound, a member of monochlorobenzenes and an aromatic ketone. This molecule is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).  Bupropion was originally classified as an ""atypical"" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs, bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors. Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.  When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor. A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT).  Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD.  When used in combination with [naltrexone] in the marketed product Contraveâ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure. The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo. This molecule is an Aminoketone. The mechanism of action of bupropion is as a Dopamine Uptake Inhibitor, and Norepinephrine Uptake Inhibitor. The physiologic effect of bupropion is by means of Increased Dopamine Activity, and Increased Norepinephrine Activity. This molecule is an aminoketone with antidepressant activity. The molecular mechanism of the antidepressant effect of bupropion is unknown.  This agent does not inhibit monoamine oxidase and, compared to classical tricyclic antidepressants, is a weak blocker of the neuronal uptake of serotonin and norepinephrine. Buproprion also weakly inhibits the neuronal re-uptake of dopamine. This molecule is a selective catecholamine (norepinephrine and dopamine) reuptake inhibitor. It has only a small effect on serotonin reuptake. It does not inhibit MAO. The antidepressant effect of bupropion is considered to be mediated by its dopaminergic and noradrenergic action. This molecule has also been shown to act as a competitive alpha-3-beta-4- nicotinic antagonist, the alpha-3-beta-4-antagonism has been shown to interrupt addiction in studies of other drugs such as ibogaine. This alpha-3-beta-4-antagonism correlates quite well with the observed effect of interrupting addiction. A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment; This molecule is a selective catecholamine (norepinephrine and dopamine) reuptake inhibitor. It has only a small effect on serotonin reuptake. It does not inhibit MAO. The antidepressant effect of bupropion is considered to be mediated by its dopaminergic and noradrenergic action. This molecule has also been shown to act as a competitive alpha-3-beta-4-nicotinic antagonist, the alpha-3-beta-4-antagonism has been shown to interrupt addiction in studies of other drugs such as ibogaine. This alpha-3-beta-4-antagonism correlates quite well with the observed effect of interrupting addiction. This molecule (amfebutamone) (brand names Wellbutrin and Zyban) is an antidepressant of the aminoketone class, chemically unrelated to tricyclics or selective serotonin reuptake inhibitors (SSRIs). It is similar in structure to the stimulant cathinone, and to phenethylamines in general. It is a chemical derivative of diethylpropion, an amphetamine-like substance used as an anorectic. This molecule is both a dopamine reuptake inhibitor and a norepinephrine reuptake inhibitor. It is often used as a smoking cessation aid."
CCCSc1nc(N[C@@H]2CC[C@H](CC2)C(=O)O)ccc1C(=O)NC3CCCCC3,2.02,
NC1(Cc2ccc(Cl)cc2)CCN(CC1)c3ncnc4[nH]ccc34,2.72,
CC(C)CCCC(C)\N=C\1/C=CN(Cc2ccccc2)c3cc(Cl)ccc13,1.58,
CC1=CC(=O)Oc2c3CCCNc3c(C)cc12,2.9,
CC#Cc1cncc(c1)c2cccc(c2)C3(N=C(C)C(=N3)N)C4CC4,3.3,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cncn6C)c3C1=O,2.69,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccc(F)cc4,2.01,
Cc1c(Sc2ccc(Cl)cc2)c3cccc(Cl)c3n1CC(=O)O,2.0,
OC(CCN1CCCCC1)(C2CCCCC2)c3ccccc3,2.68,
Fc1ccc(N2CCN(CC2)C(=O)COCc3ccncc3)c(Cl)c1,2.63,
COc1cc(F)ccc1c2cncc(CNC[C@@H]3CCCO3)n2,2.0,
Nc1ncnc2nc(cc(c3cccc(Br)c3)c12)c4ccc(nc4)N5CCOCC5,3.2,
CC1=CN(Cc2ccccc2)C(=O)NC1=O,1.19,
CCCCCC1=CC(=O)NC(=N1)N,1.62,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2cccc(CN3CCOCC3)c2)c4ccccc4)C(C)(C)C,0.29,
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(Cc4cocc4)C3=O,0.6,
O=C1CCOc2nc(COc3ccccc3)ccc12,2.3,
Nc1nc2ccccc2n1C(=O)c3ccccc3,1.56,
CC(C)c1nnc2ccc(cn12)c3ocnc3c4cc(F)ccc4F,2.44,
CC(=O)N1CCN(CC1)c2ccc(OCC3COC(Cn4ccnc4)(O3)c5ccc(Cl)cc5Cl)cc2,3.7,
CC1=CN([C@H]2CCCN(Cc3cccc(Oc4cccc(Br)c4)c3)C2)C(=O)NC1=O,3.68,
COc1cc(ccc1Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)N4CCN(C)CC4,3.9,
CCN(C1CCN(CC[C@H](c2ccc(cc2)S(=O)(=O)C)c3cccc(Cl)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.37,
CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4cc(F)ccc34)cc2OC)cn1,3.93,
COc1cc(F)ccc1c2cncc(CNC(=O)C3CC3)c2,2.9,
Cn1cc(cc1c2c3C(=O)N(CC=C)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56)C#N,4.27,
O=C(NCC#N)c1ccc(cc1)c2ccnc(Nc3ccc(cc3)N4CCOCC4)n2,2.37,
CNC(=O)C1(CCN(CC[C@H](CN(C)C(=O)c2cc(cc3ccccc23)C#N)c4ccc(Cl)c(Cl)c4)CC1)N5CCCCC5=O,2.5,
O[C@@H]1CNC[C@H]1N2C=Cc3c(NC(=O)Cc4ccc(F)c(c4)C(F)(F)F)cccc3C2=O,1.33,
CC(C)OC(=O)N1CCC(CC1)Oc2ncnc(Oc3cccnc3C)c2C,3.8,
Cc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4n12,3.4,
CCN(C1CCN(CC[C@H](C2CCN(CC2)S(=O)(=O)C(F)(F)F)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,3.39,
CN1C(=O)c2c(onc2c3ccncc3)C=C1c4ccccc4,3.17,
Cc1cc(N)n(n1)c2ccccc2,1.25,
Cn1cc(nc1c2c3C(=O)N(CC=C)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56)C#N,3.92,
OC(=O)C[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4cc(F)ccc4[nH]3,1.26,
NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl,-0.09,
CC(=O)N1CCN(CC(O)COc2ccc(Br)cc2)CC1,1.6,
Clc1ccc(cc1Cl)C2=CSC3=NCCN23,1.54,
O=S(=O)(NCC(N1CCCCCC1)c2ccccc2)c3ccc(cc3)C#N,2.86,
O=C1C=CN=C2C=C(C=CN12)C#Cc3ccccc3,2.9,
COc1ncc2N=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2n1,-0.14,
CC(C)N(C(C)C)C(=O)C(C(CNC(=O)NCc1ccccc1F)c2ccccc2)c3cccnc3,4.2,
Cc1sc(CN2CCNCC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,2.55,
Cc1cc(CCCOc2c(C)cc(cc2C)c3noc(n3)C(F)(F)F)on1,3.63,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2ccccc2)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,2.12,
COc1cc2ncnc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)c2cc1OCCN6CCCCC6,3.35,
NC(=O)c1cncc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)n1,1.1,
COc1cc2c(Nc3cccc(Cl)c3Cl)c(cnc2cc1NCCN(C)C)C(=O)N,3.41,
CN1C(C(=O)Nc2ncc(C)s2)C(=O)c3ccccc3S1(=O)=O,0.3,
CC1=CN([C@H]2CCCN(Cc3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3)C2)C(=O)NC1=O,-0.55,
CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C)cc(O)c4c3C2=O,1.19,
CCN1C=C(C(=O)O)C(=O)c2cc(F)c(nc12)N3CCNCC3,-0.83,
COc1ccc2c(C)cc(N[C@H]3CC[C@@H](C3)NCc4cn(C)c5ccccc45)nc2c1,2.53,
Cc1ccn2c(c(C)nc2c1)c3ccnc(N)n3,2.39,
Cc1cc2NC(=O)C(=CC(=O)c2cc1C)O,1.99,
COc1cc(N2CCCN(C)CC2)c3NC(=CC(=O)c3c1)C(=O)Nc4ccc(cc4)N5CCOCC5,2.1,
CC(C)(c1cc(nc(n1)c2cccc3[nH]ccc23)N4CCOCC4)S(=O)(=O)C,2.65,
CC(C)(C)OC(=O)c1ncn2c1[C@@H]3CCCN3C(=O)c4c(Br)cccc24,2.48,
COc1cc2ncnc(Nc3cccc(O)c3)c2cc1OC,2.6,
CC[C@H](NC(=O)c1c(CC[S+](C)[O-])c(nc2ccccc12)c3ccccc3)c4ccccc4,3.15,
CCS(=O)(=O)c1ccc(c(C)c1)c2cc(Cl)ccc2OCC(=O)O,-0.65,
Fc1ccccc1Nc2oc(nn2)C(=O)Nc3ccc(cc3)N4CCOCC4,3.05,
Nc1ccc2c(c1)C(=O)C(=O)c3cc(N)ccc23,1.72,
COC(=O)N1CCOc2cc(COc3ccccc3)cnc12,2.5,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NS(=O)(=O)c3ccccc3)C(=O)C(F)(F)F,2.26,
N[C@@H]1CCCN(C1)c2c(Cl)cccc2\C=C\3/SC(=O)NC3=O,1.97,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2ccccc12)c3cccs3)c4ccccc4,3.56,
CCN(C)C(=O)c1ccc(cc1)C(=C2CCN(Cc3ccc(F)cc3)CC2)c4ccccc4NC(=O)C,2.79,
Nc1nccc(n1)c2cc3C(=O)NC[C@@H](CCF)c3[nH]2,0.51,
CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C,2.21,
COc1ccc2nccc([C@@H](O)[C@@H]3C[C@H]4CCN3C[C@@H]4C=C)c2c1,2.26,
FC(F)(F)c1ccc(cc1)S(=O)(=O)N2CCN(CC2)C(=O)N3CCN(CC3)c4ccncc4Cl,3.54,
OCC(CO)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.56,
Cn1c(ccc1c2ccc3NC(=S)OC(C)(C)c3c2)C#N,3.4,
CS(=O)(=O)c1ccc(c[n+]1[O-])C(=O)Nc2ccc(F)cc2,0.84,
Nc1nccc(n1)n2ccc3ccccc23,2.71,
CCN(C1CCN(CCC(N2CCC(CC2)C(=O)C)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,0.9,
CCN(CC)C(=O)c1ccc(cc1)[C@@H](N2CCN(Cc3ccc(F)cc3)CC2)c4cccc(NC(=O)C5CC5)c4,3.99,
CC(C)Cc1ccc(cc1)C(C)C(=O)NS(=O)(=O)C,0.78,
Cc1cc(NC(=O)c2ccccc2)n[nH]1,1.75,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3NC(=O)C=Nc13,3.1,
CC1=CN([C@H]2CCCN(C2)[C@@H](CC(C)(C)C)c3ccc(C(=O)O)c(Oc4cccc(Br)c4)c3)C(=O)NC1=O,1.12,
CC(C)(NC(=O)c1sccc1Oc2ccc(F)cc2[N+](=O)[O-])C#C,3.0,
Nc1nc2nc(cc(n2n1)C(F)(F)F)c3cccs3,2.01,
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c2nc3ccccc3[nH]2,2.7,
NC1=CC2=NNC(=O)N2c3cc(ccc13)c4cccs4,3.26,
Nc1nc2ccc(cc2[nH]1)C(=O)c3ccccc3,2.29,
NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)C2(F)F,-1.5,
CN1C=C(C(=O)c2c(O)cc(O)cc12)c3ccc(O)cc3,2.2,
CC(C)Oc1ccc2C(=O)C(=COc2c1)c3ccccc3,4.07,
NC(=O)N(c1ccc(C(=O)N)c(n1)c2ccc(F)cc2F)c3c(F)cccc3F,1.6,
CCCNC(=O)c1nnc2c(cccc2c1N)c3cc(C)ccc3OC,3.99,
CNC(=O)c1ccc(CN2CCC(CC2)c3ccc(cc3)C(=O)Nc4ccccc4N)cc1,1.99,
C[C@H](NC(=O)c1c(C)nn(C2CCSCC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,1.29,
CC[C@H]1[C@@H](Cc2cncn2C)COC1=O,-0.37,
NC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccc[nH]4,2.3,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3c[nH]c4ncccc34)c2C(=O)N5CC[C@@H](O)C5,1.71,
CCOc1cccc(\C=C\2/SC(=O)NC2=O)c1N3CCC[C@@H](N)C3,1.86,
CS(=O)(=O)C1(CCOCC1)c2cc(nc(n2)c3cccc4[nH]ccc34)N5CCOCC5,2.4,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)OCc3ccncc3)C(=O)C(F)(F)F,2.41,
Cc1ccc(cc1)S(=O)(=O)Nc2c(C(=O)NC3CCCCC3)c(C)nn2c4ccccc4,1.68,
CN1C(=O)C(=Cc2cnc(NC3CCOCC3)nc12)Oc4ccc(F)cc4F,2.76,
O=C1Oc2ccccc2C=C1c3ccccc3,3.22,
COc1ccccc1C(=O)NCC23CC4CC(CC(C4)C2)C3,4.43,
Cc1nc(cs1)C(=O)N2CCCC3(CCN(Cc4ccccc4)CC3)C2,0.24,
CS(=O)(=O)n1c2ccccc2c3cc(NC(=O)N4CCOCC4)ccc13,2.7,
CCOc1ccccc1c2ccc(cc2)c3nc4ccc(F)cc4c(C(=O)O)c3C,1.18,
CC(C)(C)C(=O)Nc1ccc2c(c1)C(=O)C(=O)c3ccccc23,2.83,
CN1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4,1.1,
Nc1ncnc2oc(c3cocc3)c(c4occc4)c12,3.1,
OC(=O)c1ccc(Nc2ncc(Br)c(Nc3ccccc3)n2)cc1,1.65,
Oc1ccc(O)c2C(=O)C=CC(=O)c12,1.91,
CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc2ccccn2,0.24,
C[C@@H](Oc1cccc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c12)C(=O)N(C)CCO,3.56,
Oc1ccc2C(=O)C(=COc2c1)c3ccc(O)c(O)c3,1.88,
Brc1ccc2oc3C(=O)NC(=Nc3c2c1)[C@@H]4CCCN4,2.19,
C[C@@H]1CN(CCN1c2ncc(OCc3ccc(cc3C#N)S(=O)(=O)C)cn2)C(=O)OC(C)(C)C,3.3,
CN1CCN(CC1)c2cc(Nc3cc(C)[nH]n3)nc(Sc4ccc(NC(=O)C5CC5)cc4)n2,3.47,
Cc1cnc(NS(=O)(=O)c2ccccc2)c(C)n1,-0.03,
CCCC(=O)NCc1cncc(c1)c2ccc(F)cc2OC,2.9,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)Cc3ccc(cc3)C(=O)O)C(=O)C(F)(F)F,0.35,
Cc1nnc2CN=C(c3ccccc3Cl)c4cc(Cl)ccc4n12,2.34,
C[C@@H]1CN(CCN1C(=O)[C@@H]2CCCC[C@H]2C(=O)NC3(CC3)C#N)c4ccc5c(c4)c(C)nn5C,2.8,
Cn1cc(cc1c2c3C(=O)N(CCO)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56)C#N,3.0,
Cc1cccc(n1)c2nc3cc(Cl)ccc3[nH]2,4.1,
COC(=O)c1ccc(CC(=O)N(C)C2CCN(CCC(c3ccccc3)c4ccccc4)CC2)cc1,4.0,
F[C@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@H]1NCc4ccc5OCC(=O)Nc5n4,0.66,
C[C@H](NC(=O)c1c(C)nn(C2CCN(CC(F)(F)F)CC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,1.08,
C[C@@H]1CN(CC2(CC2)C(=O)N)CCN1S(=O)(=O)c3ccc(cc3)C(C)(O)C(F)(F)F,1.03,
c1ccc2[nH]ncc2c1,1.9,This molecule is an indazole. It is a tautomer of a 2H-indazole.
COCCS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc(C)n3C(C)C)cc1,2.56,
Oc1ccc(CCNCCS(=O)(=O)CCCOCCc2ccccc2)c3sc(O)nc13,2.61,
COc1ccc(OC(F)(F)F)cc1CN[C@H]2CCCN[C@H]2c3ccccc3,2.9,
Nc1nc(cs1)c2ccc(Cl)cc2,3.31,
NS(=O)(=O)c1cc(C(=O)O)c(NCc2occc2)cc1Cl,-0.9,
CCOC(=O)c1ccc(N)cc1,1.83,"This molecule is a benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina. It has a role as a topical anaesthetic, an antipruritic drug, an allergen and a sensitiser. It is a benzoate ester and a substituted aniline. This molecule is an ester local anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. It is commonly used for local anesthesia in many over the counter products. This molecule was first used for local anesthesia in dentistry. This molecule is a Standardized Chemical Allergen. The physiologic effect of benzocaine is by means of Increased Histamine Release, and Cell-mediated Immunity. This molecule is an ester of paraaminobenzoic acid, lacking the terminal diethylamino group of procaine, with anesthetic activity. This molecule binds to the sodium channel and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited, thereby blocking the initiation and conduction of nerve impulses. This molecule is a surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. This molecule is a local anesthetic commonly used as a topical pain reliever. It is the active ingredient in many over-the-counter analgesic ointments. This molecule is an ester, a compound made from the organic acid PABA (para-aminobenzoic acid) and ethanol. The process in which this ester is created is known as Fischer esterification."
CCN(C1CCCCC1)C(=O)c2cnn(c2NS(=O)(=O)c3ccc(cc3)c4ocnc4)c5ccccc5,1.46,
Oc1nc2cc(Cl)c(Cl)c(c2nc1O)[N+](=O)[O-],0.21,
CNCC[C@@H](Oc1cc(OC)ccc1C#N)c2ccccc2,0.87,
CCc1c(C)nc2sc(C(=O)N)c(N)c2c1C,2.62,
OC(=O)c1ccc(OCC(=O)COc2ccc(SCCCCCc3ccccc3)cc2)cc1,3.63,
COc1cc2ncc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1NCCN4CCOCC4,2.68,
OCCCN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.49,
OC(=O)CC[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4sc(Cl)c(Cl)c4[nH]3,2.84,
OCCO[C@H]1C[C@H]([C@H](O)[C@@H]1O)n2nnc3c(N[C@@H]4C[C@H]4c5ccc(F)c(F)c5)nc(SCCC(F)(F)F)nc23,4.17,
Cc1cc(CNc2ncc(Cl)c(Nc3cc(C)[nH]n3)n2)on1,2.68,
CCCc1cc(cc(OC)c1OC)C2=N[C@H](CO2)C(=O)NO,1.69,
ON(C=O)C1(CS(=O)(=O)N2CCN(CC2)c3ccc(F)cc3)CCOCC1,0.85,
CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c2cccc(O)c2)NC(=O)[C@H]3Cc4ccc(O)cc4CN3,2.39,
OC(=O)c1cccc(c1)c2cccc(c2)C#N,0.3,
CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)N3CCN(CC3)c4ccc(cn4)C(F)(F)F)C(=O)C2,3.8,
CC1=CN([C@H]2CCCN(C2)[C@H](CC(C)(C)C)c3ccc(C(=O)O)c(Oc4cccc(Br)c4)c3)C(=O)NC1=O,1.09,
COc1cc2ncc(C(=O)N)c(Nc3cc(C)ccc3F)c2cc1OC,3.16,
COc1cc(Oc2ccnc3ccc(F)cc23)ccc1CC(=O)Nc4noc(C)c4C,4.06,
Cc1cc(NC(=O)c2ccc(Cl)cc2)n(n1)c3ccccc3,3.25,
OC(=O)c1ccc(cc1)n2ncc(C(=O)NC3C4CC5CC(CC3C5)C4)c2C6CCCC6,1.72,
CC1=C(CCC(=O)O)C(=O)Oc2cc(O)ccc12,-0.7,
CC(C)(O)c1ccc(Nc2nc3ccc(cc3[nH]2)C#N)cc1,2.73,
CN(C)CC(O)COc1ccc(Nc2cc(Nc3ccc(F)cc3F)ncn2)cc1,1.48,
COc1cc2ncc(C(=O)N)c(Nc3ccccc3Cl)c2cc1OC,2.89,
C1CNCC(C1)c2nc3ccccc3s2,1.0,
[O-][N+](=O)c1cccc2ccc(nc12)C(Cl)(Cl)Cl,3.7,
C[C@H](Nc1ncc(Cl)c(Nc2cc([nH]n2)N(C)C)n1)c3ncc(F)cn3,2.33,
CN(C)C(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.07,
CN(C)c1ccccc1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.74,
O=C1NC(=NC(=C1C#N)c2ccccc2)SCc3ccccc3,1.56,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)NCc3ccncc3)C(=O)C(F)(F)F,2.16,
C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2)nc3nc(N)sc13,3.31,
CCN1CCN(Cc2ccc(cc2)c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)CC1,3.97,
OC(CN1CCOCC1)c2ccccc2,1.0,
OCCN1CCN(CCCN2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1,3.8,
CC(=O)Nc1ccc2ccn(c3cc(NCCCN4CCCC4)n5ncc(C#N)c5n3)c2c1,1.87,
CN(C)c1cccc2c(cccc12)S(=O)(=O)N,1.95,
Cc1[nH]c(C(=O)NC2CCN(CC2)c3nc(cs3)C(=O)O)c(Cl)c1Cl,0.14,
CCC[C@H](CO)Nc1nc(S[C@@H](C)c2cccc(c2)C#N)nc3NC(=O)Sc13,3.7,
O[C@H](CNC(=O)C1=CNC(=O)C=C1C(F)(F)F)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,2.71,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NS(=O)(=O)C(F)(F)F)C(=O)C(F)(F)F,1.01,
Fc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)c3ccc(F)cc3,2.9,
CC(C(=O)O)c1cccc(c1)C(=O)c2ccccc2,-0.12,
Nc1nccc(\C=C\c2ccc(Cl)cc2)n1,3.5,
CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)C)C=O,2.6,
OC(=O)c1cccnc1Nc2cccc(c2)C(F)(F)F,1.0,
CC1(C)COCc2sc(nc12)N3CCN(CC3)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,2.4,
COc1cc2ncc(C(=O)N)c(Nc3cccc(F)c3F)c2cc1OC,2.82,
OCCN1CCN(Cc2ccc3c(NC(=O)CC45CC6CC(CC(C6)C4)C5)c(Cl)ccc3n2)CC1,2.93,
O=C1CCOc2cc(OCc3cccc(c3)C#N)ccc12,2.8,
Cc1nc(C)c(nc1C(=O)N)c2ccc([C@@H]3CC[C@H](CC(=O)O)CC3)c(F)c2,1.2,
Cn1cnc(c1Sc2ncnc3nc[nH]c23)[N+](=O)[O-],0.19,
CC(C)(C)OC(=O)NCCCSC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)ncnc23,1.2,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCc4[nH]c5ncccc5c4C3,2.13,
Nc1scc2C(=NN(C(=O)c12)c3ccc(F)cc3)C(=O)NC4CC4,2.8,
O[C@@H](CNCCc1ccc(NC[C@H](O)c2ccccc2)cc1)c3ccc(O)c(NC=O)c3,0.02,
CCCC1CCCCC(=N1)N,1.1,
NNC1=Nc2ccccc2NC1=O,0.44,
Clc1c(NCC2CCNCC2)nccc1C(=O)NCC34CC5CC(CC(C5)C3)C4,0.6,
COCCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+](=O)[O-])C(=O)OC(C)C)C,3.8,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N4CCN(CC4)C(=O)CN(C)C)n2,3.31,
COCC[C@H](Oc1ncnc2c1cnn2c3ccccc3Cl)C(=O)Nc4ccc(C)cn4,3.6,
OC(=O)[C@H](N1CCC(CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)CC1)c4ccccc4,2.14,
Cn1c(CN2CCN(CC2)c3cccc(Cl)c3)nc4ccccc14,3.75,
CCN1C(=O)C2=C(OC(=CC2=O)O)c3ccccc13,1.13,
CN([C@@H]1CCN(Cc2ccc(cc2)C(F)(F)F)C[C@@H]1F)C(=O)Cc3ccc(cc3)S(=O)(=O)C,2.7,
Cc1ccc(Oc2ccc(cc2)C(=O)NCc3ccncc3)cc1,3.65,
O[C@H](CNC(=O)C1=CNC(=O)c2ccccc12)CN3CCC(CC3)Oc4ccc(C#N)c(Cl)c4,2.56,
NC(=N)Nc1ccc(Cl)c(Cl)c1,-0.31,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4c(cccc34)S(=O)(=O)C,-0.34,
CCOC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c2cccc3ccccc23,3.12,
FC(F)(F)c1cccc(c1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.12,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4cccc(F)c4)c1,3.15,
NCCCCN(Cc1nc2ccccc2[nH]1)C3CCCc4cccnc34,0.83,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCN(CC3)c4cnccn4)c(F)c2,1.49,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4cccc(c4)C#N)c1,2.41,
CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2,1.33,
Fc1cccc(COc2ccc3C(=O)CCOc3c2)c1,3.4,
Fc1ccc(cc1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NCC#N,1.92,
Fc1ccc(Nc2oc(nn2)C(=O)Nc3ccc(nc3)N4CCOCC4)cc1F,2.9,
Cc1c(Sc2ccc(Cl)cc2)c3cc(ccc3n1CC(=O)O)c4ccccc4,3.7,
FC(F)(F)c1cc(COCC(N2CCNCC2)c3ccccc3)cc(c1)C(F)(F)F,2.9,
COc1cc2ncnc(Nc3cccc(C)c3)c2cc1OC,3.5,
C[C@H](NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.67,
CN1C(=O)N(CCCCC(=O)C)C(=O)c2c1ncn2C,0.22,
C[C@H]1CN(Cc2cc(Cl)ccc2CC(=O)O)CCN1S(=O)(=O)Cc3ccccc3,1.12,
C(Nc1nc2ccccc2[nH]1)c3ccccc3,2.76,
CS(=O)(=O)N1CCOc2cc(COc3ccccc3)cnc12,2.4,
OCCOCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,3.08,
COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,1.39,"This molecule is a viscous brown liquid. (NTP, 1992) This molecule is an ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group. It has a role as a H1-receptor antagonist. It is an ethylenediamine derivative and an aromatic ether. This molecule, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions."
OC(=O)c1ccc(CN2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2)cc1,1.1,
OC[C@H]1CCCN1CCCOc2ccc3c(Nc4cc(CC(=O)Nc5cccc(F)c5F)[nH]n4)ncnc3c2,2.06,
FC1(CCN(CC1)C(=O)COCc2ccncc2)c3ccc(Cl)cc3,3.03,
COc1cnccc1COc2cnc(nc2)N3CCN(CC3)C(=O)OC(C)(C)C,3.8,
NC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.22,
CN(C)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,1.75,
Fc1ccc(Nc2oc(nn2)C(=O)Nc3ccc(nc3)N4CCOCC4)cc1,3.0,
CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)Cc4ccccc4,0.99,
Cc1[nH]c(C(=O)NC2CCN(CC2)c3cc(cc(Cl)n3)C(=O)O)c(Cl)c1Cl,1.74,
COc1ccc(cc1)C(=O)Nc2cc(NC(=O)c3cccc(c3)N(C)C)ccc2C,3.17,
Cc1cc(C)cc(c1)c2[nH]c3ccc(cc3c2CCNCCCCc4ccncc4)C(C)(C)C(=O)N5C6CCC5CC6,4.3,
C[C@H]([C@H](O)c1ccc(O)cc1)N2CCC(O)(CC2)c3ccccc3,0.91,
CCCSc1nc(ccc1C(=O)NC2CCCCC2)N3CCC[C@H](CC(=O)O)C3,2.18,
NC(=O)Nc1sc(cc1C(=O)N[C@H]2CCCNC2)c3ccc(F)cc3,1.76,
CCCSc1nc(ccc1C(=O)NC2CCCCC2)N3CCCCC3C(=O)O,1.36,
Oc1ccc(cc1)C(c2ccc(O)cc2)C(Cl)(Cl)Cl,3.86,
CNc1c(Br)cnc2[nH]c(nc12)c3ccc(OCCCN4CCOCC4)cc3,2.96,
CSc1ccc(OCc2ccccc2)c(\C=C\c3ccc(cn3)C(=O)O)c1,2.45,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3c(C)cc(C)cc3C)C(=O)O)cc2)n1,0.52,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cc(cn6C)S(=O)(=O)C)c3C1=O,3.18,
CCCc1c(O)c(ccc1OCc2ccc(\C=C\c3nn[nH]n3)cc2)C(=O)C,3.3,
C1CN=C(N1)c2ccc3ccccc3n2,0.6,
CCCNCc1cnc(s1)c2ccc(cc2)C(=O)Nc3ccccc3N,1.75,
COC(=O)CCn1cc(c2cc(NC3CC3)n4ncc(C#N)c4n2)c5cc(NC(=O)C)ccc15,2.72,
CC(C#Cc1ccccc1)N2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3,1.4,
CC1=CC(=O)Oc2cc3NCCCc3cc12,2.7,
OC(=O)COc1ccc(cc1c2cccc(c2)C#N)C(F)(F)F,0.05,
CNc1nc(C)c(s1)c2nc(Nc3cccc(c3)N4CCCNCC4)ncc2C#N,1.64,
O[C@@H](CNCCCSCCOCCc1ccccc1)c2ccc(O)c3NC(=O)Sc23,2.3,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C(=O)N)n4ccc(n4)C(F)(F)F,1.81,
C\N=C(/S)\n1nc(nc1N)c2ccc(Cl)cc2,4.12,
CC1=C(CCC(=O)O)C(=O)Oc2c(C)c(O)ccc12,-0.3,
CC(Cc1ccccc1)N(C)CC#C,2.16,
C[C@H](NC(=O)c1c(C)nn(C2CCOCC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,0.5,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NS(=O)(=O)NCc3ccccc3)C(=O)C(F)(F)F,2.57,
Cc1c(CC(=O)O)c2cc(F)ccc2n1S(=O)(=O)c3ccc(cc3)S(=O)(=O)C,-0.44,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(C1)S(=O)(=O)c2ccccc2)C(C)(C)C,0.9,
CCCN(CCC)CCc1cccc2NC(=O)Cc12,0.76,
CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4cccnc4,1.2,
Clc1ccc(cc1C(=O)NCCc2ccccc2)N3N=CC(=O)NC3=O,0.74,
Cc1ccc2c(c1)c([S+]([O-])c3ccc(Cl)cc3)c(C)n2CC(=O)O,0.05,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCNCC2)c3ccc(Cl)c(Cl)c3,2.4,
OC(=O)[C@H](Cc1cccc(c1)C#N)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.26,
COc1ccccc1C(=O)Nc2nc3ccccc3[nH]2,2.9,
CNc1ncc(s1)C(=O)c2ccccc2,2.36,
COc1cc2ncnc(Nc3ccccc3)c2cc1OC,3.04,
CN1CCN(CC1)c2ccc(Nc3ccnc4ccccc34)cc2,1.3,
CNC[C@H](O)c1ccc(Cl)c(c1)C(=O)NCC23CC4CC(CC(C4)C2)C3,1.41,
OC(CCN1CCCCC1)(C2CC3CC2C=C3)c4ccccc4,2.49,
COc1ccc(CNC(=O)CSc2nc3cccnc3s2)cc1,2.5,
C[C@@H](NC(=O)C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.18,
CC1=CN([C@H]2CCCN(Cc3ccc(C(=O)O)c(Oc4cccc(C)c4)c3)C2)C(=O)NC1=O,-0.82,
CCCc1c(O)c(O)c(C(=O)O)c2cc(Cc3ccccc3)c(C)cc12,2.6,
CS(=O)(=O)Nc1cccc(NC(=O)CN2CCN([C@H](Cc3ccccc3)C2)C(=O)C[C@H](N)Cc4ccc(F)c(F)c4)c1,2.06,
O=S1NC(=NO1)Cc2ccc3ccccc3c2,1.85,
O=C(N1CCN(CC1)c2ccccn2)c3cccc(CC4=NNC(=O)c5ccccc45)c3,2.36,
COc1cnc(nc1N(C)c2ccccc2)c3ccccn3,2.79,
CS(=O)(=O)c1ccc(cc1Cl)[C@@H](C[C@H]2CCC(=O)C2)C(=O)Nc3cnccn3,1.39,
Cc1nc(cs1)C(=O)N2CCOC3(CCN(Cc4ccc(Cl)cc4)CC3)C2,2.17,
CN(C(=O)N1CCC(CC1)N2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)S(=O)(=O)c4ccc(C)cc4,4.49,
Cc1ccnc(NCc2ccccc2)c1,3.08,
CN1C=CNC1=S,-0.42,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN4CCC[C@@H]4C(=O)N,3.58,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4ccoc34)n2)c1,3.7,
NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc(cc2)[N+](=O)[O-],0.5,
CCN(C1CCN(CCC(C2CCN(Cc3ccccc3)CC2)c4ccccc4)CC1)C(=O)Cc5ccc(cc5)S(=O)(=O)C,2.41,
CN(C)C(=O)CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.4,
Clc1cccc(c1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.62,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4c(C)cccn34)N5CCN(CC5)C(=O)C,3.2,
CS(=O)(=O)c1ccc(nc1)c2nnc(\C=C\c3oc(nn3)c4ccc(cc4)C#N)n2c5ccccc5Cl,2.66,
Oc1ccc(cc1)C2=Cc3cc(O)ccc3OC2=O,2.9,
CN1C(=O)CN=C(c2ccccc2F)c3cc(ccc13)[N+](=O)[O-],2.1,
CCN1CCN(CC(=O)Nc2ccc(c3cccc4C(=O)C=C(Oc34)N5CCOCC5)c6sc7ccccc7c26)CC1,3.05,
COc1ccc(CNCc2ccc(cc2)c3cc(C(=O)N)c(NC(=O)N)s3)cc1,2.55,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(F)cc3)n2,3.62,
COc1ccc2C(=NC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2c1)C,0.29,
COC(=O)C1C(CC2CCC1N2C)OC(=O)c3ccccc3,1.06,
Cc1nc2ccc(NC(=O)CCNC(=O)N)cc2s1,0.9,
O[C@H](CNC(=O)c1c[nH]c2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.91,
C[C@H](CO)Nc1nc(SCc2occc2)nc3NC(=O)Sc13,2.21,
Clc1ccc(CNc2nc(nc3ncccc23)N4CCN(CC4)C(=O)[C@@H]5CCCN5)c(Cl)c1,2.41,
O=C(CN1CCN(CC1)c2ccccc2)Nc3c(cnn3c4ccccc4)C#N,2.3,
Cc1ncc([N+](=O)[O-])n1CCO,-0.11,"This molecule is a white to pale-yellow crystalline powder with a slight odor. Bitter and saline taste. pH (saturated aqueous solution) about 6.5. (NTP, 1992) This molecule is a nitroimidazole derivative bactericidal agent widely used in the treatment of many anaerobic and certain protozoan and parasitic infections. This molecule has been linked to rare instances of acute, clinically apparent liver injury. This molecule is a member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. This molecule is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. It has a role as an antitrichomonal drug, a prodrug, an antibacterial drug, an antimicrobial agent, an antiparasitic agent, a xenobiotic, an environmental contaminant, a radiosensitizing agent and an antiamoebic agent. It is a member of imidazoles, a C-nitro compound and a primary alcohol. It is a conjugate base of a metronidazole(1+). This molecule is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. This molecule has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. This molecule is a Nitroimidazole Antimicrobial. This molecule is a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. This molecule is a natural product found in Euglena gracilis and Streptomyces hygroscopicus with data available. A nitroimidazole used to treat amebiasis; vaginitis; trichomonas infections; giardiasis; anaerobic bacteria; and treponemal infections. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985) this substance may reasonably be anticipated to be a carcinogen."
COCCN1CCN(CC(=O)Nc2ccc(C3=CC=CN4C(=O)C=C(N=C34)N5CCOCC5)c6sc7ccccc7c26)CC1,3.2,
CNS(=O)(=O)c1ccc2C(=CNC(=O)c2c1)C(=O)NC[C@@H](O)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.77,
OC1(CN2CCC1CC2)c3ccc(cc3)c4ccccc4,1.5,
Oc1nnc(Cc2cccc(c2)C(=O)N3CCOCC3)c4ccccc14,1.0,
C[C@H](Nc1ncc(Br)c(Nc2cc(C)[nH]n2)n1)c3ncc(F)cn3,2.39,
CN(C1CCCCC1)C(=O)c2cnn(c2NS(=O)(=O)c3ccc(C)cc3)c4ccccc4,2.01,
CSc1ncccc1C(=O)NCc2ccc(C)cc2,2.71,
CNCC[C@@H](Oc1cc(ccc1C#N)C(F)(F)F)c2ccccc2,1.3,
CCC(C)Nc1nc(nc(N2CCOCC2)c1N)C#N,2.8,
C1Cc2ccccc2CN1c3ccncc3,1.4,
CC(N)(COP(=O)(O)O)C(=O)O,2.5,
Oc1ccc(Cl)cc1C(=O)Nc2ccc(F)cc2F,3.6,
CN(C)C(=O)N[C@@H]1CC[C@@H](CCN2[C@@H]3CC[C@H]2C[C@H](C3)Oc4cccc(c4)C(=O)N)CC1,0.12,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)C2CCCCC2)c3ccccc3)C(C)(C)C,1.75,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccc(Cl)cc4,2.78,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCN(Cc3ccc(F)cc3)CC2)c4ccc(NC(=O)OC)cc4,4.01,
Cc1ccccc1CCOCCCS(=O)(=O)CCNCCc2ccc(O)c3nc(O)sc23,2.84,
CCN(C)C(=O)c1ccc(cc1)[C@@H](N2CCN(Cc3cccnc3)CC2)c4cccc(NC(=O)C5CCC5)c4,3.27,
CC(C)CN1C(=O)N(C)C(=O)c2cn(Cc3cccc4ccccc34)cc12,4.41,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)c4onc(n4)C(F)(F)F,3.1,
C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)c4cnc(N)nc4)N5CCOCC5)CC1,1.9,
Oc1ccc(cc1)C2=Cc3ccccc3OC2=O,3.0,
COc1cc(OC)c2nc(C)c3CCN(c4ccc(O)cc4)c3c2c1,1.5,
COc1ccccc1N2CCN(CC3=C(Br)C(=O)N(N3C)c4ccccc4)CC2,2.5,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(ccc4C)C(=O)Nc5ccon5,1.87,
O[C@@H](CNCCSCCCNCCc1cccc(Cl)c1)c2ccc(O)c3NC(=O)Sc23,0.98,
CCc1[nH]c2nc(Sc3cnc4ccc[n+]([O-])c4c3)nc(N5CC[C@@H](N)C5)c2c1Cl,2.0,
OC1(C(=O)Nc2ccccc12)c3ccccc3,1.71,
NC(=O)c1ccccc1O,1.09,"This molecule appears as odorless white or slightly pink crystals. Bitter taste, leaves a sensation of warmth on the tongue. pH (saturated aqueous solution at 82 Â°F) about 5. Sublimation begins at the melting point. (NTP, 1992) This molecule is the simplest member of the class of salicylamides derived from salicylic acid. It has a role as a non-narcotic analgesic and an antirheumatic drug. It is a member of salicylamides and a member of phenols. This molecule is the common name for the substance o-hydroxybenzamide, or amide of salicyl. This molecule is a non-prescription drug with analgesic and antipyretic properties. It has similar medicinal uses to aspirin. This molecule is used in combination with both aspirin and caffeine in the over-the-counter pain remedies This molecule is a natural product found in Streptomyces spectabilis and Streptomyces rimosus with data available."
OCC(CO)NC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,2.61,
CC(C)Oc1cc(OCCN2CCOCC2)cc3ncnc(Nc4c(Cl)ccc5OCOc45)c13,3.68,
Brc1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.12,
NC(Cc1ccccc1)c2ccccc2,1.32,
CCOC(=O)c1ccc(OC(=O)CCCCCN=C(N)N)cc1,2.41,"This molecule is a benzoate ester. This molecule is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. This molecule has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis."
COc1ccc2c(c1)[nH]c3c(C)nccc23,2.9,
Cc1cc(ccc1O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)C(=O)N,2.23,
OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1,1.79,
Clc1cccc(NC(=O)N2CCN(C[C@@H]3CCCN(C3)C4CC4)CC2)c1,2.74,
COc1ccccc1CNCCc2cccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)c2,0.91,
Cn1ncc(Cl)c1c2cc(sc2Cl)C(=O)N[C@H](CN)Cc3cccc(F)c3,2.99,
Nc1nc(O)c2ncn(COCCO)c2n1,-1.42,"This molecule is a nucleoside analogue and antiviral agent used in therapy of herpes and varicella-zoster virus infections. This molecule has not been associated with clinically apparent liver injury. This molecule is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. This molecule is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.  This molecule was granted FDA approval on 29 March 1982. This molecule is a Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor, and Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor, and Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor. The mechanism of action of acyclovir is as a DNA Polymerase Inhibitor. This molecule is an oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections. It has a role as an antiviral drug and an antimetabolite. It is an oxopurine and a member of 2-aminopurines. It is functionally related to a guanine. This molecule is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses of the herpesvirus family. After conversion in vivo to the active metabolite acyclovir triphosphate by viral thymidine kinase, acyclovir competitively inhibits viral DNA polymerase by incorporating into the growing viral DNA chain and terminating further polymerization. This molecule is a natural product found in Epicoccum nigrum with data available."
CN(C)C(=O)N[C@@H]1CC[C@@H](CCN2CCN(CC2)c3cccc(Cl)c3Cl)CC1,3.6,
O[C@H](CNC(=O)c1c[nH]nc1C(F)(F)F)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,3.34,
Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1,3.21,This molecule has been used in trials studying the treatment of Major Depressive Disorder.
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(Cc4ccncc4)C3=O,-0.16,
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1.87,"This molecule is an odorless white to off-white crystalline powder with a slightly bitter taste. (NTP, 1992) This molecule is a fluorinated steroid that is 9-fluoropregna-1,4-diene substituted by hydroxy groups at positions 11, 17 and 21, a methyl group at position 16 and oxo groups at positions 3 and 20. It is a synthetic member of the class of glucocorticoids. It has a role as an adrenergic agent, an antiemetic, an antineoplastic agent, an environmental contaminant, a xenobiotic, an immunosuppressive agent and an anti-inflammatory drug. It is a fluorinated steroid, a 3-oxo-Delta(1),Delta(4)-steroid, a glucocorticoid, a 20-oxo steroid, an 11beta-hydroxy steroid, a 17alpha-hydroxy steroid and a 21-hydroxy steroid. It derives from a hydride of a pregnane. This molecule is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].  Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. This molecule is a Corticosteroid. The mechanism of action of dexamethasone is as a Corticosteroid Hormone Receptor Agonist. This molecule is a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) This molecule is a natural product found in Aspergillus ochraceopetaliformis, Penicillium chrysogenum, and other organisms with data available. An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]"
CS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4CCOc34)n2)c1,3.0,
CS(=O)(=O)c1ccc(s1)C(=O)NC[C@@H](O)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,2.86,
COc1cccc(c1)S(=O)(=O)c2c(C)n(CC(=O)O)c3ccc(C)cc23,-0.42,
Clc1ccc2C(=C3CCNCC3)c4ncccc4CCc2c1,1.48,
OC(=O)CCCCn1nnc(n1)c2ccc(cc2)C(=O)N3CCC(CC3)N4CCC(CC4)Oc5ccc(Cl)c(Cl)c5,1.6,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4nc5ccncc5s4,1.6,
O=C(C1CCN(CC1)c2nnc(s2)n3cccc3)N4CCN(Cc5ccc6OCOc6c5)CC4,2.5,
CCN1CCOC(C1)C(=O)N2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3,2.1,
O=C1COC2(CCN(CC2)S(=O)(=O)c3ccc(cc3)c4ccc5cccnc5c4)CN1C6CC6,3.24,
COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OC[C@@H]4CCCN(C)C4,3.05,
NC(=N)NC(=O)c1nc(Cl)c(NCc2ccncc2)nc1N,-0.51,
Oc1ccccc1OCC(=O)NC2CCCC2,2.31,
Clc1ccc(cc1C(=O)NCC23CC4CC(CC(C4)C2)C3)C5CCNCC5,1.58,
CCC[C@@H](CNC(=O)c1nc(Cl)c(N)nc1N)[N+](C)(C)CCCc2ccc(OC)cc2,0.4,
Oc1ccc(cc1)c2oc3cc(O)ccc3n2,3.3,
NC(=O)c1sc(cc1NS(=O)(=O)c2ccc(cc2)C(F)(F)F)c3ccsc3,2.39,
Clc1ccc(N2CCN(CC2)C(=O)COCc3ccncc3)c(Cl)c1,3.38,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5oncc5)ccc4C,1.75,
CS(=O)(=O)c1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,-0.51,
CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc2cccc(c2)C(=N)N)NS(=O)(=O)c3c(cc(cc3C(C)C)C(C)C)C(C)C,1.67,
CNC1=Nc2ncccc2C(=NC1c3cccs3)c4cc[nH]c4,1.73,
CC1(C)CC(=O)c2c(N)c3ccccc3nc2C1,3.0,
C[C@H]1O[C@H]([C@H](O)[C@H]1Cl)n2cnc3c(N)nc(OCC4CC45CC5)nc23,3.68,
CC(C)Oc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)nc(OC(CO)CO)c2Cl)n[nH]1,2.77,
CCS(=O)(=O)c1ccc(c(F)c1)c2cc(Cl)ccc2OCC(=O)O,-0.92,
C[S+]([O-])CCN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.17,
Clc1c(ccnc1N2CCNCC2)C(=O)NCC34CC5CC(CC(C5)C3)C4,1.77,
COc1ccc(cc1OC)N2CCN([C@H](C)C2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,1.85,
O[C@H](CNC(=O)C1=CNC(=O)c2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.42,
Nc1cc(cc(c1)C(F)(F)F)C(=O)Nc2cccc(c2)c3nnn[nH]3,0.2,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCNCC2)c3ccccc3,1.2,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N(C)C)n2,3.51,
Fc1ccc(cc1)C(=O)N2CCC[C@@H](C2)c3onc(n3)c4ccc(F)cc4,3.73,
CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)c3c(C)cc4c(C(C)C)c(O)c(O)c(C=O)c4c3O,2.75,
CN(CCCOCCOCCc1ccccc1)CCc2ccc(O)c3nc(O)sc23,2.44,
CCn1cc(NC(=O)Cc2ccc(Oc3ccnc4ccc(F)cc34)cc2OC)cn1,3.88,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)NCc3ccc[n+]([O-])c3)C(=O)C(F)(F)F,1.48,
OC(=O)c1ccc2c(c1)nc(Nc3cccc(c3)C#C)c4ncncc24,0.92,
CCS(=O)(=O)c1ccc(Oc2cc3nc([nH]c3cc2CN4C(=O)CCC4=O)c5ccccn5)cc1,2.0,
Oc1ccc(CCNCCCS(=O)(=O)NCCSCCc2ccccc2)c3sc(O)nc13,1.77,
Clc1ccc(cc1C(=O)NCC23CC4CC(CC(C4)C2)C3)N5N=CC(=O)NC5=O,2.1,
CCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,1.38,
Cc1ccccc1C[C@H](N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2)C(=O)O,2.54,
CNC(=O)c1nc(cnc1N)c2ccc(Cl)c(c2)S(=O)(=O)Nc3cccc(F)c3F,2.8,
O=C(Nc1nccs1)c2ccccc2,2.43,
Fc1ccc(cc1Cl)C(=O)Nc2ccc(Cl)nc2,3.64,
CC(C)CN1C(=O)N(C)C(=O)c2c(SC3CCCCC3)c(Cc4ccccc4C(F)(F)F)sc12,4.14,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CCNCC5,2.4,
CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cccc(C)c2,0.3,
OC(=O)c1cncc(c1)c2cnc3[nH]c(cc3c2n4ccc(n4)C(F)(F)F)C(=O)NC5CC5,-0.98,
NC(=O)c1sc(cc1N)c2ccc(Cl)cc2,3.3,
CN1C(=O)N(Cc2ccc(Br)cc2)c3ccccc13,2.81,
Nc1nc2cc3CCN(Cc4cccc(F)c4)CCc3cc2s1,3.3,
COc1ccc(Cl)cc1C(=O)Nc2nc3ccccc3[nH]2,4.05,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c3C1=O)c6nc(cn6C)S(=O)(=O)C,2.64,
CN(CCN(C)C(=O)CCOCCc1ccccc1)CCc2ccc(O)c3nc(O)sc23,2.59,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC4CCN(CC4)S(=O)(=O)C,2.82,
CC1(C)C(=O)Nc2ccccc12,2.3,
CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1,0.48,"This molecule is a sulfonamide, a member of tryptamines and a heteroarylpiperidine. It has a role as a serotonergic agonist and a vasoconstrictor agent. This molecule is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches. This molecule is a Serotonin-1b and Serotonin-1d Receptor Agonist. The mechanism of action of naratriptan is as a Serotonin 1b Receptor Agonist, and Serotonin 1d Receptor Agonist. This molecule is only found in individuals that have used or taken this drug. It is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism."
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3cc(C)nc4ccccc34,2.88,
C1CN(CCO1)c2cc(Nc3nccc(Nc4cccc5[nH]ncc45)n3)cc(c2)N6CCOCC6,3.05,
CC(C)(C)CNc1nc(nc(N2CCOCC2)c1N)C#N,3.08,
O=C1Nc2ccc(cc2C1=O)S(=O)(=O)N3CCC[C@H]3CNc4ccccc4,2.4,
Fc1ccc(cc1)C(=O)N2CCC(CC2)C(=O)c3ccc(Cl)cc3,3.49,
OC(=O)COc1ccc(Cl)cc1CN2CCN(CC2)S(=O)(=O)c3ccccc3,0.49,
Nc1[nH]nc2cccc(Cl)c12,1.92,This molecule is a member of indazoles.
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N2CCC3(CC2)CN(c4ccccc34)S(=O)(=O)C,1.4,
C[C@H]1C[C@H](CN1C#N)NS(=O)(=O)c2cc(Br)ccc2Br,2.13,
CC(C)(C)NC(=O)Nc1ccc(cc1)c2c(N)nc(N)nc2COCc3ccccc3,3.09,
COc1ccc(N(C(C(=O)NC[C@@H](C)O)c2ccccc2F)C(=O)c3ccoc3Cl)c(OC)c1,2.36,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)cnc1C#N)c3ccc(F)cn3,2.51,
CC(=O)Nc1ccc2ccn(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,3.29,
CCN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cncn6C)c3C1=O,2.87,
CCCNC[C@H](O)COc1ccccc1C(=O)CCc2ccccc2,1.69,
Fc1ccc(Oc2cc(F)c(cc2F)S(=O)(=O)Nc3ncc(Cl)s3)c(c1)c4cn[nH]c4,2.7,
CC1=CN([C@H]2CCCN(C2)[C@H](CC3CCOCC3)c4ccc(C(=O)O)c(Oc5cccc(Cl)c5)c4)C(=O)NC1=O,-0.25,
CC(=O)Nc1nc(cs1)c2cccs2,2.77,
O=C1N(Cc2ccccc12)C3CCN(CCC(c4ccccc4)c5ccccc5)CC3,4.1,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C(=O)O)n4nc(cc4C)C(F)(F)F,-0.88,
OC(=O)[C@H](Cc1ccccc1F)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.58,
COc1cc2cc(nc(C)c2cc1OC)c3ccc(O)cc3O,3.9,
Cc1cc(NC(=O)Nc2ccc(Cl)cc2)n(n1)c3ccccc3,4.15,
[O-][N+](=O)c1cccc(c1)c2ccc(OCC(CCc3ccc(cc3)C(=O)N4CCCC4)N5C(=O)CCCC5=O)cc2,2.31,
Oc1ccc(cc1)C2=Cc3cccc(O)c3OC2=O,2.8,
OC(=O)Cc1cccc(c1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,1.58,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)N4CCN(CC4)C(=O)CO)ncc2F,2.19,
Cc1ccc(cc1)S(=O)(=O)Nc2c(cnn2c3ccccc3)C(=O)NC4CCCCC4,0.8,
Cn1cncc1c2c3C(=O)N(C4CC4)C(=O)N(CC5CC5)c3nn2Cc6ccnc7ccc(Cl)cc67,3.53,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4cccc(F)c4)c3)C(=O)NC1=O,1.6,
CC(C)[C@H](NC(=O)CCc1ccccc1)C(=O)N2CCCC2,2.49,
COc1ccccc1C(=O)Nc2nc3ccccc3s2,3.61,
COc1ccc(cc1)c2csc(n2)N(CCCN3CCOCC3)C(=O)c4occc4,3.34,
O=C1CCCc2nc(ccc12)C#Cc3ccccc3,3.53,
C(CCNc1cc(nc2ccccc12)c3ccccc3)CNc4cc(nc5ccccc45)c6ccccc6,3.65,
CCCSc1nc(N[C@@H]2C[C@H]2c3ccccc3)c4nnn([C@@H]5C[C@H](CO)[C@@H](O)[C@H]5O)c4n1,3.99,
NC(=O)c1cccc(C[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,1.19,
OC(CN1CCCCC1)(C(=O)c2ccccc2)c3ccccc3,3.41,
CCc1ccc(CCNCCCSCCNC[C@H](O)c2ccc(O)c3NC(=O)Sc23)cc1,0.86,
CN1CCN(CC1)S(=O)(=O)c2ccc(c(C)c2)c3cnc(N)c(n3)C(=O)Nc4cccnc4,2.6,
C[C@H](O)C(=O)N1CCN(CC1)c2ccc(Nc3nccc(n3)c4cnc(C)n4C(C)C)cc2,2.15,
CN(C)c1nc(nc(n1)N(C)C)N(C)C,2.44,
COC(=O)c1ccc(NC(=O)c2cc(OC)c(OC)c(OC)c2)cc1,3.2,
OC1=NC(=O)CN1N=Cc2oc(cc2)c3ccc(cc3)[N+](=O)[O-],1.35,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(CCCN4CCCC4)c5ccc(Cl)cc5,1.3,
O=C(CS(=O)(=O)c1ccccc1)c2ccccc2,1.86,
Cc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)cc4C,1.79,
COc1cccc(NC(=O)CC23CC4CC(CC(C4)C2)C3)c1C,4.21,
O=C(Cc1ccccc1)Nc2nccs2,2.5,
O=C(Nc1cccc2cccnc12)[C@@H]3CC[C@H](CC3)N4C(=O)[C@@H]5[C@@H]6CC[C@@H](C6)[C@@H]5C4=O,3.94,
O=C(Cc1cccc2ccccc12)Nc3ccccc3,3.9,
CNC1(C)C2CCC(C2)C1(C)C,-0.84,"This molecule is a primary aliphatic amine. This molecule is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. This molecule is a natural product found in Wettsteinia inversa with data available."
N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc3cc(F)c(F)cc3F,0.31,
CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],3.46,
C[C@H](CO)Nc1nc(SCc2csc(C)n2)nc3nc(N)sc13,1.73,
COc1cc(cc(OC)c1OC)C(=O)N2CC[C@@](CCN3CCC(CC3)(C(=O)N)c4ccccc4)(C2)c5ccc(Cl)c(Cl)c5,3.23,
C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc5cscn5)c3)c12)C(=O)N6CCOCC6,2.81,
O=S(=O)(Nc1cccnc1)c2cccs2,0.54,
Brc1ccc(cc1)C(=O)Cn2cnc3ccccc23,3.22,
CCCc1nc2c(N)nc3ccccc3c2s1,4.09,
OC(=O)C1Cc2c([nH]c3ccccc23)C(N1)c4ccccc4,0.78,
COc1cc(CNc2nc3ccccc3[nH]2)cc(OC)c1OC,2.36,
OC1=C(C(=O)Nc2cc(Cl)ccc12)c3cccc(Oc4ccccc4)c3,2.96,
CCn1c2ccccc2c3cc(NC(=O)C(C)C)ccc13,4.2,
COc1ccc(CNC(=O)N(CC=C)C2CCN(CCC(c3ccccc3)c4ccccc4)CC2)cc1,3.6,
COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OC[C@@H]4CCCN(C)C4,2.9,
CN(c1cccc(CO)c1)c2ccnc(Nc3cc(cc(c3)N4CCOCC4)N5CCOCC5)n2,2.6,
C[C@H](CO)Nc1nc(SCc2csc(C)n2)nc3NC(=O)Sc13,1.73,
Cn1nnc(n1)c2ccc(cn2)c3ccc(cc3F)N4C[C@H](COc5ccon5)OC4=O,1.24,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4OCOc34)n2)c1,2.83,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccc(F)cc4F,1.97,
CCN(C(=O)c1oc(cc1)c2ccc(Cl)cc2)c3ccc(cc3)N4CCNCC4,3.3,
O=C(CCN1CCCCC1)Nc2ccc(C3=CC=CN4C(=O)C=C(N=C34)N5CCOCC5)c6sc7ccccc7c26,2.9,
Cc1ccc(cc1)S(=O)(=O)N2CCN(CC2)C(=O)c3occc3,2.17,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3ccncc3F)cn2,3.6,
Cc1ccc(CN2C(=O)CCSc3ccc(Cl)cc23)cc1,3.7,
CC(C)C(NC(=O)CN1C(=O)c2nc(O)nc(O)c2C=C1c3ccccc3)C(=O)C(F)(F)F,1.88,
NC(=O)c1cccc(C[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,1.11,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3c(C)n[nH]c3C)c2C(=O)N4C[C@H](O)CO4,1.07,
O=C1N(C(=Nc2c1cnn2c3ccccc3)c4occc4)c5ccccc5,3.29,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)C4=CNC(=O)c5ccccc45)cc1Cl,3.51,
COc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.87,
Nc1ncnc2c1nc(Sc3nc4cccc(Cl)c4s3)n2CCO,2.37,
COc1cc2ncnc(Nc3cc(NC(=O)c4cccc(c4)N5CCOCC5)ccc3C)c2cc1OC,3.6,
Cc1ccccc1C(=O)N2CCN(CC2)c3ccccn3,2.18,
OC(=O)[C@H](Cc1ccc(F)cc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)cc4Cl)CC2,2.6,
COc1ccc(c(OC)c1)c2cncc(CNC3CCCC3)n2,2.14,
COC1CCN(CC1)C(=O)C2CCN(CCc3c([nH]c4sc(cc34)C(C)(C)C(=O)N5C6CCC5CC6)c7cc(C)cc(C)c7)CC2,4.09,
C1NCC(CC=C1)c2oc3ccccc3c2,1.94,
O[C@H](CNC(=O)C1=CC(=O)Nc2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.48,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1C(C)C)NC(=O)OCc2ccccc2)C(=O)C(F)(F)F,2.63,
CCN(CC)C(=O)c1ccc(cc1)[C@@H](N2CCN(CCOC)CC2)c3cccc(NC(=O)C4CC4)c3,2.35,
CN(C)CCCNS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4ccccn34)cc1,1.9,
Cc1nc2ncnn2c(O)c1CCOC(=O)c3c(F)cccc3F,0.16,
COc1ccc(F)c(F)c1C(=O)c2cnc(NC3CCN(CC3)S(=O)(=O)C)nc2N,2.08,
NC(=O)c1cccc(N[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,1.01,
Clc1ccc(cc1)c2cn3ccccc3n2,4.0,
CCN1C(=O)NC(C1=O)c2ccccc2,1.0,
CN1CCC(CC1)Oc2nccc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)n2,1.8,
Nc1nc(NCc2ccccc2)nc3c1nc(O)n3Cc4ccccc4,3.69,
CCN(C1CCN(CC[C@H](C2CCN(CC2)S(=O)(=O)C)c3cccc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.44,
Cc1nc(C)c(nc1C(=O)N)c2ccc([C@@H]3CC[C@H](CC(=O)O)CC3)c(Cl)c2,1.7,
FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c3ccccc3)cc(c1)C(F)(F)F,3.6,
CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c3ccccc3)C(=O)O)cc1)c4oc5ccccc5n4,2.47,
Cc1cccc(c1)C(=O)N2CCC(CC2)C(=O)c3ccc(F)cc3,3.4,
Clc1ccc(cc1Cl)[C@@H]2CNCC=CC2,1.95,
COC(=O)c1ccc(CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3)cc1,1.17,
CCN(CC)c1ncnc2c1ncn2Cc3c(Cl)cccc3Cl,1.25,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CC6CNCC(C5)O6,2.3,
CCCS(=O)(=O)N1N=Cc2cc(Cl)ccc2B1O,-0.4,
CNc1ccc2ncc(c3cccc(O)c3)n2n1,2.99,
CC(=O)Nc1cccc(Nc2nc(NC3CC3)n4ncc(C#N)c4n2)c1,2.1,
CN1CCN(CC1)C(=O)c2cc(CC3=NNC(=O)c4ccccc34)ccc2F,1.03,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(N)cnc13,2.89,
OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4c3n2)c5c(F)cccc5F)cc1,2.58,
Cc1cc(CN2Cc3ccccc3C2C(=O)Nc4ccc(Cl)cc4Cl)ccc1OCC(=O)O,2.62,
CCO\N=C(\C1CCN(CC1)C2(C)CCN(CC2)C(=O)c3c(C)cc[n+]([O-])c3C)/c4ccc(Br)cc4,2.14,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)N)C(=O)C(F)(F)F,1.74,
CCOc1ccc(cc1)N2C(=O)c3cccnc3N=C2[C@@H](C)N(Cc4cccnc4)C(=O)Cc5ccc(OC(F)(F)F)cc5,3.7,
COc1cc2nc(Nc3ccc(cc3)[C@@H](C)NC(=O)C)ncc2cc1c4ccncc4,3.11,
O=C(Nc1nccs1)[C@H](CC2CCOCC2)c3ccc(cc3)S(=O)(=O)C4CC4,2.55,
Cc1cccc(NS(=O)(=O)c2cccc3nonc23)c1,3.0,
CCOc1cc2nnc(C(=O)N)c(Nc3cc(C)ccc3F)c2cc1N4CCN(C)CC4,3.02,
O=S(=O)(Nc1ccccc1c2ccccc2)c3ccccc3,3.96,
CC1=C(C)C(=O)C(=C(C)C1=O)C(CCCCCC(=O)O)c2ccccc2,2.48,
Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)CC2)c1Cl,3.14,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4ccc(N)nn4,2.47,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2cc(Cl)ccc12)c3ccccc3)c4ccccc4,3.07,
Fc1ccc(cc1)C(NC(=O)CC2CCN(Cc3ccn(c3)c4ccc(cc4)C(F)(F)F)CC2)C5=CNC(=O)C=C5,3.04,
CCS(=O)(=O)c1ccc(c(C)c1)c2cc(ccc2OCC(=O)O)C(F)(F)F,-0.45,
CC(N1NC(=O)C2=C(C1=O)C(=O)c3ccc(Cl)cc3N2)c4oc5ccccc5c4,2.1,
Cc1cc(CNc2nccc(Nc3cc(C)[nH]n3)n2)on1,1.86,
CCCC(=O)Nc1ccc2c3ccccc3C(=O)C(=O)c2c1,2.81,
CC(C)(O)c1ccccc1CC[C@@H](SCC2(CC(=O)O)CC2)c3cccc(\C=C\c4ccc5ccc(Cl)cc5n4)c3,3.45,
Clc1ccc(Nc2nnc(Cc3ccncc3)c4ccccc24)cc1,3.7,
Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2,0.88,
COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CCN3C[C@@H]4C=C)c2c1,2.21,
Cc1nc(C)c(nc1C(=O)N)c2ccc(cc2)[C@@H]3CC[C@@H](CCC(=O)O)CC3,1.6,
NC(=O)Cc1ccccc1,0.3,"This molecule is a monocarboxylic acid amide that is acetamide substituted by a phenyl group at position 2. It has a role as a mouse metabolite. It is functionally related to a phenylacetic acid. This molecule is a natural product found in Streptomyces abikoensis, Streptomyces chrestomyceticus, and other organisms with data available."
CC(=O)O[C@H]1CC[C@]2(C=O)[C@H]3CC[C@]4(C)[C@H](CC[C@]4(O)[C@@H]3CC[C@]2(O)C1)C5=CC(=O)OC5,0.64,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN4CCC[C@H]4C(=O)N,3.58,
CC(C)NNC(=O)c1ccncc1,0.33,This molecule is a carbohydrazide and a member of pyridines. Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
NC(=O)Nc1sc(cc1C(=O)N)c2ccccc2,2.42,
Nc1ccc(N=Nc2ccccc2)c(N)n1,3.22,"This molecule is a diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. It has a role as a local anaesthetic, a non-narcotic analgesic, a carcinogenic agent and an anticoronaviral agent. It is a diaminopyridine and a monoazo compound. It is a conjugate base of a phenazopyridine(1+)."
CCCSc1nc(NC)ccc1C(=O)N[C@@H]2C3CC4CC2C[C@@](O)(C4)C3,3.27,
Oc1ccc(cc1)c2oc3c(cc(O)cc3n2)C#N,3.6,
OC(=O)[C@H](Cc1ccc(cc1)C#CCCNc2ccccn2)NC(=O)c3c(Cl)cccc3Cl,0.27,
O=C1CCOc2nc(ccc12)C#CC3CCCCC3,3.3,
Cc1ccc(cc1)N2NC(=O)c3cccnc23,2.1,
COc1ccc(cc1)C(=O)N2CCCC2=O,0.93,
CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,1.17,
Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]56[C@@H](Oc1c25)c7[nH]c8[C@@H]9Oc%10c(O)ccc%11C[C@H]%12N(CC%13CC%13)CC[C@@]9(c%10%11)[C@@]%12(O)Cc8c7C[C@@]36O,1.41,
Clc1cccc2[nH]ncc12,2.5,
Brc1ccccc1NC(=O)Nc2ccc(C#N)c3[nH]nnc23,1.64,
Nc1ccc(Cl)c(c1)c2oc3cccnc3n2,1.97,
C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc3ccc(Cl)cc3NC(=O)N,1.91,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)c4ccncc4,2.8,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C#N)n2,3.62,
O[C@@H]1CCN(C1)c2ccc3c(NC(=O)CNc4cccc(c4)C#N)c(Cl)ccc3n2,2.39,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4nc5CCOCc5s4,1.42,
Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)c5ccccn5,2.55,
Cc1ccc(cc1)C(=O)Oc2ccc(cc2OC(=O)c3ccc(C)cc3)C(O)CNC(C)(C)C,3.57,
CCCCC(CC)CNC(=O)c1ccc2c(c1)c(Cc3ccc(cc3OC)C(=O)NS(=O)(=O)c4ccccc4C)cn2C,3.66,
CCN(C1CCN(CCC(c2ccccc2)c3ccc(cc3)S(=O)(=O)C)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.73,
C[C@H](NC(=O)c1c(C)nn(C2CCS(=O)(=O)CC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,0.25,
COCCOc1nc(N)c2NC(=O)N(Cc3ccccc3)c2n1,2.26,
CC(C)N(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,3.9,
NC(=O)c1cc(C(=O)N)n(n1)c2cccc(c2)c3cc(ccc3C(F)(F)F)C(F)(F)F,3.4,
CS(=O)(=O)Nc1cc(Nc2nccc(Nc3c(Cl)ccc4OCOc34)n2)cc(c1)C(=O)N,2.28,
Oc1cc(cc(c1)C(F)(F)F)C(=O)Nc2cccc(c2)c3nnn[nH]3,0.8,
N#Cc1cccc(c1)c2cccc(c2)c3nn[nH]n3,0.7,
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3NC(=O)COc23)cc1,0.79,
NC1(CCC1)c2ccc(cc2)c3ncc4cnccc4c3c5ccccc5,2.2,
Fc1ccccc1C(=O)Nc2c(cnn2c3ccccc3)C#N,1.7,
CC1=CC(=O)Nc2ccccc12,1.9,
C[C@H](Cc1cccc(CC(=O)NC23CC4CC(CC(C4)C2)C3)c1)NC[C@H](O)c5ccc(O)c(CO)c5,2.4,
Oc1ccc(cc1)c2ccc(cc2)C3(O)CN4CCC3CC4,0.95,
CNC(=O)c1snnc1c2ccccc2,1.23,
CC(C)(C)NC(=O)Nc1cccc(CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3)c1,1.77,
CN1CCN(CC1)c2nc(NCCNc3ccc(cc3)[N+](=O)[O-])c4ccccc4n2,2.91,
OC(=O)CSCC(=O)Nc1nc(cs1)c2ccc(F)cc2,-0.2,
OC(=O)[C@H](Cc1ccc(OCCNc2ccccn2)cc1)NC(=O)c3c(Cl)cccc3Cl,-0.48,
CC(C)(C)OC(=O)N1CCC(CC1)c2ncc(OCc3ccc(cc3)S(=O)(=O)C)cn2,2.8,
CC(C)CN1C(=O)NC(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CCC4,3.0,
Nc1ncnc2c1c(COc3cccc(Cl)c3)nn2C4CCOCC4,3.17,
O=C(COCc1ccccc1)Nc2ccc3c(c2)C(=O)C(=O)c4ccccc34,3.21,
OCc1ccc2ccn(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,3.09,
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,-0.96,"This molecule is a sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It is a sulfonamide and a member of tryptamines. It is functionally related to a N,N-dimethyltryptamine. It is a conjugate acid of a sumatriptan(1+). This molecule is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. This molecule is the first of the triptans and was made available in Europe in 1991 to treat migraines. This molecule was granted FDA approval on 28 December 1992. This molecule is a Serotonin-1b and Serotonin-1d Receptor Agonist. The mechanism of action of sumatriptan is as a Serotonin 1b Receptor Agonist, and Serotonin 1d Receptor Agonist. This molecule is a sulfonamide triptan with vasoconstrictor activity. This molecule selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. This molecule may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve. Oftentimes, serotonin levels in the brain become extremely erratic before the onset of a migraine. In an attempt to stabilize this, sumatriptan is administered to help aid in leveling the serotonin levels in the brain. Sumatriptan is structurally similar to serotonin, and is a 5-HT (5-HT1D) agonist, which is one of the receptors that serotonin binds to. The specific receptor subtype it activates is present in the cranial and basilar arteries. Activation of these receptors causes vasoconstriction of those dilated arteries. Sumatriptan is also shown to decrease the activity of the trigeminal nerve. Sumatriptan is a triptan drug including a sulfonamide group structurally similar to serotonin, and is a 5-HT (5-HT1D) agonist, which is one of the receptors that serotonin binds to. Oftentimes, serotonin levels in the brain become extremely erratic before the onset of a migraine. In an attempt to stabilize this, sumatriptan is administered to help aid in leveling the serotonin levels in the brain. A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of migraines. Sumatriptan (Imitrex, Imigran, Imigran Recovery) is a triptan drug including a sulfonamide group which was originally developed by Glaxo for the treatment of migraine headaches."
NC1(CCC1)c2ccc(cc2)c3c(ccc4ccnn34)c5ccccc5,2.9,
CN(C1CCN(Cc2ccc(cc2)C(F)(F)F)CC1)C(=O)Cc3ccc(cc3)n4cnnn4,3.0,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccoc3C(=O)N2Cc4ccccc4,1.37,
COc1ccc(N(C(C(=O)NC[C@@H](C)O)c2ccccc2F)C(=O)c3occc3C)c(OC)c1,2.04,
CCCc1c(O)c(ccc1OCc2cccc(NC(=O)Cc3ccccc3C(=O)O)c2)C(=O)C,2.95,
CC(C)OC(=O)N1CC2COCC(C1)C2Oc3ncnc(Oc4cccnc4C)c3C,3.1,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nccnc13,3.15,
NC(=O)c1cnc(c2ccc(cc2)C3(N)CCC3)c(c1)c4ccccc4,1.3,
C[C@H](CO)Nc1nc(SCc2ccccc2)nc3NC(=O)Sc13,2.86,
NCC[C@@H](Oc1cc(Cl)c(F)cc1C#N)c2ccccc2,0.77,
CN(c1ccnc(Nc2cc(OC3CCOCC3)cc(c2)N4CCOCC4)n1)c5cc(CO)ccc5C,3.7,
CC(C)(CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(N)sc13,3.37,
Oc1cc(O)c2C(=O)C=C(Oc2c1)c3ccccc3,3.83,
CC(C)(C)NS(=O)(=O)c1cncc(c1)c2ccc3nc(NC(=O)NCC(=O)N4CCCC4)nn3c2,1.37,
O=C(Nc1ccccn1)c2ccccc2,2.2,
ON1C(=O)N(CC2COc3ccccc3O2)c4ccsc4C1=O,1.44,
S(c1ccccc1)c2ccc3ccccc3n2,3.92,
FC(F)(F)c1cc(C(=O)Nc2cccc(c2)c3nnn[nH]3)c4nc[nH]c4c1,1.1,
COC[C@H](C)Oc1cc(Oc2ccc(Cl)cc2)cc(c1)C(=O)Nc3ccc(cn3)C(=O)O,1.69,
C[C@@H]1CN(CCN1C(=O)[C@@H]2CCCC[C@H]2C(=O)NC3(CC3)C#N)c4ccccc4,2.35,
COc1ccc2N=CC(=O)N(CCN3CC[C@@H](NCc4cc5OCCOc5cn4)[C@H](O)C3)c2c1,0.9,
COCCOCCOc1ccc(cc1)c2cc(C(=O)N)c(NC(=O)N)s2,2.21,
CCc1nc(N)nc(N)c1c2ccc(Cl)cc2,2.31,
C[C@@H](C(=O)NCCN1CCCC1)c2ccc(OS(=O)(=O)C(F)(F)F)cc2,1.64,
Nc1ccc(OCCc2ccccc2)cc1,2.71,
OC(=O)CCc1ccc(OCc2cccc(Br)c2)cc1,1.67,
Fc1cnc(NC(=O)C(CC2CCOCC2)c3ccc(cc3)S(=O)(=O)C4CC4)s1,3.3,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)NC4CCN(C)CC4)ncc2F,2.13,
Oc1ccc2OC(=CC(=O)c2c1)c3ccccc3,3.6,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2cccs2)NC(=O)OCC(F)(F)F)C(=O)C(F)(F)F,2.32,
ONC(=O)C1COC(=N1)c2ccc(F)c(c2)C(F)(F)F,1.53,
CCCc1c(O)c(ccc1OCCCOc2ccc3C(=O)C=C(Oc3c2CCC)C(=O)O)C(=O)C,3.0,
NS(=O)(=O)c1ccc(Nc2nccc(n2)c3ccccc3)cc1,2.86,
CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc3ccccc13)C(C)C,0.2,
CCN(CC)CCNc1ncnc2c1sc3nc(N4CCOCC4)c5CCCCc5c23,3.3,
CC1CC(NC(=O)C)c2ccccc2N1C(=O)c3ccccc3,2.0,
CCN(CCNCCc1ccc(O)c2NC(=O)Sc12)C(=O)CCOCCc3ccccc3,1.92,
OCC(O)CN1CCN(CC1)c2ccccc2,0.4,
C[C@@H](CO)Oc1cc(Oc2ccc(cc2)S(=O)(=O)C)cc(c1)C(=O)Nc3nccs3,2.63,
COc1cc(OC)c(cc1NC(=O)Cc2ccnc(F)c2)S(=O)(=O)N3C(C)CCc4ccccc34,2.49,
Cc1sc2ncnc(N3CCN(CC3)c4ncccn4)c2c1C,3.66,
OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.27,
Nc1n[nH]c2nnc(c3ccccc3)c(c4ccccc4)c12,2.6,
O[C@@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NCc5ccncc5)cc3,2.31,
Oc1ccc(N2C(=O)c3ccc(O)cc3C2=O)c(F)c1,2.1,
C[C@H]1COCCN1c2cc(nc(n2)c3cccc4[nH]ccc34)C5(CC5)S(=O)(=O)C,2.8,
Cc1ccc(C[C@H](N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2)C(=O)O)cc1,3.01,
COc1ccc(CC(=O)NC(N\C(=N\C#N)\Nc2ccccc2C)C(C)(C)C)cc1OC,2.48,
CN1CC(c2ccc(Cl)cc2)c3ccccc3C1,3.64,
OC(=O)CSc1c[nH]c2ccccc12,-1.31,
OC1=C(CC2=C(O)c3ccccc3OC2=O)C(=O)Oc4ccccc14,1.22,
C[C@@H](Oc1ccc(cc1C(=O)N2CCN(CC2)c3ncc(cc3F)C(F)(F)F)S(=O)(=O)C)C(F)(F)F,3.49,
O=C(NCC#N)[C@@H]1CCCC[C@H]1C(=O)N2CCCCC2,0.9,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3ccccc3Cl)C(=O)O)cc2)n1,-0.31,
Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4n12,1.98,
COCCC(=O)N[C@@H](C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.05,
COc1ccc(cc1OC2CCCC2)[C@@]3(CC[C@H](CC3)C(=O)O)C#N,0.76,
CCOc1ccccc1c2ccc(cc2)c3nc4ccc(F)cc4c(C(=O)NCCOCCN)c3C,2.46,
Cc1ccc(cc1c2cc(ccc2OCC(=O)O)C(F)(F)F)C#N,0.15,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1,2.91,
COCCNS(=O)(=O)c1ccc(cc1)c2cnc(N)c(n2)C(=O)Nc3cccnc3,2.26,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(C2)C(=O)c3ccccc3,0.87,
Oc1c(NC(=O)Nc2cccc(F)c2Cl)ccc(Cl)c1S(=O)(=O)N3CCNCC3,2.6,
CN1CCC(=CC1)c2cccc(O)c2,0.53,
OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,-0.84,
COCC1=C(N2[C@H](SC1)[C@H](NC(=O)\C(=N/OC)\c3csc(N)n3)C2=O)C(=O)OC(C)OC(=O)OC(C)C,1.7,
OCCN(CCO)c1nc(N2CCCCC2)c3nc(nc(N4CCCCC4)c3n1)N(CCO)CCO,3.97,
CS(=O)(=O)c1ccc(cc1)C(CCNC(=O)c2ccc(cc2)C#N)c3ccc(F)cc3,2.9,
Cc1cccc2c(CCNCc3cccc(CCNC[C@H](O)c4ccc(O)c5NC(=O)Sc45)c3)c[nH]c12,1.13,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(CO)c(Oc4cccc(Cl)c4)c3)C(=O)NC1=O,2.69,
Nc1ncnc2c1ncn2[C@@H]3O[C@H](CSCCCNC(=O)Nc4ccccc4)[C@@H](O)[C@H]3O,1.9,
CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,3.72,
CC12NC(Cc3ccccc13)c4ccccc24,1.7,
COc1ccc(cc1)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,1.74,
C[C@@H]1CN([C@@H](CO1)c2ccccc2)c3ccc4OCC(=O)Nc4n3,2.75,
CC(C)c1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,4.1,
Cc1nc2ccccn2c1c3ccnc(Nc4cccc(Cl)c4)n3,2.7,
OC(=O)COc1ccc(Cl)cc1CN2CCN(CC2)S(=O)(=O)c3ccc(F)cc3,0.99,
Oc1ccc(CCNCCCS(=O)(=O)NCCOCCSc2ccccc2)c3sc(O)nc13,1.84,
CCc1nc2ccc(cn2c1N(C)Cc3cccs3)C(=O)NCc4ccc5OCOc5c4,4.1,
COCc1ccoc1C(=O)N(C(C(=O)NC[C@@H](C)O)c2ccccc2F)c3ccc(OC)cc3OC,1.98,
CN(C)c1cccc(c1)C(=O)Nc2ccc(C)c(NC(=O)c3ccc(O)cc3)c2,2.65,
COc1cc(F)ccc1c2cncc(CNC3CCC3)n2,2.23,
Cc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1,3.7,
COc1cc2CC(CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC,2.41,
CCN(CC)C(=O)c1ccc2[nH]c(c(CCNCCCCc3ccncc3)c2c1)c4cc(C)cc(C)c4,3.3,
Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc4cccc(c4)S(=O)(=O)NC(C)(C)C,2.11,
Nc1ncc(cc1c2oc3ccccc3n2)c4cnn(c4)C5CCNCC5,1.85,
Nc1cc(nc2c(cnn12)C#N)c3ccc(F)cc3,2.23,
NS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1,2.6,
C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c2ccc(Cl)cc2)c3ccc(F)cc3CCCC(=O)O,3.1,
Cc1nc(CS(=O)(=O)c2ccccc2)cc(n1)N3CCOCC3,1.07,
COc1ccc(cc1)[C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(=O)C,1.99,
Cc1ccc(cc1)S(=O)(=O)N2N=Cc3ccccc3B2O,0.05,
S=C(NC1CCCCC1)N2CCC(CC2)c3cnc[nH]3,2.3,
Nc1cc(nc2ccccc12)c3ccccc3,2.2,
CN(C1CCN(Cc2ccc(nc2)C(F)(F)F)CC1)C(=O)Cc3ccc(cc3)n4cnnn4,1.8,
COc1ccc(cc1)c2cc3c(N[C@H]4CCCNC4)ncc(C(=O)N)c3s2,1.82,
C[N+]1(C)[C@@H]2C[C@H](C[C@H]1[C@@H]3O[C@H]23)OC(=O)C(O)(c4cccs4)c5cccs5,-0.25,
NC(=N)c1cc2c(cccc2s1)c3ccccc3,1.27,
Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1,3.1,
COc1ccccc1O[C@H]([C@@H]2CNCCO2)c3ccccc3,0.9,
CCCNC(=O)c1nnc2c(cccc2c1N)c3ncccn3,1.86,
O[C@@H](CNCCc1ccc(CNCCc2c(Cl)cccc2Cl)cc1)c3ccc(O)c4NC(=O)Sc34,2.3,
CC1CN(CCN1Cc2cc(Cl)ccc2OCC(=O)O)S(=O)(=O)c3ccccc3,0.69,
Clc1ccc(cc1)C2CCN(CC2)C(=O)COCc3ccncc3,2.74,
CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c2ccncc2)C(F)(F)F,2.15,
CCN(CC)CCN1C(=O)[C@@](O)(c2ccccc2Cl)c3c1cc(cc3C(F)(F)F)C(=O)N,2.4,
OCCNS(=O)(=O)c1ccc2C(=CNC(=O)c2c1)C(=O)NC[C@@H](O)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.06,
CN(c1ccnc(Nc2cc(nc(c2)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,3.44,
Clc1ccc(cc1)C(=O)N[C@H]2CN3CCC2CC3,0.6,
CC1=C(OCc2ccc(F)cc2)C(=O)C=CO1,1.91,
Clc1ccc(cc1)C(=O)Cc2ccccn2,2.96,
COc1nc(Br)cnc1NS(=O)(=O)c2cccc3c(cccc23)N(C)C,1.9,
NC(=O)c1sc2nccc(Nc3ccccc3)c2c1N,2.91,
COc1ccccc1OCC(O)COC(=O)N,0.36,
Clc1ccc2C(=O)NC(=Nc2c1)c3ccccc3,3.31,
Oc1cc(O)c2C(=O)c3ccccc3Oc2c1,3.39,
CCC(Oc1ccc(cc1c2ccc(cc2C)S(=O)(=O)CC)C(F)(F)F)C(=O)O,0.31,
COC(=O)N1CCN([C@@H](CN2CCCC2)C1)C(=O)Cc3ccc(Cl)c(Cl)c3,1.97,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)S(=O)(=O)CCCN(C)C)n2,1.32,
CC1(C)CCC(CC1)NC(=O)[C@@H](N)CCC(=O)O,-0.27,
NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C3CC4CC3C=C4)cc1Cl,2.12,
Oc1ccc(Br)c2ccccc12,4.3,
CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C23CCC3)c4ccc(C#N)c(c4)C(F)(F)F,3.3,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(CCc3cccc(F)c3)C2,2.64,
CCCC1=CC(=CC(=O)N1Cc2ccc(cc2)c3ccccc3c4nn[nH]n4)OCc5ccccc5,2.4,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4nccs4,1.3,
CCSc1ccc(cc1)c2cc(ccc2OCC(=O)O)C(F)(F)F,1.54,
COc1ccc(CN2C(=O)CCC2(C)C(=O)NC3CCCCC3)c(OC)c1,2.38,
O=C1C(=O)c2cc(ccc2c3ccccc13)c4ccsc4,3.1,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1,2.9,
CN(C)CCCNC(=O)c1nc(Cl)c(N)nc1N,-1.0,
Cc1ccc(cc1)\C(=C/CN2CCCC2)\c3ccccn3,1.88,
COc1cc(ccc1Nc2ncc(C#N)c(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)C,2.8,
CCCCC(CC)CNC(=O)c1cc(ccc1Cl)N2N=CC(=O)NC2=O,2.41,
CN(C)C(=O)N[C@@H]1CC[C@@H](CCN2CCN(CC2)c3ccc(Cl)c(Cl)c3)CC1,3.15,
Oc1c2ncc3ccccc3c2nn1c4ccccc4,0.8,
Cc1c(Sc2ccc(Cl)cc2)c3c(cccc3n1CC(=O)O)c4cnccn4,0.03,
C(Oc1ccccc1)C2CNCCO2,0.2,
COc1ncc(C)cc1c2cccc3c(N)c(nnc23)C(=O)NC4CC4,3.4,
OC(=O)COc1ccc(Cl)cc1CN2CCCN(CC2)S(=O)(=O)c3ccccc3,1.01,
O[C@@H](CNCCc1cccc(CNCCc2c(Cl)cccc2Cl)c1)c3ccc(O)c4NC(=O)Sc34,3.15,
CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,2.26,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)NS(=O)(=O)c4ccccc4)cc1Cl,1.5,
Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3,1.78,
O=C(N1CCOCC1)N2CCn3cc(C4=C(C(=O)NC4=O)c5cnc6ccccn56)c7cccc(C2)c37,1.79,
CN1CCN(CCCOc2ccc(cc2)c3onc(c3)c4ccc(F)cc4)CC1,3.81,
N#Cc1nc(nc(n1)N2CCOCC2)N3CCOCC3,1.51,
CNc1ccc(cc1)c2nc3ccc(O)cc3s2,3.5,
CN1CCN(CC1)C(=O)c2cc3cc(F)ccc3[nH]2,1.97,
Clc1ccc(cc1)C(=O)\C=C\Sc2nc[nH]n2,3.1,
O=C1C2CCC(N2)C(=O)N1Cc3ccccc3,2.21,
CN1N=Nc2c(ncn2C1=O)C(=O)N,-1.08,
Fc1cc2[nH]cnc2cc1Cl,2.35,
CC(=O)Nc1ccc(CNc2[nH]nc3cccc(Oc4ccc(F)cc4)c23)cc1,4.28,
N[C@H](CNC(=O)c1cc2c(cccc2[nH]1)c3ccccc3Cc4ccccc4)C(=O)O,3.25,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)NCc4ccc(cc4)S(=O)(=O)C,2.86,
CCN(CC)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1,1.67,
CCCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4F)[nH]n3)ncnc2c1,2.19,
CCCc1c(cnn1c2ccccc2)C(=O)Nc3cc(C)on3,3.7,
O=C(CC1CCCCCC1)Nc2cccc3C(=O)N(C=Cc23)[C@H]4CCNC4,1.15,
OC(=O)c1cc(ccc1O)N=Nc2ccc(cc2)S(=O)(=O)Nc3ccccn3,-0.58,
OC(=O)c1c(Sc2ccccc2)c3cc(Cl)ccc3n1Cc4ccc(Cl)cc4,2.96,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4ncc(CN5CCOCC5)s4,3.1,
Cc1oc(cc1C(=O)Nc2cccc(c2)C(=O)O)c3ccccc3,1.63,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCN(Cc3ccc(F)cc3)CC2)c4cccc5cccnc45,3.86,
CCN(CC)S(=O)(=O)c1ccc(NC(=O)C(C)(O)C(F)(F)F)cc1,2.63,
COc1ccc2NC(=O)C(NC(=O)c3ccccc3OC)N=C(c4ccccc4)c2c1,3.8,
CC(CO)(CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(N)sc13,2.87,
C[C@@H](Oc1ccc(SCCCCCc2ccccc2)cc1)C(=O)c3nc(C)c(CCCC(=O)O)s3,3.58,
COC(=O)COc1ccc(OCCNCC(O)COc2ccccc2)cc1,1.54,
COc1ccnc(CSc2nc3ccccc3[nH]2)c1,2.89,
Oc1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,2.3,
Oc1c2C(=O)N(NC(=O)c2nc3cc(Cl)ccc13)C(C4CC4)c5ccccn5,1.0,
CN(C1CCN(Cc2ccc(cc2)C(F)(F)F)CC1)C(=O)Cc3ccc(cc3F)S(=O)(=O)C,2.7,
Fc1ncccc1OC[C@@H]2CCN2,-1.2,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4ccccc4C#N)c1,2.34,
COc1ccc(cc1)c2nc3c(NCCCNC(=O)C)c(Br)cnc3[nH]2,3.28,
COc1ccc(N(C(C(=O)NC2CCCC2)c3ccccc3F)C(=O)c4ccccc4)c(OC)c1,3.86,
Cc1ccnc(NCc2ccc(Cl)cc2)c1,3.6,
CCN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,3.8,
CCN(CCO)CCCOc1cc2ncnc(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)c2cc1OC,2.12,
CCCc1c(O)c(ccc1OCc2ccc(cc2OC)c3nn[nH]n3)C(=O)C,2.8,
Nc1nc(N)c(c(COCc2ccccc2)n1)c3ccc(NC(=O)C4CC4)cc3,2.46,
O=C(N1CCOCC1)c2ccc(cc2)C(=C3CCN(Cc4cscn4)CC3)c5cccc6cccnc56,2.12,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)NS(=O)(=O)Cc4ccccc4)cc1Cl,2.13,
C[C@@H](Oc1nc(Nc2cc(C)[nH]n2)c(C)nc1C#N)c3ccc(F)cn3,2.72,
O[C@]1(CN2CCC1CC2)C#Cc3ccc(Oc4ccc(cc4)C(=O)NCc5ccncc5)cc3,2.42,
COc1cc(Nc2cc(Oc3cc(C)c(C)nc3c4ccccn4)ccn2)cc(OC)c1OC,3.22,
CSc1nc(C(=O)N)c(N)s1,1.21,
COc1ccccc1CN(C(=O)C)c2cnccc2Oc3ccccc3,3.0,
COc1cccc(CNc2nc(NC(C)C)nc3ccsc23)c1OC,3.7,
OCCN1C=Cc2c(NC(=O)Cc3ccc(Cl)c(c3)C(F)(F)F)cccc2C1=O,3.36,
C[C@H](NC(=O)c1c(C)nn(C2CCOCC2)c1NS(=O)(=O)c3ccc(cc3)C4CC4)C(C)(C)C,1.23,
CCC(NC(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4ccccc4,4.14,
OC[C@@H](O)CN1C(=O)[C@H](Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.27,
COc1ccc2N=CC(=O)N(CCN3CC[C@@H](NCc4ccc5OCC(=O)Nc5n4)[C@@H](O)C3)c2c1,0.37,
c1ccc2ncccc2c1,2.09,"This molecule appears as a colorless liquid with a peculiar odor. Slightly denser than water. Contact may irritate to skin, eyes, and mucous membranes. May be toxic by ingestion. Used to make other chemicals. This molecule is the simplest member of the quinoline class of compounds, comprising a benzene ring ortho fused to C-2 and C-3 of a pyridine ring. It is a mancude organic heterobicyclic parent, a member of quinolines, an azaarene and an ortho-fused heteroarene. This molecule is used mainly as an intermediate in the manufacture of other products. Potential exposure to quinoline may occur from the inhalation of cigarette smoke. This molecule breaks down quickly in the atmosphere and water. Acute (short-term) inhalation exposure to quinoline vapors irritates the eyes, nose, and throat and may cause headaches, dizziness, and nausea in humans. Information on the chronic (long- term), reproductive, developmental, or carcinogenic effects of quinoline in humans is not available. Liver damage has been observed in rats chronically exposed to quinoline by ingestion. An increased incidence of liver vascular tumors has been observed in rats and mice orally exposed to quinoline. EPA has provisionally classified quinoline as a Group C, possible human carcinogen This molecule is a natural product found in Gymnodinium nagasakiense, Averrhoa carambola, and other organisms with data available. This molecule is found in alcoholic beverages. This molecule is an alkaloid from various plant species including Mentha species. Also present in cocoa, black tea and scotch whiskey. This molecule is a flavouring ingredient This molecule is a heterocyclic aromatic organic compound. It has the formula C9H7N and is a colourless hygroscopic liquid with a strong odour. Aged samples, if exposed to light, become yellow and later brown. This molecule is only slightly soluble in cold water but dissolves readily in hot water and most organic solvents. This molecule is mainly used as a building block to other specialty chemicals. Approximately 4 tonnes are produced annually according to a report published in 2005.[citation needed] Its principal use is as a precursor to 8-hydroxyquinoline, which is a versatile chelating agent and precursor to pesticides. Its 2- and 4-methyl derivatives are precursors to cyanine dyes. Oxidation of quinoline affords quinolinic acid (pyridine-2,3-dicarboxylic acid), a precursor to the herbicide sold under the name Assert.

This molecule has been shown to exhibit catabolic, anti-microbial, anti-tumor, anti-fungal and anti-cancer functions (A7755, A7756, A7757, A7759, A7760)."
C[C@H](NC1=NC(=O)[C@@](C)(S1)C(F)(F)F)c2ccccc2F,3.1,
C[C@@H](N)COc1c(C)cccc1C,0.6,
CC1N=C(N)N=C(N)N1c2ccc(Cl)cc2,-0.8,
COc1cc2ncnc(Nc3cc(Cl)ccc3F)c2cc1OCCCN4CCOCC4,3.4,
Cc1ccccc1N2C(=Nc3cccc(C)c3C2=O)Cn4cnc5c(N)ncnc45,2.6,
COc1ccc2nc3ccccc3c(N)c2c1,1.0,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4c(cccc34)C(F)(F)F,1.27,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2ccccc12)c3ccsc3)c4ccccc4,2.66,
Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F,3.9,
C[C@@H]1CN(C[C@H](C)O1)c2nc(N3CCOCC3)c4ccc(Nc5ccccc5)nc4n2,4.12,
OCC(=O)N1CCC(CC1)c2n[nH]c(c3ccc(Cl)cc3)c2c4ccncn4,1.85,
COc1ccc(cc1OC)C(=O)Nc2cc(NC(=O)c3cccc(c3)N(C)C)ccc2C,3.12,
CNCc1cccc(c1)c2ccc3c(nc(nc3n2)N4C[C@@H](C)O[C@@H](C)C4)N5CCOCC5,1.26,
COc1ccc(cc1)c2nc3c(OCC4CCNCC4)c(Br)cnc3[nH]2,1.55,
COc1ccc(cc1)c2nc3c(NCCCNC(=O)c4ccccc4)c(Br)cnc3[nH]2,0.25,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OCC4CC(F)(F)C4(F)F)nc23,1.42,
O=C(NC1CC1)Nc2c[nH]nc2c3nc4cc(CN5CCOCC5)ccc4[nH]3,2.3,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4ncc[nH]4,3.01,
Nc1cc(ncn1)c2ccccc2,1.91,
Cc1onc(NS(=O)(=O)c2ccc(N)cc2)c1,-0.56,
Clc1ccc2C(=O)C3=C(Nc2c1)C(=O)NN(Cc4cc5ccccc5s4)C3=O,2.0,
OC(=O)[C@H](Cc1ccc(OCCCNc2ccccn2)cc1)NC(=O)c3c(Cl)cccc3Cl,-0.22,
CC(C)(C)OC(=O)N1CCN(CC1)c2cnc(OCc3ccc(cc3)S(=O)(=O)C)cn2,3.4,
CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,2.5,"This molecule is a member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor. It has a role as a Hsp90 inhibitor and an antineoplastic agent. It is a member of resorcinols, a member of benzamides, a tertiary carboxamide, a member of isoindoles and a N-alkylpiperazine. This molecule is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. This molecule selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins."
COC1(CCOCC1)c2cc(F)cc(OCc3ccc4N(C)C(=O)C=Cc4c3)c2,3.52,
Oc1ccc(CCNCCS(=O)(=O)CCCOCCNc2ccccc2)c3sc(O)nc13,1.98,
C[C@H](Nc1ncc(F)c(Nc2cc(C)[nH]n2)n1)c3ncc(F)cn3,1.79,
COc1cc2c(Nc3ccc(F)c(Cl)c3)c(cnc2cc1OCCN(C)CCO)C(=O)N,3.2,
C(Nc1ncnc2ccccc12)c3ccccc3,3.21,
CC(N1C(=O)c2ccccc2C1=O)C(=O)N3CCc4ccccc4C3,2.47,
Nc1ccc(cc1)C2(CCCCC2)c3ccc(N)cc3,3.2,
CS(=O)(=O)c1ccc(cc1)[C@@H](CC2CCCC2)C(=O)Nc3nccs3,3.86,
CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(Cl)cc23)c1C,2.75,
CC(C)(C)OC(=O)N1CCC(CC1)OCc2onc(n2)c3ccncc3,3.0,
C[C@@](O)(C(=O)Nc1ccc(cc1Cl)S(=O)(=O)C)C(F)(F)F,2.08,
Clc1ccc2nsnc2c1NC3=NCCN3,0.71,
CCS(=O)(=O)Nc1cccc2c1c(Oc3ccc(Cl)cc3)c(C)n2CC(=O)O,-0.29,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3ccc(F)cc3Cl)C(=O)O)cc2)n1,-0.04,
CCCc1c(O)c(ccc1OCc2ccc(cc2)c3nn[nH]n3)C(=O)C,3.1,
COc1cc(OC)c(cc1NC(=O)C)S(=O)(=O)N(C)c2ccccc2,1.1,
OCCCN(Cc1ccc(F)cc1)C(=O)CC2CCN(Cc3ccn(c3)c4ccc(cc4)C(F)(F)F)CC2,3.04,
CN(C1CCN(Cc2ccc(cc2)c3noc(C)n3)CC1)C(=O)Cc4ccc(cc4)n5cnnn5,2.1,
CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,2.5,
CCCCNc1nc(SCCC)nc2c1nnn2[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O,3.07,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccccn2)C1)C(C)(C)C,-0.55,
OC(=O)c1ccccc1Nc2cccc(c2)C(F)(F)F,2.01,
CC1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1S(=O)(=O)c3ccccc3,0.31,
O[C@H](CNC(=O)C1=CNC(=O)c2ccc(F)cc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.93,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2S(=O)(=O)N4CC[C@@H](O)C4,3.32,
Cc1ccccc1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.71,
COc1cccc(n1)N(C)c2ccnc(Nc3cc(cc(c3)N4CCOCC4)N5CCOCC5)n2,3.37,
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,-0.41,
OC(=O)c1cn(Cc2ccccc2)c3ccccc13,1.19,
CN(C)c1cccc(c1)C(=O)Nc2ccc(C)c(NC(=O)c3ccc(OCc4ccccn4)cc3)c2,2.83,
CC(C)(C)Cn1c(CN2C(=O)CC3(CCNCC3)C2=O)cc4cnc(nc14)C#N,0.75,
CCN1CCN(Cc2cnc(c(Cl)c2)c3ccc(cc3)C(=O)Nc4ccccc4N)CC1,1.81,
CNC(=O)Nc1cc(sc1C(=O)N)c2ccccc2,2.71,
CCCSc1ncccc1C(=O)NC2CCC(F)(F)CC2,2.85,
Cc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)c3ccc(C)cc3,3.43,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4cc(CO)ccn34)N5CCN(CC5)C(=O)C,3.1,
Cc1ncc(c2ccnc(Nc3ccc(cc3)S(=O)(=O)N)n2)n1C,1.6,
CNc1nc(C)c(s1)c2nc(Nc3cccc(c3)N4CCNCC4)ncc2C#N,1.9,
Clc1ccc(NC(=O)N2CCN(C[C@H]3CN(CCO3)C4CC4)CC2)cc1Cl,3.32,
CCC(N(CCCN)C(=O)c1ccccc1)C2=Nc3ccsc3C(=O)N2Cc4ccccc4,1.38,
NC1=NC(Nc2cccc(F)c12)c3cccs3,0.91,
CN1C(=O)CN=C(c2ccccc2)c3cc(Cl)ccc13,2.69,
Cn1cncc1c2c3C(=O)N(CC=C)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56,3.62,
CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc3c[nH]c4ccccc34)NC=O,1.0,
c1ccc(cc1)c2c[nH]c(n2)c3ccccc3,3.8,
CCC1(NC(=O)N(C)C1=O)c2ccccc2,1.59,
O[C@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@H]1NCc4cc5OCCOc5cn4,0.45,
Cc1c(CCC(=O)O)c[nH]c1\C=C\2/C(=O)Nc3ccccc23,1.05,
COCCOc1cc2ncc(C(=O)N)c(Nc3ccc(C)cc3F)c2cc1N4CCN(C)CC4,2.24,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC4CCN(C)CC4,2.72,
Clc1cccc(Cl)c1\C(=C\n2cncn2)\OC3CCCCCC3,4.1,
Brc1oc(cc1)c2nc3cc(NS(=O)(=O)c4ccccc4)ccc3[nH]2,4.38,
Nc1c2C(=O)N(Cc2nc3c(cccc13)c4ncccn4)C5CCC5,1.85,
COc1ccc(cc1)c2c(C)[nH]nc2c3ccc(O)cc3O,3.37,
CNCC[C@H](Oc1cccc2ccccc12)c3cccs3,2.09,
CC(N1Cc2ccccc2C1=O)c3ccccc3,3.0,
COc1ccc(N(C(C)C(=O)NC2CCCC2)C(=O)c3ccccc3)c(OC)c1,3.02,
NC1=NC(=CC(=O)N1)CCc2ccccc2,1.4,
COCCOc1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.1,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(F)cc1C#N)c3ccc(F)cn3,3.11,
OC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4sc(Cl)c(Cl)c4[nH]3,0.67,
CC(C)n1c2ccccc2c3c(C)c(NC(=O)N4CCOCC4)ccc13,3.5,
Fc1ccccc1c2ccc3c(c2)C(=O)C(=O)c4ccccc34,2.92,
Cc1cc(C)cc(CCOCCS(=O)(=O)NCCNCCc2ccc(O)c3nc(O)sc23)c1,2.45,
Cc1ccc2c(N)c(C#N)sc2n1,2.23,
O=S(=O)(Nc1ccc(cc1)S(=O)(=O)Nc2nccs2)c3ccc4OCCOc4c3,1.97,
COc1ccc(cc1)C(CNC(=O)Nc2ccccc2)N3CCN(C)CC3,1.5,
COc1ccc(Nc2cc(Oc3cc(C)c(C)nc3c4ccccn4)ccn2)cc1,3.51,
COc1ccc(NC(=O)c2ccc(c(C)c2)c3ccncc3)cc1N4CCN(C)CC4,2.56,
CCCSc1ncccc1C(=O)N(C)C2CCCCC2,3.36,
CCOC(=O)C1=Cc2ccc(O)cc2OC1=O,1.2,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC,3.67,
OC(=O)COc1ccc(cc1c2ccccc2)[N+](=O)[O-],-0.69,
CCCSc1c(cnn1c2cccc(c2)C(=O)O)C(=O)NC3CCCCC3,0.7,
Nc1ncnc(Nc2ccccc2)n1,1.4,"This molecule is a diamino-1,3,5-triazine. This molecule is a triazine-based diuretic agent. This molecule is structurally similar to the diuretic agent chlorazanil."
NC(=O)Nc1sc(cc1C(=O)N[C@H]2CCCNC2)c3ccsc3,1.06,
CCN(CC)CCOc1ccc(cc1)\C(=C(\Cl)/c2ccccc2)\c3ccccc3,4.09,
COc1cc(O)c2C(=O)O[C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)C\C=C\c2c1,1.64,
CCN1N(C2CCCC2)c3nc(Nc4ccc(cc4OC)C(=O)NC5CCN(C)CC5)ncc3N(C)C1=O,2.75,
COc1ccccc1Oc2ccc(cc2)N(Cc3cccnc3)S(=O)(=O)CC(F)(F)F,1.5,
O=C1C=C(C=CN1c2ccc3c(cnn3CCN4CCCC4)c2)c5ccccc5,1.6,
CC1=NC(=C(NC1=O)c2ccccc2)c3ccc(CN4CCC(CC4)N5C(=O)Nc6ccccc56)cc3,3.8,
Clc1ccc(N2CCN(CC2)C(=O)COCc3ccccn3)c(Cl)c1,3.47,
CC(C)C[C@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,0.93,
C[C@H](c1c[nH]cn1)c2cccc(C)c2C,2.79,
OC1CCN(CC1)C(=O)c2ccc(cc2)C(=C3CCN(Cc4cscn4)CC3)c5cccc6cccnc56,1.89,
COc1ccc(cc1)N2Sc3ccccc3C2=O,3.02,
CCC(N(CC1CCNCC1)C(=O)c2ccc(C)cc2)C3=Nc4ccsc4C(=O)N3Cc5ccccc5,1.33,
CC(=O)Nc1nc(CCc2ccc(NC(=N)N)cc2)cs1,-0.82,
CN1C[C@H](c2ccccc2)c3cccc(N)c3C1,2.11,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)N4CC[C@@H](C4)N(C)C)ncc2F,2.16,
COc1ccc(NC(=O)c2oc(Nc3ccccc3F)nn2)cn1,3.2,
Cc1ccc(CCCOCCS(=O)(=O)CCCNCCc2ccc(O)c3nc(O)sc23)s1,2.41,
O[C@H](CNC(=O)c1cn2cc(F)ccc2n1)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.33,
OC(=O)[C@H](Cc1ccc(CCCCNc2ccccn2)cc1)NC(=O)c3c(Cl)cccc3Cl,0.51,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C(=O)NC)n4ccc(n4)C(F)(F)F,2.21,
COc1cc(ccc1Cn2cnc3ccc(NC(=O)CC4CCCC4)cc23)C(=O)NS(=O)(=O)c5ccccc5,0.9,
NC(=N)c1cc2c(I)cccc2s1,0.74,
Oc1ccc(cc1)C2=CC(=O)c3ccccc3N2,2.34,
CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc3c[nH]c4ccccc34)NC(=O)C(C)(C)N,2.1,
Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,3.41,
Cc1ccc(CCOCCNS(=O)(=O)CCCNCCc2ccc(O)c3nc(O)sc23)cc1,2.07,
Cc1ccc2NC(=O)OC3(CCN(CCc4nc(oc4C)c5ccccc5)CC3)c2c1,4.2,
CCn1c(SCC(=O)Nc2c(cnn2c3ccccc3)C#N)nnc1c4cccs4,2.1,
Nc1ncnc2c1ncn2Cc3ccccc3,1.53,
CC(C)C[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1,2.8,
CC(C)OC(=O)N1CCC(CC1)Oc2ncnc(Oc3ccc(cc3F)S(=O)(=O)C)c2C,3.7,
Nc1c(cnn1c2ccc(F)cc2)C(=O)c3cccc(OC[C@@H](O)CO)c3,1.91,
CCC(N(CCCN)C(=O)c1ccc(cc1)C(C)C)C2=Nc3ccsc3C(=O)N2Cc4ccccc4,2.72,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2cccc(c2)C(=O)O)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,1.2,
Cc1ccc(cc1)C(=O)c2ccc(CC(=O)O)n2C,-1.02,
COc1cc(ccc1Cc2c[nH]c3ccc(NC(=O)CC4CCCC4)cc23)C(=O)NS(=O)(=O)c5ccccc5C,2.0,
CC(=O)Nc1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.04,
COCCNc1nc(N)c2nc(O)n(Cc3ccccc3)c2n1,2.18,
OC(=O)C1=CN(C2CC2)c3cc(N4CCN(CC4)C(=O)CC[N+](=O)[O-])c(F)cc3C1=O,0.22,
Cc1ccc(CN2[C@@H]3CC[C@H]2C[C@@H](C3)Oc4cccc(c4)C(=O)N)s1,2.44,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3NC(=O)C=Cc13,3.36,
COc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OC,3.1,
C[C@H](Nc1nc(Nc2ncc(C#N)s2)cc(n1)N3CCOCC3)c4ccc(F)cn4,3.45,
COc1cc(OC)c(cc1NC(=S)NCC(=O)O)S(=O)(=O)N2C(C)CCc3ccccc23,-1.04,
COc1ccccc1CNC(=O)c2ccc3cnccc3n2,1.8,
CC(=O)Nc1ccc2c(c1)c(cn2C)c3cc(NC4CC4)n5ncc(C#N)c5n3,2.94,
CCOc1cc(Nc2nc3c(cc2F)ncn3[C@@H](CO)c4ccc(F)cn4)n[nH]1,2.55,
CCN(CC)CCOc1ccc(cc1)C(O)(Cc2ccc(Cl)cc2)c3ccc(C)cc3,3.98,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(C(=O)N)c(Oc4cccc(Cl)c4)c3)C(=O)NC1=O,1.96,
NC1=CC2=NNC(=O)N2c3cc(ccc13)c4occc4,2.48,
Clc1ccccc1C(=O)NCC23CC4CC(CC(C4)C2)C3,4.05,
Nc1nccc(n1)c2cccs2,1.75,
CN1CCC(CC1)(C#N)c2cccc3ccccc23,2.73,
COc1cc2ncc(C(=O)N)c(Nc3cccc(Cl)c3Cl)c2cc1OC,3.4,
N\C(=C(\C#N)/c1ccccc1C(F)(F)F)\Sc2ccc(N)cc2,3.3,
CN(C)c1ccc2N=C3C=CC(=[N+](C)C)C=C3Sc2c1,-0.88,
CC[C@H](NC(=O)c1c(CS(=O)(=O)C)c(nc2ccccc12)c3ccccc3)c4ccccc4,3.25,
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,0.63,"This molecule is a cardioselective beta-blocker used in the treatment of hypertension. This molecule has not been linked to instances of clinically apparent drug induced liver injury. This molecule is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent and a sympatholytic agent. A cardioselective beta-1-adrenergic antagonist with no partial agonist activity. This molecule is a beta-Adrenergic Blocker. The mechanism of action of betaxolol is as an Adrenergic beta-Antagonist. This molecule is a racemic mixture and selective beta-1 adrenergic receptor antagonist with antihypertensive and anti-glaucoma activities and devoid of intrinsic sympathomimetic activity. This molecule selectively and competitively binds to and blocks beta-1 adrenergic receptors in the heart, thereby decreasing cardiac contractility and rate. This leads to a reduction in cardiac output and lowers blood pressure. When applied topically in the eye, this agent reduces aqueous humor secretion and lowers the intraocular pressure (IOP). In addition, betaxolol prevents the release of renin, a hormone secreted by the kidneys that causes constriction of blood vessels."
Cc1nsc(C)c1CCC2CCN(CC2)S(=O)(=O)CC3(CCOCC3)N(O)C=O,1.5,
COc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4cc(Cl)ccc34,1.16,
Nc1nc(OC2CCCC2)nc3c1ncn3[C@@H]4O[C@H](CO)[C@H](Cl)[C@H]4O,2.16,
COc1cc2N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)C(=O)C=Cc2cn1,0.68,
O=C(NCC12CC3CC(CC(C3)C1)C2)c4ccccc4,4.21,
Cc1ccn2c(NC(=O)c3ccccc3)c(nc2c1)c4cccs4,2.87,
Fc1cc(ccc1C2=CCOCC2)N3C[C@H](COc4ccon4)OC3=O,2.61,
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc3ccccc3)C(=O)N[C@@H]4[C@H](O)Cc5ccccc45,2.9,
OC(=O)COc1cccc(c1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,1.99,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4ccc(F)cc4)c1,3.2,
CC(=O)Nc1ccc(O)cc1,0.25,"This molecule is an odorless white crystalline solid. Bitter taste. pH (saturated aqueous solution) about 6. (NTP, 1992) This molecule is a widely used nonprescription analgesic and antipyretic medication for mild-to-moderate pain and fever. Harmless at low doses, acetaminophen has direct hepatotoxic potential when taken as an overdose and can cause acute liver injury and death from acute liver failure. Even in therapeutic doses, acetaminophen can cause transient serum aminotransferase elevations. This molecule is a member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. It has a role as a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, a non-narcotic analgesic, an antipyretic, a non-steroidal anti-inflammatory drug, a cyclooxygenase 3 inhibitor, a xenobiotic, an environmental contaminant, a human blood serum metabolite, a hepatotoxic agent, a ferroptosis inducer and a geroprotector. It is a member of phenols and a member of acetamides. It is functionally related to a 4-aminophenol. This molecule is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the U.S. FDA in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms.  Acetaminophen is often found combined with other drugs in more than 600 over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products. Confusion about dosing of this drug may be caused by the availability of different formulas, strengths, and dosage instructions for children of different ages. Due to the possibility of fatal overdose and liver failure associated with the incorrect use of acetaminophen, it is important to follow current and available national and manufacturer dosing guidelines while this drug is taken or prescribed. This molecule is a p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus. This molecule is a natural product found in Streptomyces xiamenensis and Euglena gracilis with data available. This molecule is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. The excellent tolerability of therapeutic doses of paracetamol (acetaminophen) is a major factor in the very wide use of the drug. The major problem in the use of paracetamol is its hepatotoxicity after an overdose. Hepatotoxicity has also been reported after therapeutic doses, but critical analysis indicates that most patients with alleged toxicity from therapeutic doses have taken overdoses. Importantly, prospective studies indicate that therapeutic doses of paracetamol are an unlikely cause of hepatotoxicity in patients who ingest moderate to large amounts of alcohol. (A7820). Single doses of paracetamol are effective analgesics for acute postoperative pain and give rise to few adverse effects. (A7821). Acetaminophen (AAP) overdose and the resulting hepatotoxicity is an important clinical problem. In addition, AAP is widely used as a prototype hepatotoxin to study mechanisms of chemical-induced cell injury and to test the hepatoprotective potential of new drugs and herbal medicines. Because of its importance, the mechanisms of AAP-induced liver cell injury have been extensively investigated and controversially discussed for many years. (A7822)."
Cc1cc(NCc2ccccc2)nc3ccccc13,3.69,
Cc1c(cnn1c2ccc(cc2)C(=O)O)C(=O)NC3C4CC5CC(CC3C5)C4,0.8,
NC(=O)Nc1sc(cc1C(=O)N[C@H]2CCCNC2)c3cc(F)cc(F)c3,2.18,
COc1ccc(cc1)c2cc(ccc2OCC(=O)O)C(F)(F)F,0.29,
Nc1ccccc1NC(=O)c2ccccn2,1.0,
O=C(Nc1nccs1)c2cccnc2,2.25,
Nc1nc(nc(N)c1Cc2ccccc2F)c3ccccn3,2.12,
COc1ccc2C(=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2c1)C,1.72,
N#Cc1cnn2c(NC3CC3)cc(nc12)c4cccs4,2.88,
OC(=O)COc1ccc(Cl)cc1c2cccc(c2)C#N,-0.25,
CCC(CC)NC(=O)c1cn(nc1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,2.51,
FC(F)(F)c1nnc2ccc(nn12)N3CCCC3,2.41,
COc1cc2c(Nc3cc(CC(=O)Nc4cccc(F)c4F)[nH]n3)ncnc2cc1OCCCN5CCC[C@@H]5CO,1.96,
c1ccc2ccccc2c1,3.29,"This molecule appears as a white crystalline volatile solid with a strong coal-tar odor. The solid is denser than water and insoluble in water. Burns, but may be difficult to ignite.  In the molten form it is very hot. Exposure to skin must be avoided. Also the vapors given off by the material may be toxic.  Used as a moth repellent, fumigant, lubricants, and to make other chemicals, and for many other uses This molecule is an aromatic hydrocarbon comprising two fused benzene rings. It occurs in the essential oils of numerous plant species e.g. magnolia. It has a role as a volatile oil component, a plant metabolite, an environmental contaminant, a carcinogenic agent, a mouse metabolite and an apoptosis inhibitor. It is an ortho-fused bicyclic arene and a member of naphthalenes. This molecule is used in the production of phthalic anhydride; it is also used in mothballs. Acute (short- term) exposure of humans to naphthalene by inhalation, ingestion, and dermal contact is associated with hemolytic anemia, damage to the liver, and neurological damage. Cataracts have also been reported in workers acutely exposed to naphthalene by inhalation and ingestion. Chronic (long-term) exposure of workers and rodents to naphthalene has been reported to cause cataracts and damage to the retina. Hemolytic anemia has been reported in infants born to mothers who ""sniffed"" and ingested naphthalene (as mothballs) during pregnancy. Available data are inadequate to establish a causal relationship between exposure to naphthalene and cancer in humans. EPA has classified naphthalene as a Group C, possible human carcinogen. This molecule is a white, volatile, solid polycyclic hydrocarbon with a strong mothball odor. This molecule is obtained from either coal tar or petroleum distillation and is primarily used to manufacture phthalic anhydride, but is also used in moth repellents. Exposure to naphthalene is associated with hemolytic anemia, damage to the liver and neurological system, cataracts and retinal hemorrhage. This molecule is reasonably anticipated to be a human carcinogen and may be associated with an increased risk of developing laryngeal and colorectal cancer. (NCI05) This molecule is a metabolite found in or produced by Saccharomyces cerevisiae. This molecule is a natural product found in Herbertus norenus, Swertia japonica, and other organisms with data available. This molecule is the simplest polyaromatic hydrocarbon (PAH) consisting of two fused benzene rings. It has a distinct, pungent odor that can be detected at levels as low as 0.08 ppm.  This molecule is the most abundant single component of coal tar so most of it is now industrially derived from coal tar. From the 1960s until the 1990s, significant amounts of naphthalene were also produced from heavy petroleum fractions during petroleum refining, but today petroleum-derived naphthalene represents only a minor component of naphthalene production. This molecule is also produced naturally with trace amounts of naphthalene being produced by black walnuts, magnolias and specific types of deer, as well as the Formosan subterranean termite. Some strains of the endophytic fungus (Muscodor albus) also produce naphthalene. This molecule and other polycyclic aromatic hydrocarbons (PAHs) are released from incomplete combustion processes originating in industry, cigarette smoke and motor vehicle exhaust, as well as natural events such as forest fires. Industrially, naphthalene is used in the production of phthalic anhydride, as a solvent for chemical reactions, as a wetting agent and as a fumigant.  It is also used in pyrotechnic special effects such as the generation of black smoke and simulated explosions. In the past, naphthalene was administered orally to kill parasitic worms in livestock. This molecule was once the primary ingredient in mothballs, though its use has largely been replaced in favor of alternatives such as 1,4-dichlorobenzene. In a sealed container containing naphthalene pellets, naphthalene vapors build up to levels that are toxic to both the adult and larval forms of many moths. This molecule has been shown to exhibit apoptotic and catabolic functions (4, 5). Exposure to large amounts of naphthalene may damage or destroy red blood cells. Humans, in particular children, have developed this condition, known as hemolytic anemia, after ingesting mothballs or deodorant blocks containing naphthalene."
CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccccc4,2.17,
O=C1COc2ccc(CNC3CCN(CCN4C(=O)COc5ccc(cc45)c6occc6)CC3)nc2N1,2.19,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3sccc3C(=O)N2Cc4ccccc4,2.06,
O=C(CN1CCOCC1)Nc2ccc(cc2c3ccccc3)c4cccc5C(=O)C=C(Oc45)N6CCOCC6,3.4,
Cc1onc(CO)c1C(=O)Nc2nccs2,1.53,
Cc1ccnc(NCc2c(O)ccc3ccccc23)c1,4.24,
CC(C)CN1C(=O)N(C)C(=O)c2c1nn(Cc3cccc4ccccc34)c2c5ccncc5,4.3,
COc1ccc(C(CN2CCCC2)N(C)C(=O)Cc3ccc(Cl)c(Cl)c3)c(OC)c1,3.07,
CNC(=O)c1ccc(Nc2ncc(F)c(n2)c3cnc(C)n3C(C)C)cc1F,3.31,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCCCC4,3.3,
CN[C@H]1CCN(C1)C(=O)c2ccc(Nc3nccc(n3)c4cnc(C)n4C(C)C)cc2,1.22,
Cc1cc(C)n(n1)c2cccc(Cl)c2C#N,3.0,
Fc1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.03,
NCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,1.5,
Cn1ccc2c(cccc12)c3nc(CS(=O)(=O)C)cc(n3)N4CCOCC4,2.0,
Oc1nc2ccccc2nc1NCc3ccccc3,3.3,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(Br)cc2)C1)C(C)(C)C,2.92,
CCCCCCN1CC[C@@]2(C)[C@@H](C)C1Cc3ccc(O)cc23,2.5,
CC(C)NC[C@@H](O)COc1cccc2ccccc12,1.13,This molecule is a propranolol.
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)OCc3ccc(cc3)C(=O)O)C(=O)C(F)(F)F,0.84,
Cc1nc(CSc2ccc(Cl)cc2)cc(n1)N3CCOCC3,3.38,
Cc1nc(C)c(nc1C(=O)N)c2ccc3c(CC[C@@]34CC[C@H](CC4)C(=O)O)c2,1.3,
C[C@H]1COCCN1c2nc(N3CCOC[C@@H]3C)c4ccc(nc4n2)c5cccc(c5)C(=O)NCCO,2.49,
Clc1ccc(cc1Cl)[C@]23CNC[C@H]2C3,1.96,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)C5CC5)ccc4C,2.17,
O=C1C=C(OCc2ccccc2)C=CN1c3ccc4c(cnn4CCN5CCCC5)c3,2.0,
Fc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)NCc3ccccc3,3.15,
CN(C)S(=O)(=O)c1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.15,
O\N=C\1/C(=O)N(Cc2ccccc2[N+](=O)[O-])c3ccccc13,2.07,
Cc1ccc(NC(=O)[C@H]2CCCN2S(=O)(=O)c3cccc4cccnc34)c(C)c1,3.9,
Cc1cccc(C[C@H](N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2)C(=O)O)c1,2.84,
Cc1cc(nn1C[C@H](O)CN)c2ccc(Cl)c(c2)C(=O)NCC3(O)CCCCCC3,0.57,
CCCSc1nc(ccc1C(=O)N[C@@H]2C3CC4CC2C[C@@](O)(C4)C3)N5CCOCC5,3.2,
COc1cc(OC)c(cc1NC(=O)CCC(=O)O)S(=O)(=O)N(c2ccccc2)c3ccccc3,-0.8,
OC1(CCN(CC1)c2ccc3nnc(n3n2)C(F)(F)F)c4ccc(F)cc4,3.5,
Cc1cc(Cl)ccc1OC2CCN(C[C@H](O)CNC(=O)C3=CNC(=O)c4cc(ccc34)S(=O)(=O)C)CC2,2.42,
CC(=O)Nc1cc2c(ccn2c3cc(NC4CC4)n5ncc(C#N)c5n3)cc1C,2.66,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)NCc4ccccc4,3.4,
OC(=O)\C=C\c1cccc(c1)c2cnc3[nH]ccc3c2,0.58,
Clc1ccccc1N2CCN(CC2)C(=O)NC3CCCCC3,3.78,
COc1cc(OC)c(cc1NC(=O)C)S(=O)(=O)N2C(C)Cc3ccccc23,1.95,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3CCN(CC3)c4ccc(cn4)C#N)c(F)c2,1.98,
O=C1Nc2ccc(cc2C1=O)S(=O)(=O)N3CCC[C@H]3COc4ccccc4,2.7,
Clc1cc(Cl)cc(NC(=O)NCC2(CCN(CC3CC3)CC2)c4ccc(cc4)c5cccc(c5)C#N)c1,3.37,
Oc1ccc(CCc2ccc(O)cc2)cc1,3.3,This molecule is a stilbenoid. This molecule is a natural product found in Gastrodia elata with data available.
CC(C)c1ccc(NC(=O)NCCCSC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n3cnc4c(N)ncnc34)cc1,2.5,
CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)c4nccc5ccccc45,1.16,
CCCSc1ncccc1C(=O)N[C@@H]2[C@@H]3CC4C[C@H]2C[C@@](O)(C4)C3,2.27,
CCCC(C)(C)C[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,1.99,
CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2,-0.22,
CN(C(CN1CCCC1)c2ccccc2)C(=O)Cc3ccc(Cl)c(Cl)c3,3.38,
[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1,3.72,
CN(CCCc1ccccc1)S(=O)(=O)c2cc(C(=O)N3CCc4ccc(cc4C3)S(=O)(=O)NCCc5ccccc5)c(O)c(O)c2O,0.75,
COc1ccc(N(C(C(=O)NC[C@@H](C)O)c2ccccc2F)C(=O)c3ccccc3)c(OC)c1,2.55,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(CCc3ccccc3F)C2,2.51,
COc1cc(Nc2ncnc(Nc3c(Cl)ccc4OCOc34)n2)cc(OC)c1OC,3.01,
CCCNC(=O)c1nnc2c(cccc2c1N)c3cnc(OC)nc3OC,3.26,
CN(Cc1ccc(Cl)cc1)C(=O)C2(N)CCN(CC2)c3ncnc4[nH]ccc34,2.8,
Fc1ccc(cc1)S(=O)(=O)Cc2cc(nc(n2)c3ccccn3)N4CCOCC4,1.59,
OC(=O)[C@H](Cc1ccc(NC(=O)Cc2ccc3CCCNc3n2)cc1)NC(=O)c4c(Cl)cccc4Cl,-0.63,
OC(=O)C(N1CCO[C@@H](CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)C1)c4ccccc4,1.71,
NC(=O)c1cc(sc1N)c2ccccc2,2.7,
OC1=CC(=O)C2=C(O1)c3ccccc3N(C2=O)c4ccccc4,0.96,
Clc1ccc(NCCNCC(=O)N2CCC[C@H]2C#N)nc1,0.99,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)c4ccc(cc4)c5nn[nH]n5)cc1Cl,1.53,
CCc1[nH]c2nc(Sc3cnc4ccc[n+]([O-])c4c3)nc(N5C[C@@H]6[C@@H](N)[C@@H]6C5)c2c1Cl,2.3,
O=C1NC(=O)c2cc(OCc3ccccc3)ccc12,3.1,
Fc1cc(c(F)cc1Oc2ccc(Cl)cc2c3ccnn3C4CNC4)S(=O)(=O)Nc5ncns5,1.0,
Clc1cccc(c1)c2cnc3ccc(NC4CCOCC4)nn23,4.3,
CC(C)(C)OC(=O)N1CCN(CC1)c2ccc(OCc3ccc(cc3)S(=O)(=O)C)nn2,2.8,
COc1ccccc1N2CCN(CCCCNC(=O)c3ccc4ccccc4c3)CC2,3.53,
CCOC(=O)\C=C\[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC#C)N2C=CC=C(NC(=O)c3cc(C)on3)C2=O,1.75,
CC[C@@H]1COCCN1c2cc(nc(n2)c3cccc4[nH]ccc34)C5(CC5)S(=O)(=O)C,3.0,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)N4CC[C@H](C4)N(C)C)ncc2F,2.36,
CC1=C(C(=O)N(C[C@H](N)c2ccccc2)C(=O)N1Cc3c(F)cccc3F)c4ccc5OCOc5c4,2.67,
Oc1ccc(cc1)C2=CC(=O)c3cc(O)ccc3O2,3.3,
CN(C1CCN(Cc2nc3cc(F)ccc3s2)CC1)C(=O)Cc4ccc(cc4)n5cnnn5,2.85,
ONC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,2.4,
CCN1C=C(C(=O)O)C(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,-1.1,
O=C1C=COc2ccccc12,1.4,
CS(=O)(=O)N1CC[C@@H](C1)N(Cc2ccccc2Cl)c3ccc(C#N)c(Cl)c3,4.0,
Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,1.67,
Oc1ccccc1NC(=O)c2cc(ccc2Cl)[N+](=O)[O-],2.49,
CCN1CCC[C@H]1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N,-0.84,
CS(=O)(=O)c1cccc(Nc2nccc(Nc3cccc4ocnc34)n2)c1,2.9,
ONC(=O)Cc1ccc(Oc2ccccc2)cc1,2.03,
Cc1cn(C[C@H]2CN(C(=O)O2)c3ccc(C4=CCS(=O)(=O)CC4)c(F)c3)nn1,1.25,
C[C@H](CNCCc1ccncc1)c2c([nH]c3ccc(cc23)C(C)(C)C(=O)N4C5CCC4CC5)c6cc(C)cc(C)c6,4.35,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N4CCN(CC4)C(=O)CO)n2,1.69,
CCN1CCC[C@H](C1)C(=O)N2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3,1.6,
Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F,3.42,
C(Oc1cccc2ccccc12)C3=NCCN3,0.68,
CC(C)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c2ccc(C)cc2,0.97,
CCOC(=O)c1ncn2c1CN(C)C(=O)c3cc(F)ccc23,1.1,
CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c3ccccc3,2.5,
CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5nn[nH]n5,1.29,
CCNC(=O)OC[C@@H](C)N(c1cc(Cl)ccc1CO)S(=O)(=O)c2ccc(Cl)cc2,3.4,
C1Oc2ccc(Oc3cc(Oc4ccc(cc4)n5ccnc5)ncn3)cc2O1,3.17,
O=C1NN=C(Cc2ccccc2)c3ccccc13,2.8,
Cc1[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN4CCOCC4,2.22,
COc1ccc(NC(=O)CCc2c(C)nc3nc(C)nn3c2C)cc1,1.4,
Cc1nc(C)c(nc1C(=O)N)c2ccc3c(CC[C@@]34CC[C@H](Cc5nnn[nH]5)CC4)c2,2.0,
CO[C@H]1CN(Cc2ccc(cc2)C(F)(F)F)CC[C@H]1N(C)C(=O)Cc3ccc(cc3)n4cnnn4,3.0,
CCOC(=O)c1ccc(OCCC2CCN(CC2)c3ccc(C)nn3)cc1,4.42,
COc1ccc(cc1C(=O)NCc2cccnc2)C(=O)NCc3cccnc3,1.23,
CN(C)CCOc1ccc(cc1)c2cc(C(=O)N)c(NC(=O)N)s2,1.16,
Fc1cccc(COc2ccc(Nc3ncnc4ccc(cc34)c5cccc(c5)N6CCOCC6)cc2Cl)c1,3.2,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)NS(=O)(=O)c4cccc(c4)C#N)cc1Cl,1.81,
Cc1ccc(cc1)c2cc(C(=O)N3CCOCC3)c4cc(C)ccc4n2,3.6,
N[C@@H](Cc1cccs1)C(=O)N[C@@]2(C[C@@H]2c3ccccc3)C#N,1.3,
CCCSc1nc(ccc1C(=O)NC2CCCCC2)N3CCC(CC3)C(=O)O,1.6,
Fc1ccc(cc1)C(COCc2cc(cc(c2)C(F)(F)F)C(F)(F)F)N3CCNCC3,3.0,
CC(C)(C)C(O)\C(=C/c1ccc(Cl)cc1Cl)\n2cncn2,3.8,
C[C@@H]1C2CCCC1(CCN2C)c3cccc(O)c3,0.52,
Fc1cc2N=CNC(=O)c2cc1F,1.5,
CCOc1ccc2C=CC(=O)Oc2c1,2.2,
COc1cc2c(Nc3cnc(NC(=O)c4ccccc4)nc3)ncnc2cc1OCCCN5CCOCC5,2.7,
CN1C(=O)N(C)c2nc[nH]c2C1=O,-0.09,
CCCS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc(C)n3C(C)C)cc1,3.37,
COc1cc(ccc1Cn2ccc3ccc(NC(=O)OC4CCCC4)cc23)C(=O)O,2.1,
Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c4cccs4,4.13,
CCOc1ccc(CCNCCCSCCNC[C@H](O)c2ccc(O)c3NC(=O)Sc23)cc1,0.41,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)N4CCN(CC4)S(=O)(=O)C)n2,2.57,
OC(=O)CCc1oc(c2ccccc2)c(n1)c3ccccc3,1.2,
C[C@@H](Oc1cccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c12)C(=O)N5CCOCC5,4.14,
COc1ccc(nc1OC)N2CCN([C@H](C)C2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,2.3,
CC(C)OC(=O)N1CCC(CC1)Oc2ncnc3c2cnn3c4ccc(cc4F)S(=O)(=O)C,3.0,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)[C@H](C)C(=O)N,3.44,
N(c1cccnc1)c2ncnc3ccccc23,1.57,
CCOc1ccc2oc(C(=O)NC(CCSC)c3nc4cnccc4[nH]3)c(C)c2c1,4.31,
COCCOc1ccc(cc1)C(=O)Nc2cc(NC(=O)c3cccc(c3)N(C)C)ccc2C,2.74,
O=C(CSC1=NC2=C(SCC2)C(=O)N1c3ccccc3)Nc4ncc(s4)c5ccccc5,3.95,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3ccncc3C#N)cn2,2.81,
NC(=O)Nc1cc(sc1C(=O)N[C@H]2CCCNC2)c3ccc(cc3)C#N,0.61,
CC(C)Cn1cnc2c(N)nc3ccccc3c12,2.52,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4ncc(C)n4C,2.67,
C[S+]([O-])c1ccc(\C=C/2\C(=C(CC(=O)O)c3cc(F)ccc23)C)cc1,-0.01,
CN1C2CC(CC1C3OC23)OC(=O)C(CO)c4ccccc4,0.17,
CN(CCNC[C@H](O)c1ccc(O)c2NC(=O)Sc12)C(=O)CCOCCc3ccccc3,1.21,
Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5,3.5,
CN(C)CCCN1c2ccccc2Sc3ccc(cc13)C(F)(F)F,3.59,
CCN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c3C1=O)c6cc(cn6C)C#N,4.13,
CN(C)c1ccnc2sc(C(=O)N)c(N)c12,1.7,
CC1=C(C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O)C4=C(C)C(=O)c5c(Cc6ccccc6)c(O)c(O)cc5C4=O,2.73,
CN(C)CCCOc1ccc(cc1)c2cc(C(=O)N)c(NC(=O)N)s2,0.64,
COc1cccc(c1)c2cc3c(N[C@H]4CCCNC4)ncc(C(=O)N)c3s2,1.82,
COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2,0.99,
Cc1cc(CN2CCC2)cnc1c3ccc(cc3)C(=O)Nc4ccccc4N,1.18,
Cc1oc2C=NN(B(O)c2c1)S(=O)(=O)c3ccc(C)cc3,-0.28,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)N4CCN(C)CC4)n2,2.1,
Oc1ccc(CCNCCNS(=O)(=O)CCOCCCc2ccccc2)c3sc(O)nc13,2.22,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4cc(ccn34)C#N)N5CCN(CC5)C(=O)C,2.3,
COC(=O)c1ccc(cc1)C(C)N2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3,1.3,
NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c4ccccc4)c5ccccc5,2.79,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4ccc(C)cc4,1.69,
NCC[C@@H](Oc1nc(ccc1C#N)C(F)(F)F)c2oncc2,-0.49,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4cc(ccc34)C(F)(F)F,1.78,
CN(C)CCN(Cc1ccccc1)c2ccccn2,1.28,
COc1ncc(cc1NS(=O)(=O)c2ccc(F)cc2F)c3ccc4nccc(c5ccnnc5)c4c3,2.5,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)NS(=O)(=O)c4ccccc4Cl)cc1Cl,1.93,
CC(CCc1ccccc1)NCC(O)c2ccc(O)c(c2)C(=O)N,1.06,
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,0.34,"This molecule is an oral prokinetic and antiemetic agent used in the therapy of gastroesophageal reflux disease, gastroparesis and severe or chemotherapy induced nausea. This molecule has been linked to rare instances of clinically apparent liver injury that are typically cholestatic and can be associated with bile duct loss. This molecule is a member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine. It has a role as an antiemetic, a dopaminergic antagonist, a gastrointestinal drug, a xenobiotic and an environmental contaminant. It is a tertiary amino compound, a substituted aniline, a member of benzamides and a member of monochlorobenzenes. It is a conjugate base of a metoclopramide(1+). This molecule is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures.   One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. This molecule is a Dopamine-2 Receptor Antagonist. The mechanism of action of metoclopramide is as a Dopamine D2 Antagonist. This molecule is a substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. This molecule exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. This molecule may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting."
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)NCc3ccccn3)C(=O)C(F)(F)F,2.15,
OC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl,1.08,
COc1ccccc1CCNCc2ccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)cc2,0.8,
NC(=O)C1=CN(Cc2ccc(Cl)cc2Cl)C(=O)C=C1,2.36,
CCc1cc(ccn1)C(=S)N,1.52,
COc1cccc(NC(=O)c2cccc(Cc3c(C)nn(CCO)c3c4ccccc4)c2)c1,4.29,
COc1ccc(CC(=O)Nc2nc3ccccc3[nH]2)cc1,2.9,
COc1cc(OC)cc(c1)c2cc3cnc(N)nc3nc2N,2.14,
COc1ccc(cc1CO)c2ccc3c(nc(nc3n2)N4C[C@@H](C)O[C@@H](C)C4)N5CCOCC5,3.25,
CC(=O)N1CCN(CCOc2ccc(cc2)C3(O)CCN(CC3)c4ccc5nnc(n5n4)C(F)(F)F)CC1,2.2,
Clc1ccc2nc(ccc2c1C(=O)NCC34CC5CC(CC(C5)C3)C4)N6CCC[C@@H](C6)NCCc7nnn[nH]7,3.08,
Cc1c(Sc2ccc(Cl)cc2)c3ccc(Cl)cc3n1CC(=O)O,2.51,
Cc1nc2c(cnn2c(O)c1Cc3ccccc3)C#N,0.68,
CNC(=O)c1ccc(Nc2nccc(n2)c3cnc(C)n3C(C)C)cc1F,2.95,
CC12CCC3C(CCC4=CC(=O)CCC34C)C1CCC2O,3.3,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CCCC4,3.8,
O=C1N2CCS(=O)(=O)C2=Nc3ccccc13,0.8,
CCOC(=O)c1c(C)n(Cc2occc2)c3ccc(O)cc13,3.5,
Cc1cccc(NC(=O)c2ccc(c3ccccc3)c(c2)C#N)n1,3.71,
CONC(=O)c1cnc(s1)N2CCC(CC2)NC(=O)c3[nH]c(C)c(Cl)c3Cl,3.1,
NC(=O)c1ccc(cc1)c2cc3c(N[C@H]4CCCNC4)ncc(C(=O)N)c3s2,0.28,
COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)c1c2ccc(F)cc2)C(C)C,1.72,
[O-][N+](=O)c1ccc2C(=O)C(=O)c3ccccc3c2c1,2.56,
CCC[C@H](CO)Nc1nc(SCc2ccccc2)nc3nc(N)sc13,3.8,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(C(=O)N(C)C)c(C)c3)ncc2F,2.86,
CNC(=O)C1(CCN(CC[C@H](CN(C)C(=O)c2c(OC)c(cc3ccccc23)C#N)c4ccc(Cl)c(Cl)c4)CC1)N5CCCNC5=O,2.2,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4cccnc4)c1,1.59,
CC12CC3CC(C)(C1)CC(N)(C3)C2,0.06,"This molecule is an oral N-methyl-D-aspartate glutamate receptor antagonist used in the therapy of Alzheimer disease and dementia. This molecule is associated with a minimal rate of serum enzyme elevations during therapy and has only rarely been implicated as a cause of clinically apparent acute liver injury. This molecule is a primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. It has a role as a dopaminergic agent, an antiparkinson drug, a NMDA receptor antagonist, a neuroprotective agent and an antidepressant. It is a member of adamantanes and a primary aliphatic amine. It is a conjugate base of a memantinium(1+). It derives from a hydride of an adamantane. This molecule is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).  It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease.  Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease.  In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million.  Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025. This molecule is a N-methyl-D-aspartate Receptor Antagonist. The mechanism of action of memantine is as a NMDA Receptor Antagonist. This molecule is a low-affinity, voltage-dependent, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. This molecule binds to and inhibits cation channels of glutamanergic NMDA receptors located in the central nervous system (CNS), preventing the prolonged influx of calcium ions and the associated neuronal excitotoxicity, and thereby potentially enhancing cognitive function. This molecule is also a 5-hydroxytryptamine type 3 (5HT3) receptor and nicotinic receptor antagonist. This molecule is an amantadine derivative with low to moderate-affinity for NMDA receptors. It is a noncompetitive NMDA receptor antagonist that binds preferentially to NMDA receptor-operated cation channels. It  blocks the effects of excessive levels of glutamate that may lead to neuronal dysfunction. It is under investigation for the treatment of Alzheimer's disease, but there has been no clinical support for the prevention or slowing of disease progression."
CO[C@H]1CN(CCN2C(=O)C=Nc3ccc(OC)cc23)CC[C@@H]1NCc4cc5OCCOc5cn4,1.25,
Brc1ccc(s1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.52,
Cc1cc(Nc2ccc(F)cc2)nc(N)n1,2.08,
CC(=O)Nc1ccccn1,0.5,
Clc1ccc(cc1)c2oc(cc2)C(=O)Nc3ccc(cc3)N4CCNCC4,2.4,
Nc1cc(nc(N)[n+]1[O-])N2CCCCC2,0.77,
NC1(CCC1)c2ccc(cc2)c3c(ccn4ccnc34)c5ccccc5,2.0,
Oc1ccc(CCNCCS(=O)(=O)CCCOCCc2nccc3ccccc23)c4sc(O)nc14,2.35,
CCOC(=O)c1ccccc1c2csc(NS(=O)(=O)c3ccc(Cl)cc3)n2,2.43,
CN1CCN(CC1)C(=O)c2cc(sc2NC(=O)N)c3ccccc3,2.17,
Oc1ccc(cc1)N2C(=O)c3ccccc3C2=O,2.0,
COCCNc1nc(NCc2ccccc2F)c3sccc3n1,3.4,
Cn1cc(cc1C=O)C(=O)CCCCOc2ccc(cc2)C(=O)O,0.14,
Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,1.26,
Cc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(C)c4Cl,2.2,
CN1CCC(CC1)n2cc(cn2)c3cnc(N)c(c3)c4oc5cc(F)ccc5n4,3.35,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)cnc1C#N)c3ncc(F)cn3,1.96,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(C)cc2)C1)C(C)(C)C,2.05,
CC(C)[C@@H](CN1CCCCC1)N(C)C(=O)Cc2ccc(Cl)c(Cl)c2,2.87,
COc1ccc(cc1OC)C(=O)Nc2cccc(NC(=O)c3ccc(OC)c(OC)c3)n2,3.5,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN4CCCC4,3.28,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(F)c2)n3ccnc3,0.7,
CN1SC(=O)c2cc(ccc12)S(=O)(=O)N,0.3,
Nc1nc(OC2CCCC2)nc3c1ncn3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O,0.79,
Cc1ncsc1CCOCCCS(=O)(=O)CCNCCc2ccc(O)c3nc(O)sc23,1.44,
COc1ccccc1CN(C)Cc2cccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)c2,1.52,
OC1CCN(CC1)C(=O)CN2C(=O)C(Cc3ccccc23)NC(=O)c4cc5cc(Cl)sc5[nH]4,2.86,
C(Cc1nc2ccccc2[nH]1)Cc3nc4ccccc4[nH]3,3.5,
Cc1ccc2c(c1)c(Sc3ccccc3Cl)c(C)n2CC(=O)O,1.71,
Oc1ccc(cc1)c2ccc3cc(O)ccc3n2,3.1,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6oc(cc6C)C#N)c3C1=O,4.34,
CO[C@H]1CN(CCN2C(=O)C=Nc3ccc(OC)cc23)CC[C@H]1NCc4ccc5OCC(=O)Nc5n4,0.51,
CCN(C1CCN(CC[C@H](N2CCN(CC2)S(=O)(=O)C(F)(F)F)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.86,
NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)n1,1.71,
NC1=NC(=CC(=O)N1)CCc2cccc(Br)c2,2.52,
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,0.42,"This molecule is an N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have R configuration. The active enantiomer of formoterol, it is administered by inhalation (generally as the tartrate salt) as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema). It has a role as a bronchodilator agent, an anti-asthmatic drug and a beta-adrenergic agonist. It is a conjugate base of an arformoterol(1+). It is an enantiomer of a (S,S)-formoterol. This molecule is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. This molecule inhalation is used to prevent bronchoconstriction in people with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients using long-acting beta agonists for the treatment of asthma. This molecule is a beta2-Adrenergic Agonist. The mechanism of action of arformoterol is as an Adrenergic beta2-Agonist. This molecule is a long-acting beta-2 adrenergic agonist and isomer of formoterol with bronchodilator activity. This molecule selectively binds to and activates beta-2 adrenergic receptors in bronchiolar smooth muscle, thereby causing stimulation of adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased intracellular cAMP levels cause relaxation of bronchial smooth muscle and lead to a reduced release of inflammatory mediators from mast cells. This may eventually lead to an improvement of airway function."
OC[C@H](O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)ccc4[nH]3,3.4,
CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,0.8,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2ccccc12)c3cccc(F)c3)c4ccccc4,3.14,
CC(C)C[C@H](CO)Nc1nc(SCc2ccccc2)nc3NC(=O)Sc13,4.2,
CC(=O)N1CCN(CC1)c2ccc(NC(=O)c3oc(Nc4ccccc4F)nn3)cc2,2.51,
CC1=C(C(=O)N(C[C@H](N)c2ccccc2)C(=O)N1Cc3c(F)cccc3F)c4ccccc4F,2.76,
OS(=N)(=O)Cc1noc2ccccc12,0.55,
Clc1ccc2[nH]ccc2c1,3.28,
CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)c2cc3cc(F)ccc3[nH]2,3.5,
COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1c4ocnc4,3.6,
CCN1C(=O)N(CC)c2[nH]c(nc2C1=O)c3ccccc3,3.3,
CN(C)C(=O)N[C@@H]1CC[C@@H](CCN2CCN(CC2)c3ccc(Cl)cc3)CC1,2.81,
Clc1ccc(cc1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.59,
CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O,1.5,"This molecule is a member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups. It is functionally related to a barbituric acid. This molecule is effective as a hypnotic and sedative. This molecule is only found in individuals that have used or taken this drug. It is a barbiturate that is effective as a hypnotic and sedative. [PubChem]This molecule binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged."
COc1cc(Nc2nccc(Oc3cnc4ccccc4c3)n2)cc(OC)c1OC,3.41,
Clc1ccc2N(C3CCN(CCCN4C(=O)Nc5ccccc45)CC3)C(=O)Nc2c1,3.45,
COc1cc(cc(OC)c1O)[C@H]2[C@@H]3C(COC3=O)C(O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)c6cc7OCOc7cc26,0.91,
CC1=C(C(=O)Oc2cc(O)ccc12)c3ccc(O)cc3,2.8,
CCN1C=C(C(=O)O)C(=O)c2cc(F)c(cc12)N3CCNCC3,-0.87,
COc1cc(OC)c(cc1NC(=O)C)S(=O)(=O)N(C(C)C)c2ccccc2,1.6,
COC(=O)c1c(O)cccc1OC\C=C\c2ccc(F)c(c2)c3onc(c3)C(=O)O,0.66,
Nc1nccc(n1)c2c[nH]c3ccccc23,1.68,
OC(=O)c1ccc(cc1)n2ncc(C(=O)NC3C4CC5CC(CC3C5)C4)c2C(F)(F)F,1.5,
Fc1ccc(cc1)c2ncn(C3CCNCC3)c2c4ccncc4,0.3,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4ccc(OC)cc4,2.15,
Cc1cc(nc(n1)n2ccnc2)N3CCC[C@@H]3C(=O)NCCc4ccc5OCOc5c4,2.5,
CC(C)c1c(cnn1c2ccc(cc2)C(=O)O)C(=O)NC3C4CC5CC(CC3C5)C4,1.15,
CCn1cnc2cnc(c3ccc(cc3)C4(N)CCC4)c(c5ccccc5)c12,2.0,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)N(C)C)n2,2.45,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3cncc4ccccc34)c2C(=O)N5CC[C@@H](O)C5,1.74,
OCCNC(=O)COc1ccc(OCCNCC(O)COc2ccccc2)cc1,0.42,
CCc1cc(C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N)n(C)n1,2.6,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)NC4CC4)n2,3.06,
Cc1cnccc1COc2cnc(nc2)N3CCN(CC3)C(=O)OC(C)(C)C,3.8,
C=CCCCCCCCCC(=O)N[C@H]1CCC(=O)NC1=O,2.64,
COc1cc2nnc(C(=O)N)c(Nc3cc(C)ccc3F)c2cc1N4CCN(C)CC4,2.57,
O[C@H](CNC(=O)c1cnnc2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.28,
CCCCc1nc2c(N)nc3ccccc3c2n1Cc4ccccc4,4.17,
COc1ccccc1CNC(=O)NS(=O)(=O)c2ccc(Cl)cc2,0.87,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4cscn4)c1,1.56,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3c(F)cncc3F)cn2,3.7,
Clc1ccc(cc1)C(=O)CN2C3=NCCN3c4ccccc24,2.62,
COc1cc(C)c(c(C)c1)S(=O)(=O)N(C)CCOCC(=O)N2CCC(CC2)C3CCN(C)CC3,0.3,
CCC(CC)NC(=O)c1cnn(c1NS(=O)(=O)c2ccc(cc2)c3ocnc3)c4ccccc4,0.8,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3cccc(Oc4ccccc4)c3)C(=O)NC1=O,2.32,
COc1nccnc1NS(=O)(=O)c2ccc(N)cc2,-0.65,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(sc13)c4ccc(Cl)c(F)c4,2.76,
CC(=O)Nc1cccc2c1c(c(C)n2CC(=O)O)S(=O)(=O)c3ccc(Cl)cc3,0.4,
CCCNc1nc(ccc1C(=O)NC2CCCCC2)N3CCC[C@@H](CC(=O)O)C3,2.33,
NC1CCc2cc(OC(=O)c3ccccc3)c(OC(=O)c4ccccc4)cc2C1,2.6,
CC(C)C(=O)Nc1ccc2C(=O)NC(=O)c2c1,1.55,
Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+](=O)[O-],0.74,
COc1cc(F)ccc1c2cncc(CNC(C)C)c2,1.5,
Cc1c(Oc2ccc(Cl)cc2)c3cc(F)ccc3n1CC(=O)O,1.26,
COc1cccc2c1c(NS(=O)(=O)c3ccc(Cl)s3)nn2Cc4cccc(CNC(=O)C(C)(C)O)c4,2.09,
CC(=O)Nc1cc(CN2C(=O)N(C(=O)C2(C)C)c3ccc(SC(F)(F)F)cc3)ccn1,2.93,
COc1ccc2SCC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2c1,1.78,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4c(CO)cccn34)N5CCN(CC5)C(=O)C,3.1,
CCOc1ccc(cc1)N2C(=O)c3ccccc3N=C2[C@@H](C)N(Cc4cccnc4)C(=O)Cc5ccc(cc5)C(F)(F)F,4.25,
CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2,3.65,
Brc1ccccc1C(=O)NCC23CC4CC(CC(C4)C2)C3,4.15,
COc1ccc(cc1)c2nc3c(NCCCNC(=O)C4CCCC4)c(cnc3[nH]2)C(=O)N,3.13,
CN1C(=O)CC(C1=O)c2ccccc2,0.68,
[O-][N+](=O)c1ccc2[nH]c(nc2c1)c3ccccn3,2.8,
c1ccc(cc1)C#Cc2n[nH]c3ccccc23,4.31,
CSc1ccc(cc1)C(=O)C(C)(C)N2CCOCC2,3.49,
CCN1C(=O)C=Cc2cnc(Nc3ccc(OC)c(OC)c3)nc12,2.7,
CN(CCOc1ccc(NS(=O)(=O)C)cc1)CCc2ccc(NS(=O)(=O)C)cc2,0.6,
CCOc1nc2cccc(C(=O)O)c2n1Cc3ccc(cc3)c4ccccc4c5nnn[nH]5,0.3,
CCN1CCC[C@@H](CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,1.94,
CC(C)N1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CCS(=O)(=O)C4,2.55,
COc1cc(OC)cc(c1)C2=CC=C(NC(=O)OCc3ccccc3)C(=O)N2CC(=O)NC(C(C)C)C(=O)C(F)(F)F,2.26,
COc1cc2c(Nc3ncc(NC(=O)c4ccccc4)cn3)ncnc2cc1OCCCN5CCOCC5,2.32,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C#N)n4ccc(n4)C(F)(F)F,2.62,
CCS(=O)(=O)c1ccc(c(Cl)c1)c2cc(Cl)ccc2OCC(=O)O,-0.43,
CCCOc1nc(ccc1C(=O)NC2CCCCC2)N3CCC[C@@H](CC(=O)O)C3,2.81,
CNC(=O)c1ccc(cc1)c2cc(C(=O)N[C@H]3CCCNC3)c(NC(=O)N)s2,0.7,
CC(C)(C)OC(=O)N1CCN(CC1)c2ccc(OCc3ccc(cc3)S(=O)(=O)C)nc2,3.1,
COc1cnc(nc1Oc2ccc(F)cc2F)c3ccccn3,3.1,
CN1CCN(CC1)c2ccc3nc([nH]c3c2)C4=C(N)c5c(F)cccc5NC4=O,3.45,
CN(C(=O)C)c1ccc2ccn(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,2.9,
COc1cc2ncnc(Nc3cc(NC(=O)c4ccnc(c4)N5CCOCC5)ccc3C)c2cc1OCCN(C(C)C)C(C)C,3.5,
Cc1cc(O)nc(n1)n2nc(C)c(Oc3ccccc3O)c2C,1.4,
NC(=O)c1c(N)sc2CCCCc12,1.84,
Fc1ccc(C2CCN(CC2)C(=O)COCc3ccncc3)c(Cl)c1,2.7,
FC(F)(F)c1nnc2ccc(nn12)N3CCCCCC3,3.29,
OCCN(C(=O)CNC(=O)c1cc2cc(Cl)ccc2[nH]1)c3ccccc3,3.37,
Cc1ccc(NC(=O)c2ccnc(c2)N3CCOCC3)cc1NC(=O)c4ccc(OCc5ccccn5)cc4,3.47,
COc1ccc(OC)c(CNc2[nH]nc3cccc(Oc4ccc(cc4)S(=O)(=O)C)c23)c1,3.71,
CCN(C1CCN(CC[C@H](c2ccc(cc2)S(=O)(=O)C)c3cc(F)cc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.2,
Nc1cccc(CCc2ccc3cc[nH]c3c2)n1,2.8,
CNc1nc2ccccc2n1Cc3sc4N(CC(C)C)C(=O)N(C)C(=O)c4c3C(=O)N5C[C@H](O)CO5,1.77,
CN1CCN(CC(=O)Nc2c(cnn2c3ccccc3)C#N)CC1,0.0,
Cc1cc(Oc2ccnc(Nc3ccc(cc3)S(=O)(=O)N)c2)c(nc1C)c4ccccn4,2.34,
CCCc1nn(C)c2C(=O)NC(=Nc12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4,2.8,
CN(C)CCOc1ccc(cc1)c2oc3ncnc(NC[C@@H]4CCCO4)c3c2c5ccccc5,3.6,
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,2.9,"This molecule is an aminoquinoline used for the therapy of malaria. This molecule has been linked to severe cases of acute hepatitis which can be fatal, for which reason it is recommended for use only as treatment and not for prophylaxis against malaria. This molecule is a quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position. It has a role as an antimalarial, a non-steroidal anti-inflammatory drug, a drug allergen, a prodrug, an EC 2.1.1.8 (histamine N-methyltransferase) inhibitor and an anticoronaviral agent. It is a member of phenols, an aminoquinoline, a secondary amino compound, a tertiary amino compound and an organochlorine compound. It is a conjugate base of an amodiaquine(1+). A 4-aminoquinoquinoline compound with anti-inflammatory properties. This molecule is an orally active 4-aminoquinoline derivative with antimalarial and anti-inflammatory properties. Similar in structure and activity to chloroquine, amodiaquine is effective against some chloroquine-resistant strains, particularly Plasmodium falciparum, the most deadly malaria parasite. Although the mechanism of plasmodicidal action has not been fully elucidated, like other quinoline derivatives, amodiaquine likely is able to inhibit heme polymerase activity in the body. This results in accumulation of free heme, which is toxic to the parasites."
CCN(CCCOCCOCCc1ccccc1)CCc2ccc(O)c3nc(O)sc23,2.45,
Fc1ccccc1Nc2oc(nn2)C(=O)Nc3ccc(N4CCOCC4)c(F)c3,3.6,
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1.05,"This molecule is a benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. It has a role as an antihypertensive agent, a sodium channel blocker, a vasodilator agent, a K-ATP channel agonist, a beta-adrenergic agonist, a cardiotonic drug, a bronchodilator agent, a sympathomimetic agent and a diuretic. It is a benzothiadiazine, a sulfone and an organochlorine compound. This molecule is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels. It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. This molecule is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. This molecule also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. This molecule is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates. This molecule is a benzothiadiazine derivate with antihypertensive and hyperglycemic activities. This molecule increases membrane permeability to potassium ions in vascular smooth muscle, thereby stabilizing the membrane action potential and preventing vascular smooth muscle contraction; this results in peripheral vasodilatation and decreases in peripheral vascular resistance. This agent also inhibits insulin release by interacting with ATP-sensitive potassium channels of pancreatic islet beta-cells."
CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c3cnc4NC(=O)CCc4c3,2.36,
COc1ccc(cc1Oc2cccc(Cl)c2)S(=O)(=O)N3CCC[C@@H](C3)N4C=C(C)C(=O)NC4=O,2.73,
CCOC(=O)C1=C(C)NC(=C([C@H]1c2cccc3C(=O)C=C(C)Oc23)C(=O)C)C,2.63,
Nc1nc2OC(COc3ccccc3)Cc2c(N)c1C#N,2.08,
COc1ncc(cn1)c2cccc3OC[C@H](Cc23)NC(=O)c4ccc(OCC(F)(F)F)nc4,4.3,
Fc1ccc(F)c(NS(=O)(=O)c2ccc(Cl)cc2)c1,2.9,
COC(=O)N1CCN([C@H](CN2CCCC2)C1)C(=O)Cc3ccc(Cl)c(Cl)c3,2.05,
CCN(C(=O)Nc1ccccc1)c2ccccc2,3.1,
Clc1ccc2[nH]c(cc2c1)C(=O)N3CCNCC3,1.65,
O=C(Nc1cccnc1C(=O)NCC2CCOCC2)c3cccc4ccccc34,4.4,
COc1cnc(nc1NC(C)C)c2ccccn2,2.01,
CCCCN(CCNCCc1ccc(O)c2NC(=O)Sc12)C(=O)CCOCCc3ccccc3,3.0,
CCN(CC)CCNC(=O)c1cc(ccc1OC)S(=O)(=O)C,-0.9,
CC(C)(CS(=O)(=O)N1CCN(CC1)c2ccc(F)cc2)N(O)C=O,1.07,
CC(C)N1CCC[C@H](CN2C(=O)c3cc(ccc3N=C2C(C)C)c4ccc(F)cc4)C1,3.6,
COCCN1CCC(Cc2ccc(cc2)C(=O)NCc3cnc(nc3NCC(C)(C)C)C#N)CC1,3.5,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cn3c(C)nc4ccccc34)c2C(=O)N5CC[C@@H](O)C5,1.34,
COc1cc(OC)c(cc1NC(=O)C)S(=O)(=O)N2C(C)CCc3ccccc23,1.97,
Brc1ccc(s1)N2C[C@@]3(CN4CCC3CC4)OC2=O,2.0,
OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\3/CCN(C3=O)c4ccccc4,1.85,
CCN(C1CCN(CC[C@H](c2ccc(cc2)S(=O)(=O)C)c3cc(F)cc(Cl)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.71,
CO[C@@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@H]1NCc4ccc5OCC(=O)Nc5n4,0.81,
CNC1CCN(C1)c2ccc(NC(=O)c3ccc(cc3)c4ccccc4)cn2,2.35,
FC1(F)Oc2ccc(\C=C\3/SC(=O)NC3=O)cc2O1,2.8,
C[C@H](NC(=O)C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.17,
OC(=O)COc1ccc(cc1c2ccccc2)c3nccs3,-0.16,
O[C@H](CNC(=O)C1=NNC(=O)c2ccccc12)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.69,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)NCc3cc[n+]([O-])cc3)C(=O)C(F)(F)F,1.13,
COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)\CCC(=O)OCCN3CCOCC3,2.26,
CC(=N)NCc1ccccc1,-0.28,
OC1CS(=O)(=O)CC1N2CCC(CC2)c3ccccc3,1.4,
COc1ccc2[nH]c(cc2c1)C(=O)N3CCN(C)CC3,1.62,
CC(C)C1NCCc2c1sc3ccccc23,2.8,
Nc1nc(Nc2ccc(cc2)S(=O)(=O)N)nn1C(=O)c3c(F)cccc3F,1.87,
CCCCCc1ccc(cc1)c2nnc(N)s2,4.13,
Cc1sc2ncnc(SCC(=O)N3CCCC3)c2c1C,2.89,
OC(=O)[C@H](Cc1cccc(OCCCNc2ccccn2)c1)NC(=O)c3c(Cl)cccc3Cl,0.16,
Cc1ccc(cc1)S(=O)(=O)Nc2c(C(=O)NC3CCOCC3)c(C)nn2c4ccccc4,0.16,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4cc(Cl)ccn34)N5CCN(CC5)C(=O)C,4.2,
Cc1cc(F)ccc1OC2CCN(CC3CCN(CC3)[C@@H](Cc4ccc(F)cc4)C(=O)O)CC2,1.81,
FC(F)(F)c1nnc2ccc(NCn3nnc4ccccc34)nn12,2.34,
C[C@@H]1N[S@@](=O)(=NC1=O)c2cccc(c2)c3cccc(c3)C#N,0.4,
CCCSc1ncccc1C(=O)N(C)C2CCOCC2,1.63,
CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,0.03,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)C)C(=O)C(F)(F)F,1.78,
CN(C)CCCN1c2ccccc2CCc3ccc(Cl)cc13,3.36,
COc1ccc(N(C(C(=O)NC[C@@H](C)O)c2ccccc2F)C(=O)c3occc3Cl)c(OC)c1,2.18,
OC(=O)c1ccccc1C2=C3C=CC(=O)C=C3Oc4cc(O)ccc24,0.0,
Oc1nc2ccccc2c(O)c1c3ccccc3,0.73,
COc1ccc(OC)c(c1)C(O)CNC(=O)CN,-0.71,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5cccnc5)ccc4C,1.5,
COc1ccc(cc1CO)c2ccc3c(nc(nc3n2)n4ccnc4)N5CCOC[C@@H]5C,2.6,
C[C@H](C(=O)O)c1cccc(c1)C(=O)c2ccccc2,-0.06,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5cncs5)ccc4C,2.11,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(C(=O)N(C)C)c(F)c3)ncc2F,3.14,
COC(=O)CCC(=O)Nc1ccc2c(c1)C(=O)C(=O)c3cc(NC(=O)CCC(=O)OC)ccc23,2.67,
CCS(=O)(=O)c1ccc(Oc2c(C)n(CC(=O)O)c3ccc(cc23)C(F)(F)F)cc1,0.29,
O=C(NC1CCCCC1)C2CCCN(C2)S(=O)(=O)c3cccs3,2.93,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(CS(=O)(=O)N)c4ccc(Cl)cc4,2.2,
CCC(N1NC(=O)C2=C(C1=O)C(=O)c3ccc(Cl)cc3N2)c4ccncc4,0.6,
O=C(Nc1ccc(nc1)N2CCOCC2)c3oc(Nc4cccc(OCc5cccnc5)c4)nn3,3.3,
CCOC(=O)c1ccc(OCCC2CN(CCO2)c3ccc(C)nn3)cc1,2.7,
Cc1nc(C)c(nc1C(=O)N)c2ccc3c(CC[C@@]34CC[C@H](CC(=O)O)CC4)c2,1.5,
COC[C@@H](O)CN1C(=O)C=NN(C1=O)c2ccc(Cl)c(c2)C(=O)NCC3(O)CCCCCC3,1.44,
Nc1nc2nc(SCc3ccccc3)nc(N)c2s1,3.1,
CCN(C1CCN(Cc2ccc(cc2)C(F)(F)F)CC1)C(=O)Cc3ccc(cc3)S(=O)(=O)C,2.9,
COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c3ccc4OCOc4c3)c(OC)c1,4.3,
CCNc1nc(N)c(s1)C(=O)c2ccc(Cl)s2,3.63,
CS(=O)(=O)c1ccc(c(Cl)c1)c2cc(ccc2OCC(=O)O)C(F)(F)F,-0.52,
Oc1ccc(cc1)N2C(=O)c3ccc(O)cc3C2=O,1.8,
C1CCC(CC1)NC2CCCCC2,-0.38,
CN1CC=CCC(C1)c2ccc(Cl)c(Cl)c2,3.32,
Oc1ccc(Br)cc1C(=O)C(=O)c2cc(Br)ccc2O,3.85,
CNc1c(cnc2[nH]c(nc12)c3ccc(OCCN4CCOCC4)cc3)C(=O)N,2.14,
CC[C@H](CO)Nc1nc(SCc2ccccc2)nc3nc(N)sc13,3.27,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(cc2)C(F)(F)F)c3ccc(F)cc3)C(C)(C)C,2.35,
Nc1nc2nc(SCc3cccc(F)c3F)nc(O)c2s1,2.5,
CC(N)COc1c(C)cccc1C,0.62,
CCCCC(O)c1[nH]c2cc(C)c(cc2c1CCc3ccccc3)C(=O)O,2.59,
CC(C(=O)Nc1ccc(Cl)cc1)c2ncc(cc2Cl)C(F)(F)F,4.19,
CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c3ccccc3)C(=O)O)cc1)c4ccccn4,2.15,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3ccccc3)n2)cc1,1.58,
C(CN1CCCC1)Oc2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,2.66,
OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O,-0.96,
CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c2cc3cc(Cl)ccc3[nH]2,3.6,
CO[C@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@@H]1NCc4cc5OCCOc5cn4,1.05,
CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3,1.56,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccc(cc2)[N+](=O)[O-])C1)C(C)(C)C,1.54,
CCc1nc2c(N)nc3ccccc3c2n1CC(C)C,2.55,
COc1ccc(cc1)c2nc3c(NCCCNC(=O)C4CC4)c(Br)cnc3[nH]2,1.71,
CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(=O)(=O)N,0.27,
CCCNC(=O)c1nnc2c(cccc2c1N)c3cnccc3OC,2.83,
CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12,0.48,This molecule is a member of tryptamines. It is functionally related to a serotonin.
C1CC2(CCN1)OC(c3ccccc3)c4ccccc24,0.75,
COc1cc(ccc1Nc2ncc(Br)c(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)C,3.7,
CCN(C1CCN(CC[C@@H](c2ccccc2)c3ccc(cc3)S(=O)(=O)C)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.38,
CN1CCN(CC1)C2=Nc3ccccc3Oc4ccc(Cl)cc24,3.24,
COc1cc(O)c(cc1NC(=O)CCC(=O)O)S(=O)(=O)N2C(C)CCc3ccccc23,-0.27,
Cn1ncc2C(=O)NC(=Nc12)c3ccccc3,1.61,
CN(C)CCCn1c2CCCCCCc2c3ccccc13,2.96,
COc1ccc(cc1)C2=COc3cc(O)ccc3C2=O,3.05,
NC(=O)c1cccnc1Oc2ccccc2,1.13,
N(c1ccccc1)c2ccnc(Nc3ccccc3)n2,4.06,
CCN1CCC[C@H]1CNC(=O)c2cc(Br)cc(OC)c2OC,1.2,
CC(O)c1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.25,
CCN(CC)C(=O)c1ccc(cc1)C2=CC3(CCNCC3)Oc4cccc(O)c24,0.54,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cccc(Cl)c3)n2)cc1,2.5,
CC(=O)Nc1ccccc1C,1.0,"This molecule appears as colorless crystals. Insoluble in water. (NTP, 1992) This molecule is a member of toluenes."
Clc1ccc(OC2CCNCC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,1.83,
COc1cccc(\C=C\2/SC(=O)NC2=O)c1N3CCC[C@@H](N)C3,1.27,
COc1ccccc1CN2C(C(=O)NC3CCC(C)CC3)c4ccccc4C2=O,3.74,
C[C@@H](Oc1cccc2ncnc(Nc3ccc4c(cnn4Cc5ccccn5)c3)c12)C(=O)N(C)C,2.89,
COCCNC(=O)c1cccc(CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3)c1,1.2,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4[nH]cnc4C,2.87,
CCn1c2ccccc2c3cc(NC(=O)C)ccc13,3.5,
CNc1c(Br)cnc2[nH]c(nc12)c3ccc(OCCN4CCCCC4)cc3,2.56,
Cc1c(Sc2ccc(Cl)cc2)c3c(Cl)cccc3n1CC(=O)O,2.15,
Oc1cccc(c1)c2nc3ccc(O)cc3s2,3.7,
CN(C)C(=O)C1(CCN(CC[C@H](CN(C)C(=O)c2cc(cc3ccccc23)C#N)c4ccc(Cl)c(Cl)c4)CC1)N5CCCCC5=O,2.52,
Cc1c(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)cccc1C(=O)N,1.6,
[O-][N+](=O)c1oc(C=NN2CCOC2=O)cc1,-0.12,
Cc1ccc2c(c1)c(Sc3ccc(cc3)S(=O)(=O)C)c(C)n2CC(=O)O,-0.08,
Cc1ccc(cc1S(=O)(=O)n2ccc(n2)c3c(C)nc4ccc(Br)cn34)[N+](=O)[O-],3.52,
OC1(CCc2ccc(Oc3ccc(cc3)C(=O)NCc4ccncn4)cc2)CN5CCC1CC5,0.76,
CC(C)CN1C(=O)N(C)C(=O)c2c(SC(C)C)c(Cc3ccccc3C(F)(F)F)sc12,4.42,
O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4,2.19,
c1ccc2cnccc2c1,1.6,"This molecule is an ortho-fused heteroarene that is a benzopyridine in which the N atom not directly attached to the benzene ring. It is a mancude organic heterobicyclic parent, an azaarene, an ortho-fused heteroarene and a member of isoquinolines. This molecule is a natural product found in Lonicera japonica with data available."
C[C@](N)(Cc1ccccc1)c2ccccc2,1.7,
Clc1ccc2oc3C(=O)NC(=Nc3c2c1)[C@@H]4CCCN4,2.01,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(C1)S(=O)(=O)Cc2ccccc2)C(C)(C)C,0.78,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)C(=O)N5CCOCC5,3.4,
O=C(NCCN1CCCC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,2.39,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(C(=O)NC4CCN(C)CC4)c(F)c3)ncc2F,2.41,
Cc1nc(C)c(nc1C(=O)N)c2ccc([C@@H]3CC[C@@H](CC(=O)O)CC3)c(Cl)c2,1.8,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)N4CCCN(C)CC4)ncc2F,2.02,
C[C@H](CO)Nc1nc(SCc2ccccc2)nc3nc(N)sc13,3.12,
O=C(CCc1ccncc1)Nc2ccc(cc2)C(=O)c3ccccc3,3.4,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)c4noc(n4)C(F)F,2.85,
CCN(C1CCN(CCC(c2ccccc2)c3ccc(NC(=O)C(C)(C)C)cc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.98,
COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCCN4CCOCC4,3.4,
Cc1c(Cl)ccc(OC2CCN(CC2)C3CCN(CC3)C(=O)c4cccc(c4)S(=O)(=O)C)c1Cl,3.33,
CCCCc1nc2c(N)nc3ccccc3c2n1CC(C)C,3.82,
CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,0.54,This molecule is a member of benzamides. This molecule is a dopamine antagonist used as an antiemetic. Its prokinetic properties are similar to those of metoclopramide. It is unavailable in America or the United Kingdom.
OC(=O)Cc1ccc(cc1)c2ccc(NC(=O)c3oc(Nc4ccccc4F)nn3)cc2,1.5,
O=S(=O)(N1CCCC1)c2ccccc2c3ccc(CNC4CCOCC4)cc3,1.4,
Cc1ccc(NC(=O)C=C)cc1,2.25,
COc1cc(F)ccc1c2cncc(CNC3CCCC3)c2,2.29,
CC(Cc1ccc(O)cc1)NCC(O)c2cc(O)cc(O)c2,-0.06,
C[C@@H](Oc1cccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c12)C(=O)N(C)CCO,3.85,
COc1cc(ccc1N)C(=O)NC[C@@H](O)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,3.12,
CNc1c(Br)cnc2[nH]c(nc12)c3ccc(OCCN4CCN(C)CC4)cc3,2.91,
COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)c4occc4,1.9,
Cc1c(sc2ncnc(O)c12)C(=O)Nc3ccccc3,2.13,
COCC(=O)N1CCC(CC1)n2cc(cn2)c3cnc(N)c(c3)c4oc5ccccc5n4,3.4,
CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc2ccc(OC)cc2)NC(=O)[C@@H](N)Cc3cncn3C)c4ccccc4,2.51,
CCN(C1CCN(CC[C@H](N2CCN(CC2)S(=O)(=O)CC(F)(F)F)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.8,
CCN1C(=O)C=Cc2cc(COc3cc(F)cc(c3)C4(CCOCC4)OC)ccc12,3.89,
CC(=O)OCCn1c(Sc2nc3cccc(Cl)c3s2)nc4c(N)ncnc14,3.16,
CN1CCN(CC1)[C@@H]2C[C@@H](C2)c3nc(c4ccc5ccc(nc5c4)c6ccccc6)c7c(N)nccn37,3.2,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(C(=O)N)c(F)c3)n2,2.8,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C4=NNC(=O)O4)n5ccc(n5)C(F)(F)F,1.65,
CN(C)CCCN1c2ccccc2Sc3ccccc13,2.56,
Cc1cc(Cl)ccc1OC2CCN(CC3CCN(CC3)[C@@H](Cc4ccc(F)cc4)C(=O)O)CC2,2.53,
Nc1ncc(cc1c2oc3ccccc3n2)c4cnn(c4)C5CCN(CC5)C(=O)CO,3.2,
CCc1cc(OCc2ccc(cc2)c3ccccc3c4nn[nH]n4)c5CCCCc5n1,1.7,
C[C@@H]1CN(Cc2oc(nn2)c3cc(cc4[nH]ncc34)c5cccc6[nH]ccc56)C[C@H](C)O1,4.01,
NC(=O)Nc1sc(cc1C(=O)N2CCOCC2)c3ccccc3,2.24,
O=C(NCCCN1CCCCC1)C(c2ccccc2)c3ccccc3,1.33,
Nc1c(Nc2ccccc2)nc(nc1N3CCOCC3)C#N,2.72,
COc1cc(N2CCN(C)CC2)c3NC(=CC(=O)c3c1)C(=O)Nc4ccc(cc4)N5CCOCC5,2.7,
O=C(NCc1occc1)c2ccc3[nH]c(COc4ccc(cc4)C56CC7CC(CC(C7)C5)C6)nc3c2,4.0,
NC(=O)Nc1cc(sc1C(=O)N)c2ccccc2,2.43,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NS(=O)(=O)c3cccc(NC(=O)C)c3)C(=O)C(F)(F)F,2.43,
CCN(c1ccccc1)c2cc(NC)[n+](C)c(C)n2,-0.91,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ncccc3C(=O)N2Cc4ccccc4,-0.04,
Nc1ncnc2OCCN(C(=O)c12)c3ccc(cc3)[C@@H]4CC[C@@H](CC(=O)O)CC4,-0.5,
Cc1cnc(Oc2ccc(cc2)n3ccnc3)nc1Oc4ccc5OCOc5c4,3.56,
Cc1csc(NC(=O)c2cc(Sc3nncn3C)ccc2N)n1,2.3,
C[C@@](CCc1ccc(cc1)c2ccc(Cl)cc2)(C(=O)NO)S(=O)(=O)C,2.4,
CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc4cccnc24)CC1,-0.49,
O=C(NCC#N)[C@@H]1CCCC[C@H]1C(=O)N2CCN(CC2)c3ccc(cc3)C#N,1.79,
Nc1ccc2nc(sc2c1)c3ccc(O)cc3,3.1,
COCCC(Oc1ncnc2c1cnn2c3ccccc3C(F)(F)F)C(=O)Nc4ccc(C)cn4,3.5,
CCN(C)C(=O)c1ccc(cc1)C(=C2CCN(Cc3cscn3)CC2)c4cccc5cccnc45,2.65,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OC4CC5CC5C4)nc23,1.66,
Cc1cccc(n1)c2nn3CCCc3c2c4ccnc5ccc(cc45)C(=O)N,1.71,
CC1=C(Oc2c(cccc2C1=O)C(=O)OCCN3CCCCC3)c4ccccc4,3.42,
CCC(CC)NC(=O)c1cnn(c1NS(=O)(=O)C2CCCC2)c3ccccc3,0.69,
CC[C@@H](CO)Nc1nc(SCc2ccccc2)nc3nc(N)sc13,2.99,
Nc1nc(N)c2cc(Br)ccc2n1,1.78,
CCC(=C)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,0.02,
Oc1c2C(=O)N(NC(=O)c2nc3cc(Cl)ccc13)C(c4ccccc4)c5ccncc5,1.1,
CSc1ccc2Sc3ccccc3N(CCC4CCCCN4C)c2c1,3.76,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OC4CCOC4)nc23,-0.06,
COc1cc(Nc2cc(Nc3c(Cl)ccc4OCOc34)ncn2)cc(OC)c1OC,3.07,
CC1=CN(C2CCCN(Cc3cccc(Oc4ccc(Cl)cc4)c3)C2)C(=O)NC1=O,3.38,
CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O,0.67,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)N4CC[C@H](C4)NC(=O)C)ncc2F,3.3,
CC[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,0.22,
COc1ccc(cc1OC)c2csc(NC(=O)c3c(C)onc3C)n2,3.16,
CS(=O)(=O)Cc1cc(nc(n1)c2ccccc2)N3CCOCC3,1.94,
CN([C@@H]1CCN(Cc2nc3cc(F)ccc3s2)C[C@@H]1F)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.2,
CC(C)N1CCN[C@@H](CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,1.92,
Cn1cnc(c2ccccc2)c1c3nc4c(N)ncnc4s3,2.69,
CCCN(CCO)CCCOc1cc2ncnc(Nc3cc(CC(=O)Nc4cccc(F)c4F)[nH]n3)c2cc1OC,1.28,
CC(C)C[C@H](N[C@@H](c1ccc(cc1)c2ccc(cc2)S(=O)(=O)C)C(F)(F)F)C(=O)NCC#N,3.24,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)N,2.3,
C[C@@H]1CN(CCN1c2ncc(OCc3ccc(cc3)S(=O)(=O)C)cn2)C(=O)OC(C)(C)C,3.6,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4cn[nH]c4,2.13,
CNc1cccc(CCOc2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)cc2)n1,-0.15,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3nccnc3C(=O)N2Cc4ccccc4,-0.14,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2cccnc2)NC(=O)OCc3ccccc3)C(=O)C(F)(F)F,2.15,
OC(=O)CCn1c2ccccc2c3ccccc13,0.6,
CSc1ncccc1C(=O)NCCc2ccc(Cl)cc2,3.31,
COc1nc(Cl)cnc1NS(=O)(=O)c2cccc3c(cccc23)N(C)C,1.74,
O[C@@H](CNCCc1cccc(CNCCCc2ccccc2)c1)c3ccc(O)c4NC(=O)Sc34,1.11,
CCCN(CCCOCCOCCc1ccccc1)CCc2ccc(O)c3nc(O)sc23,2.74,
C[C@H](CO)Nc1nc(SCc2cccc(Cl)c2F)nc3NC(=O)Sc13,3.53,
C1CC(CCN1)c2ccccc2,0.54,
Nc1cccc(NS(=O)(=O)c2ccc(cc2)c3ccc(cc3)C#N)n1,2.2,
CS(=O)(=O)c1ccc(CC(=O)N(CC=C)C2CCN(CCC(c3ccccc3)c4ccccc4)CC2)cc1,3.1,
COc1cc2c(Nc3c(Cl)ccc4OCOc34)ncnc2cc1OCCCN5CCCC5,1.62,
CN(C)CCOc1ccccc1Cc2ccccc2,2.53,
Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1,-1.33,"This molecule is a white powder. (NTP, 1992) This molecule is a sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2. It has a role as an antimicrobial agent, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor, an antiinfective agent and a drug allergen. It is a sulfonamide, a member of thiadiazoles and a sulfonamide antibiotic. A sulfathiazole antibacterial agent. This molecule is a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial property. This molecule competes with PABA for the bacterial enzyme dihydropteroate synthase, thereby preventing the incorporation of PABA into dihydrofolic acid, the immediate precursor of folic acid. This leads to an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, ultimately resulting in cell growth arrest and cell death. This molecule is a natural product found in Apis cerana with data available."
Cc1c[nH]c(n1)c2cnc(NCCNc3ccc(cn3)C#N)nc2c4ccc(Cl)cc4Cl,3.86,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4c[nH]cn4,2.81,
ONC(=O)[C@@H](Cc1ccc2ccccc2c1)NS(=O)(=O)c3ccc4ccccc4c3,3.23,
COc1cc(\C=C/2\SC(=O)NC2=O)cc(OC)c1O,0.74,
NC(=O)c1sc(cc1N)c2ccsc2,2.23,
CC(C)CNc1nc(nc(N2CCOCC2)c1N)C#N,2.79,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccc(CO)cc4,2.86,
Fc1ccc(cc1F)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,2.84,
CCc1cc(O)c(Oc2ccc(cc2F)C(=O)N)cc1F,2.87,
Clc1ccc(OC2CCN(CC2)C3CCN(CC3)S(=O)(=O)NC(=O)c4ccccc4)cc1Cl,2.14,
OC(=O)c1cc2cc(ccc2n1Cc3ccc(Cl)c(Cl)c3)C(F)(F)F,3.07,
C[C@H](CO)N1C=Cc2c(NC(=O)Cc3ccc(Cl)c(c3)C(F)(F)F)cccc2C1=O,3.49,
COc1ccc2COC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,0.5,
Nc1ncnc2ccccc12,1.26,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cc(cnc3OC)C4=NNC(=O)O4)n5ccc(n5)C(F)(F)F,2.91,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3[nH]c(N)nc13,3.22,
CCN(CC)CCn1c2ccccc2c3cnc(N)c(C#N)c13,2.7,
CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(O)c3ccccc3,-1.29,
C[C@H](N)COc1c(C)cccc1C,0.6,
CC(C(=O)O)c1ccc2oc(nc2c1)c3ccc(Cl)cc3,1.3,
Cn1c(CN2CCC(CC2)c3ccccc3)nc4ccccc14,3.6,
COc1cccc(c1OC)c2ccc(\C=C\3/SC(=S)N([C@@H](Cc4ccccc4)C(=O)O)C3=O)cn2,1.5,
Cc1cnc([nH]1)c2cc(NC(=O)c3ccc(nc3C)C(F)(F)F)ccc2Cl,3.3,
Nc1cccc(C(=O)NCC23CC4CC(CC(C4)C2)C3)c1Cl,3.29,
Nc1c(nc(nc1N2CCOCC2)C#N)N3CCCC3,2.25,
COCCNCc1cncc(n1)c2ccc(F)cc2OC,1.61,
CCN1CCN(Cc2cnc(c3ccc(cc3)C(=O)Nc4ccccc4N)c(c2)C#N)CC1,1.14,
CSc1nc(N)nc(n1)c2ccccc2,2.98,
O=C1N=C2C(=C1C#N)c3ccc(N4CCSCC4)c5cccc2c35,3.22,
CC1=C(C(=O)c2ccc(O)cc2O1)c3ccccc3,2.95,
COc1ccc(OC)c(c1)c2c(F)ccc3c(N)c(nnc23)C(=O)NC(C)C,3.77,
Oc1c2ncc3ccccc3c2nn1c4ccc(Cl)cc4,1.52,
CC(NC(=O)C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,3.1,
CCN(C1CCN(CC[C@@H](c2ccc(F)cc2)c3ccc(cc3)S(=O)(=O)C)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.88,
O=C(Nc1ccc(nc1)N2CCOCC2)c3oc(Nc4ccccc4)nn3,2.9,
CC1(C)CNC(=O)c2sc(nc2C1)N3CCOCC3,1.29,
C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O,2.98,
Clc1ccc2OCOc2c1Nc3ccnc(Nc4cc(cc(c4)N5CCOCC5)N6CCOCC6)n3,3.25,
CC(C)Cn1cnc(c2ccccc2)c1c3nc4c(N)ncnc4s3,3.72,
NC(=O)Nc1sc(cc1C(=O)N[C@H]2CCCNC2)c3ccccc3,1.27,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCNCC2)c3ccccc3OC,1.0,
COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C,1.67,
CC(C)(C(=O)N)C(=O)NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1Br,2.32,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N(C)[C@H]2CCCN(CCc3ccccc3)C2,2.34,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccncc4,2.29,
COc1cc2CC[C@H](NC(=O)C)c3cc(O)ccc3c2c(OC)c1OC,1.81,
Nc1ncc(NC(=O)c2cc(NC(=O)c3cccc(c3)C(F)(F)F)ccc2Cl)cc1Cl,3.26,
CCCCNc1ccc(cc1)C(=O)OCCN(C)C,2.11,
CC(Oc1c(Cl)cccc1Cl)C2=NCCN2,0.48,
C[C@H](NC(=O)c1c(C)nn(c1NS(=O)(=O)c2cccnc2)c3ccc(F)cc3)C(C)(C)C,0.4,
Cc1c(Oc2ccc(Cl)cc2)c3c(NS(=O)(=O)C)cccc3n1CC(=O)O,-0.98,
c1ccc(nc1)c2n[nH]c(n2)c3ccncc3,1.48,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4ccccc4,1.81,
C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N,3.19,
Fc1ccc(CN2CCN(CC2)c3ccc4nnc(n4n3)C(F)(F)F)cc1,3.46,
Oc1c2C(=O)NNC(=O)c2nc3cc(Cl)cc(Cl)c13,0.89,
CCN(CC)C(=O)c1ccc(cc1)C(=C2CCNCC2)c3cccc(c3)C(F)(F)F,1.9,
CC[C@H](C)[C@@H](CO)NS(=O)(=O)c1ccc(Cl)s1,2.7,
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C,-0.69,"This molecule is a proton pump inhibitor (PPI) and a potent inhibitor of gastric acidity used in the therapy of gastroesophageal reflux and peptic ulcer disease. This molecule therapy is associated with a low rate of transient and asymptomatic serum aminotransferase elevations and is a rare cause of clinically apparent liver injury. This molecule is a member of benzimidazoles, a sulfoxide and a member of pyridines. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. It is a conjugate acid of a rabeprazole(1-). This molecule is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. This molecule inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. This molecule is a Proton Pump Inhibitor. The mechanism of action of rabeprazole is as a Proton Pump Inhibitor. This molecule is an alpha-pyridylmethylsulfinyl benzimidazole and a selective and irreversible proton pump inhibitor with antisecretory property. This molecule enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen. Binding to cysteine 813, in particular, is essential for inhibition of gastric acid production."
NS(=O)(=O)c1ccc2C(=CNC(=O)c2c1)C(=O)NC[C@@H](O)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.17,
O=C1OC(=Cc2ccccc12)c3ccccc3,3.84,
CC(C)[C@@H]1N(C)c2ccccc2C[C@@H](CO)NC1=O,2.03,
CC(=O)NCc1ccc(CN2CCN(CC2)c3ccccc3)cc1,1.78,
COc1ccc(CN2C(=O)NC3=C(C=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C3=O)c4ccccc4)C2=O)cc1,2.93,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN(C)C,2.9,
CCOC(=O)c1ccc(COC2CN(C2)c3ccc(C)nn3)cc1,2.5,
CC1=CC(=O)Oc2c(C)c3oc(C)cc3cc12,3.47,
CC(C)N1CCC[C@@H](CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,1.62,
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(=O)O,2.31,
CS(=O)(=O)N1CCC(CC1)NC(=O)NC23CC4CC(CC(C4)C2)C3,2.7,
Oc1ncnc2onc(c3ccc(F)cc3)c12,1.97,
Cc1c(Sc2ccc(Cl)cc2)c3c(cccc3n1CC(=O)O)S(=O)(=O)C,0.58,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(CCO)c4ccc(Cl)cc4,2.5,
OC(=O)c1ccc2[nH]c(nc2c1)C(F)(F)F,-1.08,
CN(C)CCCN1c2ccccc2Sc3ccc(Cl)cc13,3.37,
C[C@H]1NC(C)(C)CO[C@]1(O)c2cccc(Cl)c2,1.69,
CS(=O)(=O)C1(CC1)c2cc(nc(n2)c3cccc4[nH]ccc34)N5CCOCC5,2.2,
Cc1nc(C)c(nc1C(=O)N)c2ccc(cc2)[C@@H]3CC[C@@H](Cc4nnn[nH]4)CC3,1.4,
COc1cc2c(Nc3ccc(F)cc3F)c(cnc2cc1NCCN(C)C)C(=O)N,1.71,
COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c4cccc(c4)C(=O)N(C)C)C(=O)N)c1,2.69,
O=C1C=C(N=C2N1C=Cc3ccccc23)N4CCOCC4,2.78,
O=S(=O)(N1CCOCC1)c2cccc(c2)c3cn4cccnc4n3,1.3,
CC(C)Oc1cc(ccc1NC(=O)CN2CCOCC2)c3cccc4C(=O)C=C(Oc34)N5CCOCC5,3.0,
COc1ccnc(NC2CCN(CC2)C(=O)c3ccc(Cl)cc3)c1,2.82,
CN1CCN(CC1)C(=O)c2cccc(CC3=NNC(=O)c4ccccc34)c2,0.92,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCCN(Cc3ccccc3)C2,2.12,
Clc1ccc(cc1)C(N2CCNCC2)c3ccccc3,1.94,
CC(=O)N1CCOc2nc(OCc3ccccc3)ccc12,2.4,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(ccc4C)C(=O)NC5CCC5,2.25,
NC1(CCC1)c2ccc(cc2)c3nc4ccccn4c3c5ccccc5,2.8,
CC(C)(C)NC(=O)C(N(Cc1occc1)C(=O)c2ccc([nH]2)c3ccccc3)c4ccncc4,4.13,
Cc1cc(Nc2nc(NCc3ccccn3)ncc2Br)n[nH]1,2.8,
CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O,1.48,
CCOC(=O)C1=COc2ccccc2C1=O,1.81,
CN(C(=O)C)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4)cc1,2.88,
CC1CCCCC1NC(=O)c2c(C)nn(c2NS(=O)(=O)c3ccc(C)cc3)c4ccccc4,1.94,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccnc4ccc(F)cc34)c2C(=O)N5CC[C@@H](O)C5,1.95,
COc1ccccc1CNCc2ccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)cc2,0.15,
C[C@@](O)(C(=O)Nc1ccc(cc1Cl)S(=O)(=O)NCCCO)C(F)(F)F,2.1,
CN1c2ccccc2C(NCCCCCCC(=O)O)c3ccc(Cl)cc3S1(=O)=O,1.33,
COc1ccc(\C=C\2/SC(=S)NC2=O)cc1OC,1.42,
CS(=O)(=O)c1ccc2[nH]c3CCN(Cc3c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,1.5,
COc1cc2ncc(C(=O)N)c(Nc3cc(F)ccc3F)c2cc1OC,2.9,
Cc1cc(C)cc(c1)c2oc(SCC(=O)N3CCN(CC3)C(=O)c4occc4)nn2,3.0,
COc1cc(ccc1Nc2ncc(OC)c(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)C,3.2,
OC(=O)[C@H](Cc1ccc(OCCc2ccc3CCCNc3n2)cc1)NC(=O)c4c(Cl)cccc4Cl,0.33,
COc1cc(CCc2cc(Nc3ccnc(NCc4onc(C)c4)n3)n[nH]2)cc(OC)c1,3.1,
CS(=O)(=O)Cc1cc(nc(n1)c2ccc(NS(=O)(=O)C)cc2)N3CCOCC3,0.85,
COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1,2.27,
NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc3ccccc3)C(=O)O,-0.94,
Cc1nccn1CCC(C(=O)N)(c2ccccc2)c3ccccc3,1.79,
CC(C(=O)O)c1cccc(Oc2ccccc2)c1,0.71,"This molecule is a nonsteroidal antiinflammatory drug (NSAID) used in the treatment of acute pain and chronic arthritis. This molecule has been linked to a low rate of serum enzyme elevations during therapy and to rare instances of clinically apparent acute liver injury. This molecule is a monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. It has a role as a non-steroidal anti-inflammatory drug, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, an antipyretic, a non-narcotic analgesic and a drug allergen. It is a conjugate acid of a fenoprofen(1-). An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding. This molecule is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of fenoprofen is as a Cyclooxygenase Inhibitor. This molecule is a propionic acid derivative with analgesic, non-steroidal antiinflammatory and antirheumatic properties. This molecule inhibits both isozymes of cyclooxygenase; resulting in prostaglandin synthesis inhibition, thereby blocking the conversion of arachidonic acid to prostaglandins. In addition, fenoprofen activates both peroxisome proliferator activated receptors (PPAR)-alpha and -gamma, by which it may down-regulate leukotriene B4 production."
CNC(=O)c1cccc2c1c(Sc3ccc(Cl)cc3)c(C)n2CC(=O)O,-0.89,
O=C1C=C(Oc2c1cccc2c3cccc4c5CCCCc5sc34)N6CCOCC6,4.1,
CN1CCCC1CCNC(=O)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,2.01,
CC(=O)c1noc(C)c1C(=O)Nc2nccs2,1.94,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4c(N)cccn34)N5CCN(CC5)C(=O)C,3.4,
O=C(N[C@@H]1CN2CCC1CC2)c3ccc(s3)c4ccccc4,1.77,
Cc1c(c2ccc(O)cc2)n(C)c3ccc(O)cc13,3.8,
CNC(=O)c1ccc(Nc2ncc(F)c(n2)c3cnc(C)n3C(C)C)cc1,3.0,
COC(=O)C1=C(C)NC(=C([C@@H]1c2cccc3nonc23)C(=O)OC(C)C)C,3.77,
COc1cc(F)ccc1c2cncc(CNC(=O)C3CCC3)c2,3.2,
Oc1cc(Cl)cc(Cl)c1,3.58,"Prisms (from petroleum ether) or pink crystals. (NTP, 1992) These molecules is a dichlorophenol in which the two chloro substituents are located at positions 3 and 5."
CSc1ccc(cc1)c2nc(c3ccc(F)cc3)c([nH]2)c4ccncc4,2.97,
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc4C(=O)C(=CN(C5CC5)c14)C(=O)O,-0.18,
CCOc1cc2nnc(C(=O)N)c(Nc3ccc(F)cc3F)c2cc1N4CCN(C)CC4,2.63,
CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc2ccc(Cc3ccncc3)cc2,2.8,
NC(=O)c1cccc(OC2CCN(Cc3ccccc3)CC2)c1,1.92,
C[C@H](Nc1nc(Nc2cc(C)[nH]n2)c(Cl)c(n1)N3CCOCC3)c4ncc(F)cn4,2.61,
CN(C(=O)C)c1ccccc1,1.1,
CN(C)C(=O)c1ccc(CN2CCC(CC2)c3ccc(cc3)C(=O)Nc4ccccc4N)cc1,1.53,
COC1=CC=C2C(=CC1=O)[C@H](CCc3cc(OC)c(OC)c(OC)c23)NC(=O)C,0.82,
CC(C)(C)c1ccc(cc1)c2n[nH]c(NC(=O)c3ccccc3Cl)c2Br,4.3,
CC(C)[C@@H]1N=C(c2ccccc2)c3ccccc3NC1=O,3.05,
OC(=O)COc1cccc(c1)C(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,1.09,
O=C1COc2ccccc2N1CCN3CCC(CC3)NCc4cc5OCCOc5cn4,1.04,
CNCCC=C1c2ccccc2CCc3ccccc13,1.58,
CN1CCCC(CC1)N2N=C(Cc3ccc(Cl)cc3)c4ccccc4C2=O,2.46,
O=C(Nc1ccccc1)N2CCOCC2,1.0,
CCn1c2ccccc2c3cc(NC(=O)N4CCOCC4)ccc13,3.2,
Cc1ccc(NC(=O)c2cccc(c2)N3CCOCC3)cc1NC(=O)c4ccc(OCc5ccncc5)cc4,3.2,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(C)ccc3Cl)n2)cc1,2.6,
CC(=O)Nc1cccc(OCc2cnc(Cl)s2)c1,2.38,
OCC(=O)N1CCC[C@H]1COc2cccc3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23,3.62,
COc1ccc(cc1)c2nc(nc(O)c2C#N)N3CCOCC3,0.2,
CN1CCC(COc2cc(OC3CCOCC3)c4c(Nc5c(Cl)ccc6OCOc56)ncnc4c2)CC1,2.59,
COc1cc2ncnc(NCc3ccccc3)c2cc1OC,3.29,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccccc3C(F)(F)F)c2C(=O)N4CC=CC4,3.53,
CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc3ccc(OC)cc13,2.17,
Cc1ccc(Oc2ccc(OCC(=O)Nc3ccncc3)cc2)cc1,4.3,
Cn1cnc2cc(OC(=O)c3ccccc3)cnc12,2.4,
Brc1cc(Br)cc(COC[C@@H](N2CCNCC2)c3ccccc3)c1,2.8,
Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2,0.01,
Oc1ccc(cc1)C2CC(=O)c3c(O)cc(O)cc3O2,2.6,
Nc1c(c(CN2CCOCC2)nn1c3ccc(F)cc3)c4ccccc4,2.33,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3NC(=O)C(=Cc13)C#N,3.32,
Nc1nc2ccc(Cl)cc2c3nc(nn13)c4occc4,3.98,
COc1ccc2ncc(F)c(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2n1,1.78,
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c3cc(Cl)ccc13,2.38,
NC1(CCC1)c2ccc(cc2)c3ncc4ccccc4c3c5ccccc5,3.6,
CS(=O)(=O)c1ccc(cc1Cl)[C@@H](CC2CCCC2)C(=O)Nc3cnc(cn3)[C@H](O)CO,2.58,
CCN(C(=O)C)c1cccc2c1c(Sc3ccc(Cl)cc3)c(C)n2CC(=O)O,1.61,
COc1ccc(COC(=O)N2CCC(CNc3ncccn3)CC2)cc1,3.14,
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,-0.76,
O[C@H](CNC(=O)c1cccc(c1)C#N)CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3,3.48,
CN(C)C(=O)Nc1ccc(CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3)cc1,1.1,
COc1cc(Nc2cc(Oc3cccnc3C)ccn2)cc(OC)c1OC,3.19,
CCOc1ccccc1c2ccc3c(c2)C(=O)C(=O)c4ccccc34,2.67,
Cc1cccc(NC(=O)NCC(N2CCOCC2)c3cccnc3)c1,2.0,
Fc1ccc2c3CN(CCc3[nH]c2c1)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,2.99,
CNC1=Nc2ncccc2C(=NC1c3cccs3)c4ccns4,2.15,
CCC(N(CCCN)C(=O)c1ccc(C)nc1)C2=Nc3ccsc3C(=O)N2Cc4ccccc4,2.56,
C[C@@H]1CN(CCN1c2ncc(OCc3ccc(cc3F)S(=O)(=O)C)cn2)C(=O)OC(C)(C)C,3.7,
CN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,3.92,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(c4ccccc4)c5ccc(Cl)cc5,4.1,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(c3ccccc3)c4ccccc4)C(=O)OC,2.42,
O=C1C=C(Nc2cc(Cc3ccccc3)ccc12)c4cccnc4,3.46,
COc1cc(O)ccc1\C=C\2/CCCN=C2c3cccnc3,2.2,
CCCNC(=O)c1nnc2c(cccc2c1N)c3ccccc3,3.8,
COc1cc(ccc1Cn2ncc3ccc(NC(=O)CC4CCCC4)cc23)C(=O)NS(=O)(=O)c5ccccc5,1.6,
COc1cc2c(ncnc2cc1OCCCN3CCCCC3)N4CCN(CC4)C(=O)Nc5ccc(OC(C)C)cc5,2.6,
CC1=CC(=O)Nc2sc(C(=O)c3ccc(Br)cc3)c(N)c12,2.57,
COC(=O)CCCCCCC(=O)Nc1ccc2c(c1)C(=O)C(=O)c3ccccc23,2.9,
Cc1cc(Cl)ccc1OC2CCN(C[C@H](O)CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)CC2,2.37,
CCCSc1c(cnn1C)C(=O)NC2CCCCC2,2.99,
CS(=O)(=O)c1ccc(cc1)c2cc(ccc2OCC(=O)O)C(F)(F)F,-0.87,
O=C(OCCN1CCCCC1)c2c[nH]c3ccccc23,2.0,
CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c3cc(Cl)c(N)cc3OC,3.56,
CN(C)CC(C)(C)COc1nccc(Nc2cc(NC(=O)c3ccnc(c3)N4CCOCC4)ccc2C)n1,2.2,
CCc1cc2C(=NCc3nnc(C)n3c2s1)c4ccccc4Cl,2.52,
OC(=O)COc1ccc(cc1c2ccccc2)C#N,-1.08,
CS(=O)(=O)Cc1cc(nc(n1)c2ccc3[nH]ccc3c2)N4CCOCC4,2.06,
FC(F)(F)c1nn(cc1C(=O)NCCNC(=O)c2ccc(Cl)cn2)c3ccccc3,3.8,
CNC(=O)c1cccc(NC(=O)Nc2cccc(c2)C#N)c1CN3CCC(Cc4ccc(F)cc4)CC3,3.97,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(Cc4ccccc4)c5ccc(Cl)cc5,4.1,
Cc1oc(cc1C(=O)O)c2ccc(Cl)cc2,1.67,
CSc1nc2cc(Cl)ccc2[nH]1,3.22,
CC(C)C[C@H](CO)Nc1nc(SCc2cccc(c2)C#N)nc3nc(N)sc13,3.9,
OC(=O)C[C@@H]1CC[C@H](CC1)c2ccc(cc2)c3ccc(Nc4ccc(nc4)C(F)(F)F)cn3,3.8,
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,0.63,"This molecule is an odorless white powder. Bitter taste. (NTP, 1992) This molecule is an aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge. It has a role as an EC 1.5.1.3 (dihydrofolate reductase) inhibitor, a xenobiotic, an environmental contaminant, a drug allergen, an antibacterial drug and a diuretic. It is a member of methoxybenzenes and an aminopyrimidine. This molecule is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. This molecule is often used in combination with [sulfamethoxazole] due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to [pyrimethamine], another antifolate antimicrobial used in the treatment of plasmodial infections. This molecule is a Dihydrofolate Reductase Inhibitor Antibacterial. The mechanism of action of trimethoprim is as a Dihydrofolate Reductase Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Organic Cation Transporter 2 Inhibitor. This molecule is a synthetic derivative of trimethoxybenzyl-pyrimidine with antibacterial and antiprotozoal properties.  As a pyrimidine inhibitor of bacterial dihydrofolate reductase, trimethoprim binds tightly to the bacterial enzyme, blocking the production of tetrahydrofolic acid from dihydrofolic acid.  The antibacterial activity of this agent is potentiated by sulfonamides. (NCI04)"
CN(C)C(=O)N[C@@H]1CC[C@@H](CN2[C@@H]3CC[C@H]2C[C@H](C3)Oc4cccc(c4)C(=O)N)CC1,-0.07,
O[C@@H](CNCCc1cccc(CNCCc2ccccc2F)c1)c3ccc(O)c4NC(=O)Sc34,1.06,
Cc1ccc(CNC(=O)C2CCCN2S(=O)(=O)c3ccc(F)cc3)cc1,2.9,
CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(cc4)S(=O)(=O)C,1.0,
OC(=O)COCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,1.27,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)C(=O)OC(C)(C)C#N,2.3,
CN(C1CCN(Cc2ccc(cc2)C(F)(F)F)CC1)C(=O)Cc3ccc(c(F)c3)S(=O)(=O)C,3.0,
CCOc1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,3.1,
Oc1cc(nc2ncnn12)c3ccccc3,-0.21,
NC(=O)c1nnn(c1N)c2ccccc2,0.74,
OC(c1ccccc1)c2cccnc2,1.72,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(ccc4C)C(=O)Nc5nccs5,2.56,
CN1C(=O)N(CC2CC2)c3nn(Cc4cn(C)c5ccc(Cl)cc45)c(c6cc(oc6C)S(=O)(=O)C)c3C1=O,4.48,
CC(CN1c2ccccc2Sc3ccccc13)N(C)C,2.67,
CCc1nc2c(N)nc3ccccc3c2n1Cc4ccccc4,3.29,
NCC[C@@H](Oc1ccc(Cl)cc1C#N)c2ccccc2,0.91,
CCn1c(nc2c(ncc(OCC3CCCNC3)c12)C#CC(C)(C)O)c4nonc4N,0.6,
Cc1cc(Oc2ccnc(Nc3cccc(c3)N4CCOCC4)c2)c(nc1C)c5ccccn5,3.27,
Cc1c(Cl)c(ccc1OC2CCN(CC3CCN(CC3)[C@@H](Cc4ccc(F)cc4)C(=O)O)CC2)C#N,2.19,
c1ccc2[nH]c(nc2c1)c3cscn3,2.35,
CCN(C1CCN(CC[C@H](C2CCN(CC2)S(=O)(=O)C)c3cc(Cl)cc(Cl)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.6,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(C)cnc13,3.55,
COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1,2.99,
Oc1nc(nc2ccccc12)c3ccccc3,2.46,
CN1C(=O)N(CC2CC2)c3nn(Cc4ccnc5ccc(Cl)cc45)c(c6cc(oc6C)S(=O)(=O)C)c3C1=O,3.2,
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN(C)C,3.26,
NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc(Cl)cc2,0.7,
C[C@@](O)(C(=O)Nc1ccc(cc1Cl)C(=O)N2CCCCC2)C(F)(F)F,2.62,
CC1(CC(=O)NC(=N1)N)c2ccc(Cl)c(Cl)c2,1.59,
CC(C)[C@H](NC(=O)C[C@H](NC(=O)\C=C\c1ccccc1)c2ccccc2)C(=O)[C@H]3[C@H](C)C(=O)NC3=O,1.91,
O=C1O[C@]2(CN3CCC2CC3)CN1c4cccs4,0.9,
CCN(CCO)CCCOc1cc2ncnc(Nc3cc(CC(=O)Nc4cccc(F)c4F)[nH]n3)c2cc1OC,1.94,
OC[C@H](O)CN1C(=O)[C@H](Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.3,
CC(O)C(C)OC(=O)[C@@H]1CC2C(Cc3cn(C(C)C)c4cccc2c34)N(C)C1,2.8,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CC6COCC(C5)N6,3.0,
COc1ccnc(NC2CCN(CC2)C(=O)c3ccc(cc3)C#N)c1,1.73,
Cc1c(Cl)c(Cl)ccc1OC2CCN(CC3CCN(CC3)[C@@](C)(Cc4ccc(F)cc4)C(=O)O)CC2,2.98,
O=C(Nc1ccc(nc1)N2CCOCC2)c3oc(Nc4cccc(OCc5ccccn5)c4)nn3,3.1,
CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)Nc2ccccc2)C(F)(F)F,3.07,
CNc1nc2nc(SCc3cccc(F)c3F)nc(N[C@H](C)CO)c2s1,3.7,
CC(C)CN1C(=O)N(C)C(=O)c2c(SCCCO)n(Cc3cccc4ccccc34)cc12,4.36,
CC(C)C(NC(=O)CN1C(=O)C(=CC=C1c2ccccc2)NC(=O)CN3C(=O)CCC3=O)C(=O)C(F)(F)F,0.96,
CN1CCC(CC1)NC(=O)c2ccc(Oc3ccc(cc3)C#C[C@]4(O)CN5CCC4CC5)cc2,1.0,
CN1CCN(CC1)c2ccc3ncc(C(=O)N)c(Nc4ccc(Cl)cc4Cl)c3c2,3.23,
COc1ccc(CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)c2)cc1,0.86,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(CCc3ccc(F)cc3)C2,2.39,
COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCC4CCNCC4,1.1,
Nc1nc2cc3CCN(Cc4cnc[nH]4)CCc3cc2s1,-0.12,
CCN(C1CCN(CCC(c2ccccc2)c3ccc(NC(=O)Cc4ccccc4)cc3)CC1)C(=O)Cc5ccc(cc5)S(=O)(=O)C,3.61,
FC(F)(F)CCS(=O)(=O)Oc1ccc(NC(=O)c2ccc(Cn3ccnn3)c4ccccc24)c(n1)C(=O)NCC5CCOCC5,4.2,
CC(CC(=O)NCc1ccccc1)C2CCCO2,2.1,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCN(CCCc3ccccc3)C2,1.9,
CNc1cc(nc2c(cc(OC)cc12)N3CCN(C)CC3)C(=O)Nc4ccc(cc4)N5CCOCC5,2.93,
CS(=O)(=O)Cc1ccc2ccn(c3cc(NC4CC4)n5ncc(C#N)c5n3)c2c1,2.49,
CCn1c2ccccc2c3cc(NC(=O)CN(C)C)ccc13,3.2,
OC(=O)COc1ccc(Cl)cc1C2CCCCC2,0.93,
Oc1ccc2[nH]c(CN3CCC(Cc4ccc(F)cc4)CC3)nc2c1,3.8,
Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCCNCC4,0.1,
Cn1cc(cc1c2c3C(=O)N(CC#N)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56)C#N,3.33,
Clc1ccccc1NC(=O)c2cc[nH]n2,2.58,
CN(C)S(=O)(=O)c1ccc(CC(=O)N(C)C2CCN(CCC(c3ccccc3)c4ccccc4)CC2)cc1,3.5,
C[C@@H](NC1=CC(=O)CCC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,3.17,
O=C1C=C(Nc2ccccc12)c3occc3,2.21,
Nc1nc2cc3CCN(Cc4ccccc4)CCc3cc2s1,2.66,
Cc1onc(C)c1CCC2CCN(CC2)S(=O)(=O)CC3(CCC(F)(F)CC3)N(O)C=O,2.1,
Oc1ccc(CCNCCCNS(=O)(=O)CCOCc2cccc3ccccc23)c4sc(O)nc14,1.69,
c1ccc(cc1)c2ccc3ccccc3n2,4.0,
O=C(NCC#N)[C@@H]1CCCC[C@H]1C(=O)N2CCC=CC2,0.9,
CNS(=O)(=O)NC1=CC=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C1=O)c2ccccc2,1.79,
O=S(=O)(NCCNc1ncccn1)c2cccc3cnccc23,0.61,
COc1ccc2nc(C)cc(c2c1)n3cc(CNC(=O)C)nn3,1.6,
Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc3ccc(Cl)c(Cl)c3)c4OCC(=O)Nc14,2.23,
CCCCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,2.37,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(N)sc13,3.29,
CCCS(=O)(=O)c1ccc(cc1)C(CNS(=O)(=O)c2ccc(cc2)C(F)(F)F)N3CCCCCC3,3.32,
NC(=N)c1cc2c(\C=C\c3ccc4OCOc4c3)cccc2s1,2.2,
OC(=O)C(N1CCCC(CN2CCC(CC2)Oc3ccc(Cl)c(Cl)c3)C1)c4ccccc4,2.6,
CCOC(=O)c1cc(O)c(nn1)c2ccccc2,0.69,
c1ccc2c(c1)nnn2c3ccncc3,1.69,
Cc1cccc(CN2C=CN3C(=O)C=C(N=C23)N4CCOCC4)c1,2.8,
Nc1nc(O)cc(n1)c2ccc(O)cc2,1.05,
O=C(NCc1ccccc1)c2cccnc2Oc3ccccc3,3.0,
CC(C)CNc1nc(nc(N2CC(O)C2)c1N)C#N,2.0,
CN(C)C(=O)N1CCC(CC1)C(=O)NCc2cccs2,1.1,
CN(c1ccnc(Nc2cc(cc(c2)C(=O)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,2.2,
Fc1ccc(cc1Cl)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.98,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)[N+](=O)[O-],4.1,
Clc1ccc(cc1)c2c[nH]nn2,2.97,
COc1cc(cc2cnc(Nc3ccc(cc3)[C@@H](C)NC(=O)C)nc12)c4ccncc4,2.73,
CC(C)N1C(=O)N(C)C(=O)c2cn(Cc3cccc4ccccc34)cc12,3.97,
CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)c4ccccc4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(=O)O,-0.94,
C[C@H](Nc1nc(Nc2ncc(C)s2)cc(n1)N3CCOCC3)c4ncc(F)cn4,2.68,
CC(C)N1CCN(Cc2cnc(c(C)c2)c3ccc(cc3)C(=O)Nc4ccccc4N)CC1,1.44,
COc1ccccc1OCCNCC(O)COc2cccc3[nH]c4ccccc4c23,3.27,
NC1(CCC1)c2ccc(cc2)c3nc4ccccc4cc3c5ccccc5,3.6,
OC(=O)c1ccc(cc1)n2ncc(C(=O)NC3C4CC5CC(CC3C5)C4)c2C6CCC6,1.33,
O=C1Nc2cc(ccc2C1c3ncnc4cc(OCCCN5CCOCC5)ccc34)C#N,2.99,
CC(C)(C)C(=O)NCc1ccc(NC(=O)N2CCCC(O)(C2)c3ccc(Cl)c(Cl)c3)cc1,3.93,
CC[C@H]1N(C2CCCC2)c3nc(Nc4ccc(cc4OC)C(=O)NC5CCN(C)CC5)ncc3N(C)C1=O,3.14,
CCCCn1c(Cc2cc(OC)c(OC)c(OC)c2)nc3c(N)ncnc13,2.39,
NC(=N)c1cc2c(OCc3ccccc3)cccc2s1,1.16,
OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1,2.1,
CCCSc1nc(N[C@@H]2C[C@H]2c3ccccc3)c4nnn([C@@H]5C[C@H](OCCO)[C@@H](O)[C@H]5O)c4n1,3.87,
Cc1c(N)cccc1CN2C=CC(=CC2=O)OCCc3cccs3,2.78,
Cc1ccc(NC(=O)c2ccnc(c2)N3CCOCC3)cc1Nc4ccnc(Cl)n4,3.1,
OC(=O)C[C@H]1[C@@H](Cc2ccccc12)NC(=O)c3cc4cc(Cl)ccc4[nH]3,1.79,
COc1ccc(cc1Cl)C(=O)NCCN2CCN(Cc3ccc(Cl)c(Cl)c3)CC2,3.74,
O[C@@H](CNCCc1cccc(CNCc2ccccc2Cl)c1)c3ccc(O)c4NC(=O)Sc34,1.85,
CC(C)CC(N(C)C)C1(CCC1)c2ccc(Cl)cc2,3.6,
Cc1cc(CNc2nccc(Nc3cc(CCc4ccccc4)[nH]n3)n2)on1,3.56,
NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)c1,1.76,
COc1cc(Nc2c(cnc3cc(OC)c(OC)cc23)C#N)cc(OC)c1,3.5,
Cc1cc(CNc2ncc(Br)c(Nc3cc([nH]n3)C4CC4)n2)on1,3.43,
CCCCC1(CC)C(=O)NC(=O)NC1=O,1.5,"This molecule is a member of barbiturates. This molecule is a sedative and a hypnotic drug. This molecule is only found in individuals that have used or taken this drug. It is a sedative and a hypnotic drug.This molecule binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission."
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN4CCC[C@H]4CC(=O)N,2.64,
COc1cc2ncnc(NCc3cccc(C)c3)c2cc1OC,3.5,
COc1ccc(cc1)c2cc(O)nc(N)n2,1.52,
OC(=O)c1ccc(NC(=O)c2cc(OCc3ccccc3)cc(OCc4ccccc4)c2)nc1,2.7,
OCC(CO)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)ccc4[nH]3,3.64,
CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N4CCN(C)CC4)c2C1)c5ccccc5,2.0,
CCN(C1CCN(CC[C@H](N2CCN(CC2)S(=O)(=O)C)c3cc(F)cc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.25,
Cc1ccc(cc1)S(=O)(=O)Nc2ccc(\C=C\C(=O)Nc3ccccc3N)cc2,2.82,
Clc1ccc(C2CCN(CC2)C(=O)COCc3ccncc3)c(Cl)c1,2.63,
CC(C)N(CCNCCc1ccc(O)c2NC(=O)Sc12)C(=O)CCOCCc3ccccc3,2.33,
CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12,2.83,
CCOc1ccc(cc1)c2cnc3CCCn23,2.65,
C[C@@H](NC(=O)[C@@H]1CCCC[C@H]1C(=O)N2CCc3[nH]c4ccc(F)cc4c3C2)C#N,3.1,
COc1ccc2nc(C)cc(OCC(=O)NCc3ccccc3)c2c1,3.2,
CNC1=CN=C(N(CC(=O)NC(C(C)C)C(=O)C(F)(F)F)C1=O)c2ccc(F)cc2,1.86,
CC(=O)Nc1ccc2c(c1)c(cn2CCC(=O)O)c3cc(NC4CC4)n5ncc(C#N)c5n3,-0.87,
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)N(C)C,3.7,
CN1CCN(CC1)c2nc3ccccc3cc2Cn4nc(c5ccc6nc(N)sc6c5)c7c(N)ncnc47,3.09,
Oc1cccc2ccc(nc12)C#N,1.81,
COCCNC(=O)c1ccc(Nc2ncc3cc(ccc3n2)c4ccncc4OC)cc1,3.14,
NCCCCCc1c[nH]c2ccc(F)cc12,0.6,
CN1C(=O)N(Cc2ccc(cc2)C(=O)O)C(=O)c3cc(ccc13)C#CCc4ccccc4,2.5,
COc1c(cc2ccccc2c1C(=O)N(C)C[C@@H](CCN3CCC(CC3)c4ccc(O)cc4[S+](C)[O-])c5ccc(Cl)c(Cl)c5)C#N,3.5,
CN1C(=O)N(C)c2ncn(C)c2C1=O,-0.03,
Cn1c(ccc1c2cc(F)c3NC(=O)C(C)(C)c3c2)C#N,3.21,
CN(C)CC(O)COc1ccc(Nc2cc(ncn2)N(CCC#N)c3cc(Cl)ccc3Cl)cc1,2.1,
OC1(CNC(=O)c2cc(ccc2Cl)N3N=CC(=O)NC3=O)CCCCCC1,0.26,
COc1ccccc1N2CCN(CCN(C(=O)C3CCCCC3)c4ccccn4)CC2,3.0,
Fc1ccccc1NC(=O)N[C@H]2N=C(c3ccccc3)c4ccccc4NC2=O,4.0,
CCC[C@@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,0.6,
CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)c2cc3sccc3[nH]2,3.1,
Cc1cccc(Br)c1C(=O)N[C@@H](Cc2ccc(NC(=O)c3c(Cl)cccc3Cl)cc2)C(=O)O,-0.13,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3nc(NS(=O)(=O)C)sc13,0.92,
Cc1nc(C)c(nc1C(=O)N)c2ccc3c(CC[C@@]34CC[C@@H](CC4)c5nnn[nH]5)c2,1.4,
Brc1cnc(NCc2ccccc2)nc1Nc3cc([nH]n3)C4CC4,4.11,
Cc1ccc(cc1NC(=O)CC23CC4CC(CC(C4)C2)C3)C(=O)N5CC6CNCC(C5)O6,2.12,
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14,2.12,
C[C@H](Nc1nc(Nc2ncc(C)s2)cc(n1)N3CCN(C)CC3)c4ccc(F)cn4,2.9,
CN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCOCC4)n1)c5cccc6[nH]ncc56,3.23,
Fc1ccccc1NC(=O)NC2N=C(c3ccccc3)c4ccccc4NC2=O,3.8,
CN1C(=O)C=C(CCc2ccc3cc[nH]c3c2)N=C1N,2.1,
CC1=C(Cc2ccccc2)C(=O)n3nc(NCc4cccc(Cl)c4)nc3N1,3.6,
Clc1ccc(Cl)c(c1)S(=O)(=O)Nc2nc(cs2)c3sccc3Cl,2.11,
COc1cc2ncc(C(=O)N)c(Nc3ccccc3C)c2cc1OC,3.4,
N[C@@H](Cc1cccs1)C(=O)N[C@]2(C[C@H]2c3ccccc3)C#N,1.5,
COc1ccc(C)c(NC(=O)CC23CC4CC(CC(C4)C2)C3)c1,3.96,
CC1=CN(C2CCCN(Cc3cccc(Oc4ccccc4)c3)C2)C(=O)NC1=O,3.04,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4ccccc4)c1,3.07,
C[C@@H](NC1=CC(=O)CNC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,2.49,
CN1CCOc2cc(COc3ccccc3)cnc12,3.3,
O[C@H](CNC(=O)c1c[nH]nc1C2CC2)CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,3.15,
CCOc1noc2cc(OCCC3CCN(CC3)c4ccc(C)nn4)ccc12,4.23,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccsc3C(=O)N2Cc4cscn4,0.02,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OC4CCC(F)(F)CC4)nc23,1.42,
O[C@@H](CNCCc1cccc(CNCCc2ccccc2Cl)c1)c3ccc(O)c4NC(=O)Sc34,1.63,
CC(C)n1c2ccccc2c3cc(NC(=O)N4CCOCC4)ccc13,3.55,
CC(C)Oc1ccc(cc1C(=O)N2CCN(CC2)c3ccc(cc3)C(F)(F)F)S(=O)(=O)C,3.33,
CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N[C@H]2CCCN(Cc3ccccc3)C2,2.01,
CN1CCN(CC1)C(=O)Cc2csc(NS(=O)(=O)c3cccc(Cl)c3C)n2,0.57,
CCOC(=O)c1cnc2c(N)cccc2c1O,0.9,
CN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCCOCC4)n1)c5cc(CO)ccc5C,3.3,
N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O,-1.08,"This molecule is a white powder with a flat taste. An essential amino acid; occurs in isomeric forms. (NTP, 1992) This molecule is the L-enantiomer of tryptophan. It has a role as an antidepressant, a nutraceutical, a micronutrient, a plant metabolite, a human metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is an erythrose 4-phosphate/phosphoenolpyruvate family amino acid, a proteinogenic amino acid, a tryptophan and a L-alpha-amino acid. It is a conjugate base of a This moleculeium. It is a conjugate acid of a This moleculeate. It is an enantiomer of a D-tryptophan. It is a tautomer of a This molecule zwitterion. This molecule is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals. This molecule is the least plentiful of all 22 amino acids and an essential amino acid in humans (provided by food), This molecule is found in most proteins and a precursor of serotonin. This molecule is converted to 5-hydroxy-tryptophan (5-HTP), converted in turn to serotonin, a neurotransmitter essential in regulating appetite, sleep, mood, and pain. This molecule is a natural sedative and present in dairy products, meats, brown rice, fish, and soybeans. (NCI04) This molecule is a metabolite found in or produced by Escherichia coli (strain K12, MG1655). This molecule is a natural product found in Bupleurum chinense, Trichoderma virens, and other organisms with data available. This molecule is an essential amino acid which is the precursor of serotonin. Serotonin is a brain neurotransmitter, platelet clotting factor and neurohormone found in organs throughout the body. Metabolism of tryptophan to serotonin requires nutrients such as vitamin B6, niacin and glutathione. Niacin is an important metabolite of tryptophan. High corn or other tryptophan-deficient diets can cause pellagra, which is a niacin-tryptophan deficiency disease with symptoms of dermatitis, diarrhea and dementia. Inborn errors of tryptophan metabolism exist where a tumor (carcinoid) makes excess serotonin. Hartnup's disease is a disease where tryptophan and other amino acids are not absorbed properly. This molecule supplements may be useful in each condition, in carcinoid replacing the over-metabolized nutrient and in Hartnup's supplementing a malabsorbed nutrient. Some disorders of excess tryptophan in the blood may contribute to mental retardation. Assessment of tryptophan deficiency is done through studying excretion of tryptophan metabolites in the urine or blood. Blood may be the most sensitive test because the amino acid tryptophan is transported in a unique way. Increased urination of tryptophan fragments correlates with increased tryptophan degradation, which occurs with oral contraception, depression, mental retardation, hypertension and anxiety states. The requirement for tryptophan and protein decreases with age. Adults' minimum daily requirement is 3 mg/kg/day or about 200 mg a day. This may be an underestimation, for there are 400 mg of tryptophan in just a cup of wheat germ. A cup of low fat cottage cheese contains 300 mg of tryptophan and chicken and turkey contain up to 600 mg per pound. This molecule is an L-alpha-amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of L-tryptophan; major species at pH 7.3. It is a tryptophan zwitterion and a L-alpha-amino acid zwitterion. It is a tautomer of a L-tryptophan. This molecule is a metabolite found in or produced by Saccharomyces cerevisiae."
NS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4ccccn34)cc1,2.7,
COc1cc(OC)c(cc1NC(=O)CCC(=O)O)S(=O)(=O)N2C(C)CCc3ccccc23,-0.87,
Cc1cc(CN2Cc3cccnc3CC2C(=O)Nc4ccc(Cl)cc4Cl)ccc1OCC(=O)O,1.15,
C1CN2CCC1C(C2)c3oc(nn3)c4oc(cc4)c5cccnc5,1.2,
O=C(NC1(CC1)C#N)[C@@H]2CCCC[C@H]2C(=O)N3CCN(CC3)c4nc(cs4)c5ccccc5,3.5,
NC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccsc4,3.18,
CCc1cccc(CC)c1NC(=O)N2Cc3[nH]nc(NC(=O)c4ccc(cc4)N5CCN(C)CC5)c3C2,3.31,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(C(=O)N)c(F)c3)ncc2F,3.14,
[O-][N+](=O)c1cc(C(=O)NCC=C)c2N=C(Nc3ccc(Cl)c(Cl)c3)NC(=O)c2c1,2.7,
c1ccc(cc1)c2cn3ccccc3n2,2.9,
COC[C@H](O)CN1C(=O)C=NN(C1=O)c2ccc(Cl)c(c2)C(=O)NCC3(O)CCCCCC3,1.46,
FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F,1.8,
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,1.55,
NC(=O)c1cccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3CC4CCCCC4)c1,1.55,
Oc1ccc(cc1)c2sc3cc(O)ccc3c2C(=O)c4ccc(OCCN5CCCCC5)cc4,4.13,
OC(=O)c1ccccc1N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.83,
COc1ccc(CC(=O)N(C)C2CCN(CCC(c3ccccc3)c4ccccc4)CC2)cc1OC,3.4,
CCN1CCN(Cc2cnc(c(C)c2)c3ccc(cc3)C(=O)Nc4ccccc4N)CC1,1.2,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3snc(C)c3C(=O)N2Cc4ccccc4,1.61,
CCOC(=O)Cc1csc(NS(=O)(=O)c2ccc(Cl)cc2)n1,1.32,
Clc1ccc2Oc3ccccc3N=C(N4CCNCC4)c2c1,2.28,
Cc1cc2nc(NC(=N)N)nc(C)c2cc1C,0.7,This molecule is a member of quinazolines.
CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c3ccccc3)c4ccccc4)C(=O)CC(C)C,1.82,
Cc1nc(C)c(s1)C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)NCC#N,2.0,
COc1ccc(cc1)c2nc3CCCn3c2Br,3.3,
OC(=O)[C@H](Cc1ccc(cc1)C#N)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.17,
CN1C[C@@H](c2ccccc2)c3cccc(N)c3C1,2.11,
Cn1c(ccc1c2ccc3NC(=O)OC(C)(C)c3c2)C#N,2.85,
CN([C@H](CN1CCCC1)c2ccccc2)C(=O)Cc3ccc(Cl)c(Cl)c3,3.42,
Cn1c2ccccc2c3cc(NC(=O)CCc4ccncc4)ccc13,3.8,
OC(c1ccccc1)c2ccc3C(=O)C=C(Nc3c2)c4cccnc4,2.27,
CC(C)COc1ccc(cc1C#N)c2nc(C)c(s2)C(=O)O,0.94,
O[C@@H](CNCCc1cccc(CNCc2ccccc2F)c1)c3ccc(O)c4NC(=O)Sc34,0.69,
CN1C(=O)C=C(CCc2cccc(c2)c3cccnc3)N=C1N,2.5,
NS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4OCOc34)n2)c1,2.97,
CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(N3Cc4ccncc4C3)c(F)c2,3.02,
CC1=C(Cc2ccccc2)C(=O)n3nc(NCc4cccc(Br)c4)nc3N1,3.68,
CC(C)n1nc(c2ccc(C)cc2)c3c(N)ncnc13,3.2,
O=C1CCOc2nc(OCc3ccccc3)ccc12,3.1,
COc1ccc(OC)c(c1)c2c(F)ccc3c(N)c(nnc23)C(=O)NC4CC4,3.47,
CC(C)N1CCO[C@@H](CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,2.77,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2cccc(OC)c2)C1)C(C)(C)C,1.47,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(C(=O)N(C)C)c(F)c3)n2,2.74,
OC(=O)[C@H](Cc1ccc(Cl)cc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.86,
Cc1cc(C)nc(N)c1,0.85,
C[C@@H]1COCCN1c2cc(nc(n2)c3cccc4[nH]ccc34)C5(CC5)S(=O)(=O)C,2.7,
Fc1cccc(CN2CCN(CC2)c3ccc4nnc(n4n3)C(F)(F)F)c1F,3.6,
CCCCCCCN(CCc1ccc(OC(C)(C)C(=O)O)cc1)C(=O)Nc2ccc(F)cc2F,1.93,
COc1ccc(cn1)[C@@]2(O)CC[C@H](CC2)N3CC[C@H](C3)NC(=O)CNC(=O)c4cccc(c4)C(F)(F)F,1.72,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)N[C@@H](CCN4CCCCC4)c5ccc(Cl)cc5,2.4,
CN(C)CCNc1cc(nc2cc(nn12)c3ccc(F)cc3)c4ccccc4,4.5,
O=S(=O)(Nc1cccnc1)c2ccc3OCCOc3c2,1.34,
CNCCC(Oc1ccccc1OC)c2ccccc2,0.22,
OC[C@H]1C[C@H]([C@H](O)[C@@H]1O)n2nnc3c(N[C@@H]4C[C@H]4c5ccccc5)nc(SCCC(F)(F)F)nc23,4.06,
CC(=O)NCc1ccc(CN2CCN(CC2)c3ccc(F)cc3F)cc1,2.5,
O=C(N1CCC1)c2ccc(cc2)C(=C3CCN(Cc4cscn4)CC3)c5cccc6cccnc56,2.52,
Clc1ccc(cc1C(=O)NCC23CC4CC(CC(C4)C2)C3)N5CCNCC5,1.77,
Fc1ccccc1Nc2oc(nn2)C(=O)Nc3ccc(cn3)N4CCOCC4,2.4,
CN(C)CCC=C1c2ccccc2COc3ccccc13,2.15,
CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1,3.63,
NCC(O)(c1ccccc1)c2ccccc2,0.9,
[O-][N+](=O)c1cccc(c1)c2ccc(OCC(CCc3ccncc3)N4C(=O)CCC4=O)cc2,3.88,
CC(Nc1ccccc1)C2=CC(=CN3C(=O)C=C(N=C23)N4CCOCC4)C,3.6,
Cc1cc(N)c2cc(NC(=O)CC(=O)Nc3ccc4nc(C)cc(N)c4c3)ccc2n1,1.35,
COc1cc2OC[C@H]3Oc4c5C[C@@H](Oc5ccc4C(=O)[C@H]3c2cc1OC)C(=C)C,3.57,
Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,2.64,
Fc1ccc(cc1F)C(=O)Nc2ccc(Cl)nc2,3.31,
CCN(CC)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1,3.66,
COc1cc(F)ccc1c2cncc(c2)C3CCCN3,1.1,
COc1ccc(Nc2ccccc2C(=O)O)cc1,1.2,
CN(C)CCCC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,1.4,
C[C@H](CO)Nc1nc(SCc2cccc(F)c2F)nc3ncc(C)nc13,3.5,
COc1ccc2c(Oc3ccc(CC(=O)Nc4n[nH]c(C)c4C)c(OC)c3)ccnc2c1,3.78,
C[C@H](Nc1nc(NC[C@@H](O)CO)c(Cl)c(Nc2cc([nH]n2)C3CC3)n1)c4ccc(F)cc4,3.39,
CCCSc1c(cnn1[C@@H]2CC[C@H](CC2)C(=O)O)C(=O)NC3CCCCC3,1.03,
c1cnc2cccnc2c1,0.89,This molecule is a naphthyridine.
Oc1c(C#N)c(nc2ccncc12)c3ccc(cc3)c4ccccc4CN5CCOCC5,2.0,
CS(=O)(=O)C1(CCNCC1)c2cc(nc(n2)c3cccc4[nH]ccc34)N5CCOCC5,0.7,
O=C(C1CC1)c2ccc(OCCCc3c[nH]cn3)cc2,2.68,
Nc1nc2ccc(OC(F)(F)F)cc2s1,3.34,"This molecule is a neuroprotective agent used for therapy of amyotrophic lateral sclerosis. This molecule is associated with a low rate of serum aminotransferase elevations during therapy and has been linked to rare instances of clinically apparent, acute liver injury. This molecule is a member of benzothiazoles. A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. This molecule for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in This molecule is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis. This molecule is a Benzothiazole. This molecule is a benzothiazole derivative with neuroprotective and potential anti-depressant and anxiolytic activities. While the mechanism of action of riluzole is unknown, its pharmacological activities in motor neurons include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. In animal models, this agent has been shown to exhibit myorelaxant and sedative activities, apparently due to the blockade of glutamatergic neurotransmission. This molecule is only found in individuals that have used or taken this drug. It is a glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. [PubChem]The mode of action of riluzole is unknown. Its pharmacological properties include the following, some of which may be related to its effect: 1) an inhibitory effect on glutamate release (activation of glutamate reuptake), 2) inactivation of voltage-dependent sodium channels, and 3) ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors."
CN(C)Cc1ccccc1Sc2ccc(C)cc2N,2.6,
Cc1cc(CN2CCc3ccccc3C2C(=O)Nc4ccc(Cl)cc4Cl)ccc1OCC(=O)O,2.63,
CN(C1CCN(Cc2ccc(cc2)C(F)(F)F)CC1)C(=O)Cc3ccc(cc3)S(=O)(=O)C,2.5,
O=C(N1CCCCC1)c2csc3CCCCc23,3.2,
SC1=Nc2[nH]cnc2C(=O)N1,-1.48,
Nc1ncnc2c1ncn2[C@@H]3O[C@H](CSCCCNC(=O)Nc4ccc(Cl)cc4)[C@@H](O)[C@H]3O,2.5,
N#Cc1cccc(c1)c2onc(n2)c3ccccn3,2.2,
COc1ccc2nccc(C(O)C3CC4(CCN3CC4)C=C)c2c1,2.08,
Cn1cc(cn1)c2cccc(C[C@H](NC(=O)c3cc(nn3C)C(C)(C)C)C(=O)NCC#N)c2,2.6,
OC1=NC(=O)C(N1)(c2ccccc2)c3ccccc3,2.41,
C[C@H](Nc1ncc(F)c(Nc2cc([nH]n2)C3CC3)n1)c4ccc(F)cn4,3.14,
CCC[C@@H](CN1CCCC1)N(C)C(=O)Cc2ccc(Cl)c(Cl)c2,2.27,
COc1ccc2N=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2c1,0.93,
CCN(CC)C(=O)c1ccc(cc1)C(N2CCNCC2)c3cccc4cccnc34,0.7,
CC1=C2C(=CC(=O)N1Cc3ccccn3)NN(C2=O)c4ccccc4Cl,0.2,
COc1ccc2N=NC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,-0.65,
Cc1ccccc1CN2CCC(CC2)N3CCC(CC3)N4C(=O)Nc5ccccc45,2.68,
O=C(CSc1ccccc1)N2CCN(CC2)c3ccccc3,3.2,
CCN(CC)CCCNCc1cc(Cl)c2cccnc2c1O,0.72,
O[C@@H](CNCCc1ccc(CNCCc2ccccn2)cc1)c3ccc(O)c4NC(=O)Sc34,-0.25,
Clc1ccc2OCOc2c1Nc3ncnc4cc(OCCN5CCCC5)cc(OC6CCOCC6)c34,2.6,
CCN1C=C(C(=O)O)C(=O)c2ccc(C)nc12,-0.1,
CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc3cncs3)Cc4ccccc4,4.3,
CSc1ncccc1C(=O)NCC2CCCCC2,2.93,
Cc1c(F)cc(cc1c2ccc(cn2)C(=O)NCC(C)(C)C)C(=O)NC3CC3,3.5,
COc1ccccc1C(=O)Nc2ccc(C)c(c2)N3C=Nc4ccc(cc4C3=O)N5CCN(C)CC5,2.93,
COc1ccc(cc1)c2cc(N)n3ncc(C#N)c3n2,2.42,
CN(C)CCNS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4ccccn34)cc1,2.7,
COCCCCC(=NOCCN)c1ccc(cc1)C(F)(F)F,1.55,
CNC1=Nc2ncccc2C(=NC1c3cccs3)c4ccccc4,2.68,
CCN1C2=NC(=O)N(C)C(=O)C2=Cc3ccccc13,1.1,
CN(C)c1cccc(c1)C(=O)Nc2ccc(C)c(c2)C(=O)Nc3cccnc3,3.01,
NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)cn1,1.51,
CCc1nn(C2CCCC2)c3c1CCn4c(nnc34)c5cccs5,3.6,
CCCN1CCC(CC1)Oc2nccc(Nc3cc(NC(=O)c4cccc(c4)N5CCOCC5)ccc3C)n2,2.6,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4cc(C)ccn34)N5CCN(CC5)C(=O)C,3.3,
COc1cnc(nc1N2CCOCC2)c3ccccn3,1.52,
C[C@@H]1CN(CCN1c2ncc(OCc3ccc(cn3)S(=O)(=O)C)cn2)C(=O)OC(C)(C)C,3.0,
Nc1nccc(n1)c2cc3C(=O)NC[C@H](CCF)c3[nH]2,0.51,
COc1ccc(cc1)c2nc3c(NCC4CCNCC4)c(Br)cnc3[nH]2,1.36,
CCCSc1nc(Oc2ccc(CC(=O)O)cc2)ccc1C(=O)NC3CCCCC3,1.79,
O=C(Nc1ccc(cc1)N2CCOCC2)c3oc(Nc4ccccc4)nn3,3.15,
CNC(=O)c1[nH]cnc1C(=O)Nc2ccc(OC)cc2,2.2,
Cc1ccc([nH]1)C(=O)NC2CCN(CC2)c3cc(cc(Cl)n3)C(=O)N,2.64,
COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OC)C,3.29,
Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CCCO5,0.9,
O=C(Nc1ccccc1)c2ccc(OCCCN3CCCC3)cc2OCc4ccccc4C#N,2.66,
COc1cccc(c1)[C@@H](C)NCCCc2ccccc2Cl,3.0,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5cocc5)ccc4C,2.43,
COc1cccc(c1)C(=O)Nc2ccc(C)c(c2)N3C=Nc4ccc(cc4C3=O)N5CCN(C)CC5,3.08,
COc1ccc(CNC(=O)c2ccc(Oc3ccc(cc3)C#C[C@]4(O)CN5CCC4CC5)cc2)nc1,3.1,
Cn1cc(cc1c2c3C(=O)N(CC#CCn4cncn4)C(=O)N(CC5CC5)c3nn2Cc6ccnc7ccc(Cl)cc67)C#N,3.43,
CCNCc1cncc(n1)c2ccc(F)cc2OC,1.18,
COc1cc(cc(OC)c1OC)C(=O)NCc2ccc(OCCN(C)C)cc2,0.74,
CCCNC(=O)c1nnc2c(c(F)ccc2c1N)c3ccc(OC)cc3OC,3.52,
CC(C)OC(=O)N1CCC(CC1)Oc2ncnc3N(CCc23)c4ccc(cc4F)S(=O)(=O)C,3.4,
CCO\N=C(\C1CCN(CC1)C2(C)CCN(CC2)C(=O)c3c(Cl)cncc3Cl)/c4ccc(Br)cc4,4.0,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(OCC4CC45CC5)nc23,1.78,
CCN(C1CCN(CCC(N2CCN(CC2)c3cccc(F)c3)c4ccccc4)CC1)C(=O)Cc5ccc(cc5)S(=O)(=O)C,3.21,
FC(F)(F)c1cccc(c1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)Oc4ccc(Cl)c(Cl)c4,2.94,
OC(=O)CCC(=O)N1CCC(CC1)c2onc(n2)c3cccs3,-1.27,
Oc1ccc2C(=O)N(C(=O)c2c1)c3ccccc3,2.3,
COc1ccc2C=CC(=O)N(CCN3CCC(CC3)NCc4cc5OCCOc5cn4)c2n1,1.16,
Cc1cc(C)nc(SCC(=O)N)n1,0.23,
Cc1oc(CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3)cc1C,1.0,
O[C@@H](CNCCCSCCNCCc1cccc(Cl)c1)c2ccc(O)c3NC(=O)Sc23,1.06,
Cc1ccsc1C(=CCCN2CCC[C@H](C2)C(=O)O)c3sccc3C,1.49,
CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(=O)(=O)N,1.83,
C[C@H]1CN(Cc2cc(Cl)ccc2CC(=O)O)CCN1C(=O)Cc3ccc(Cl)cc3,1.66,
C[C@@](N)(Cc1ccccc1)c2ccccc2,1.7,
Cc1cc(CN2Cc3ccccc3C2C(=O)Nc4cc(Cl)ccc4Cl)ccc1OCC(=O)O,2.19,
CCC(CC)NC(=O)c1c(C)nn(C(C)C)c1NS(=O)(=O)c2ccc(C)cc2,0.92,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4cc(n[nH]4)C(F)(F)F,2.44,
ONC(=O)Cc1ccc(OCc2ccccc2)cc1,1.92,
CS(=O)(=O)c1cccc(Nc2nccc(n2)N(CC#N)c3c(Cl)ccc4OCOc34)c1,3.16,
CN(CCOc1ccccc1c2cc(C(=O)N)c(NC(=O)N)s2)Cc3ccccc3,3.46,
Nc1nc(N)c2nc(CO)cnc2n1,-0.45,
CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,2.22,"This molecule is an aminopyridine. This molecule is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia."
OC(=O)c1ccccc1NC(=O)Nc2ccccc2,-0.12,
CC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccccn4,1.3,
Cc1nc(NC(=N)N)nc2ccccc12,-0.49,
CNC(=O)c1ccc(Nc2nccc(n2)c3cnc(C)n3C(C)C)cc1,2.69,
COC(=O)C1=C(C)NC(=C(C1c2ccccc2[N+](=O)[O-])C(=O)OCC(C)C)C,3.59,
Clc1ccccc1CN2CCc3sccc3C2,3.46,
Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,1.1,
OCCN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.05,
NC(=O)c1ccc(O[C@H]2C[C@H]3CC[C@@H](C2)N3Cc4ccccc4)nc1,1.25,
NC(=O)c1cnc(N[C@H]2CCCNC2)c3cc(Br)sc13,1.08,
CCC(CC)NC(=O)c1c(C)nn(c1NS(=O)(=O)c2ccc(C)cc2)c3ccccc3,1.35,
OC(=O)C[C@@H]1CC[C@H](CC1)c2ccc(NC(=O)c3oc(Nc4ccccc4F)nn3)cc2,2.48,
NCC[C@@H](Sc1cc(Cl)ccc1C#N)c2ccccc2,1.26,
FC(F)(F)Oc1cccc2c3CN(CCc3[nH]c12)C(=O)[C@@H]4CCCC[C@H]4C(=O)NC5(CC5)C#N,4.01,
Clc1ccc(NC(=O)N2CCN(C[C@@H]3CCCN(CC4CC4)C3)CC2)cc1Cl,2.54,
CN1CCN(CC1)c2ccc3N=CN(C(=O)c3c2)c4cc(NC(=O)c5cccc(c5)N6CCOCC6)ccc4C,2.69,
OC(=O)c1cncc(c1)c2ccc(Cl)c(c2)C(=O)NCC34CC5CC(CC(C5)C3)C4,0.85,
COc1cncc(NC(=O)c2cc(NC(=O)c3cccc(c3)C(C)(C)C#N)ccc2C)c1,3.04,
Nc1nc(nc2c1nc(O)n2Cc3ccccc3)c4ccccc4,4.16,
[O-][N+](=O)c1ccc2c(c1)C(=O)C(=O)c3ccccc23,2.42,
CC(C)Nc1ccc2cnn(c3cncc(n3)n4ccc(CC(=O)O)c4)c2c1,1.24,
NC1=NC(c2cccc(c2)c3cncnc3)(c4ccnc(c4)C(F)(F)F)c5cccc(F)c15,3.4,
Cc1sc(nc1C(F)(F)F)N2CCN(CC2)C(=O)[C@@H]3CCCC[C@H]3C(=O)NC4(CC4)C#N,2.87,
COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN(C)C4(CCN(C)CC4)C(=O)N,2.16,
COC(=O)c1c(C)[nH]c(C)c1C(=O)c2ccccc2Cl,2.7,
CNc1c(Br)cnc2[nH]c(nc12)c3ccc(O)cc3,2.47,
CCNC(=O)c1ccc(CN2CCC(CC2)c3ccc(cc3)C(=O)Nc4ccccc4N)cc1,2.24,
COCCOc1cc(Nc2nccc(n2)N(C)c3cc(CO)ccc3C)cc(c1)N4CCOCC4,3.3,
COc1cc(Nc2cc(Oc3cccnc3)ccn2)cc(OC)c1OC,2.66,
C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc3ccc(F)cc3)C(=O)NCCCc4ccccc4O1,3.3,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2c(F)cccc12)c3ccccc3)c4ccccc4,2.84,
Cc1ccc2cc(C)c3nnc(SCC(=O)N4CCN(CC4)C(=O)c5occc5)n3c2c1,2.3,
Nc1ccc2cccc(Nc3ncccn3)c2n1,2.7,
O=C1C=C(N=C2C=CC=CN12)N3CCOCC3,1.0,
Clc1ccc(cc1Cl)C2CNCC=CC2,1.86,
Oc1cc(O)c2C(=O)C(=COc2c1)c3ccc4OCOc4c3,3.5,
N(c1ccccc1)c2ncnc3ccccc23,2.94,
FC(F)(F)Oc1ccc2OCC(=O)N(CCN3CCC(CC3)NCc4ccc5OCC(=O)Nc5n4)c2c1,1.82,
Nc1c(NC2CCCCC2)nc(nc1N3CCOCC3)C#N,2.81,
OC(CCN1CCCC1)(C2CCCCC2)c3ccccc3,1.78,
COc1cc(F)ccc1c2cncc(CNC(=O)c3cnccn3)c2,2.5,
COc1cc(cc(OC)c1OC)c2nnc(S)n2c3cccc(c3)C(F)(F)F,2.27,
COCCOc1ccc(cc1)c2cc(C(=O)N)c(NC(=O)N)s2,2.34,
C[C@H](NC1=NC(=O)[C@](C)(S1)C(F)(F)F)c2ccccc2F,3.1,
Fc1ccc(NC(=S)N2CCC(CC2)C(=O)c3ccc(F)cc3)cc1,3.4,
COc1cc(F)ccc1c2cccc(CNC3CCCC3)n2,2.06,
CC(C)n1c(C)ncc1c2ccnc(Nc3ccc(cc3)C(=O)NC4CCN(C)CC4)n2,1.87,
NS(=O)(=O)c1cccc2c3nc(O)c(O)nc3cc(c12)[N+](=O)[O-],0.36,
Nc1c(nc(nc1N2CCOCC2)C#N)N3CCCCC3,2.71,
Brc1ccc(OC(=O)N2CCN3CCC2CC3)cc1,1.58,
COc1ccc(COc2nc(Br)cnc2NS(=O)(=O)c3ccc(C)cc3)cc1OCCN(C)C,1.68,
CCN(C1CCN(CC[C@H](c2ccc(cc2)S(=O)(=O)C)c3cccc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,2.9,
COc1ccc(cc1OC)C(=O)Nc2cccc(NC(=O)c3cccc(c3)N(C)C)c2,3.67,
OC(=O)COc1ccc(Cl)cc1CN2CCC(CC2)S(=O)(=O)c3ccccc3,0.48,
COc1cc(OC2CCN(C)CC2)c3c(Nc4cccc5OCOc45)ncnc3c1,3.02,
CC[C@H](N)C(=O)N[C@@H](Cc1ccc(cc1)c2ccccc2)C#N,2.6,
OC(=O)CCc1ccc(OCc2cccc(Oc3ccccc3)c2)cc1,2.47,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)C(CO)CO,3.1,
COc1cc2c3N([C@H](C)c4ccccn4)C(=O)Nc3cnc2cc1c5c(C)onc5C,3.15,
COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN5CCOCC5,3.5,
CNS(=O)(=O)c1ccc(Nc2nccc(n2)c3cnc4cccnn34)cc1,2.8,
OCCn1cc(cn1)c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2,1.7,
NC(=O)C(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.2,
NC(=O)C1CCN(CC(=O)Nc2ccc3OCOc3c2)CC1,0.4,
CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c2ccccc2)C(F)(F)F,2.98,
CC(C)(Cc1cccc(CC(=O)NCc2cccc(c2)c3ccc(O)cc3)c1)NC[C@H](O)c4ccc(O)c(NS(=O)(=O)C)c4,1.91,
COCCN(c1ccnc(Nc2cc(cc(c2)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,2.8,
Cc1ccc(NC(=O)[C@@H]2CCCN2S(=O)(=O)c3cccc4cccnc34)c(C)c1,3.8,
OCCCNc1ccc2c(NC(=O)CC3CCCCC3)c(Cl)ccc2n1,3.29,
O=C(Nc1ccncc1)c2cccc3ccccc23,3.1,
O[C@@H]1CN(CCN2C(=O)C=Cc3ccc(cc23)C#N)CC[C@@H]1NCc4cc5OCCOc5cn4,0.46,
CNc1ncnc2c(CNc3cc(NC(=O)c4ccc5OCCOc5c4)ccc3C)cccc12,4.0,
Oc1cccc2nc(cc(O)c12)c3ccccc3,3.37,
CC(C)Oc1cc(OCCN2CCN(CC2)C(=O)C)cc3ncnc(Nc4c(F)ccc5OCOc45)c13,3.06,
NC(=O)Cc1nc(cs1)c2ccccc2,1.3,
COC(=O)N1CCN(C(CC(=O)NCc2ccc3OCOc3c2)C1)c4ccnc(n4)n5ccnc5,1.88,
C(C1NCCc2ccccc12)c3ccccc3,1.89,
CC(C)N1CCC(CC1)N(C(=O)Cc2ccccc2)c3ccc(Cl)cc3,2.3,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(O)cc4,3.3,
OC(=O)c1cc2cc(ccc2n1Cc3ccc(Cl)c(Cl)c3)[N+](=O)[O-],1.79,
CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24,2.19,
Cc1cc(F)ccc1OC2CCN(CC3CCN(CC3)[C@@](C)(Cc4ccc(F)cc4)C(=O)O)CC2,2.0,
CCN1CCC[C@H](CN2CCN(CC2)C(=O)Nc3ccc(Cl)c(Cl)c3)C1,1.86,
COCC(C)n1nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c1NS(=O)(=O)c2ccc(C)cc2,0.61,
OC(Cn1cncn1)(Cn2cncn2)c3ccc(F)cc3F,0.48,
COc1ccc(N(C(C(=O)NC2CCCC2)c3ccccc3F)C(=O)C)c(OC)c1,2.81,
c1ccc(nc1)c2n[nH]cc2c3ccnc4ccccc34,2.57,
Clc1ccccc1CNC[C@@H]2CC[C@@H](CNCc3ccccc3Cl)CC2,2.74,
CCC[C@H](N1CCC[C@@H](C1)N2C=C(C)C(=O)NC2=O)c3ccc(C(=O)O)c(Oc4cccc(Cl)c4)c3,0.5,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(O)c(Oc4ccc(Cl)c(C)c4)c3)C(=O)NC1=O,2.4,
C[C@H](NC(=O)\C=C\c1ccccc1)c2cccc(c2)N3CCOCC3,3.24,
CC(C)CN1C(=O)N(C)C(=O)c2c1nn(Cc3cccc4ccccc34)c2c5cncn5C,4.1,
COCCNc1nc(nc(NCC(C)C)c1N)C#N,2.8,
Nc1nccc2ccccc12,1.5,
CC(C)n1c(C)ncc1c2nc(Nc3ccc(cc3)C(=O)N4CCN(C)CC4)ncc2F,2.49,
CO[C@@H]1C[C@@H](N(Cc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)C1)C(=O)N,3.09,
CN[C@@H](C)C(=O)N[C@H](C(=O)N[C@H]1CCCN(CCc2ccccc2OC)C1)C(C)(C)C,1.61,
Nc1ncc(cc1c2oc3ccccc3n2)c4cnn(c4)C5CCOCC5,4.0,
CCN(C1CCN(CC[C@H](C2CCN(CC2)S(=O)(=O)C)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,1.05,
O=C1N2C=CC=CC2=Nc3ccccc13,2.1,
CN(c1ccnc(Nc2cc(nc(n2)N3CCOCC3)N4CCOCC4)n1)c5cc(CO)ccc5C,3.9,
CCCNC(=O)c1nnc2c(c(F)ccc2c1N)c3ncccn3,2.07,
CCC(N(CCCN)C(=O)c1ccc(C)cc1)C2=Nc3ccn(C)c3C(=O)N2Cc4ccccc4,1.8,
COC(=O)c1cccc(CN2NC(=O)C3=C(C2=O)C(=O)c4ccc(Cl)cc4N3)c1,1.1,
CCN1CCN(CC1)C(=O)c2cc3ccccc3[nH]2,1.95,
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(N)nc(Oc4ccccc4)nc23,1.05,
Cc1ccc(NC(=O)N2CCN(C[C@@H]3CCCN(C3)C4CC4)CC2)cc1Cl,3.37,
COc1cc(Nc2ncc(C)s2)nc(N[C@@H](C)c3ncc(F)cn3)n1,2.99,
OC(=O)c1[nH]c2ccccc2c1CC(=O)Nc3cccc(c3)C(F)(F)F,1.33,
CC(C)(C)c1ccc(cc1)C2=NC(=O)C(CC(=O)O)S2,-0.1,
C[C@H]1CN(Cc2cc(Cl)ccc2OCC(=O)O)CCN1C(=O)Cc3cccc(Cl)c3,0.78,
O=C(Oc1ccc2C(=O)CCOc2c1)c3ccccc3,3.6,
COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1,3.5,
O=C(Nc1cc(ccn1)c2ccnc(Nc3ccccc3)c2)C4CCOCC4,3.7,
COc1ccc(cc1)c2nc3c(NCCCNC(=O)C4(CN)CC4)c(Br)cnc3[nH]2,1.9,
COc1cccc(OC)c1c2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)cc2,-0.27,
COc1cc(OC)c(cc1NC(=O)\C=C\C(=O)O)S(=O)(=O)N2c3ccccc3Oc4ccccc24,-0.71,
C[C@H](Nc1nc(Nc2cc([nH]n2)C3CC3)cnc1C#N)c4ccc(F)cn4,3.18,
COc1ccccc1Oc2c(NS(=O)(=O)c3ccc(cc3)C(C)(C)C)nc(nc2OCCO)c4ncccn4,1.03,
NC1(CCC1)c2ccc(cc2)C3=Nc4ccccc4C(=O)N3c5ccccc5,1.5,
OC(C(=O)c1ccccc1)c2ccccc2,2.13,
CC(=O)Nc1ccc(O)cc1OC[C@@H](O)CN2CCC3(CC2)Cc4cc(F)ccc4O3,2.1,
COc1cccc(Nc2ncnc3cc(OC)c(OC)cc23)c1,3.1,
COc1cc2ncc(C(=O)N)c(Nc3ccc(C)cc3F)c2cc1OC,3.34,
CN(c1ccc(c(Cl)c1)c2cc(F)ccc2OCC(=O)O)S(=O)(=O)C,-1.17,
Nc1cc(nc2c(cnn12)C#N)c3ccccc3,2.48,
CN1CCN(CC1)S(=O)(=O)c2ccc(cc2)c3cnc(N)c(n3)C(=O)Nc4cnccc4CN5CCCC5,3.28,
N[C@@H](Cc1ccc(F)cc1)C(=O)O,-1.06,"This molecule is a L-phenylalanine derivative that is L-phenylalanine in which the hydrogen at position 4 on the benzene ring is replaced by a fluoro group. It is a 4-fluorophenylalanine, a L-phenylalanine derivative and a non-proteinogenic L-alpha-amino acid."
CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(CO)c3ccccc3,-0.66,
Brc1ccc(cc1)C2NC(=O)c3ccccc3N2,2.68,
COc1cc(nc2c(cc(F)cc12)N3CCN(C)CC3)C(=O)Nc4ccc(cc4)N5CCOCC5,3.85,
CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(=O)C,-0.27,
CN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)Cc4ccc(cc4)C#N,3.7,
Cc1c(Cl)ccc(OC2CCN(CC3CCN(CC3)[C@@H](Cc4ccc(F)cc4)C(=O)O)CC2)c1Cl,3.15,
OC(=O)C1CCn2c1ccc2C(=O)c3ccccc3,-0.93,
CN1C2CCC1CC(C2)OC(=O)C(CO)c3ccccc3,-0.09,
C[C@@H]1CN(CCN1c2ncc(OCc3ccncc3C#N)cn2)c4noc(n4)C(F)(F)F,3.95,
CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC2CCCCC2,-0.49,
NC(=O)Nc1sc(cc1C(=O)N)c2ccc(CN3CCCCC3)cc2,1.75,
Cc1oc(CN2CCNCC2)cc1C(=O)NCC34CC5CC(CC(C5)C3)C4,1.03,
C[C@H](CO)Nc1nc(SCc2ccccc2F)nc3NC(=O)Sc13,3.0,
OC(=O)COc1ccc(Br)cc1c2ccccc2,0.15,
CN1CCC(=C2c3ccccc3C=Cc4ccccc24)CC1,3.06,
CCC(=O)N1CCN(CC1)C(=O)c2cc(CC3=NNC(=O)c4ccccc34)ccc2F,1.22,
CCCOc1cc(OCCCN2CCCC2)ccc1C(=O)Nc3cccc(O)c3,2.46,
CC(=O)N1CCOc2cc(COc3ccccc3)cnc12,2.8,
Cc1sc(N)nc1c2ccccc2,2.75,
CN(C)C(=O)c1ccc(cc1)C(=C2CCN(Cc3cscn3)CC2)c4cccc5cccnc45,2.3,
Cc1ccc(\C=C(/C#N)\C(=O)N)cc1,2.09,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4cccnc4,2.72,
Nc1ccccc1[N+](=O)[O-],-0.96,"This molecule is an orange solid with a musty odor. Sinks and mixes slowly with water. (USCG, 1999)"
C1CN2CCC1C(=C2)c3oc4ccccc4c3,2.59,
OCC1=CC2=NNC(=O)N2c3cc(ccc13)c4ccc[nH]4,2.19,
Nc1ccc2c3ccccc3C(=O)c2c1,2.9,
Clc1ccc(CNc2nc(nc3ncccc23)N4CCN(CC4)C(=O)[C@H]5CCCCN5)c(Cl)c1,2.27,
Nc1ncnc2sc(nc12)c3c(ncn3Cc4ccccc4N5CCOCC5)c6ccccc6,3.58,
CC1=CN([C@H]2CCCN(C2)[C@H](CC3CCCCC3)c4ccc(C(=O)O)c(Oc5cccc(Cl)c5)c4)C(=O)NC1=O,1.83,
CN1CCN(CCOc2n[nH]c3ncnc(Nc4ccc(OCc5ccccn5)c(Cl)c4)c23)CC1,2.45,
NC(=O)N1c2ccccc2C=Cc3ccccc13,1.65,
CCCN1CCN(CC1)c2ccc(cc2)C(=O)NC3(CCCCC3)C(=O)NCC#N,1.33,
CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c5ccccc5)(C2)c6ccc(Cl)c(Cl)c6)c1,1.23,
COc1nc(Br)cnc1NS(=O)(=O)c2ccc(Cl)s2,0.99,
CC(C)NC(=O)c1ccc2c(Nc3ccc(Cl)cc3)nc(nc2c1)N4CCOCC4,2.78,
Oc1ncnc2scc(c3ccccc3)c12,2.07,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(CCCN4CCOCC4)c5ccc(Cl)cc5,2.7,
COc1cc(ccc1Nc2nccc(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)C,3.0,
Cc1onc(c2ccccc2)c1c3ccc(cc3)S(=O)(=O)N,2.37,
O=C1NC(=O)C(Cc2cccc(Oc3ccccc3)c2)S1,2.84,
CCCc1c(cnn1c2ccccc2)C(=O)Nc3ccc(F)cc3C,3.89,
OCCNC(=O)CN1C(=O)C(Cc2ccccc12)NC(=O)c3cc4cc(Cl)sc4[nH]3,3.05,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4nc5ccccc5[nH]4,3.24,
O[C@@H](CNCCOc1cccc(CNCCc2ccccc2F)c1)c3ccc(O)c4NC(=O)Sc34,1.86,
Clc1ccc2OCOc2c1Nc3ncnc4cc(OCCCN5CCCC5)cc(OC6CCOCC6)c34,2.3,
O=C(NCC#N)[C@@H]1CCCC[C@H]1C(=O)N2CCN(CC2)c3ccccc3,1.75,
CC1=CN([C@H]2CCCN(C2)S(=O)(=O)c3ccc(C(=O)O)c(Oc4ccc(Cl)c(Cl)c4)c3)C(=O)NC1=O,-0.87,
CC(C)C(NC(=O)CN1C(=O)C2=C(C=C1c3ccccc3)C(=O)N(CCN4CCOCC4)C(=O)N2)C(=O)C(F)(F)F,1.91,
Clc1cccc(c1)S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,3.39,
C[C@H](Oc1nc(Nc2cc(C)[nH]n2)c(C)nc1C#N)c3ccc(F)cn3,2.86,
CO[C@@H]1CC[C@@]2(CC1)Cc3ccc(cc3C24N=C(C)C(=N4)N)c5cc(Cl)cc(c5)C#N,3.8,
Cn1cnc2c(c3ccc(cc3)C4(N)CCC4)c(ccc12)c5ccccc5,2.5,
CC(C)NC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C(=O)O)n4ccc(n4)C(F)(F)F,-0.62,
Cc1[nH]c(C(=O)NC2CCN(CC2)c3ncc(s3)C(=O)O)c(Cl)c1Cl,0.02,
COc1cc(OC2CCNCC2)ccc1Nc3ncc(Cl)c(n3)c4cnc5ccccn45,1.8,
CC(C)CCOc1ccc(N)cc1,2.67,This molecule is a substituted aniline and an aromatic ether.
CC(C)c1ccc(Sc2cnc(O)c(c2)C(=O)NCc3ccccc3)cc1,3.7,
Cc1ccc2c(c1)c(c(C)n2CC(=O)O)c3ccnc4c(C)cccc34,1.29,
Fc1ccccc1Nc2oc(nn2)C(=O)Nc3ccc(Oc4cccnc4)nc3,3.1,
CN(C)CCCOc1nn(Cc2ccccc2)c3ccccc13,2.4,
Cc1ccc(cc1)c2nnc(N3CCN(CC3)C(=O)c4occc4)c5ccccc25,3.78,
CC(=O)Nc1ccc(CNc2[nH]nc3cccc(Oc4ccc(cc4)S(=O)(=O)C)c23)cc1,2.63,
CCS(=O)(=O)c1ccc(c(C)c1)c2cc(ccc2CCC(=O)O)C(F)(F)F,0.76,
COc1ccc(OC)c(CNc2n[nH]c3ccnc(Oc4ccccc4)c23)c1,4.25,
CC(C)Cc1ccc(cc1)[C@H](C)C(=O)NS(=O)(=O)C,0.56,
COCCC(NC(=O)C1(N)CCN(CC1)c2ncnc3[nH]ccc23)c4ccc(Cl)cc4,2.95,
COc1cc(OC)c(cc1NC(=O)NCC(=O)O)S(=O)(=O)N2C(C)CCc3ccccc23,-1.02,
NC(=O)Nc1cc(sc1C(=O)N)c2ccsc2,2.3,
COc1cc(F)ccc1c2cncc(CNCC3CC3)n2,1.8,
CCCNC(=O)c1cc2c(c(cnc2[nH]1)c3cncc(c3)C(=O)O)n4ccc(n4)C(F)(F)F,-0.79,
COc1cc(OC2CCN(C)CC2)c3c(Nc4cccc5OCCOc45)ncnc3c1,2.26,
FC(F)(F)Oc1ccccc1S(=O)(=O)NCC(N2CCCCCC2)c3ccccc3,4.09,
CC(C)COc1cc(ccc1NC(=O)CN2CCOCC2)c3cccc4C(=O)C=C(Oc34)N5CCOCC5,3.8,
CN1CCOc2cc(OC(=O)c3ccccc3)cnc12,3.3,
Nc1sc2CCCCc2c1C(=O)NCc3ccccc3,3.52,
CN1CCC(CC1)Oc2cccc3ncnc(Nc4ccc(OCc5cnccn5)c(Cl)c4)c23,3.21,
CC(C)CNc1nc(nc(N2CCN(CC2)C(=O)C)c1N)C#N,2.4,
CC(C)COCC(CN(Cc1ccccc1)c2ccccc2)N3CCCC3,3.66,
CC1=CC2=NNC(=O)N2c3cc(ccc13)c4cccc(CO)c4,3.36,
O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1c3ccc(F)cc3)C4CC4)CC(=O)O,0.91,
Nc1cccc2c3ccccc3C(=O)C(=O)c12,2.95,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3ccncc3S(=O)(=O)C)cn2,2.4,
C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,2.87,
CNc1cccc(CCCc2ccc(C[C@H](NC(=O)c3c(Cl)cccc3Cl)C(=O)O)cc2)n1,0.57,
O=C(NCc1ccncc1)c2ccc(Oc3ccccc3)cc2,3.26,
OC(=O)COc1ccc(Cl)cc1CN2CCN(CC2)S(=O)(=O)Cc3ccccc3,0.33,
C[C@@H](NC(=O)C1CCNCC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,0.4,
CN(C)C[C@H](O)Cc1ccc(Cl)c(c1)C(=O)NCC23CC4CC(CC(C4)C2)C3,2.19,
Oc1ccnc2ccccc12,0.8,"This molecule is a quinolone that is 1,4-dihydroquinoline substituted by an oxo group at position 4. It is a tautomer of a quinolin-4-ol. This molecule is a natural product found in Glycosmis parviflora and Glycosmis citrifolia with data available."
CN1CCN(CCCN2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1,4.31,
COc1cc(Nc2cc(Oc3ccc(C)nc3)ccn2)cc(OC)c1OC,3.21,
CC1=NC(C)(N=C1N)c2cccc(c2)c3cccnc3,1.7,
COc1cc(F)ccc1c2cc(CNC3CCCC3)ccn2,1.71,
NC(=N)Nc1oc2ccccc2n1,1.91,
Cc1nc2nc(NC(=O)c3ccc(F)cc3)nn2c(O)c1Cc4ccccc4,2.2,
CN(C)C(=O)C(CCN1CCC(O)(CC1)c2ccc(Cl)cc2)(c3ccccc3)c4ccccc4,3.47,
CN(C)CCCOc1nccc(Nc2cc(NC(=O)c3ccnc(c3)N4CCOCC4)ccc2C)n1,1.3,
NNC(=O)c1ccncc1,-0.57,"This molecule appears as odorless colorless or white crystals or white crystalline powder. Taste is slightly sweet at first and then bitter. pH (1% aqueous solution) 5.5-6.5. pH (5% aqueous solution) 6-8. (NTP, 1992) This molecule is the most reliable and most commonly used medication for tuberculosis. This molecule therapy is often associated with minor, transient and asymptomatic elevations in serum aminotransferase levels but, more importantly, isoniazid is a well known cause of acute clinically apparent liver injury which can be severe and is sometimes fatal. This molecule is a carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. It has a role as an antitubercular agent and a drug allergen. It is functionally related to an isonicotinic acid. Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. This molecule is an Antimycobacterial. This molecule is a synthetic derivative of nicotinic acid with anti-mycobacterial properties.  Although its mechanism of action is still unclear, isoniazid appears to block the synthesis of mycolic acids, major components of the mycobacterial cell wall. This agent is only active against actively growing mycobacteria because, as a pro-drug, it requires activation in susceptible mycobacterial species. This molecule also interferes with mycobacterial metabolism of vitamin B6.  Resistance occurs due to decreased bacterial wall penetration. (NCI04) This molecule is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of tuberculosis (TB). This molecule is a natural product found in Aspergillus ochraceopetaliformis, Ganoderma colossus, and other organisms with data available. Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis."
CCS(=O)(=O)c1ccc(cc1)c2cc(Cl)ccc2OCC(=O)O,-0.78,
Cn1cc(cc1c2c3C(=O)N(CC#C)C(=O)N(CC4CC4)c3nn2Cc5ccnc6ccc(Cl)cc56)C#N,3.96,
COc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)nc(N4CCOCC4)c2F)n[nH]1,2.64,
Cc1cccc(Nc2ncnc3ccccc23)c1,3.21,
OCCCNCCCOc1ccc(Cl)c(c1)C(=O)NCC23CC4CC(CC(C4)C2)C3,1.41,
CCOC(=O)c1ccc(OCCC2(CCN(CC2)c3ccc(C)nn3)C#N)cc1,3.54,
C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(=O)C)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)CCC(=O)C=C14,3.25,
Fc1ccc(cc1)C(=O)C2CCN(CC2)C(=O)N3CCOCC3,1.61,
Cc1cc(Cl)ccc1N2CCN(CC2)C(=O)COCc3ccncc3,3.22,
CC1CN(CCN1)C(=O)c2cc3ccccc3[nH]2,0.94,
Clc1ccc(cc1)C2(CCNCC2)c3ccc(cc3)c4cn[nH]c4,1.51,
Cc1cc(C)cc(c1)c2c(O)nc3cc(Cl)c(cc3c2OCCC4CCCCN4)C(=O)Nc5ccncn5,1.7,
Clc1cccc(C(=O)NCC23CC4CC(CC(C4)C2)C3)c1Cl,4.37,
CCOc1ccc(cc1)c2cnc3CCCCCn23,3.01,
CNc1c(Br)cnc2[nH]c(nc12)c3ccnc(N)c3,2.83,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CCN(CC5)C(=O)C,3.65,
FC(F)(F)c1ccc(NC(=O)N2CCN(C[C@@H]3CCCN(C3)C4CC4)CC2)cc1Cl,4.06,
OCC(O)COC(=O)c1ccccc1Nc2ccnc3cc(Cl)ccc23,3.5,
CN[C@@H](C)C(=O)N[C@H](C(=O)N1CC[C@H]2CC[C@H](NC(=O)c3cccc4ccccc34)[C@@H]12)C(C)(C)C,1.94,
COc1cc(F)ccc1c2cccc(CNC3CCCC3)c2,2.29,
COc1cc(ccc1NC(=O)CN2CCOCC2)c3cccc4C(=O)C=C(Oc34)N5CCOCC5,2.3,
CCOc1cc(ccc1NC(=O)CN2CCOCC2)c3cccc4C(=O)C=C(Oc34)N5CCOCC5,2.8,
C1CN2CCC1C(C2)c3ccc(cc3)c4ccccc4,1.76,
Cc1cc(NC(=O)c2oc(Nc3ccccc3F)nn2)ccc1N4CCOCC4,4.0,
Nc1ccc(cc1)S(=O)(=O)Nc2ccccn2,-0.01,
Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CCOC5,0.8,
CCNC(=O)c1cc2c(c(cnc2[nH]1)c3cnc(OC)c(c3)C4=NNC(=O)O4)n5ccc(n5)C(F)(F)F,2.32,
Clc1cc(Cl)c2c3C(=O)NNC(=O)c3[nH]c2c1,1.02,
CCCCC(NC(=O)CC1CCN(Cc2ccn(c2)c3ccc(cc3)C(F)(F)F)CC1)C4=CNC(=O)C=C4,2.89,
Fc1cccc(Nc2oc(nn2)C(=O)Nc3ccc(nc3)N4CCOCC4)c1,3.2,
CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(C)ccc3F)n2)cc1,2.1,
O=C(NC1CC1)c2cc(on2)c3cccs3,2.54,
CCOc1ccc(NC(=O)CCc2c(C)nc3nc(C)nn3c2C)cc1,2.1,
CNc1c(Br)cnc2[nH]c(nc12)c3cccc(N)c3,2.96,
Nc1nc(N)nc(n1)c2ccc(Cl)cc2,2.12,
COc1cc(c2nc(cc(n2)C3(CC3)S(=O)(=O)C)N4CCOCC4)c5cc[nH]c5c1,2.4,
CN(C1CCCCC1)C(=O)c2c(C)nn(c2NS(=O)(=O)c3ccc(C)cc3)c4ccccc4,1.69,
CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c3ccc(F)cc3,1.48,
COc1ccc(Nc2cc(Nc3ccc(OCC(O)CN(C)C)cc3)ncn2)cc1,1.5,
CC(C)S(=O)(=O)NCC(C)c1ccc(cc1)c2ccc(cc2)C#N,3.5,
O=C(CSc1ccccc1)N2CCN(CC2)C(=O)c3occc3,1.6,
NC1=NC2(CCN(CC2)C(=O)c3ccc(cc3)C#N)Nc4c(F)ccc(F)c14,0.86,
CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N,-1.2,
CNC1=Nc2ccc(Cl)cc2C(=[N+]([O-])C1)c3ccccc3,2.41,
CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)c2cc3ccsc3[nH]2,3.1,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2cc(F)cc(F)c2)N)C(=O)C(F)(F)F,1.38,
CC(C)N(C(C)C)c1nnc(N)s1,1.49,
CS(=O)(=O)c1ccc(CC(=O)N(C2CC2)C3CCN(CCC(c4ccccc4)c5ccccc5)CC3)cc1,2.89,
Nc1ccc(OCc2ccccc2)cc1,2.2,
NNCCc1ccccc1,-0.01,"This molecule is a monoamine oxidase inhibitor (MAO inhibitor) used in therapy of moderate-to-severe depression. This molecule therapy is associated with rare instances of clinically apparent acute liver injury. This molecule is a primary amine. This molecule is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil. This molecule is a Monoamine Oxidase Inhibitor. The mechanism of action of phenelzine is as a Monoamine Oxidase Inhibitor. This molecule is only found in individuals that have used or taken this drug. It is an irreversible non-selective inhibitor of monoamine oxidase. May be used to treat major depressive disorder.Although the exact mechanism of action has not been determined, it appears that the irreversible, nonselective inhibition of MAO by phenelzine relieves depressive symptoms by causing an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron."
CCN(C1CCN(CCC(c2ccccc2)c3ccccc3)CC1)C(=O)NCc4ccc(F)cc4,3.9,
Nc1n[nH]c2ncc3CCCCCCc3c12,2.54,
C[C@@H](NC(=O)[C@H]1CCCNC1)c2ccc(Nc3ncc4cc(ccc4n3)c5ccncc5)cc2,1.69,
Cc1c(Sc2ccc(Cl)cc2)c3c(C#N)c(Cl)ccc3n1CC(=O)O,1.6,
CC1(C)NC(=O)N(C1=O)c2ccc(c(c2)C(F)(F)F)[N+](=O)[O-],1.74,
NS(=O)(=O)c1ccc2NC(C3CC=CC3c2c1)c4cccc5ccccc45,1.9,
CC[C@H](NC(=O)c1c([S+](C)[O-])c(nc2ccccc12)c3ccccc3)c4ccccc4,3.17,
Cc1ccnc(NCc2ccccc2O)c1,3.35,
CC(C)c1onc(n1)N2CCN([C@H](C)C2)c3ncc(OCc4ccncc4C#N)cn3,3.3,
O[C@@H](CNCCCSCCOCCc1cccc2ccccc12)c3ccc(O)c4NC(=O)Sc34,3.12,
COc1cc(ccc1Nc2ncc(Cl)c(n2)c3cnc4ccccn34)N5CCN(CCS(=O)(=O)C)CC5,3.1,
COc1ccc(cc1)c2nc(N)s[n+]2c3ccccc3,2.19,
O=C1NC(=O)C(Cc2ccc3ccccc3c2)S1,2.41,
Cc1ccc(cc1NC(=O)c2ccc(OCc3ccccn3)cc2)c4cn(C)cn4,2.54,
O=C(CN1CCOCC1)Nc2ccc(cc2OCC3CC3)c4cccc5C(=O)C=C(Oc45)N6CCOCC6,3.3,
c1ccc(cc1)c2[nH]nc3ccccc23,3.79,
CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c2cccnc2)C(F)(F)F,2.08,
CCCCC(N1NC(=O)c2nc3cc(Cl)ccc3c(O)c2C1=O)c4ccncc4,1.4,
OC12CC3CC(C1)CC(C3)(C2)NCC(=O)N4CCC[C@H]4C#N,-0.48,
CCOc1ccccc1N2CCN(Cc3c[nH]nc3c4ccc(F)cc4)CC2,3.38,
COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c3ccccc3,2.9,
Fc1cc(ccc1C2=CCS(=O)(=O)CC2)N3C[C@H](Cn4nncc4F)OC3=O,3.54,
C[C@@H]1CC[C@H](CC1)Oc2nc(N)c3ncn([C@@H]4O[C@H](C)[C@@H](O)[C@H]4O)c3n2,2.35,
CC(C)CN1C(=O)N(C)C(=O)c2c1sc(Cc3ccnc4ccccc34)c2C(=O)N5CC[C@@H](O)C5,1.65,
CC(=O)C1=Cc2ccc(O)cc2OC1=O,0.87,
C[C@@](O)(C(=O)Nc1ccc(cc1Cl)S(=O)(=O)NCCN2CCOCC2)C(F)(F)F,2.14,
[O-][N+](=O)c1cccc2C(=O)C(=O)c3ccccc3c12,2.6,
CC(=O)N[C@@H]1CC2(CCN(Cc3ccc4[nH]c5ccccc5c4c3)CC2)c6ccccc16,2.96,
CC(C)(C)C(=O)N[C@H]1CCCCNC1=O,0.58,
Oc1cc(ccc1NC(=O)CN2CCOCC2)c3cccc4C(=O)C=C(Oc34)N5CCOCC5,2.4,
CCCSc1c(cnn1c2ccc(cc2)C(=O)O)C(=O)NC3CCCCC3,0.64,
Cc1ccc(cc1)c2c[nH]nn2,2.58,
CCCCOc1nc(N)c2NC(=O)N(Cc3cccc(CC(=O)O)c3)c2n1,0.14,
O=S(=O)(Nc1cccc2[nH]ncc12)c3cccs3,1.7,
COc1cc(OC)c(cc1NC(=O)C)S(=O)(=O)NCc2ccccc2N3CCC(CO)CC3,1.03,
COCCNCc1ccc(cc1)c2cc(C(=O)N)c(NC(=O)N)s2,0.87,
C[C@H](NC(=O)c1c(C)nn(C2CCCCC2)c1NS(=O)(=O)c3ccc(C)cc3)C(C)(C)C,1.97,
CC(C)N1CCC[C@H](CN2C(=Nc3ccc(Oc4ccc(F)cc4)cc3C2=O)C)C1,2.4,
Nc1ccc2cn[nH]c2c1,0.52,This molecule is a member of indazoles.
Cc1cc(n[nH]1)c2ccc(Cl)c(c2)C(=O)NCC3(O)CCCCCC3,3.41,
Nc1ccc(cn1)C(=O)Nc2cccc(c2)c3nc(N4CCOCC4)c5oc6ncccc6c5n3,3.44,
Fc1ccc(CNC(=O)CCS(=O)(=O)c2ccc(Br)cc2)cc1,3.1,
CC1(CC(=O)NC(=N1)N)c2ccccc2,0.62,
CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)c2cc3ccccc3[nH]2,3.4,
C[C@H](Nc1cncc(Nc2ncc(C)s2)n1)c3ncc(F)cn3,1.91,
Cc1ccc(Oc2ccc(Nc3ncnc4[nH]nc(OCCN5CCC(O)CC5)c34)cc2Cl)cn1,3.4,
OC(=O)c1ccc(cc1)N2CCC(CN3CCC(CC3)Oc4ccc(Cl)c(Cl)c4)CC2,2.31,
COc1ccc(cc1N2CC(=O)NS2(=O)=O)c3ccccc3,-1.01,
CCOc1ccccc1CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4NC(=O)Sc34)c2,1.13,
CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O,-0.3,
OC(=O)COc1ccc(cc1c2ccccc2c3ccccc3)C(F)(F)F,1.38,
Cc1nc(cs1)C(=O)N2CCCC3(CCN(Cc4ccc(Cl)cc4)CC3)C2,0.64,
COc1cc(Nc2nc3c(cc2F)ncn3[C@@H](CO)c4ccc(F)cn4)n[nH]1,2.18,
CC1(CCN(CC1)C(=O)COCc2ccncc2)c3ccc(Cl)cc3,2.79,
NC1(CCN(CC1)c2ncnc3[nH]ccc23)C(=O)NC(CO)c4ccc(Cl)cc4,2.4,
CNC(=O)c1cccc(c1c2ccc(CC(C)C)cc2)S(=O)(=O)Nc3ncc(C)nc3OC,1.68,
Oc1ccc(cc1)[N+](=O)[O-],1.5,
CCC(CC)NC(=O)c1cnn(Cc2ccccc2)c1NS(=O)(=O)c3ccc(C)cc3,1.52,
Oc1cccc2Oc3ccccc3C(=O)c12,3.8,
COc1cc2c(Nc3cc(CC(=O)Nc4cccc(F)c4F)[nH]n3)ncnc2cc1OCCCN(CCO)CC(C)C,3.61,
COc1cc2c(Nc3c(Cl)ccc4OCOc34)ncnc2cc1OCCCN5CCCCC5,2.05,
COc1cc2ncnc(Oc3cnn(CC(=O)Nc4ccc(cn4)N(C)C)c3)c2cc1OC,2.36,
C(Cn1c2CCCCc2c3c(nc(nc13)N4CCCC4)N5CCCC5)N6CCOCC6,3.6,
CC(C)(C)OC(=O)N1CCN(CC1)c2ncc(OCc3ccc(cc3)S(=O)(=O)C)nn2,2.93,
CC(C)C(NC(=O)CN1C(=O)C(=CN=C1c2cccs2)N)C(=O)C(F)(F)F,0.68,
Cc1ccnc2nc(nn12)C(=O)Nc3nccs3,0.31,
OC(=O)[C@H](Cc1ccc(cc1)N2CCN(CC2)c3ccccc3)NC(=O)c4c(Cl)cccc4Cl,0.08,
CCNC(=O)Nc1nc2cc(ccc2[nH]1)c3cccnc3,2.34,
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,2.93,"This molecule is an orally available, over-the-counter laxative and stool softener used to treat or prevent constipation. This molecule has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury with jaundice. This molecule is a diester and an organosulfonic acid. This molecule is a stool softener indicated for the treatment of constipation. Docusate acts by increasing the amount of water the stool absorbs in the gut, making the stool softer and easier to pass. Docusate can be orally or rectally administered. Docusate is on the World Health Organization's List of Essential Medicines. However the effectiveness of docusate in treating constipation remains unclear, as several studies report docusate to be no more effective than placebo for increasing the frequency of stool or stool softening. Recently there has been pressure to stop prescribing docusate as it has been identified as an ineffective medicine. Additionally, it does not appear to lessen symptoms associated with constipation such as abdominal cramps. Still docusate is available in over-the-counter products as a common laxative. This molecule is a dioctyl salt and an emollient laxative, with stool-softening activity. Upon administration, docusate decreases surface tension and emulsification of fecal matter and allows water to penetrate and mix with stool. As a result, it softens the stool."
CN1CCCC1CCOC(C)(c2ccccc2)c3ccc(Cl)cc3,3.04,
NC1=NC(CC(=O)N1)c2ccc(Cl)c(Cl)c2,1.46,
Oc1c(C#N)c(nc2ccncc12)c3ccc(cc3)c4ccccc4OC(F)(F)F,3.45,
NCC(O)(c1ccc(Cl)cc1)c2ccc(Cl)cc2,2.69,
Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,-0.51,"This molecule is a sulfonamide consisting of pyrimidine with a methyl substituent at the 4-position and a 4-aminobenzenesulfonamido group at the 2-position. It has a role as an antiinfective agent and a drug allergen. It is a member of pyrimidines, a sulfonamide and a sulfonamide antibiotic. It is functionally related to a sulfanilamide. This molecule is used as an antibacterial agent. This molecule is a long-acting sulfanilamide antibacterial agent. This molecule inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for the binding site on dihydropteroate synthase."
O[C@@H](CNCCOCCCNCCc1cccc(Cl)c1)c2ccc(O)c3NC(=O)Sc23,0.83,
CN1CCC[C@@H]([C@H]1C(=O)Nc2ccc(OCc3cc(C)nc4ccccc34)cc2)C(=O)NO,2.41,
COC(=O)COc1ccc(cn1)C(=O)Nc2ccc(F)cc2,2.43,
CCC(N1NC(=O)c2nc3cc(Cl)ccc3c(O)c2C1=O)c4ccccn4,0.8,
Cc1cccc(Nc2oc(nn2)C(=O)Nc3ccc(nc3)N4CCOCC4)c1,3.42,
CCOC(=O)c1ccc(OCC2CN(C2)c3ccc(C)nn3)cc1,3.1,
COc1cc(F)ccc1c2cncc(CNC3CCCCC3)c2,2.6,
Oc1cccc(NC(=O)c2ccc(OCCCN3CCCC3)cc2OCc4ccccn4)c1,1.78,
CC1CC(N(C(=O)C)c2ccccc2)c3ccccc3N1S(=O)(=O)c4ccccc4,3.68,
OCCc1ccc(NC(=O)c2cc3cc(Cl)ccc3[nH]2)cc1,3.85,
CCN(C1CCN(CCC(c2ccc(F)cc2)c3ccc(F)cc3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,3.21,
COc1cccc2[nH]ncc12,2.1,
Clc1ccc2ncccc2c1C(=O)NCC3CCCCC3,2.65,
CN1C(=O)C=C(CCc2ccc3ccccc3c2)N=C1N,2.7,
